Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cardiovascular Disease Inhibitors & Modulators

(+)-Medioresinol

Cat. No.: HY-N3307

(+)-Medioresinol is a furofuran type lignan with antifungal, antibacterial and lesishmanicidal activities. (+)-Medioresinol leads to intracellular **ROS** accumulation and mitochondria-mediated **apoptotic** cell death in Candida albicans.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-Blebbistatin

((S)-(-)-Blebbistatin)

Cat. No.: HY-13441

(-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle **myosin II**.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

(-)-Chromanol 293B

Cat. No.: HY-110015

(-)-Chromanol 293B is a potent and selective inhibitor of the slow component of delayed rectifier K^+ current (**IKs**). (-)-Chromanol 293B can be used for the research of antiarrhythmic.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

(-)-Denudatin B

(Denudatin B)

Cat. No.: HY-N3729

(-)-Denudatin B is an antiplatelet agent. (-)-Denudatin B relaxed vascular smooth muscle by inhibiting the Ca2+ influx through voltage-gated and receptor-operated **Ca2+ channels**. And (-)-Denudatin B has nonspecific antiplatelet action.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-Limonene

((S)-(-)-Limonene)

Cat. No.: HY-Z0478

(-)-Limonene ((S)-(-)-Limonene) is a monoterpene found in many pine-needle oils and in turpentine. (-)-Limonene can induce a mild bronchoconstrictive effect.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

(-)-Sparteine sulfate pentahydrate

((-)-Lupinidine sulfate pentahydrate)

Cat. No.: HY-B1304

(-)-Sparteine sulfate pentahydrate ((-)-Lupinidine sulfate pentahydrate) is a class 1a antiarrhythmic agent and a sodium channel blocker. It is an alkaloid, can chelate the bivalents calcium and magnesium.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

(2-Chloropyridin-4-yl)methanamine hydrochloride

Cat. No.: HY-101771A

(2-Chloropyridin-4-yl)methanamine hydrochloride is a selective **LOXL2** inhibitor with an IC_{50} of 126 nM.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

(20S)-Protopanaxatriol

(20(S)-APPT; g-PPT)

Cat. No.: HY-N0835

(20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the **glucocorticoid receptor (GR)** and **oestrogen receptor (ER)**, and is also a **LXRα** inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(2S,4S)-Sacubitril

Cat. No.: HY-78841

(2S,4S)-Sacubitril is the impurity of Sacubitril. Sacubitril is a potent NEP inhibitor that can be used for the research of heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

(3-Carboxypropyl)trimethylammonium chloride

(γ-Butyrobetaine hydrochloride)

Cat. No.: HY-113270A

(3-Carboxypropyl)trimethylammonium chloride is angiopathic substance produced as an intermediary metabolite by gut microbiota that feed on carnitine in dietary red meat.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

(3R,5R)-Rosuvastatin

Cat. No.: HY-17504C

(3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive **HMG-CoA** reductase inhibitor with an IC_{50} of 11 nM. Rosuvastatin potently blocks **human ether-a-go-go related gene (hERG)** current with an IC_{50} of 195 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(3R,5R)-Rosuvastatin Lactone

Cat. No.: HY-135406

(3R,5R)-Rosuvastatin Lactone is an isomer of Rosuvastatin Lactone.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(3R,5S)-Fluvastatin

((3R,5S)-XU 62-320 free acid)

Cat. No.: HY-14664B

(3R,5S)-Fluvastatin is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(3S,5R)-Fluvastatin D6

((3S,5R)-XU 62-320 free acid D6)

Cat. No.: HY-14664DS

(3S,5R)-Fluvastatin D6 is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

(3S,5R)-Fluvastatin D6 sodium

((3S,5R)-XU 62-320 D6)

Cat. No.: HY-14664CS

(3S,5R)-Fluvastatin D6 sodium is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(3S,5R)-Fluvastatin sodium

((3S,5R)-XU 62-320)

Cat. No.: HY-14664C

(3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer of Fluvastatin. Fluvastatin is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

(3S,5R)-Rosuvastatin

Cat. No.: HY-17504D

(3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive **HMG-CoA** reductase inhibitor with an IC_{50} of 11 nM. Rosuvastatin potently blocks **human ether-a-go-go related gene (hERG)** current with an IC_{50} of 195 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(4-Acetamidocyclohexyl) nitrate

(BM121307)

Cat. No.: HY-100295

(4-Acetamidocyclohexyl) nitrate (BM121307) is a **guanylate cyclase** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(4E)-SUN9221

Cat. No.: HY-U00367

(4E)-SUN9221 is a potent antagonist of **α1-adrenergic receptor** and **5-HT2 receptor**, with antihypertensive and anti-platelet aggregation activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E)-Alprenoxime

(CDDD-1815)

Cat. No.: HY-101804

(E)-Alprenoxime is the isomer of the Alprenoxime. Alprenoxime is a site-activated ocular **β**-blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E)-m-Coumaric acid

Cat. No.: HY-N7127

(E)-m-Coumaric acid (3-Hydroxycinnamic acid) is an aromatic acid that highly abundant in food.
(E)-m-Coumaric acid (3-Hydroxycinnamic acid) is an antioxidant.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

(E/Z)-Eltrombopag 13C4

((E/Z)-SB-497115 13C4)

Cat. No.: HY-15306S

(E/Z)-Eltrombopag 13C4 ((E/Z)-SB-497115 13C4) is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is a **thrombopoietin (TPO) receptor** agonist developed for certain conditions that lead to thrombocytopenia.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg

(E/Z)-GSK5182

Cat. No.: HY-111226A

(E/Z)-GSK5182 is a racemic compound of (E)-GSK5182 and (Z)-GSK5182 isomers. GSK5182 is a highly selective and orally active inverse agonist of **estrogen-related receptor γ (ERRγ)** with an IC_{50} of 79 nM. GSK5182 also induces **reactive oxyen species (ROS)** generation in hepatocellular carcinoma.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(R)-(+)-Bay-K-8644

Cat. No.: HY-15125

(R)-(+)-Bay-K-8644 is a **calcium channel** inhibitor. (R)-(+)-Bay-K-8644 inhibits Ba^{2+} currents (I_{Ba}) (IC_{50}=975 nM).



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(R)-(4'-Hydroxy)-5,7-dihydroxy-4-chromanone

Cat. No.: HY-N8178

(R)-(4'-Hydroxy)-5,7-dihydroxy-4-chromanone, a homoisoflavonoid, has antiangiogenic activity against human retinal microvascular endothelial cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Carvedilol

((R)-BM 14190)

Cat. No.: HY-B0006C

(R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective **β/α-1** blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

(R)-Fadrozole

((R)-CGS 16949A free base; FAD286)

Cat. No.: HY-113986

(R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent **nonsteroidal** inhibitor. (R)-Fadrozole also inhibits human placental aromatase (pIC_{50} = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Fangchinoline

(Thalrugosine; Thaligine)

Cat. No.: HY-N1372

(R)-Fangchinoline (Thalrugosine), a alkaloids from genus Stephaniaexhibits antimicrobial and hypotensive activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Lercanidipine hydrochloride

Cat. No.: HY-B0612D

(R)-Lercanidipine hydrochloride is the R-enantiomer of Lercanidipine. (R)-lercanidipine hydrochloride is a calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Lercanidipine-d3 hydrochloride

Cat. No.: HY-B0612DS

(R)-lercanidipine D3 (hydrochloride) is a deuterium labeled (R)-Lercanidipine hydrochloride. (R)-Lercanidipine D3 (hydrochloride), the R-enantiomer of Lercanidipine, is a **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-MLN-4760

Cat. No.: HY-19414A

(R)-MLN-4760, the R-enantiomer of MLN-4760, is an **ACE2** inhibitor, with an IC_{50} of 8.4 μM. (R)-MLN-4760 is the less active isomer.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

(R)-Nicardipine

((R)-YC-93 free base)

Cat. No.: HY-12515C

(R)-Nicardipine ((R)-YC-93 free base) is the less active R enantiomer of Nicardipine. Nicardipine (YC-93) is a **calcium channel** blocker with an IC_{50} of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Propranolol hydrochloride

Cat. No.: HY-A0295

(R)-Propranolol hydrochloride is a less active enantiomer of the **β-adrenoceptor** antagonist propranolol (HY-B0573).



Purity: ≥97.0%
Clinical Data: Launched
Size: 100 mg

(Rac)-5-Keto Fluvastatin

(3-Hydroxy-5-Keto Fluvastatin)

Cat. No.: HY-135358

(Rac)-5-Keto Fluvastatin (3-Hydroxy-5-Keto Fluvastatin) is an impurity of Fluvastatin (XU 62320). Fluvastatin is a HMG-CoA reductase inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

(Rac)-Calpain Inhibitor XII

Cat. No.: HY-116171

(Rac)-Calpain Inhibitor XII is a reversible and selective inhibitor of **calpain I** (μ-calpain, K_i=19 nM). (Rac)-Calpain Inhibitor XII has lower affinities for calpain II (m-calpain, K_i=120 nM) and cathepsin B (K_i=750 nM).



Purity: ≥90.0%
Clinical Data: No Development Reported
Size: 5 mg

(rac)-Dobutamine-d4 hydrochloride

Cat. No.: HY-15746S

(Rac)-Dobutamine-d4 hydrochloride is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on **α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors)**.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 10 mg, 25 mg

(rac)-Dobutamine-d6 hydrochloride

Cat. No.: HY-15746S1

(Rac)-Dobutamine-d6 hydrochloride is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on **α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-Finerenone

((Rac)-BAY 94-8862)

Cat. No.: HY-111372A

(Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC_{50}=18 nM).



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(Rac)-HAMI 3379

Cat. No.: HY-112248

(Rac)-HAMI 3379 is the racemate of HAMI 3379. HAMI 3379 is a potent and selective **Cysteinyl leukotriene ($CysLT_2$) receptor** antagonist.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

(rac)-Indapamide-d3

Cat. No.: HY-B0259S

(Rac)-Indapamide-d3 is a labelled racemic Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

(Rac)-MGV354

Cat. No.: HY-117917

(Rac)-MGV354 is the racemate of MGV354. MGV354 is a soluble guanylate cyclase (sGC) activator with EC_{50}s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(rac)-Nebivolol-d4

Cat. No.: HY-B0203BS1

(Rac)-Nebivolol-d4 ((Rac)-R 065824-d4) is a labelled racemic Nebivolol. Nebivolol selectively inhibits β1- adrenergic receptor with IC_{50} of 0.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(rac)-Nebivolol-d8

Cat. No.: HY-B0203BS

(Rac)-Nebivolol-d8 ((rac)-R 065824-d8) is a labelled racemic Nebivolol. Nebivolol selectively inhibits β1- adrenergic receptor with IC_{50} of 0.8 nM.



Purity: >98%
Clinical Data:
Size: 500 μg, 1 mg, 5 mg, 10 mg

(rel)-AR234960

Cat. No.: HY-120006A

(rel)-AR234960 is an active relative configuration of AR234960. AR234960, a non-peptide **MAS** (a G protein-coupled receptor) agonist, increases both mRNA and protein levels of CTGF via ERK1/2 signaling in HEK293-MAS cells and adult human cardiac fibroblasts.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(S)-(-)-Bay-K-8644

Cat. No.: HY-15124

(S)-(-)-Bay-K-8644 is an agonist of L-type **Ca^{2+} channel**. (S)-(-)-Bay-K-8644 activates Ba^{2+} currents (I_{Ba}) (EC_{50}=32 nM).



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

(S)-(-)-Felodipine-d5

Cat. No.: HY-132670S

(S)-(-)-Felodipine-d5 is the deuterium labeled (S)-(-)-Felodipine. (S)-(-)-Felodipine is the S enantiomer of Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective **calcium channel** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

(S)-(-)-Propranolol hydrochloride

Cat. No.: HY-B0573A

(S)-(-)-Propranolol hydrochloride is a **β-adrenergic receptor** antagonist with log K_d values of -8.16, -9.08, and -6.93 for β_1, β_2, and β_3, respectively.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL,

(S)-Carvedilol

((S)-BM 14190)

Cat. No.: HY-B0006B

(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective **β/α-1** blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).



Purity: 99.25%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

(S)-Lercanidipine D3 hydrochloride

Cat. No.: HY-B0612ES

(S)-Lercanidipine D3 (hydrochloride) is a deuterium labeled Lercanidipine D3 hydrochloride. (S)-Lercanidipine hydrochloride is an antihypertensive agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Lercanidipine hydrochloride

Cat. No.: HY-B0612E

(S)-Lercanidipine hydrochloride is the S-enantiomer of Lercanidipine hydrochloride. (S)-lercanidipine hydrochloride is a potent calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

(S)-Nicardipine

((S)-YC-93 free base) Cat. No.: HY-12515B

(S)-Nicardipine ((S)-YC-93 free base) is the less active S enantiomer of Nicardipine. Nicardipine is a **calcium channel** blocker with an IC_{50} of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Propafenone

((S)-SA-79) Cat. No.: HY-B0432B

(S)-Propafenone ((S)-SA-79) is the S-enantiomer of Propafenone. (S)-Propafenone ((S)-SA-79) exerts beta-blocking action and the sodium channel-dependent antiarrhythmic class 1 activity.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 1 mg

(S)-Timolol Maleate

(L-714,465 Maleate; MK 950) Cat. No.: HY-17380

(S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic **β-adrenoceptor** blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

(Sar1)-Angiotensin II

Cat. No.: HY-P3138

(Sar1)-Angiotensin II, an analogue of Angiotensin II, is a specific agonist of **angiotensin AT1 receptor**. (Sar1)-Angiotensin II binds to brain membrane-rich particles, with a K_d of 2.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Z)2S,4R-Sacubitril

Cat. No.: HY-Z0075

(Z)2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.



Purity: 96.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

(±)-Befunolol

Cat. No.: HY-101752

(±)-Befunolol is a **β-adrenoceptor** blocking agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(±)-Catechin

(rel-Cianidanol; rel-Catechuic acid) Cat. No.: HY-B1890

(±)-Catechin (rel-Cianidanol) is the racemate of Catechin. (±)-Catechin has two steric forms of (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC_{50} of 1.4 μM.



Relative stereochemistry

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(±)-Equol

Cat. No.: HY-100583A

(±)-Equol is the racemate of equol. (±)-equol exhibits EC_{50}s of 200 and 74 nM for human ERα and ERβ, respectively. Equol is a metabolite of the soy isoflavones, daidzin and daidzein.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

(±)-Evodiamine

Cat. No.: HY-N0114A

(±)-Evodiamine, a quinazolinocarboline alkaloid, is a **Top1** inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 1 g

(±)-Naringenin

Cat. No.: HY-W011641

(±)-Naringenin is a naturally-occurring flavonoid. (±)-Naringenin displays vasorelaxant effect on endothelium-denuded vessels via the activation of BK_{Ca} channels in myocytes.



Purity: 96.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

(±)-Penbutolol-d9 hydrochloride ((Rac)-Penbutolol-d9 hydrochloride; (±)-Isopenbutolol-d9 hydrochloride)

Cat. No.: HY-116790BSA

(±)-Penbutolol-d9 ((Rac)-Penbutolol-d9) hydrochloride is a deuterium labeled (±)-Penbutolol hydrochloride. (+)-Penbutolol hydrochloride is a β-adrenoceptor antagonist, with an IC_{50} of 0.74 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

(±)-WS75624B

Cat. No.: HY-100312

(±)-WS75624B is an **endothelin converting enzyme (ECE)** inhibitor with an **IC_{50}** of 0.03 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(±)11(12)-EET

(11,12-EET)

Cat. No.: HY-130494

(±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 μg, 50 μg

(±)13(14)-EpDPA

(13,14-EpDPE)

Cat. No.: HY-130419

(±)13(14)-EpDPA (13,14-EpDPE) is the product of the reaction of cytochrome P-450 epoxygenase with Docosahexaenoic Acid (DHA).(±)13(14)-EpDPA has antihyperalgesic and vasorelaxative activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1,2,4-Trihydroxybenzene

Cat. No.: HY-W010451

1,2,4-Trihydroxybenzene (Hydroxyhydroquinone), a by-product of coffee bean roasting, increases intracellular Ca^{2+} concentration in rat thymic lymphocytes.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

1,3-Butanediol

Cat. No.: HY-77490A

1,3-Butanediol, an ethanol dimer providing a source of calories for human nutrition. 1,3-Butanediol is converted in the body to β-hydroxybutyrate and has cerebral protective and hypoglycaemic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

1-beta-D-Arabinofuranosyluracil

(Uracil 1-β-D-arabinofuranoside)

Cat. No.: HY-N6652

1-beta-D-Arabinofuranosyluracil (Uracil 1-β-D-arabinofuranoside) isolated from the Caribbean sponge Tectitethya crypta, is a methoxyadenosine derivative.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

1-Cinnamoylpyrrolidine

Cat. No.: HY-N1620

1-Cinnamoylpyrrolidine (Compound 3), a crude extract prepared from Piper caninum, is a **DNA** strand scission agent, induces the relaxation of supercoiled pBR322 plasmid DNA.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

1-Cyclohexyl-3-dodecyl urea

(CDU; N-Cyclohexyl-N-dodecyl urea; NCND)

Cat. No.: HY-135795

1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) is a highly selective **soluble epoxide hydrolase (sEH)** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1-Linoleoyl Glycerol

(1-Linoleoyl-rac-glycerol; 1-Monolinolein)

Cat. No.: HY-111346

1-Linoleoyl Glycerol is a fatty acid glycerol.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone

Cat. No.: HY-N9530

1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, a quinolone alkaloid, is a **diacylglycerol acyltransferase** inhibitor and **angiotensin II receptor** blocker, with IC_{50}s of 20.1 μM and 34.1 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone

Cat. No.: HY-N9520

Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is an antagonist of **angiotensin II receptor** (IC_{50}=48.2 μM).
Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is a quinolone alkaloid from Evodia rutaecarpa.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

11beta-Hydroxyprogesterone

(11β-Hydroxyprogesterone)

Cat. No.: HY-N2337

11beta-Hydroxyprogesterone is a potent inhibitors of **11β-Hydroxysteroid dehydrogenase**; also activates human mineralocorticoid receptor in COS-7 cells with an ED_{50} of 10 nM.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg

12-HETE

Cat. No.: HY-113439

12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell **apoptosis** in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1400W Dihydrochloride

Cat. No.: HY-18731

1400W dihydrochloride is a potent and selective inhibitor of human inducible **NO synthase** with K_i values of 7 nM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

17-ODYA

Cat. No.: HY-101016

17-ODYA is a **CYP450 ω-hydroxylase** inhibitor.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

18-Oxocortisol

Cat. No.: HY-113151

18-Oxocortisol is a derivative of cortisol that is produced by aldosterone synthase (CYP11B2). 18-Oxocortisol is a naturally occurring **mineralocorticoid** agonist. 18-Oxocortisol is a biomarker in adrenal vein sampling.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg

2'-Ethyl Simvastatin

Cat. No.: HY-135402

2'-Ethyl Simvastatin (compound 6) is a Mevinolin analog, with **HMG-CoA reductase** inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2'-O-Methyladenosine

Cat. No.: HY-W011552

2'-O-Methyladenosine, a methylated adenine residue is found in urine of normals as well as in urine of adenosine deaminase (ADA) deficient patients. 2'-O-Methyladenosine exhibits unique hypotensive activities .



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid

Cat. No.: HY-136584

2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a ketone compound extracted from patent WO2002030860A2, compound example II-9.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

2-Hydroxy atorvastatin lactone

Cat. No.: HY-136346

2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Hydroxy-1-Methoxyaporphine

Cat. No.: HY-N7971

2-Hydroxy-1-Methoxyaporphine is an alkaloid that can be isolated from Nelumbo nucifera. 2-Hydroxy-1-Methoxyaporphine is the major active ingredient of the Chinese traditional medicine Jiang-Zhi-Ning.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

2-Methylthio-AMP (2-MeSAMP; 2-Methylthioadenosine 5′-monophosphate; 2-Methylthioadenosine 5′-phosphate)

Cat. No.: HY-125989

2-Methylthio-AMP (2-MeSAMP) is a selective and direct **$P2Y_{12}$** antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Methylthio-AMP diTEA (2-MeSAMP diTEA; 2-Methylthioadenosine 5′-monophosphate diTEA; ...)

Cat. No.: HY-125989B

2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct **$P2Y_{12}$** antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2R,4R-Sacubitril

Cat. No.: HY-78846

2R,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

2R,4S-Sacubitril

Cat. No.: HY-78847

2R,4S-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2S,4R-Sacubitril

Cat. No.: HY-Z0081

2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

3',4'-Dihydroxyflavonol (DiOHF)

Cat. No.: HY-111804

3',4'-Dihydroxyflavonol (DiOHF) is an effective antioxidant, which reduces superoxide and improves nitric oxide (**NO**) function in diabetic rat mesenteric arteries.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3,4-Dehydro Cilostazol (OPC-13015)

Cat. No.: HY-135910

3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

3,5-Diiodothyropropionic acid

Cat. No.: HY-126236

3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to **thyroid hormone receptor (TR)**, with K_a of 2.40 and 4.06 M^{-1} for TRα1 and TRβ1, respectively.



Purity: 99.20%
Clinical Data:
Size: 5 mg, 10 mg

3-(3,4-Dimethoxyphenyl)propanoic acid

Cat. No.: HY-Y1620

3-(3,4-Dimethoxyphenyl)propanoic acid is an orally active short-chain fatty acids (SCFAs).
3-(3,4-Dimethoxyphenyl)propanoic acid stimulates γ globin gene expression, erythropoiesis in vivo and is used for the β hemoglobinopathies and other anemias.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3-(3-Hydroxyphenyl)propionic acid

Cat. No.: HY-W005255

3-(3-Hydroxyphenyl)propionic acid is a flavonoid metabolite formed by human microflora.
3-(3-Hydroxyphenyl)propionic acid shows vasodilatory activity.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 500 mg

3-Acetyldeoxynivalenol

Cat. No.: HY-N6685

3-Acetyldeoxynivalenol, a trichothecene mycotoxin deoxynivalenol (DON) acetylated derivative, is a blood-brain barrier (BBB) permeable mycotoxin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Amino-2-methylpropanoic acid

Cat. No.: HY-W012974

3-Amino-2-methylpropanoic acid could induce browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3-Chlorodiphenylamine

Cat. No.: HY-131948

3-Chlorodiphenylamine is a high affinity **Ca^{2+} sensitizer** of cardiac muscle.
3-Chlorodiphenylamine is based on diphenylamine and binds to the isolated N-domain of **cardiac troponin C (cTnC)** (K_d=6 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Epidehydrotumulosic acid

Cat. No.: HY-125437

3-Epidehydrotumulosic acid has inhibitory activity against AAPH-induced lysis of red blood cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Hydroxybenzaldehyde

Cat. No.: HY-76006

3-Hydroxybenzaldehyde is a **precursor** compound for phenolic compounds, such as Protocatechualdehyde (HY-N0295).
3-Hydroxybenzaldehyde is a **substrate** of **aldehyde dehydrogenase (ALDH)** in rats and humans (ALDH2).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3-Methylsalicylic acid

(o-Cresotic acid; Hydroxytoluic acid)

Cat. No.: HY-B1399

3-Methylsalicylic acid is a salicylic acid derivative compound with marked fibrinolytic activity in human plasma by activating its fibrinolytic system.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

3-Oxo Atorvastatin

Cat. No.: HY-135381

3-Oxo Atorvastatin is an impurity of 3-Oxo Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3α-Hydroxy pravastatin sodium

Cat. No.: HY-136347

3α-Hydroxy pravastatin sodium is the major metabolite of Pravastatin. Pravastatin is a competitive HMG-CoA reductase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4,6-Dioxoheptanoic acid

Cat. No.: HY-W010184

4,6-Dioxoheptanoic acid is a potent inhibitor of heme biosynthesis.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

4-Acetylsimvastatin

Cat. No.: HY-135405

4-Acetylsimvastatin is an acetylated simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase with a K_i of 0.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Hydroxychalcone

Cat. No.: HY-107818

4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities. 4-Hydroxychalcone suppresses angiogenesis by suppression of growth factor pathway with no signs of cytotoxicity.



Purity: 99.65%
Clinical Data:
Size: 10 mM × 1 mL, 100 mg

4-Hydroxynonenal (4-HNE)

Cat. No.: HY-113466

4-Hydroxynonenal (4-HNE) is an α,β unsaturated hydroxyalkenal and an oxidative/nitrosative stress biomarker. 4-Hydroxynonenal is a substrate and an inhibitor of **acetaldehyde dehydrogenase 2 (ALDH2)**.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg (64.01 mM * 100 µL in Ethanol),

4-Hydroxyphenyl Carvedilol-d5 (4-Hydroxycarvedilol-d5)

Cat. No.: HY-12767S

4-Hydroxyphenyl Carvedilol D5 is the deuterium labeled 4-Hydroxyphenyl Carvedilol.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Methylumbelliferone (Hymecromone; 4-MU)

Cat. No.: HY-N0187

4-Methylumbelliferone is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects.



Purity: 99.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid)

Cat. No.: HY-W000450

5-Aminolevulinic acid (5-ALA) is a non-protein amino acid that plays a rate-limiting role in heme biosynthesis.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

5-HT2 antagonist 1

Cat. No.: HY-U00365

5-HT2 antagonist 1 is a potent antagonist of **5-HT2 receptor**, with weak **α1 adrenoceptor** blocking activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT2A antagonist 1

Cat. No.: HY-U00286

5-HT2A antagonist 1 is a **5-HT2A** antagonist extracted from patent US5728835A and JP 1007727. 5-HT2A antagonist 1 may be useful in treatment of gastrointestinal disorders circulatory disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT3-In-1

Cat. No.: HY-U00413

5-HT3-In-1 is extracted from patent EP0748807A1, compound example 8. It shows **5-HT3** inhibition activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-Hydroxy Propafenone D5 Hydrochloride

(GPV-129 D5 Hydrochloride; Lu 40-545 D5)

Cat. No.: HY-12773AS

5-Hydroxy Propafenone D5 Hydrochloride is the deuterium labeled 5-Hydroxy Propafenone.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-Lipoxygenase-In-1

Cat. No.: HY-U00308

5-Lipoxygenase-In-1 is a **5-Lipoxygenase** inhibitor extracted from patent EP 331232 A2, table 4, compound example 4.10.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

5-R-Rivaroxaban

Cat. No.: HY-76948

5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct **Factor Xa** (**FXa**) inhibitor, achieving a strong gain in anti-FXa potency (IC_{50} 0.7 nM; K_i 0.4 nM).



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

5α-Hydroxy-6-keto cholesterol

Cat. No.: HY-123349

5α-Hydroxy-6-keto cholesterol is major metabolite of β-epoxide (5α,6β-epoxycholesterol) during direct exposure of intact cultured human bronchial epithelial cells (16-HBE) to ozone. 5α-Hydroxy-6-keto cholesterol inhibits **cholesterol** synthesis with an IC_{50} of 350 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6-Hydroxybenzbromarone

Cat. No.: HY-135774

6-Hydroxybenzbromarone is the major **metabolite** of Benzbromarone with a longer half-life and greater pharmacological potency than the parent compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

8-Bromo-AMP

(8-Bromoadenosine 5'-monophosphate; 8-Bromoadenylic acid)

Cat. No.: HY-134266

8-Bromo-AMP (8-Bromoadenosine 5'-monophosphate) is a membrane permeable cAMP analogue. 8-Bromo-AMP can improve the ability of the heart to recover from ischemia and reperfusion by increasing the levels of ATP, ADP, and total adenine nucleotides.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

8-Bromo-cGMP sodium

Cat. No.: HY-101379A

8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a **PKG (protein kinase G)** activator. 8-Bromo-cGMP sodium significantly inhibits Ca^{2+} macroscopic currents and impairs insulin release stimulated with high K^+.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

8-Cyclopentyl-1,3-dimethylxanthine

Cat. No.: HY-W011955

8-Cyclopentyl-1,3-dimethylxanthine (Compound 2a) is a selective **adenosine A1 receptor** antagonist with K_is of 10.9 nM and 1440 nM for A1 receptor and A2 receptor, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

9-Hydroxyellipticine hydrochloride

Cat. No.: HY-101775A

9-Hydroxyellipticine hydrochloride is a inhibitor of **Topo II** and **RyR**. 9-Hydroxyellipticine hydrochloride exhibits antitumor, antioxidant and catecholamine-releasing activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A 71915

Cat. No.: HY-P2026

A 71915 is a highly potent and competitive **natriuretic peptide receptor A (ANP, NPRA)** antagonist (pK_i= 9.18). A 71915 displaces [^{125}I]ANP dose dependently, with a K_i of 0.65 nM. A71915(pA_2= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A 779

Cat. No.: HY-P0216

A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an **Ang1-7 receptor** distinct from the classical AngII.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

A-192621

Cat. No.: HY-120295

A-192621 is a potent, nonpeptide, orally active and selective **endothelin B (ET_B) receptor** antagonist with an **IC_{50}** of 4.5 nM and a **K_i** of 8.8 nM. The selectivity of A-192621 is 636-fold higher than ET_A (**IC_{50}** of 4280 nM and **K_i** of 5600 nM). A-192621 promotes **apoptosis** in PASMCs.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg

A-935142

Cat. No.: HY-113673

A-935142 is a **human ether-a-go-go-related gene (hERG, Kv 11.1) channel** activator. A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A81988

(Abbott81988)

Cat. No.: HY-U00188

A81988 is a potent, competitive, non-peptidic antagonist of **angiotensin AT_1** receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AACOCF3

(Arachidonyl trifluoromethyl ketone)

Cat. No.: HY-108611

AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa **cytosolic phospholipase A2 (cPLA2)**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ABT-546

(A-216546)

Cat. No.: HY-135283

ABT-546 (A-216546) is a potent, highly selective and active **endothelin ET_A receptor** antagonist with a **K_i** of 0.46 nM for [^{125}I]endothelin-1 binding to cloned **human endothelin ET_A**. ABT-546 is >25,000-fold more selective for the **ET_A receptor** than for the ET_B receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abz-FR-K(Dnp)-P-OH

Cat. No.: HY-P1853

Abz-FR-K(Dnp)-P-OH is an angiotensin I-converting enzyme (ACE) substrate and an internally quenched fluorogenic substrate for real time fluorescent assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acebutolol D7

Cat. No.: HY-17497S

Acebutolol D7 is a deuterium labeled Acebutolol. Acebutolol is a selective β1 adrenergic receptor antagonist used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Acebutolol hydrochloride

Cat. No.: HY-17497A

Acebutolol hydrochloride is a **β1 adrenergic receptor (β1AR)** antagonist. Acebutolol hydrochloride is used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 5 g, 10 g

Acenocoumarol

Cat. No.: HY-B1014

Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Acenocoumarol-d4

Cat. No.: HY-B1014S

Acenocoumarol-d4 is the deuterium labeled Acenocoumarol. Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Acetazolamide

Cat. No.: HY-B0782

Acetazolamide is a **carbonic anhydrase** (**CA**) **IX** inhibitor with an **IC_{50}** of 30 nM for **hCA IX**. Diuretic effects.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Acetazolamide-d3

Cat. No.: HY-B0782S

Acetazolamide D3 is deuterium labeled Acetazolamide, which is a potent carbonic anhydrase (CA) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetildenafil

Cat. No.: HY-13927

Acetildenafil is a derivative of the phosphodiesterase 5 (PDE5) inhibitor Sildenafil.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetylhydrolase-IN-1

Cat. No.: HY-102054

Acetylhydrolase-IN-1 is a 1-Alkyl-2-acetylglycerophosphocholine esterase (**Alkylacetyl-GPC: acetylhydrolase**) inhibtor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Activated Protein C (390-404), human

Cat. No.: HY-P1918

Activated Protein C (390-404), human is a peptide of the activated protein C (a vitamin K-dependent serine protease), potently inhibits APC anticoagulant activity.

YGVYTKVSRYLDWIH

Purity: 98.20%
Clinical Data: No Development Reported
Size: 5 mg

Activated Protein C (390-404), human TFA

Cat. No.: HY-P1918A

Activated Protein C (390-404), human TFA, a peptide of the activated protein C (a vitamin K-dependent serine protease), potently inhibits APC anticoagulant activity.

YGVYTKVSRYLDWIH (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACY-775

Cat. No.: HY-19328

ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (**HDAC6**) with an **IC_{50}** of 7.5nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Adrenochrome

(Adraxone)

Cat. No.: HY-116513

Adrenochrome (Adraxone) is an oxidation product of Epinephrine. Adrenochrome is a potent coronary constricting agent in the rat heart. Adrenochrome can be used for neurological disorder research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adrenomedullin (1-50), rat

Cat. No.: HY-P1534

Adrenomedullin (1-50), rat is a 50 amino acid peptide, which induces a selective arterial vasodilation via activation of **CGRP1 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Adrenomedullin (11-50), rat

Cat. No.: HY-P1766

Adrenomedullin (11-50), rat is the C-terminal fragment (11-50) of rat adrenomedullin. Rat adrenomedullin induces a selective arterial vasodilation via CGRP1 receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adrenomedullin (16-31), human

Cat. No.: HY-P1770

Adrenomedullin (16-31), human is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human possesses pressor activity in the systemic vascular bed of the rat, but not the cat.

CRFGTCTVQKLAHQIY-NH2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adrenomedullin (16-31), human TFA

Cat. No.: HY-P1770A

Adrenomedullin (16-31), human TFA is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human TFA possesses pressor activity in the systemic vascular bed of the rat, but not the cat.

CRFGTCTVQKLAHQIY-NH2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adrenomedullin (AM) (13-52), human

Cat. No.: HY-P1457

Adrenomedullin (AM) (13-52), human is a 40 amino acid peptide, which acts as an endothelium-dependent vasodilator agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adrenomedullin (AM) (22-52), human

(22-52-Adrenomedullin (human))

Cat. No.: HY-P1471

Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an **adrenomedullin receptor** antagonist, and also antagonizes the calcitonin generelated peptide (**CGRP**) receptor in the hindlimb vascular bed of the cat.

TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH_2

Purity: 98.78%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Adrenomedullin (AM) (22-52), human TFA

(22-52-Adrenomedullin (human) (TFA))

Cat. No.: HY-P1471A

Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH_2 terminal truncated adrenomedullin analogue, is an **adrenomedullin receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AE-3763

Cat. No.: HY-19406

AE-3763 is a peptide-based **human neutrophil elastase** inhibitor with an IC_{50} of 29 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

AE0047 Hydrochloride

Cat. No.: HY-U00284

AE0047 Hydrochloride is a **calcium** blocker, used in the research of hypertensive disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AER-271

Cat. No.: HY-115460

AER-271, a phosphonate prodrug derivative of AER-270, is an **aquaporin-4** (**AQP4**) inhibitor for the research of acute ischemic stroke.



Purity: 95.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Aficamten

(CK-274; CK-3773274)

Cat. No.: HY-139465

Aficamten (CK-274) is a potent **cardiac myosin** inhibitor with an IC_{50} of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG 1295

Cat. No.: HY-101957

AG 1295 is a selective **platelet-derived growth factor receptor (PDGFR)** tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AG-13958

(AG-013958)

Cat. No.: HY-15492

AG-13958 (AG-013958), a potent **VEGFR tyrosine kinase** inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD).



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG-1478

(Tyrphostin AG-1478; NSC 693255)

Cat. No.: HY-13524

AG-1478 (Tyrphostin AG-1478) is a selective **EGFR** tyrosine kinase inhibitor with **IC_{50}** of 3 nM. AG-1478 has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG-1478 hydrochloride

(Tyrphostin AG-1478 hydrochloride; NSC 693255 hydrochloride)

Cat. No.: HY-13524A

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride) is a selective **EGFR** tyrosine kinase inhibitor with **IC_{50}** of 3 nM. AG-1478 hydrochloride has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aglafoline

(Aglafolin; Rocaglamide U; (-)-Methyl rocaglate)

Cat. No.: HY-19354

Aglafoline inhibits in a selective and concentration-dependent manner the aggregation and ATP release reaction induced in washed rabbit platelets by PAF (platelet-activating factor). The IC50 values of Aglafoline on PAF (3.6 nM)-induced platelet aggregation were about 50 μM.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

AGN 192836

Cat. No.: HY-100300

AGN 192836 is a potent and selective **α2 adrenergic** agonist with **EC_{50}**s of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ajmalicine

(Raubasine)

Cat. No.: HY-N1919

Ajmalicine (Raubasine) is found in herbs of Catharanthus roseus, is an antihypertensive drug used in the treatment of high blood pressure, decreases peripheral resistance and blood pressure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ajmaline

(Cardiorythmine; (+)-Ajmaline)

Cat. No.: HY-B1167

Ajmaline (Cardiorythmine) is a **sodium channel** blocking, class 1A anti-arrhythmic agent. Ajmaline blocks HERG currents with an IC_{50} of 1 μM in HEK cells and 42.3 μM in Xenopus oocytes. Ajmaline can be used for the research of the ventricular tachyarrhythmia.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Aladorian

(ARM036)

Cat. No.: HY-119850

Aladorian (ARM036) is a benzothiazepine derivative, with anti-arrhythmia effect. Aladorian is used for the research of heart failure and catecholaminergic polymorphic ventricular tachycardia.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 5 mg

Alamandine

Cat. No.: HY-P3108

Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg

Alcesefoliside

Cat. No.: HY-N5049

Alcesefoliside is a flavonoid isolated from Nitraria sibirica Pall, with antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aldosterone

Cat. No.: HY-113313

Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by the zona glomerulosa (ZG) of the adrenal cortex.



Purity: 99.71%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg

Aldosterone-d8

Cat. No.: HY-113313S

Aldosterone D8 is a deuterium labeled Aldosterone. Aldosterone, produced in the adrenal zona glomerulosa, regulates blood pressure.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 2 mg, 5 mg

Aligeron

Cat. No.: HY-101602

Aligeron is a non-selective **prostaglandin (PG)** antagonist, and has vasodilatory properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aliskiren

(CGP 60536; CGP60536B; SPP 100)

Cat. No.: HY-12176

Aliskiren(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM.



Purity: 99.16%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Aliskiren D6 hemifumarate (CGP 60536 D6 hemifumarate; CGP60536B D6 hemifumarate; SPP 100 D6 hemifumarate)

Cat. No.: HY-12177S

Aliskiren D6 hemifumarate (CGP 60536 D6 hemifumarate) is a deuterium labeled Aliskiren hemifumarate. Aliskiren hemifumarate is a direct and orally active **renin** inhibitor with an IC_{50} of 1.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aliskiren D6 Hydrochloride (CGP 60536 D6 Hydrochloride; CGP60536B D6 Hydrochloride; SPP 100 D6 Hydrochloride)

Cat. No.: HY-12176AS

Aliskiren D6 Hydrochloride (CGP 60536 D6 Hydrochloride) is is deuterium labeled Aliskiren, which is a direct renin inhibitor with IC50 of 1.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Aliskiren hemifumarate (CGP 60536 hemifumarate; CGP60536B hemifumarate; SPP 100 hemifumarate)

Cat. No.: HY-12177

Aliskiren hemifumarate(CGP 60536 hemifumarate) is a direct renin inhibitor with IC50 of 1.5 nM.



Purity: 98.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Alisol C 23-acetate

(23-O-Acetylalisol C; Alisol C monoacetate)

Cat. No.: HY-N0856

Alisol C 23-acetate, a natural product extracted from Alisma orientale, can significantly and strongly inhibit DTH response after oral administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Alliin

Cat. No.: HY-N0661

Alliin, an orally active sulfoxide compound derived from garlic, exhibits hypoglycemic, antioxidant and anti-inflammatory activities.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Allocryptopine

Cat. No.: HY-N1933

Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Corydalis decumbens (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (**hERG**) current.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Almitrine mesylate (Almitrine bismesylate; Almitrine bismethanesulfonate; Almitrine dimesylate)

Cat. No.: HY-107319

Almitrine mesylate, a peripheral chemoreceptor agonist, inhibits selectively the Ca^{2+}-dependent **K^+ channel**.



Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Almokalant

(H 234/09)

Cat. No.: HY-106855

Almokalant is a class Ⅲ antiarrhythmic drug, acts as a **potassium channel** blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K^+ current.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alofanib

(RPT835)

Cat. No.: HY-17601

Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (**FGFR2**). Anticancer and antiangiogenic activity.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Alogliptin

(SYR-322 free base)

Cat. No.: HY-A0023A

Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of **DPP-4** with an IC_{50} of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Alogliptin Benzoate

(SYR 322)

Cat. No.: HY-A0023

Alogliptin Benzoate (SYR-322) is a potent, selective and orally active inhibitor of **DPP-4** with an IC_{50} of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin Benzoate can be used for the research of type 2 diabetes.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AM-8123

Cat. No.: HY-139486

AM-8123 is an orally active and potent **APJ** agonist. AM-8123 inhibits Forskolin-stimulated cAMP production and promotes Gα protein activation. AM-8123 can be used for the research of cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AM-92016 hydrochloride

Cat. No.: HY-101253

AM-92016 hydrochloride is a specific blocker of rectifier potassium current (**IK**). AM-92016 hydrochloride delays rectifier potassium channel (IK), repolarizes the membrane thereby restricting the duration of the nerve impulse thereby restricting the duration of the nerve impulse.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AM12

Cat. No.: HY-128561

AM12 inhibits Lanthanide-evoked **TRPC5** activity with an IC_{50} of 0.28 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ambrisentan

(BSF 208075; LU 208075)

Cat. No.: HY-13209

Ambrisentan is a selective ET type A receptor (**ETAR**) antagonist.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amezinium methylsulfate

(Amezinium metilsulfate; Lu-1631) Cat. No.: HY-A0275

Amezinium metilsulfate has multiple mechanisms, including stimulation of alpha and beta-1 receptors and inhibition ofnoradrenaline and tyramine uptake.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

AMG 333

Cat. No.: HY-112703

AMG 333 is a potent and highly selective **TRPM8** antagonist with an IC_{50} of 13 nM.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Amiloride

(MK-870) Cat. No.: HY-B0285

Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (**ENaC**) and urokinase-type plasminogen activator receptor (**uTPA**). Amiloride is a blocker of **polycystin-2** (PC2; **TRPP2**) channel.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Amiloride hydrochloride

(MK-870 hydrochloride) Cat. No.: HY-B0285A

Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (**ENaC**) and urokinase-type plasminogen activator receptor (**uTPA**). Amiloride hydrochloride is a blocker of **polycystin-2** (PC2; **TRPP2**) channel.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Amiloride hydrochloride dihydrate

(MK-870 hydrochloride dihydrate) Cat. No.: HY-B0285B

Amiloride hydrochloride dihydrate (MK-870 hydrochloride dihydrate) is an inhibitor of both epithelial sodium channel (**ENaC**) and urokinase-type plasminogen activator receptor (**uTPA**). Amiloride hydrochloride dihydrate is a blocker of **polycystin-2** (PC2; **TRPP2**) channel.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Aminaftone

(Aminaftone; Aminaphthone) Cat. No.: HY-19890

Aminaftone, a derivative of 4-aminobenzoic acid, downregulates **endothelin-1** (**ET-1**) production in vitro by interfering with the transcription of the pre-pro-ET-1 gene.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amiodarone

Cat. No.: HY-14187

Amiodarone is an antiarrhythmic drug for inhibition of ATP-sensitive potassium channel with an IC_{50} of 19.1 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Amiodarone hydrochloride

Cat. No.: HY-14188

Amiodarone hydrochloride, a benzofuran-based Class III antiarrhythmic agent, inhibits WT outwardI**hERG** tails with an IC_{50} of 45 nM.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amiodarone-d10 hydrochloride

Cat. No.: HY-14187S

Amiodarone-d10 hydrochloride is the deuterium labeled Amiodarone. Amiodarone hydrochloride is an antiarrhythmic drug for inhibition of ATP-sensitive potassium channel with an IC_{50} of 19.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Amlodipine

Cat. No.: HY-B0317

Amlodipine, an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine can be used for the research of high blood pressure and cancer.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amlodipine aspartic acid impurity

(Amlodipine aspartate)

Cat. No.: HY-128696

Amlodipine aspartic acid impurity is the impurity of Amlodipine aspartic acid. Amlodipine aspartic acid is a calcium channel blocker with antihypertensive and antianginal properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amlodipine besylate

(Amlodipine benzenesulfonate)

Cat. No.: HY-B0317B

Amlodipine besylate (Amlodipine benzenesulfonate), an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amlodipine maleate

Cat. No.: HY-B0317A

Amlodipine maleate is a dihydropyridine **calcium channel** blocker, acts as an orally active **antianginal agent**. Amlodipine maleate blocks the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amrinone

(Inamrinone)

Cat. No.: HY-B1294

Amrinone (Inamrinone) is a positive inotropic-vasodilator agent. Amrinone is a selective **phosphodiesterase III** inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Anacetrapib

(MK-0859)

Cat. No.: HY-12090

Anacetrapib is a potent **CETP** inhibitor, with IC_{50}s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ancarolol

Cat. No.: HY-100141

Ancarolol is a **beta-adrenergic** blocking agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anemarrhenasaponin A2

(Schidigerasaponin F2; Timosaponin AII)

Cat. No.: HY-N7614

Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Anemarrhenasaponin I

Cat. No.: HY-N4213

Anemarrhenasaponin I, a traditional Chinese medicine, shows remarkable inhibiting effect on platelet aggregation.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Angiogenin (108-122)

Cat. No.: HY-P1516

Angiogenin (108-122) is an angiogenin peptide.

ENGLPVHLDQSIFRR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Angiogenin (108-122) (TFA)

Cat. No.: HY-P1516A

Angiogenin (108-122) TFA is an angiogenin peptide.

ENGLPVHLDQSIFRR (TFA salt)

Purity: 98.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Angiopeptin

Cat. No.: HY-P2090

Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak **sst_2/sst_5** receptor partial agonist with **IC_{50}** values of 0.26nM and 6.92nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Angiopeptin TFA

Cat. No.: HY-P2090A

Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak **sst_2/sst_5** receptor partial agonist with **IC_{50}** values of 0.26nM and 6.92nM, respectively.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Angiotensin (1-7)

(Ang-(1-7))

Cat. No.: HY-12403

Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine **ACE** activity (**IC_{50}**=0.65 μM).



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Angiotensin (1-7) (acetate)

(Ang-(1-7) (acetate))

Cat. No.: HY-12403A

Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Angiotensin I/II (1-5)

Cat. No.: HY-P1839

Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Angiotensin I/II (1-6)

Cat. No.: HY-P1829

Angiotensin I/II 1-6 contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Angiotensin I/II (1-6) (TFA)

Cat. No.: HY-P1829A

Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Angiotensin II (3-8), human

Cat. No.: HY-P1515

Angiotensin II (3-8), human is a less effective agonist at the **angiotensin AT_1 receptor**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Angiotensin II (3-8), human TFA

Cat. No.: HY-P1515A

Angiotensin II (3-8), human (TFA) is a less effective agonist at the **angiotensin AT_1 receptor**.



Purity: 99.14%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Angiotensin II human

(Angiotensin II; Ang II; DRVYIHPF)

Cat. No.: HY-13948

Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mg, 50 mg

Angiotensin II human acetate

(Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate) Cat. No.: HY-13948A

Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system.



Purity: 99.19%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Angiotensin II human TFA

(Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA) Cat. No.: HY-13948B

Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Angiotensin III

Cat. No.: HY-113035

Angiotensin III is an **angiotensin 1 (AT1)** and **AT2** receptor agonist.

RVY-{Aaa}-HPF

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Angiotensin III TFA

Cat. No.: HY-113035A

Angiotensin III (TFA) is an **angiotensin 1 (AT1)** and **AT2** receptor agonist.

RVY-{Aaa}-HPF (TFA salt)

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Angiotensin III, human, mouse

Cat. No.: HY-P1540

Angiotensin III, human, mouse is a heptapeptide, acts as an endogenous **angiotensin type 2 receptor (AT_2R)** agonist, with **IC_{50}**s of 0.648 nM and 21.1 nM for AT_2R and AT_1R, respectively.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Angiotensinogen (1-14), human

Cat. No.: HY-P1486

Angiotensinogen (1-14), human is a fragment of the renin substrate angiotensinogen. Angiotensinogen is naturally occurring substrate for renin and a precursor for all angiotensin peptides.

DRVYIHPFHLVIHN

Purity: 95.17%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Angiotensinogen (1-14), human TFA

Cat. No.: HY-P1486A

Angiotensinogen (1-14), human TFA is a fragment of the renin substrate angiotensinogen. Angiotensinogen is naturally occurring substrate for renin and a precursor for all angiotensin peptides.

DRVYIHPFHLVIHN (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Angoroside C

Cat. No.: HY-N0062

Angoroside C, a phenylpropanoid glycoside isolated from Radix Scrophulariae, has beneficial effects against ventricular remodeling.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Anhydrosimvastatin

(Dehydro simvastatin) Cat. No.: HY-135404

Anhydrosimvastatin (Impurity C) is an impurity of Simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anipamil

Cat. No.: HY-U00044

Anipamil is a long-acting **calcium channel** blocker, used for the treatment of cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anisindione

Cat. No.: HY-B0924

Anisindione is a synthetic anticoagulant, prevents the formation of active procoagulation factors II, VII, IX, and X.



Purity: 99.03%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Anti-Heart Failure Agent 1

Cat. No.: HY-101729

Anti-Heart Failure Agent 1 an orally available compound suitable for the treatment of heart failure without inducing nausea, vomiting and restlessness.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-hypertensive sulfonanilide 1

Cat. No.: HY-U00301

Anti-hypertensive sulfonanilide 1 is a potent antihypertensive agent extracted from patent EP0338793A2, compound XVIIIa,b*, example No.1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AP 811

Cat. No.: HY-P1419

AP 811 is a selective atrial natriuretic peptide clearance receptor **(APN-CR, NPR3)** antagonist (K_i=0.48 nM). AP 811 displays >20,000-fold selectivity for NPR3 over NPR1. AP 811 abolishes ANP-induced pump stimulation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AP14145 hydrochloride

Cat. No.: HY-120355A

AP14145 hydrochloride is a potent **K_{Ca}2 (SK)** channel negative allosteric modulator with an **IC_{50}** of 1.1 μM for K_{Ca}2.2 (SK2) and K_{Ca}2.3 (SK3) channels. AP14145 hydrochloride inhibition strongly depends on two amino acids, S508 and A533 in the channel.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AP39

Cat. No.: HY-126124

AP39 is a triphenylphosphonium derivatised anethole dithiolethione and mitochondria-targeting hydrogen sulfide (H_2S) donor. AP39 increases intracellular H_2S levels.



Purity: 95.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Apararenone

(MT-3995)

Cat. No.: HY-109002

Apararenone (MT-3995) is a novel non-steroidal **mineralocorticoid receptor** antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.



Purity: 98.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Apelin agonist 1

Cat. No.: HY-126293

Apelin agonist 1 is an oral selective apelin agonist AM-2995, a agonist of the **APJ** (APLNR, angiotensin receptor like-1) receptor, may be used in the treatment of cardiovascular conditions. Apelin agonist 1 is extracted from patent WO 2018097944 (210.0), Example 210.0.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-13

Cat. No.: HY-P1944

Apelin-13 is the endogenous ligand of the orphan G protein-coupled receptor APJ, activates APJ receptor with an EC_{50} value of 0.37 nM in CHO cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-13 TFA

Cat. No.: HY-P1944A

Apelin-13 is the endogenous ligand of the APJ receptor, activating this G protein-coupled receptor with an **EC_{50}** value of 0.37 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Apelin-36(human)

Cat. No.: HY-P1064

Apelin-36(human) is an endogenous orphan G protein-coupled receptor **APJ** agonist, with an EC_{50} of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC_{50}=8.61).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-36(human) TFA

Cat. No.: HY-P1064A

Apelin-36(human) TFA is an endogenous orphan G protein-coupled receptor **APJ** agonist, with an EC_{50} of 20 nM. Apelin-36(human) TFA shows high affinity to human APJ receptors expressed in HEK 293 cells ($pIC5_{50}$=8.61).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-36(rat, mouse)

Cat. No.: HY-P1065

Apelin-36(rat, mouse) is an endogenous orphan G protein-coupled receptor **APJ** agonist.
Apelin-36(rat, mouse) binds to APJ receptors with an IC_{50} of 5.4 nM, and potently inhibits cAMP production with an EC_{50} of 0.52 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-36(rat, mouse) TFA

Cat. No.: HY-P1065A

Apelin-36(rat, mouse) TFA is an endogenous orphan G protein-coupled receptor **APJ** agonist.
Apelin-36(rat, mouse) TFA binds to APJ receptors with an IC_{50} of 5.4 nM, and potently inhibits cAMP production with an EC_{50} of 0.52 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apixaban

(BMS-562247-01)

Cat. No.: HY-50667

Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of **Factor Xa** with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Apixaban 13C,d3

(BMS-562247-01 13C,d3)

Cat. No.: HY-50667S

Apixaban 13CD3 (BMS-562247-01 13CD3) is a deuterium labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of **Factor Xa** with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

APJ receptor agonist 1

Cat. No.: HY-133036

APJ receptor agonist 1, a biphenyl acid derivative, is a potent **APJ receptor (APJ-R)** agonist (EC_{50}s 0.093 and 0.12 nM for human and rat APJ-R, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

APJ receptor agonist 3

Cat. No.: HY-139876

APJ receptor agonist 3 is a potent and orally active **APJ receptor** agonist with an EC_{50} value of 0.027 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

APJ receptor agonist 4

Cat. No.: HY-145284

APJ receptor agonist 4 is a potent and oral active agonist of **apelin receptor** (**APJ**) with EC_{50} and **Ki** of 0.06 nM and 0.07 nM respectively. APJ receptor agonist 4 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aprindine hydrochloride

Cat. No.: HY-A0236A

Aprindine hydrochloride is a class I-b **anti-arrhythmic agent** and a hERG channel blocker with an IC_{50} of 0.23 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aprocitentan

(ACT-132577)

Cat. No.: HY-15895

Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of Macitentan. Aprocitentan is dual **ETA/ETB** antagonist with IC_{50}s of 3.4 nM and 987 nM, and pA_2 valus of 6.7 and 5.5, respectively.



Purity: 98.13%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Aprocitentan D4

(ACT-132577 D4)

Cat. No.: HY-15895S

Aprocitentan D4 (ACT-132577 D4) is a deuterium labeled Aprocitentan. Aprocitentan is a major and pharmacologically active metabolite of Macitentan. Aprocitentan is dual **ETA/ETB** antagonist with IC_{50}s of 3.4 nM and 987 nM, and pA_2 valus of 6.7 and 5.5, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aprotinin

Cat. No.: HY-P0017

Aprotinin is a **bovine pancreatic trypsin inhibitor (BPTI)** inhibitor which inhibits **trypsin** and **chymotrypsin** with K_is of 0.06 pM and 9 nM, respectively.

Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Araloside A

(Chikusetsusaponin IV)

Cat. No.: HY-N2115

Araloside A (Chikusetsusaponin IV) is a component of Panax japonicus, with low-**renin**-inhibitory activity, with an IC_{50} of 77.4 μM.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Aranidipine

(MPC1304)

Cat. No.: HY-U00212

Aranidipine (MPC1304) is a **Ca^{2+} channel** antagonist with potent and long-lasting antihypertensive effects.



Purity: 99.33%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Arborine

Cat. No.: HY-N7004

Arborine inhibits the peripheral action of acetylcholine and induces a fall in blood pressure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Arbutamine

Cat. No.: HY-16056

Arbutamine is a short-acting, potent and nonselective **β-adrenoceptor** agonist that increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine is a catecholamine for a pharmacological cardiac stress agen.



Purity: ≥98.0%
Clinical Data: Launched
Size: 1 mg

Arenobufagin 3-hemisuberate

Cat. No.: HY-N5098

Arenobufagin 3-hemisuberate is a natural compound as a cardiotonic steroid isolated from the skin of Japanese toad.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arg-Gly-Asp-Cys TFA

Cat. No.: HY-P0314A

Arg-Gly-Asp-Cys TFA is the binding motif of fibronectin to cell adhesion molecules. Arg-Gly-Asp-Cys TFA can inhibit platelet aggregation and fibrinogen binding.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Argatroban

(MD-805; MCI-9038; Argipidine)

Cat. No.: HY-B0375

Argatroban (MD-805) is a direct, selective thrombin inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Argatroban monohydrate (MD-805 monohydrate; MCI-9038 monohydrate; Argipidine monohydrate)

Cat. No.: HY-B0375A

Argatroban (monohydrate) (MD-805 (monohydrate)) is a direct, selective thrombin inhibitor.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ARL67156 trisodium salt

Cat. No.: HY-103265

ARL67156 trisodium salt is an inhibitor of **ecto-ATPase**. ARL 67156 trisodium salt is a weak competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

ARL67156 trisodium salt hydrate

Cat. No.: HY-103265B

ARL67156 trisodium salt hydrate is an inhibitor of **ecto-ATPase**. ARL67156 trisodium salt hydrate is a weak competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12μM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arotinolol

Cat. No.: HY-122537A

Arotinolol is a nonselective **α/β-adrenergic receptor** blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand ^{125}I-ICYP to **5HT$_{1B}$**-serotonergic receptor sites.



Purity: 98.23%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Arrhythmias-Targeting Compound 1

Cat. No.: HY-101750

Arrhythmias-Targeting Compound 1 is used in the research of arrhythmias, extracted from patent WO 2001028992 A2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arrhythmic-Targeting Compound 1

Cat. No.: HY-U00393

Arrhythmic-Targeting Compound 1 is used for the research of arrhythmic disease, with nitrogen-containing spirocycles.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS8351 (NSC51355)

Cat. No.: HY-100744

AS8351 (NSC51355) is a **KDM5B** inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Asiaticoside

Cat. No.: HY-N0439

Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses **TGF-β/Smad** signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Aspartic acid calcium (Calcium L-aspartate)

Cat. No.: HY-N0666B

Aspartic acid calcium (Calcium L-aspartate) is a chelate where calcium is attached to an amino acid naming L-Aspartic acid. L-Aspartic acid is an amino acid and serves as a building block for proteins in the body.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Asperosaponin VI

Cat. No.: HY-N0265

Asperosaponin VI, A saponin component from Dipsacus asper wall, induces osteoblast differentiation through BMP2/p38 and ERK1/2 pathway.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Astaxanthin

Cat. No.: HY-B2163

Astaxanthin, a red dietary carotenoid isolated from Haematococcus pluvialis, is a modulator of **PPARγ** and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity.



Purity: ≥98.0%
Clinical Data: Launched
Size: 5 mg, 10 mg

Asundexian

(BAY-2433334)

Cat. No.: HY-137431

Asundexian (BAY 2433334) is an orally active **coagulation factor Xia (FXIa)** inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC_{50} of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Asymmetric dimethylarginine

Cat. No.: HY-113216

Asymmetric dimethylarginine is an endogenous inhibitor of **nitric oxide synthase (NOS)**, and functions as a marker of endothelial dysfunction in a number of pathological states.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

AT2 receptor agonist C21

Cat. No.: HY-100113

AT2 receptor agonist C21 is a druglike selective **angiotensin II AT2 receptor** agonist with K_i values of 0.4 nM and >10 μM for the AT2 receptor and AT1 receptor, respectively.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ataciguat

(HMR-1766)

Cat. No.: HY-17500

Ataciguat (HMR-1766) is a nitric oxide-independent **soluble guanylate cyclase (sGC)** activator. Ataciguat is able to activate the ferric heme-iron redox form of sGC that stimulate the production of cyclic GMP (cGMP). Ataciguat exhibits vasodilator effects.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Atopaxar

(E5555; ER-172594-00)

Cat. No.: HY-18200

Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor **protease-activated receptor-1 (PAR-1)** antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Atopaxar hydrobromide

(E5555 hydrobromide; ER 172594-06)

Cat. No.: HY-18200B

Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor **protease-activated receptor-1 (PAR-1)** antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atorvastatin acetonide

Cat. No.: HY-135379

Atorvastatin acetonide is an impurity of Atorvastatin, and extracted from patent WO2011131605A1, Compound 4. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atorvastatin acetonide tert-butyl ester

Cat. No.: HY-135380

Atorvastatin acetonide tert-butyl ester is a useful pharmaceutical intermediate in the preparation of Atorvastatin salts. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ATP synthase inhibitor 1

Cat. No.: HY-112715

ATP synthase inhibitor 1 is a potent inhibitor of **c subunit of the F_1/F_O-ATP synthase** complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Atpenin A5

Cat. No.: HY-126653

Atpenin A5 is a potent and highly specific **complex II** inhibitor (IC_{50} ~10 nM), and is an effective **mK_{ATP} channel** agonist and cardioprotective agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Atractyloside potassium salt

Cat. No.: HY-N1462

Atractyloside potassium salt is a toxic diterpenoid glycoside that can be isolated from the fruits of Xanthium sibiricum.
Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial **ADP/ATP transport**.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 μg, 1 mg, 5 mg, 10 mg

Atrasentan

(ABT-627; (+)-A 127722; A-147627)

Cat. No.: HY-15403

Atrasentan (ABT-627) is an **endothelin receptor** antagonist with IC_{50} of 0.0551 nM for ET_A.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Atrasentan hydrochloride (ABT-627 hydrochloride; (+)-A 127722 hydrochloride; A-147627 hydrochloride)

Cat. No.: HY-15403A

Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective **endothelin A receptor** antagonist with an IC_{50} of 0.0551 nM for ET_A.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Atreleuton

(ABT-761; VIA-2291)

Cat. No.: HY-117853

Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable **5-Lipoxygenase (5-LO)** inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Atrial natriuretic factor (1-28) (human, porcine)

(Atrial natriuretic peptide (1-28))

Cat. No.: HY-P2281

Atrial natriuretic factor (1-28) (human, porcine) is a potent suppressor of pro-opiomelanocortin **(POMC) mRNA** but a weak inhibitor of βEP-LI release.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled

Cat. No.: HY-P2491

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, one of three mammalian natriuretic peptides (NPs), has endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide has the potential for cardiovascular diseases research.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate

Cat. No.: HY-P1235A

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. ANP (1-28) inhibits **endothelin-1** secretion in a dose-dependent way.



Purity: 96.81%
Clinical Data: Launched
Size: 500 μg, 1 mg, 5 mg

Atrial Natriuretic Peptide (ANP) (1-28), rat

(Atrial natriuretic factor (1-28) (rat))

Cat. No.: HY-P1236

Atrial Natriuretic Peptide (ANP) (1-28), rat is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated **endothelin-1** secretion in a concentration-dependent manner.

Purity: 95.52%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Atrial Natriuretic Peptide (ANP) (1-28), rat TFA

(Atrial natriuretic factor (1-28) (rat) TFA)

Cat. No.: HY-P1236A

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated **endothelin-1** secretion in a concentration-dependent manner.

Purity: 98.74%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Atuliflapon
(AZD5718)

Cat. No.: HY-122908

Atuliflapon (AZD5718) is an orally active inhibitor of **FLAP (5Lipoxygenase activating protein)**, with an IC_{50} of 2 nM. Atuliflapon is used in the study for coronary artery disease.



Purity: 98.14%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ATWLPPR Peptide TFA

Cat. No.: HY-P1663A

ATWLPPR Peptide TFA, a heptapeptide, acts as a selective **neuropilin-1** inhibitor, inhibits $VEGF_{165}$ binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 1 mg

Aurantio-obtusin

Cat. No.: HY-N0261

Aurantio-obtusin is an anthraquinone isolated from Semen Cassiae, with anti-Inflammatory, anti-oxidative, anti-coagulating and anti-hypertension activities.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Avanafil
(TA1790)

Cat. No.: HY-18252

Avanafil(TA-1790) is a potent and highly selective phosphodiesterase-5(PDE-5) inhibitor(IC50=5.2 nM) for erectile dysfunction; lower selectivity against PDE1, PDE6, and PDE11.



Purity: 98.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Avatrombopag hydrochloride (AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride)

Cat. No.: HY-13463B

Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide **thrombopoietin (TPO) receptor** agonist (EC_{50}=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO.



Purity: 98.53%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AVE 0991

Cat. No.: HY-15778

AVE 0991 is a nonpeptide and orally active **angiotensin-(1-7) receptor** agonist with an IC_{50} of 21 nM.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AVE 0991 sodium salt

Cat. No.: HY-15778A

AVE 0991 sodium salt is a nonpeptide and orally active **Ang-(1-7) receptor Mas** agonist. AVE 0991 competes for high-affinity binding of [^{125}I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC_{50} of 21 nM.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AVE3085

Cat. No.: HY-19504

AVE3085 is a potent endothelial **nitric oxide synthase** enhancer, used for cardiovascular disease treatment.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Avosentan
(Ro 67-0565; SPP-301)

Cat. No.: HY-15195

Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist. IC50 value: Target: ETA receptor.



Purity: 98.36%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZD1283

Cat. No.: HY-15799

AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD2906

Cat. No.: HY-113854

AZD2906 is a selective **glucocorticoid receptor (GR)** agonist, increases micronucleated immature erythrocytes in the bone marrow of rats. AZD2906 shows **IC_{50}**s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD4694

(NAV4694)

Cat. No.: HY-113938

AZD4694 (NAV4694), a fluorinated β-amyloid (Aβ) plaque neuroimaging PET radioligand, shows high affinity for **Aβ fibrils** (K_d = 2.3 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD9977

Cat. No.: HY-120274

AZD9977 is a potent, selective, and orally active **mineralocorticoid receptor (MR)** modulator. AZD9977 is used for heart failure, and chronic kidney disease research.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Azelnidipine

(CS 905)

Cat. No.: HY-B0023

Azelnidipine(CS 905; Calblock) is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Azelnidipine-d7

(CS-905-d7)

Cat. No.: HY-B0023S

Azelnidipine D7 is deuterium labeled Azelnidipine, which is a L-type calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azepexole dihydrochloride

(B-HT 933 dihydrochloride; Oxazoloazepin dihydrochloride)

Cat. No.: HY-103212

Azepexole (B-HT 933) dihydrochloride is a potent and selective **alpha 2-adrenoceptor** agonist with **pK_i**s of 8.3, 7.6, and 7.5 for α2A-, α2B- and α2C-adrenoceptor subtypes, resepctively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azilsartan

(TAK-536)

Cat. No.: HY-14914

Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC50 of 2.6 nM.



Purity: 99.09%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Azilsartan medoxomil

(TAK-491)

Cat. No.: HY-14736

Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.



Purity: 99.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Azilsartan medoxomil monopotassium

(Azilsartan kamedoxomil; TAK 491 monopotassium)

Cat. No.: HY-17458

Azilsartan medoxomil monopotassium is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Azimilide

(NE-10064)

Cat. No.: HY-18600

Azimilide(NE-10064) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Azimilide Dihydrochloride

(NE-10064 Dihydrochloride)

Cat. No.: HY-18600A

Azimilide Dihydrochloride (NE-10064 Dihydrochloride) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.



Purity: 98.02%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

BAPTA-AM

Cat. No.: HY-100545

BAPTA-AM is a well-known membrane permeable **Ca^{2+} chelator**. BAPTA-AM inhibits **hERG** channels, **hKv1.3** and **hKv1.5** channels in HEK 293 cells with **IC_{50}**s of 1.3 μM, 1.45 μM and 1.23 μM, respectively.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BAR501

Cat. No.: HY-101274

BAR501 is a potent and selective agonist of **GPBAR1** with an **EC_{50}** of 1 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Barnidipine

(Mepirodipine; YM-09730-5(Free base))

Cat. No.: HY-107322A

Barnidipine (Mepirodipine) is an L-type calcium antagonist (**CaA**) with high affinity for [^{3}H] initrendipine binding sites (**K_i**=0.21 nmol/l), has selective action against CaA receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Barnidipine hydrochloride

(Mepirodipine hydrochloride; YM-09730-5)

Cat. No.: HY-107322

Barnidipine hydrochloride (Mepirodipine hydrochloride) is an L-type calcium antagonist (**CaA**) with high affinity for [^{3}H] initrendipine binding sites (**K_i**=0.21 nmol/l), has selective action against CaA receptors.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

BAY 41-8543

Cat. No.: HY-W062836

BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of **soluble guanylyl cyclase (sGC)**. BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BAY 60-2770

Cat. No.: HY-113926

BAY 60-2770 is a potent, selective, and orally active **soluble guanylyl cyclase (sGC)** activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BAY 60-6583

Cat. No.: HY-103171

BAY 60-6583 is a potent and high-affinity agonist of **adenosine A_{2B}** receptor (**EC_{50}** = 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with **K_i** values of 750 nM, 340 nM and 330 nM, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY 73-1449

Cat. No.: HY-118941

BAY 73-1449 is a selective antagonist of **prostacyclin receptor (IP)**, with high potency (**IC_{50}** of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BBS-4

Cat. No.: HY-12124

BBS-4 is a potent and selective inducible **nitric oxide synthase (NOS2)** dimerization inhibitor, with an **IC_{50}** of 0.49 nM. BBS-4 can protect mice from the cardiovascular dysfunction of sepsis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Beauvericin

Cat. No.: HY-N6739

Beauvericin is a Fusarium mycotoxin. Beauvericin inhibits acyl-CoA: cholesterol acyltransferase (**ACAT**) activity with an IC_{50} of 3 μM in an enzyme assay using rat liver microsomes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BeKm-1

Cat. No.: HY-P1440

BeKm-1 is a HERG (human ether-a-go-go-related gene) blocking compound. BeKm-1 can be used for the research of heart disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benazepril

Cat. No.: HY-B0093

Benazepril, an angiotensin converting enzyme inhibitor, which is a medication used to treat high blood pressure.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Benazepril hydrochloride

(CGS14824A)

Cat. No.: HY-B0093A

Benazepril hydrochloride, an angiotensin converting enzyme inhibitor, which is a medication used to treat high blood pressure.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Bendazol

Cat. No.: HY-B2141

Bendazol is a hypotensive drug which can also enhance **NO synthase** activity in renal glomeruli and collecting tubules.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Benfluorex hydrochloride

(JP-992 hydrochloride)

Cat. No.: HY-B1058

Benfluorex hydrochloride (JP-992 hydrochloride) is a **hepatic nuclear factor 4 alpha** (**HNF4α**) activator.



Purity: 99.63%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Benidipine hydrochloride

(KW-3049)

Cat. No.: HY-B1448

Benidipine hydrochloride is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension).



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Benzcyclane

(Bencyclane; Benzcyclan)

Cat. No.: HY-U00134

Benzcyclane (Bencyclane; Benzcyclan) is a platelet aggregation inhibitor and a vasodilator effective in a variety of peripheral circulation disorders.



Purity: 99.39%
Clinical Data: Launched
Size: 1 mg, 5 mg

Benzofurodil

(Benfurodil; CB4091; Eudilat)

Cat. No.: HY-U00209

Benzofurodil is a cardiotonic, which is used for the chronic treatment of congestive heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benzoylpaeoniflorin

Cat. No.: HY-N0852

Benzoylpaeoniflorin, a natural product from Chinese paeony root, has the potential for coronary heart disease by decreasing apoptosis.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Benzthiazide

Cat. No.: HY-B1424

Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of **carbonic anhydrase 9 (CA9)**, with K_is of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

Bepridil hydrochloride

(CERM 1978)

Cat. No.: HY-103315

Bepridil hydrochloride (CERM 1978) is a **calcium channel** blocker, with antianginal activity.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate; Org 5730 hydrochloride hydrate)

Cat. No.: HY-16952A

Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting **Ca^+ channel** antagonist and **Na^+**, **K^+** channel inhibitor, with antianginal and type I antiarrhythmic effects.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Beraprost sodium

Cat. No.: HY-13569A

Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of **PGI2**. Beraprost sodium is a potent **vasodilator**, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation.



Purity: 99.88%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Beta-Sitosterol (purity>75%) (β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%))

Cat. No.: HY-N0171B

Beta-Sitosterol (purity>75%) includes 75% β-sitosterol and 10% campesterol. Beta-Sitosterol is a plant sterol.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Beta-Sitosterol (purity>80%) (β-Sitosterol (purity>80%); 22,23-Dihydrostigmasterol (purity>80%))

Cat. No.: HY-N0171

Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 1 g, 5 g

Beta-Sitosterol (purity>98%) (β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%))

Cat. No.: HY-N0171A

Beta-Sitosterol (purity>98%) is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Betaxolol

Cat. No.: HY-B0381

Betaxolol is a selective **beta1 adrenergic receptor** blocker that can be used for the research of hypertension and glaucoma.



Purity: 95.06%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Betaxolol hydrochloride

(SL75212)

Cat. No.: HY-B0381A

Betaxolol Hydrochloride is a selective **beta1 adrenergic receptor** blocker that can be used for the research of hypertension and glaucoma.



Purity: 98.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Betrixaban

(PRT054021)

Cat. No.: HY-10268

Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious **factor Xa** (fXa) inhibitor with IC_{50} of 1.5 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Betrixaban-d6

Cat. No.: HY-10268S

Betrixaban D6 is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious **factor Xa (fXa)** inhibitor.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 1 mg

Bezafibrate

(BM15075)

Cat. No.: HY-B0637

Bezafibrate is an agonist of **PPAR**, with EC_{50}s of 50 μM, 60 μM, 20 μM for **human PPARα**, **PPARγ** and **PPARδ**, and 90 μM, 55 μM, 110 μM for **murine PPARα**, **PPARγ** and **PPARδ**, respectively; Bezafibrate is used as an hypolipidemic agent.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

BGP-15

Cat. No.: HY-100828

BGP-15 is a **PARP** inhibitor, with an IC_{50} and a K_i of 120 and 57 μM, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BI-1935

Cat. No.: HY-124063

BI-1935 is a potent **soluble epoxide hydrolase (sEH)** inhibitor for diseases related to cardiovascular disease.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-749327

Cat. No.: HY-111925

BI-749327 is a potent, high selectivity and orally bioavailable **TRPC6** antagonist, with IC_{50}s of 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6, respectively. BI-749327 is 85-fold more selective for mouse TRPC6 than TRPC3 and 42-fold versus TRPC7.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-9627

Cat. No.: HY-18071

BI-9627 is potent sodium-hydrogen exchanger isoform 1 **(NHE1)** inhibitor, with IC_{50}s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

BI-9627 hydrochloride

Cat. No.: HY-18071A

BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIBS 39

Cat. No.: HY-19732

BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Bidisomide

(SC40230)

Cat. No.: HY-U00232

Bidisomide (SC40230) is a class I antiarrhythmic agent.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Big Endothelin-1 (1-38), human

Cat. No.: HY-P2538

Big Endothelin-1 (1-38), human is the precursor of endothelin-1. Endothelin-1 (ET-1) is a potent vasopressor peptide.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Big Endothelin-1 (1-39), porcine

Cat. No.: HY-P2539

Big Endothelin-1 (1-39), porcine is the precursor of endothelin-1. Endothelin-1 (ET-1) is a potent vasopressor peptide. Big Endothelin-1 (1-39), porcine has similar pressor effects in vivo.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bimoclomol

Cat. No.: HY-U00398

Bimoclomol is a **heat shock protein (HSP)** coinducer, used for treatment of cardiovascular diseases.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Binodenoson

(MRE-0470; WRC 0470)

Cat. No.: HY-106450

Binodenoson (MRE-0470) is a potent and selective **A2A adenosine receptor** agonist (K_D=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Bisindolylmaleimide X hydrochloride

(BIM-X hydrochloride; Ro31-8425 hydrochloride)

Cat. No.: HY-108136A

Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective **protein kinase C (PKC)** inhibitor. Bisindolylmaleimide X hydrochloride is a potent **cyclin-dependent kinase 2 (CDK2)** antagonist with an IC_{50} of 200 nM.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Bisoprolol

Cat. No.: HY-129029

Bisoprolol is a potent, selective and orally active **β1-adrenergic receptor** blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Bivalirudin

Cat. No.: HY-P1929

Bivalirudin, a peptide anticoagulant, is a direct **thrombin** inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Bivalirudin TFA

Cat. No.: HY-15664

Bivalirudin TFA is a synthetic 20 residue peptide which reversibly inhibits thrombin.

Purity: 99.89%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

BIX 02565

Cat. No.: HY-16104

BIX 02565 is a potent ribosomal S6 kinase 2 (**RSK2**) inhibitor with IC_{50} of 1.1 nM.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Bixin

Cat. No.: HY-N6884

Bixin (BX), isolated from the seeds of Bixa orellana, is a carotenoid, possessing anti-inflammatory, anti-tumor and anti-oxidant activities.



Purity: 97.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

BML-111

Cat. No.: HY-100450

BML-111, a lipoxin A_4 analog, is a **lipoxin A_4 receptor** agonist. BML-111 represses the activity of **angiotensin converting enzyme (ACE)** and increases the activity of **angiotensinconverting enzyme 2 (ACE2)**. BML-111 has antiangiogenic, antitumor and anti-inflammatory properties.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg

BMS-248360

Cat. No.: HY-114953

BMS-248360 is a potent and orally active dual antagonist of both **angiotensin II receptor (AT1)** and **endothelin A (ET_A) receptor**, with K_is of 10 nM and 1.9 nM for hAT1 and hETA receptor, respectively. BMS-248360 displays hypertensive effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-262084

Cat. No.: HY-118969

BMS-262084 is a potent, selective and irreversible inhibitor of **factor XIa**, with an IC_{50} of 2.8 nM against human factor XIa. BMS-262084 also inhibits human **tryptase** (IC_{50}=5 nM). BMS-262084 exhibits antithrombotic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-309403

Cat. No.: HY-101903

BMS-309403 is a potent, orally active and selective **adipocyte fatty acid binding protein** (also known as FABP4, aP2) inhibitor with K_is of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

BMS-309403 sodium

Cat. No.: HY-101903A

BMS-309403 sodium is a potent, orally active, and selective **adipocyte fatty acid binding protein** (also known as FABP4, aP2) inhibitor, with K_is of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

BMS-654457

Cat. No.: HY-12631

BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (**FXIa**), binding with human and rabbit FXIa with K_is of 0.2 and 0.42 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-687453

Cat. No.: HY-10678

BMS-687453 is a potent and selective **PPARα** agonist, with an EC_{50} and IC_{50} of 10 nM and 260 nM for human **PPARα** and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-690514

Cat. No.: HY-10333

BMS-690514 is a potent and orally active inhibitor of **EGFR** and **VEGFR**; has IC_{50}s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

BMS-795311

Cat. No.: HY-19614

BMS-795311 is a potent and orally bioavailable inhibitor of **cholesteryl ester transfer protein (CETP)**, with IC_{50}s of 4 nM in an enzyme-based scintillation proximity assay (SPA) and 0.22 μM in a human whole plasma assay (hWPA), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-813160

Cat. No.: HY-109593

BMS-813160 is the first dual **CCR2/CCR5** antagonist, has the potential for cardiovascular treatment.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-962212

Cat. No.: HY-117290

BMS-962212 is a direct, reversible, selective **factor XIa (FXIa)** inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

BMS-986224

Cat. No.: HY-139485

BMS-986224 is a potent, selective and orally bioavailable **APJ receptor** agonist (K_d = 0.3 nM). BMS-986224 exhibits similar receptor binding and signaling profile to (Pyr[1]) apelin-13. BMS-986224 has the potential for the research of heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-986235

(LAR-1219)

Cat. No.: HY-131180

BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 **(FPR2)** agonist, with **EC_{50}**s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Boc-Ile-Glu-Gly-Arg-AMC

(IEGR-AMC)

Cat. No.: HY-P2008

Boc-Ile-Glu-Gly-Arg-AMC (IEGR-AMC) is an activated factor X (FXa) specific fluorogenic peptide substrate used for Factor VIII determination.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bometolol Hydrochloride

Cat. No.: HY-U00386

Bometolol Hydrochloride is a **beta-adrenergic** blocking agent, used for the research of cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bopindolol

((±)-Bopindolol)

Cat. No.: HY-B1562

Bopindolol is an orally active antagonist of **β-adrenoceptors (ARs)** with partial agonist activity. Bopindolol is non-selective for β1- and β2-ARs and has low affinity for β3-AR subtype.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bopindolol fumarate

((±)-Bopindolol fumarate)

Cat. No.: HY-B1562C

Bopindolol ((±)-Bopindolol) fumarate is an orally active antagonist of **β-adrenoceptors (ARs)** with partial agonist activity. Bopindolol fumarate is non-selective for β1- and β2-ARs and has low affinity for β3-AR subtype.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bosentan

Cat. No.: HY-A0013

Bosentan is a competitive and dual antagonist of **endothelin-1 (ET)** for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Bosentan (hydrate)

Cat. No.: HY-A0013A

Bosentan hydrate is a competitive and dual antagonist of **endothelin-1 (ET)** for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Bosentan-d4

Cat. No.: HY-115417

Bosentan-d4 is the deuterium labeled Bosentan. Bosentan is a competitive and dual antagonist of **endothelin-1 (ET)** for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

BQ-123

Cat. No.: HY-12378

BQ-123 is a potent and selective **endothelin A (ETA) receptor** antagonist with an **IC_{50}** of 7.3 nM and a K_i of 25 nM. BQ-123 inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension.



Purity: 99.86%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

BQ-123 TFA

Cat. No.: HY-12378A

BQ-123 TFA is a potent and selective **endothelin A (ETA) receptor** antagonist with an IC_{50} of 7.3 nM and a K_i of 25 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BQ-3020 TFA

Cat. No.: HY-P1016A

BQ-3020 (TFA) is a selective agonist of ET_B **receptor**, inhibits [^{125}I]ET-1 binding to ET_B receptor with an IC_{50} of 0.2 nM in cerebellum, and causes vasoconstriction.

Purity: 95.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

BQ-788

Cat. No.: HY-15894A

BQ-788 is a potent, selective **ETB receptor** antagonist with IC_{50} of 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC_{50} of 1300 nM.



Purity: 98.28%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg

BQ-788 sodium salt

Cat. No.: HY-15894

BQ-788 sodium salt is a potent and selective **ETB receptor** antagonist, inhibiting ET-1 binding to ETB receptors with an IC_{50} of 1.2 nM in human Girrardi heart cells.



Purity: 98.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Bradykinin

Cat. No.: HY-P0206

Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.



Purity: 99.92%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bradykinin (1-3)

Cat. No.: HY-P1497

Bradykinin (1-3) is a 3-amino acid residue peptide. Bradykinin (1-3) is an amino-truncated Bradykinin peptide, cleaved by Prolyl endopeptidase.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Bradykinin (1-5)

Cat. No.: HY-P1488

Bradykinin (1-5) is a major stable metabolite of Bradykinin, formed by the proteolytic action of angiotensin-converting enzyme (ACE).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bradykinin (1-6)

Cat. No.: HY-P1469

Bradykinin (1-6) is an amino-truncated Bradykinin peptide. Bradykinin (1-6) is a stable metabolite of Bradykinin, cleaved by carboxypeptidase Y (CPY).



Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Bradykinin (1-7)

(Bradykinin Fragment 1-7)

Cat. No.: HY-P1484

Bradykinin (1-7) is an amino-truncated Bradykinin peptide. Bradykinin (1-7) is a metabolite of Bradykinin, cleaved by endopeptidase.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Bradykinin (2-9)

(Des-Arg1-bradykinin)

Cat. No.: HY-P1490

Bradykinin (2-9) is an amino-truncated Bradykinin peptide. Bradykinin (2-9) is a metabolite of Bradykinin, cleaved by Aminopeptidase P.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Brain Natriuretic Peptide (1-32), rat

(BNP (1-32), rat) Cat. No.: HY-P1519

Brain Natriuretic Peptide (1-32), rat (BNP (1-32), rat) is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes).

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Brain Natriuretic Peptide (1-32), rat acetate

(BNP (1-32), rat acetate) Cat. No.: HY-P1519B

Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes).

Purity: 99.66%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Brain Natriuretic Peptide-45, mouse

(BNP-45, mouse) Cat. No.: HY-P2469

Brain Natriuretic Peptide-45, mouse (BNP-45, mouse) is a circulating form of mouse brain natriuretic peptide isolated from mouse heart with potent hypotensive and natriuretic potency.

Purity: 98.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Brain Natriuretic Peptide-45, rat

(BNP-45, rat) Cat. No.: HY-P1573

Brain Natriuretic Peptide-45, rat (BNP-45, rat) is a circulating form of rat brain natriuretic peptide isolated from rat heart with potent hypotensive and natriuretic potency.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brain Natriuretic Peptide-45, rat TFA

(BNP-45, rat TFA) Cat. No.: HY-P1573A

Brain Natriuretic Peptide-45, rat TFA (BNP-45, rat TFA) is a circulating form of rat brain natriuretic peptide isolated from rat heart with potent hypotensive and natriuretic potency.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD-6929

Cat. No.: HY-100719

BRD-6929 is a potent, selective brain-penetrant inhibitor of class I histone deacetylase **HDAC1** and **HDAC2** inhibitor with **IC_{50}** of 1 nM and 8 nM, respectively.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

BRL 54443

Cat. No.: HY-13221

BRL 54443 is a potent **5-$HT_{1E/1F}$** receptor agonist (K_i values are 1.1 nM and 0.7 nM respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Bromindione

(Fluidane; Halinone) Cat. No.: HY-B0917

Bromindione is a potent, long-acting, inandione-derived, oral anticoagulant compound.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

BTK-IN-5

Cat. No.: HY-115876

BTK-IN-5 is a covalent **BTK** inhibitor for treating medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTZO-1

Cat. No.: HY-110084

BTZO-1 binds to **Macrophage migration inhibitory factor (MIF)** with a K_d value of 68.6 nM, and its binding requires the N-terminal Pro1.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Bucindolol

Cat. No.: HY-103214

Bucindolol is a **β1-adrenergic receptor** blocker, with intrinsic sympathomimetic activity, used in the research of heart failure.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 5 mg

Bufuralol hydrochloride

(Ro 3-4787 hydrochloride)

Cat. No.: HY-105124A

Bufuralol hydrochloride (Ro 3-4787 hydrochloride) is a potent non-selective, orally active **β-adrenoreceptor** antagonist with partial agonist activity. Bufuralol hydrochloride is a CYP2D6 probe substrate.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Bumetanide

(Ro 10-6338; PF 1593)

Cat. No.: HY-17468

Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a **Na^+-K^+-Cl^+ cotransporter (NKCC)** blocker. Bumetanide is a selective **NKCC1** inhibitor, but also inhibits NKCC2, with **IC_{50}**s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Bumetanide-d5

Cat. No.: HY-17468S

Bumetanide D5 is a deuterium labeled Bumetanide. Bumetanide is a selective Na^+-K^+-Cl^- (**NKCC1**) inhibitor, weakly inhibits NKCC2, with **IC_{50}**s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bunaftide

(Bunaftine; Bunaphtide; Meregon)

Cat. No.: HY-U00113

Bunaftide (Bunaftine; Bunaphtide; Meregon) is an antiarrhythmic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Burixafor hydrobromide

(TG-0054 hydrobromide)

Cat. No.: HY-19867A

Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of **CXCR4** and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Butin

Cat. No.: HY-N6020B

Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera, with strong antioxidant, antiplatelet and anti-inflammatory activities.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BW 245C

Cat. No.: HY-101987

BW 245C is a **prostanoid DP-receptor (DP1)** agonist, used to treat stroke.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

BX430

Cat. No.: HY-110237

BX430 is a potent and selective noncompetitive allosteric **human P2X4 receptor channels** antagonist with an **IC_{50}** of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C-Reactive Protein (CRP) (174-185)

Cat. No.: HY-P1823

C-Reactive Protein (CRP) 174-185 is the 174-185 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C-Reactive Protein (CRP) (201-206)

Cat. No.: HY-P1824

C-Reactive Protein (CRP) 201-206 is the 201-206 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C-Reactive Protein (CRP) (77-82)

Cat. No.: HY-P1836

C-Reactive Protein (CRP) 77-82 is the 77-82 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C-Type Natriuretic Peptide (1-53), human

Cat. No.: HY-P1815

C-Type Natriuretic Peptide (1-53), human is the 1-53 fragment of C-Type Natriuretic Peptide. C-Type Natriuretic Peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C-Type Natriuretic Peptide (CNP) (1-22), human

Cat. No.: HY-P1237

C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (**NPR-B**) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

C-Type Natriuretic Peptide (CNP) (1-22), human TFA

Cat. No.: HY-P1237A

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (**NPR-B**) agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

C16-PAF

(PAF (C16))

Cat. No.: HY-108635

C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (**PAFR**). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Calcium channel-modulator-1

Cat. No.: HY-U00135

Calcium channel-modulator-1 is a **calcium channel** modulator; blocks aortic contraction with an IC_{50} of 0.8 µM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Calcium polystyrene sulfonate

(Poly(styrenesulfonic acid) calcium salt)

Cat. No.: HY-107929

Calcium polystyrene sulfonate is an **ion-exchange resin** used for reducing blood levels of potassium. Calcium polystyrene sulfonate is used to treat hyperkalemia in patients with chronic kidney disease (CKD).

Purity: >98%
Clinical Data: Launched
Size: 500 mg, 1 g

Caldaret

(MCC-135)

Cat. No.: HY-100298

Caldaret is an intracellular Ca^{2+} handling modulator that acts through reverse mode Na^+/Ca^{2+} **exchanger** inhibition.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Calmodulin antagonist-1

Cat. No.: HY-115745

Calmodulin antagonist-1 (W-7) is a **calmodulin (CaM)** antagonist. Calmodulin antagonist-1 inhibits calmodulin-activated Ca^{2+}-phosphodiesterase (PDE) (IC_{50}=28 µM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Candesartan

(CV 11974) Cat. No.: HY-B0205

Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM. Target: Angiotensin II Receptor candesartan is indicated for the treatment of hypertension.



Purity: 98.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Candesartan Cilexetil

(TCV-116) Cat. No.: HY-17505

Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Cangrelor tetrasodium

Cat. No.: HY-19638A

Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet **P2Y12** antagonist, with prompt and potent antiplatelet effects.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Canrenoate potassium

(Aldadiene potassium; SC-14266) Cat. No.: HY-B1582A

Canrenoate (Aldadiene) potassium, a prodrug that releases canrenone, is a potent, competitive **mineralocorticoid receptor (aldosterone receptor)** antagonist. Potassium canrenoate, as a diuretic, is used for the research of hypertension.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Canrenone

(Aldadiene; SC9376) Cat. No.: HY-B1438

Canrenone (Aldadiene) is an **aldosterone** antagonist extensively used as a diuretic agent.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Capadenoson

(BAY 68-4986) Cat. No.: HY-14917

Capadenoson is a selective agonist of **adenosine-A1 receptor**.



Purity: 99.28%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Captopril

(SQ 14225) Cat. No.: HY-B0368

Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme **(ACE)** inhibitor (IC_{50}=0.025 μM) and has been widely used for research of hypertension and congestive heart failure.



Purity: 99.05%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Carbacyclin

(Carbaprostacyclin; Carba-PGI2) Cat. No.: HY-112322

Carbacyclin is a PGI2 analogue, acts as a **prostacyclin (PGI2) receptor** agonist and vasodilator, and potently inhibits platelet aggregation.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Carbazochrome

Cat. No.: HY-B1587

Carbazochrome is a capillary stabiliser and used for the research of haemorrhage. Carbazochrome is an antihemorrhagic agent.



Purity: 99.19%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg

Carbazochrome sodium sulfonate

(AC-17) Cat. No.: HY-B0491A

Carbazochrome sodium sulfonate (AC-17) is a capillary stabiliser and used for the research of haemorrhage. Carbazochrome sodium sulfonate is an antihemorrhagic agent.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Carboxy-PTIO

Cat. No.: HY-18734

Carboxy-PTIO is a potent **nitric oxide (NO)** scavenger that can make a quick reaction with NO to produce NO_2. Carboxy-PTIO can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Carboxy-PTIO potassium

Cat. No.: HY-18734A

Carboxy-PTIO potassium is a potent **nitric oxide (NO)** scavenger that can make a quick reaction with NO to produce NO_2. Carboxy-PTIO potassium can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Carboxyebselen

(HOOC-Ebs)

Cat. No.: HY-139448

Carboxyebselen (HOOC-Ebs) is a potent and selective inhibitor of endothelial nitric oxide synthase **(eNOS)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cardiogenol C hydrochloride

Cat. No.: HY-12319A

Cardiogenol C hydrochloride is a potent cell-permeable pyrimidine inducer which prompts the **differentiation of ESCs into cardiomyocytes** (EC_{50}=100 nM).



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cardiotoxin Analog (CTX) IV (6-12)

Cat. No.: HY-P1902

Cardiotoxin Analog (CTX) IV (6-12) is a part peptide of Cardiotoxin Analog (CTX) IV. Cardiotoxin analogues IV isolated from the venom of Taiwan Cobra. CTX IV is an unique snake venom cardiotoxin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cariporide

(HOE-642)

Cat. No.: HY-19693

Cariporide (HOE-642) is a selective Na^+/H^+ exchange inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Carmoxirole hydrochloride

(EMD 45609 hydrochloride)

Cat. No.: HY-103410

Carmoxirole hydrochloride (EMD 45609 hydrochloride) is a selective, peripherally acting **dopamine D2 receptor** agonist and exhibits antihypertensive activities in vivo.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Carpaine

Cat. No.: HY-N7016

Carpaine is an alkaloid isolated from Carica papaya Linn with **anti-thrombocytopenic** activity, exhibits potent activity in sustaining platelet counts with no acute toxicity. Carpaine has **anti-plasmodial** activity to prevent malaria.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Carpaine hydrochloride

Cat. No.: HY-N7016A

Carpaine hydrochloride is an alkaloid isolated from Carica papaya Linn anti-thrombocytopenic activity, exhibits potent activity in sustaining platelet counts with no acute toxicity. Carpaine hydrochloride has anti-plasmodial activity to prevent malaria.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Carperitide

(Atrial Natriuretic Peptide (ANP) (1-28), human, porcine)

Cat. No.: HY-P1235

Carperitide (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine) is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Carteolol hydrochloride

(OPC-1085 hydrochloride) Cat. No.: HY-17495A

Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Carvedilol

(BM 14190) Cat. No.: HY-B0006

Carvedilol (BM 14190) is a non-selective **β/α-1** blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC_{50} of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Carvedilol metabolite 4-Hydroxyphenyl Carvedilol

(4-Hydroxyphenyl Carvedilol; 4-Hydroxycarvedilol) Cat. No.: HY-12767

4-Hydroxyphenyl Carvedilol is a metabolite of Carvedilol, which is a nonselective beta blocker/alpha-1 blocker.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Carvedilol phosphate hemihydrate

(BM 14190 phosphate hemihydrate) Cat. No.: HY-B0006A

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective **β/α-1** blocker. Carvedilol phosphate hemihydrate inhibits **lipid peroxidation** with an IC_{50} of 5 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Catestatin

Cat. No.: HY-P1271

Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin is an endogenous peptide that regulates cardiac function and blood pressure.

RSMRLSFRARGYGFRGPGLQL

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Catestatin TFA

Cat. No.: HY-P1271A

Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure.

RSMRLSFRARGYGFRGPGLQL (TFA salt)

Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Catharanthine

((+)-3,4-Didehydrocoronaridine) Cat. No.: HY-N0252

Catharanthine is an alkaloid isolated from Madagascar periwinkle, inhibits **voltage-operated L-type Ca^{2+} channel**, with anti-cancer and blood pressure-lowering activity.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Catharanthine Sulfate

((+)-3,4-Didehydrocoronaridine Sulfate) Cat. No.: HY-N0252B

Catharanthine Sulfate ((+)-3,4-Didehydrocoronaridine Sulfate) is an alkaloid isolated from Madagascar periwinkle, inhibits **voltage-operated L-type Ca^{2+} channel**, with anti-cancer and blood pressure-lowering activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Catharanthine Tartrate

((+)-3,4-Didehydrocoronaridine Tartrate) Cat. No.: HY-N0252A

Catharanthine Tartrate is an alkaloid isolated from Madagascar periwinkle, inhibits **voltage-operated L-type Ca^{2+} channel**, with anti-cancer and blood pressure-lowering activity.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CAY 10465

Cat. No.: HY-112627

CAY 10465 is a selective and high-affinity **AhR** agonist, with a K_i of 0.2 nM, and shows no effect on estrogen receptor (K_i >100000 nM).



Purity: 99.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CB-7921220

Cat. No.: HY-101862

CB-7921220 is an **adenylate cyclase** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

CB1 antagonist 1

Cat. No.: HY-U00397

CB1 antagonist 1 is an antagonist of **CB1 receptor**, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCG-100602

Cat. No.: HY-120855

CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (**MRTF-A/SRF**) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

CCG258208

(GRKs-IN-1)

Cat. No.: HY-109562

GRKs-IN-1, Compound 14as, has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 **GRK2** (IC_{50}=30 nM) and **GRK5** (IC_{50}=7.1 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCG258208 hydrochloride

(GRK2-IN-1 hydrochloride)

Cat. No.: HY-109562A

GRKs-IN-1 hydrochloride, Compound 14as, has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 **GRK2** (IC_{50}=130 nM) and **GRK5** (IC_{50}=7.1 μM).



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CE-245677

Cat. No.: HY-112423

CE-245677 is a potent reversible inhibitor of **Tie2** and **TrkA/B** kinases with a cellular IC_{50}s of 4.7 and 1 nM.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CE3F4

Cat. No.: HY-108539

CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (**Epac1**), with IC_{50}s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cefminox sodium

(MT-141)

Cat. No.: HY-128932

Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits a broad spectrum of **antibacterial** activity.



Purity: 99.83%
Clinical Data: Launched
Size: 25 mg

Celiprolol hydrochloride

Cat. No.: HY-B1264

Celiprolol hydrochloride is a potent, selective and orally active antagonist of **β1-andrenoceptor** with partial **β2** agonist activity, therefore it is a selective adrenoreceptor modulator (SAM). Celiprolol hydrochloride demonstrates antihypertensive and antianginal activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Centhaquin

(Centhaquine; PMZ-2010)

Cat. No.: HY-106690

Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of **haemorrhagic shock**. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models.



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cerivastatin

Cat. No.: HY-129458

Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active **HMG-CoA reductase** inhibitor, with a **Ki** of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cerivastatin sodium

Cat. No.: HY-109523

Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active **HMG-CoA reductase** inhibitor, with a **Ki** of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ceruletide

(Caerulein; Cerulein; FI-6934)

Cat. No.: HY-A0190

Ceruletide is a decapeptide and a potent **cholecystokinin receptor** agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 100 µg, 500 µg x 2, 500 µg

Cesium chloride

Cat. No.: HY-107754

Cesium chloride is a blocker of **potassium channel**. Cesium chloride prevents the decrease of Na^+ transport produced by Alloxan. Cesium chloride has induced cardiac arrhythmias, including torsade de pointes in animal models.

CsCl

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cetaben

Cat. No.: HY-119964

Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic drug and potently reduces the concentration of cholesterol and triglycerides.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CETP-IN-3

Cat. No.: HY-128338

CETP-IN-3 (Compound 13) is an small molecule inhibitor of the plasma glycoprotein cholesterol ester transfer protein (**CETP**), elevating HDL-C through inhibition of CETP.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGP 20712 A

(CGP 20712 mesylate)

Cat. No.: HY-101355B

CGP 20712 A (CGP 20712 mesylate) is a highly selective <B>β1-adrenoceptor</B> antagonist with an IC_{50} of 0.7 nM. CGP 20712 A exhibits ~10,000-fold selectivity over β2-adrenoceptors.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CGP48369

Cat. No.: HY-101706

CGP48369 is a nonpeptidic **angiotensin II receptor** antagonist, used for anti-hypertensive research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGRP antagonist 1

Cat. No.: HY-112262

CGRP antagonist 1 is a highly potent **CGRP receptor** antagonist with a K_i and IC_{50} of 35 and 57 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chitoheptaose heptahydrochloride

Cat. No.: HY-N7697D

Chitoheptaose heptahydrochloride is a chitosan oligosaccharide with antioxidant, anti-inflammatory, antiapoptotic and cardioprotective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Chlorindione

(Chlophenadione; Indaliton; G-25766)

Cat. No.: HY-B0918

Chlorindione (Chlophenadione) is a potent anticoagulant. Chlorindione also is a vitamin K1 antagonist.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Chlorothiazide

Cat. No.: HY-B0224

Chlorothiazide is a diuretic and antihypertensive. (IC50=3.8 mM) Target: Others Chlorothiazide sodium (Diuril) is a diuretic used within the hospital setting or for personal use to manage excess fluid associated with congestive heart failure. It is also used as an antihypertensive.



Purity: 98.06%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Chlorotrianisene

Cat. No.: HY-B2158

Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active **estrogen receptor** modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme **COX-1** and inhibits platelet aggregation in whole blood.



Purity: 99.24%
Clinical Data: Launched
Size: 5 mg, 10 mg

Chlorthalidone

Cat. No.: HY-15833

Chlorthalidone is a thiazide-like diuretic used to treat hypertension.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Chlorthalidone-D4

Cat. No.: HY-15833S

Chlorthalidone-D4 is the deuterium labeled Chlorthalidone. Chlorthalidone is a thiazide-like diuretic used to treat hypertension.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cholestyramine

(Cholestyramine resin; Colestyramine)

Cat. No.: HY-104081

Cholestyramine (Colestyramine) is a bile acid binding resin and can inhibit intestinal bile acid absorption which results in the increasing bile acid synthesis from cholesterol.



Purity: >98%
Clinical Data: Launched
Size: 500 mg, 1 g

Choline Fenofibrate

(ABT-335)

Cat. No.: HY-14739

Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a **PPAR** activator with antihyperlipidemic effect.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 100 mg

CHPG

Cat. No.: HY-101364

CHPG is a selective **mGluR5** agonist, and attenuates SO_2-induced oxidative stress and inflammation through **TSG-6/NF-κB** pathway in BV2 microglial cells.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

Chroman 1

Cat. No.: HY-15392

Chroman 1 is a highly potent and selective **ROCK** inhibitor. Chroman 1 is more potent against ROCK2 (IC_{50}=1 pM) than ROCK1 (IC_{50}=52 pM). Chroman 1 also has inhibitory activity against **MRCK**, with an IC_{50} of 150 nM.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Chroman 1 dihydrochloride

Cat. No.: HY-15392A

Chroman 1 dihydrochloride is a highly potent and selective **ROCK** inhibitor. Chroman 1 dihydrochloride is more potent against ROCK2 (IC_{50}=1 pM) than ROCK1 (IC_{50}=52 pM). Chroman 1 dihydrochloride also has inhibitory activity against **MRCK**, with an IC_{50} of 150 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chromocarb

(Chromone-2-carboxylic acid) Cat. No.: HY-B1182

Chromocarb is a synthetic vasoprotectant.



Purity: 99.06%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Cicloprolol hydrochloride

Cat. No.: HY-U00066

Cicloprolol is a partial **β 1-adrenoceptor** agonist .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cilazapril

(Ro 31-2848) Cat. No.: HY-A0043

Cilazapril is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Cilazapril monohydrate

(Ro 31-2848 monohydrate) Cat. No.: HY-A0043A

Cilazapril Monohydrate is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure. Target: ACE Cilazapril is a new nonthiol group containing angiotensin converting enzyme (ACE) inhibitor.



Purity: 99.44%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cilnidipine

(FRC-8653) Cat. No.: HY-17404

Cilnidipine is a long-acting, second-generation dihydropyridine **Ca^{2+}-channel** blocker on L and N-type Ca^{2+} channel. Antihypertensive effects.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cilobradine hydrochloride

(DK-AH 269) Cat. No.: HY-18940A

Cilobradine is an HCN Channel blocker; an open channel blocker of neuronal Ih and related cardiac If channels. Target: HCN Channel blocker Cilobradine is a HCN channel blocker that is about 3 times more potent than ZD7288.



Purity: 98.33%
Clinical Data: Phase 1
Size: 1 mg

Cilostamide

(OPC3689) Cat. No.: HY-101312

Cilostamide is a selective and potent **PDE3** inhibitor, with **IC_{50}**s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cilostazol

(OPC 13013) Cat. No.: HY-17464

Cilostazol (OPC 13013) is a potent and selective inhibitor of **phosphodiesterase (PDE) 3A**, the isoform of PDE 3 in the cardiovascular system, with an **IC_{50}** of 0.2 μM.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Cimbuterol-D9

Cat. No.: HY-131105S

Cimbuterol-D9 is the deuterium labeled Cimbuterol. Cimbuterol is aβ-adrenergic agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cimlanod

(BMS-986231; CXL-1427) Cat. No.: HY-118643

Cimlanod (BMS-986231) is a second-generation **Nitroxyl (HNO)** donor for heart failure. Cimlanod (BMS-986231) delivers HNO via pH-dependent chemical breakdown when exposed to the neutral pH environment of the bloodstream.



Purity: 98.54%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cinacalcet

(AMG 073) Cat. No.: HY-70037

Cinacalcet (AMG 073) is an orally active, allosteric agonist of **Ca receptor (CaR)**, used for cardiovascular disease treatment.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cinacalcet hydrochloride

(AMG-073 hydrochloride) Cat. No.: HY-70037A

Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of **Ca receptor (CaR)**, used for cardiovascular disease treatment.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cinacalcet metabolite M4

Cat. No.: HY-135601

Cinacalcet metabolite M4 is a metabolite of Cinacalcet. Cinacalcet is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Cinacalcet-D3

(AMG 073-D3) Cat. No.: HY-70037S

Cinacalcet-D3 (AMG 073-D3) is the deuterium labeled Cinacalcet. Cinacalcet (AMG 073) is an orally active, allosteric agonist of **Ca receptor (CaR)**, used for cardiovascular disease treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cinacalcet-d3 hydrochloride

(AMG 073-d3 hydrochloride) Cat. No.: HY-70037AS

Cinacalcet-D3 (AMG 073-D3) hydrochloride is the deuterium labeled Cinacalcet (hydrochloride). Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of **Ca receptor (CaR)**, used for cardiovascular disease treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cinaciguat

(BAY 58-2667) Cat. No.: HY-14181

Cinaciguat is an activator of **guanylate cyclase (sGC)**, and used for acute decompensated heart failure.



Purity: 99.20%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Cinaciguat hydrochloride

(BAY 58-2667 hydrochloride) Cat. No.: HY-14181A

Cinaciguat hydrochloride is a potent soluble **guanylate cyclase** (**GC**) activator with EC_{50} of 15 nM in platelets.



Purity: 99.64%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Cinchonine monohydrochloride hydrate ((8R,9S)-Cinchonine monohydrochloride hydrate; ...)

Cat. No.: HY-Y0152A

Cinchonine ((8R,9S)-Cinchonine) monohydrochloride hydrate is a natural compound which has been effectively used as **antimalarial** agent. Cinchonine monohydrochloride hydrate activates endoplasmic reticulum stress-induced **apoptosis** in human liver cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cinepazide

Cat. No.: HY-66010A

Cinepazide is a piperazine derivative and acts as a weak **calcium channel** blocker. Cinepazide is a potent **vasodilator** and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Cinepazide Maleate

(MD-67350) Cat. No.: HY-66010

Cinepazide Maleate (MD-67350) is a piperazine derivative and acts as a weak **calcium channel** blocker. Cinepazide Maleate is a potent **vasodilator** and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al.</br>.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Cinnarizine

Cat. No.: HY-B1090

Cinnarizine is an antihistamine and a calcium channel blocker, promote cerebral blood flow, used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis.



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Cinnarizine D8

Cat. No.: HY-B1090S

Cinnarizine D8 is a deuterium labeled Cinnarizine. Cinnarizine is an antihistamine and a calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Citreoviridin

Cat. No.: HY-N6745

Citreoviridin, a toxin from Penicillium citreoviride NRRL 2579, inhibits brain synaptosomal **Na^+/K^+-ATPase** whereas in microsomes, both **Na^+/K^+-ATPase** and **Mg^{2+}-ATPase** activities are significantly stimulated in a dose-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Citric acid

Cat. No.: HY-N1428

Citric acid is a weak organic tricarboxylic acid found in citrus fruits. Citric acid is a natural preservative and food tartness enhancer.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

CKD-519

Cat. No.: HY-116078

CKD-519 is a selective and potent **cholesteryl ester transfer protein (CETP)** inhibitor, which inhibits CETP-mediated transfer of cholesteryl ester in human serum with an **IC_{50}** of 2.3 nM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Cladribine

(2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA)

Cat. No.: HY-13599

Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active **adenosine deaminase** inhibitor. Cladribine functions as an inhibitor of **DNA synthesis** to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cleistanthin B

(Diphyllin O-glucoside)

Cat. No.: HY-N9351

Cleistanthin B (Diphyllin O-glucoside) is an orally active arylnaphthalene lignan lactone glycoside. Cleistanthin B exhibits anti-SARS-CoV-2 effects in Vero cells, with **EC_{50}** of 6.51 μM. Cleistanthin B also exhibits antitumor, diuretic and antihypertensive effects in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clevidipine

Cat. No.: HY-17436

Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV) under development for treatment of perioperative hypertension.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Clofilium tosylate

Cat. No.: HY-33350

Clofilium tosylate, a **potassium channel** blocker, induces apoptosis of human promyelocytic leukemia (HL-60) cells via Bcl-2-insensitive activation of caspase-3. Antiarrhythmic agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Clonidine hydrochloride

Cat. No.: HY-B0409A

Clonidine hydrochloride is an agonist of **α2-adrenoceptor** and potent antihypertensive agent.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Clopamide

Cat. No.: HY-B1477

Clopamide is an orally active thiazide-like diuretic agent that inhibits the sodium-coupled chloride cotransporter SLC12A3. Clopamide has the potential for hypertension and cardiac failure research.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 500 mg

Clopidogrel

Cat. No.: HY-15283

Clopidogrel is an orally active platelet inhibitor that targets **P2Y12** receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.



Purity: 99.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate)

Cat. No.: HY-17459

Clopidogrel hydrogen sulfate is an **antiplatelet** agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits **CYP2B6** and **CYP2C19** with IC_{50}s of 18.2 nM and 524 nM, respectively.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Clopidogrel thiolactone

Cat. No.: HY-15876

Clopidogrel thiolactone is a P2Y12 receptor inhibitor, is a potent antiplatelet agent. Target: P2Y12 Clopidogrel thiolactone is the metabolic intermediate resulting from the first oxidative activation of clopidogrel.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CMF019

Cat. No.: HY-103080

CMF019 is a potent and small molecule agonist at **Apelin receptor (APJ)** with G protein bias. CMF019 binds to APJ with **pKi** values of 8.58, 8.49 and 8.71 for human, rat, and mouse, respectively. CMF019 mimics the beneficial cardiovascular actions of apelin in rodents.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CMPD101

Cat. No.: HY-103045

CMPD101 is a potent, highly selective and membrane-permeable small-molecule inhibitor of **GRK2/3** with IC_{50} of 18 nM and 5.4 nM, respectively.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

CNS-5161 hydrochloride

(CNS 5161A)

Cat. No.: HY-101809

CNS-5161 hydrochloride is a novel **NMDA** ion-channel antagonist that interacts with the **NMDA** receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Coenzyme Q9

(Ubiquinone Q9; CoQ9; Ubiquinone 9)

Cat. No.: HY-101415

Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Complanatuside

Cat. No.: HY-N1444

Complanatuside is a flavonoid found in the traditional Chinese medicine Semen Astragali Complanati.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Conivaptan hydrochloride

(YM 087)

Cat. No.: HY-18347A

Conivaptan (hydrochloride) is a non-peptide antagonist of **vasopressin receptor**, with K_i values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Conoidin A

Cat. No.: HY-116090

Conoidin A is a cell permeable inhibitor of **T. gondii enzyme peroxiredoxin II (TgPrxII)** with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC_{50} of 23 μM.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 100 mg

Conopressin S

(Con-S)

Cat. No.: HY-P1737

Conopressin S, isolated from Conus striatus, shows high affinity with **vasopressin V1b receptor (AVPR1B)**, with a K_i of 8.3 nM.

Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Corynoxeine

Cat. No.: HY-N0590

Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent **ERK1/ERK2** inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CP-060

Cat. No.: HY-U00354

CP-060 is a potent Ca^{2+} antagonist, inhibits Ca^{2+} overload and possesses antioxidant and cardioprotective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRA-026440

Cat. No.: HY-19754

CRA-026440 is a potent, broad-spectrum **HDAC** inhibitor. The K_i values against recombinant HDAC isoenzymes **HDAC1**, **HDAC2**, **HDAC3**, **HDAC6**, **HDAC8**, and **HDAC10** are 4, 14, 11, 15, 7, and 20 nM respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Crebanine

Cat. No.: HY-N2255

Crebanine, an alkaloid from Stephania venosa, induces G1 arrest and apoptosis in human cancer cells. Crebanine exhibits anti-inflammatory activity via suppressing MAPKs and Akt signaling. Crebanine also possesses antiarrhythmic effect.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Crocetin β-D-glucopyranoside

Cat. No.: HY-N9372

Crocetin β-D-glucopyranoside is an active part of saffron pigments extracted from patent CN 105935363 A.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CRTh2 antagonist 3

Cat. No.: HY-135773

CRTh2 antagonist 3 is a potent **chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2)** antagonist. CRTh2 antagonist 3 enhances the activity of PDK1 toward a short peptide substrate, with an EC_{50} of 2 μM and a K_d of 8.4 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Crustacean Cardioactive Peptide (CCAP)

Cat. No.: HY-P0303

Crustacean Cardioactive Peptide (CCAP) is a highly conserved, amidated cyclic nonapeptide, first isolated from the pericardial organs of the shore crab Carcinus maenas, where it has a role in regulating heartbeat; Crustacean Cardioactive Peptide (CCAP) also modulates the...

PFCNAFTGC

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Crustecdysone

(20-Hydroxyecdysone)

Cat. No.: HY-N6979

Crustecdysone (20-Hydroxyecdysone) is a naturally occurring ecdysteroid hormone isolated from Cyanotis arachnoides C.B.Clarke which controls the ecdysis (moulting) and metamorphosis of arthropods, it inhibits **caspase** activity and induces **autophagy** via the 20E nuclear...



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CS476

(NSC302998)

Cat. No.: HY-U00211

CS476 is a potent hypoglycaemic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CUDA

Cat. No.: HY-121538

CUDA is a potent inhibitor of **soluble epoxide hydrolase (sEH)**, with IC_{50}s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases **peroxisome proliferator-activated receptor (PPAR) alpha** activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CV-6209

Cat. No.: HY-109897

CV-6209 is a potent antagonist of **platelet activating factor (PAF)**. CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC_{50}s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CXCR7 modulator 2

Cat. No.: HY-112154

CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (**CXCR7**), with a K_i of 13 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cy5.5

(Sulfo-Cyanine5.5)

Cat. No.: HY-D0924

Cy5.5 (Sulfo-Cyanine5.5) is a near-infrared fluorescent dye (Ex=673 nm, Em=707 nm) used to label biological molecules, such as peptides, proteins, and oligonucleotides.



Purity: 95.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cyanidin-3-O-galactoside chloride

(Ideain chloride)

Cat. No.: HY-N4142

Cyanidin-3-O-galactoside chloride (Ideain chloride) is a component from extract peel of hawthorn fruit (EPHF) with the value of 179.4 mg/g. EPHF exhibits strong **AChE** inhibitory activity.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclandelate

(3,5,5-Trimethylcyclohexyl mandelate)

Cat. No.: HY-B1170

Cyclandelate is a vasodilator used in the treatment of claudication, arteriosclerosis, and Raynaud's disease. It is also used to treat nighttime leg cramps, and has been investigated for its effect against migraine.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Cyclic ADP-ribose

(cADPR)

Cat. No.: HY-N7395

Cyclic ADP-ribose (cADPR) is a potent second messenger for **calcium mobilization** that is synthesized from NAD^+ by an ADP-ribosyl cyclase.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 500 μg

Cyclic ADP-ribose ammonium

(cADPR ammonium)

Cat. No.: HY-N7395A

Cyclic ADP-ribose ammonium (cADPR ammonium) is a potent second messenger for **calcium mobilization** that is synthesized from NAD^+ by an ADP-ribosyl cyclase.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 500 μg

Cyclic MKEY

Cat. No.: HY-P1949

Cyclic MKEY is a synthetic cyclic peptide inhibitor of **CXCL4-CCL5** heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclic MKEY TFA

Cat. No.: HY-P1949A

Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of **CXCL4-CCL5** heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclocreatine

Cat. No.: HY-W017540

Cyclocreatine is a Creatine analogue and acts as a potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine crosses membranes, enters the brain, and can be phosphorylated and dephosphorylated by creatine kinases.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Cycloolivil

(Isoolivil)

Cat. No.: HY-N3670

Cycloolivil (Isoolivil) is a natural polyphenolic compound with a significant radical scavenging activity. Antioxidant and Antiaggregant effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclovirobuxine D

Cat. No.: HY-N0107

Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces **autophagy** and attenuates the phosphorylation of **Akt** and **mTOR**.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

CYM-5541

(ML249)

Cat. No.: HY-101419

CYM-5541 (ML249) is an selective and allosteric **$S1P_3$** receptor agonist with an **EC_{50}** between 72 and 132 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CYM50260

Cat. No.: HY-108494

CYM50260 is a potent and exquisitely selective **sphingosine-1-phosphate 4 receptor ($S1P_4$-R)** agonist with an **EC_{50}** of 45 nM. CYM50260 displays no activity against $S1P_1$-R, $S1P_2$-R, $S1P_3$-R and $S1P_5$-R.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

CYM50308

(ML248)

Cat. No.: HY-108495

CYM50308 (ML248) is a potent, selective and high affinity **sphingosine-1-phosphate receptor 4 ($S1P_4$-R)** agonist with an **EC_{50}** of 56 nM. CYM50308 displays 37-fold more selective for **$S1P_4$-R** than $S1P_5$-R.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

CYP11B2-IN-1

Cat. No.: HY-135281

CYP11B2-IN-1 is a **CYP11B2** inhibitor with an **IC_{50}** of 2.3 nM. CYP11B2-IN-1 inhibits CYP11B1 with an IC_{50} of 142 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyproheptadine hydrochloride

Cat. No.: HY-B0366A

Cyproheptadine hydrochloride is a **5-HT_{2A} receptor** antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

D-Pinitol

(3-O-Methyl-D-chiro-inositol)

Cat. No.: HY-N0655

D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system. D-pinitol has antiviral and larvicidal activities.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Dabigatran

(BIBR 953; BIBR 953ZW) Cat. No.: HY-10163

Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct **thrombin** inhibitor (K_i=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC_{50}=10 nM).



Purity: 98.65%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 50 mg, 100 mg

Dabigatran (ethyl ester)

Cat. No.: HY-17378

Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. IC50 value: Target: thrombin Dabigatran provides a stable anticoagulation effect without any need to perform periodical laboratory controls.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dabigatran etexilate

(BIBR 1048) Cat. No.: HY-10274

Dabigatran etexilate (BIBR 1048) is an orally active prodrug of Dabigatran. Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dabigatran etexilate mesylate

(BIBR 1048MS; Dabigatran etexilate methanesulfonate) Cat. No.: HY-10274A

Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran. Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dabigatran ethyl ester hydrochloride

Cat. No.: HY-77521

Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (**NQO2**) with an IC_{50} value of 0.8 μM and a **thrombin** inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dabigatran-d4 hydrochloride

(BIBR-953-d4 hydrochloride) Cat. No.: HY-10163AS

Dabigatran (BIBR-953) D4 hydrochloride is deuterium labeled Dabigatran, which is a reversible and selective, direct thrombin inhibitor (DTI) with a K_i value of 4.5 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Dabuzalgron

(Ro 115-1240) Cat. No.: HY-117071

Dabuzalgron (Ro 115-1240) is an orally active and selective **α-1A adrenergic receptor** agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dalcetrapib

(JTT-705; RO4607381) Cat. No.: HY-14950

Dalcetrapib (JTT-705; RO-4607381) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol. IC50 value: 0.2 uM Target: CETP in vitro: Dalcetrapib modulates CETP activity.



Purity: 99.42%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Daltroban

(BM-13505; SKF 96148) Cat. No.: HY-121018

Daltroban (BM-13505) is a selective and specific **thromboxane A2 (TXA2) receptor** antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury.



Purity: 95.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Danegaptide

(GAP-134; ZP 1609) Cat. No.: HY-10913

Danegaptide (GAP-134) is a potent, selective and orally active **gap-junction** modifier with an antiarrhythmic effect.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Danegaptide Hydrochloride

(GAP-134 Hydrochloride; ZP 1609 Hydrochloride) Cat. No.: HY-10913A

Danegaptide Hydrochloride (GAP-134 Hydrochloride) is a potent, selective and orally active **gap-junction** modifier with an antiarrhythmic effect.



Purity: 99.75%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Danshensu

(Dan shen suan A; Salvianic acid A) Cat. No.: HY-N1913

Danshensu, an active ingredient of Salvia miltiorrhiza, shows wide cardiovascular benefit by activating **Nrf2** signaling pathway.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Danshenxinkun A

Cat. No.: HY-N3680

Danshenxinkun A is a natural compound that could be isolated from Tanshen and is used in the study for heart diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Daphylloside

Cat. No.: HY-N6245

Daphylloside is an iridoid isolated from the aerial parts of Galium verum.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Daprodustat

(GSK1278863) Cat. No.: HY-17608

Daprodustat (GSK1278863) is an orally active **hypoxia-inducible factor prolyl hydroxylase (HIF-PH)** inhibitor being developed for the treatment of anemia associated with chronic kidney disease.



Purity: 99.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Darapladib

(SB-480848) Cat. No.: HY-10521

Darapladib is a potent inhibitor of lipoprotein-associated phospholipase A2 (**Lp-PLA$_2$**) with **IC$_{50}$** of 0.25 nM.



Purity: 99.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Darexaban

(YM150) Cat. No.: HY-14853

Darexaban (YM150) is a potent, selective and orally active **factor Xa (FXa)** inhibitor with an **IC$_{50}$** of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Darodipine

(PY 108-068; PY-108068) Cat. No.: HY-U00086

Darodipine (PY 108-068, PY-108068) is a potent **calcium channel** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Darusentan

(Lu-135252) Cat. No.: HY-15404

Darusentan (Lu-135252) is a selective **endothelin receptor A (ET-A) receptor** antagonist, which binds with a **K$_i$** of 1.4 nM to the ET-A receptor and a K$_i$ of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors.



Purity: 98.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Debutyldronedarone D6 hydrochloride

(SR35021 D6 hydrochloride) Cat. No.: HY-12753S1

Debutyldronedarone D6 hydrochloride (SR35021 D6 hydrochloride) is deuterium labeled Debutyldronedarone. Debutyldronedarone is a major circulating active **metabolite** of dronedarone (HY-A0016) in humans.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Debutyldronedarone-d7

(SR35021-d7) Cat. No.: HY-12753S

Debutyldronedarone D7 (SR35021 D7) is deuterium labeled Debutyldronedarone. Debutyldronedarone is a major circulating active **metabolite** of dronedarone (HY-A0016) in humans.Debutyldronedarone exhibits a potency that is 1/10 to 1/3 of that of the parent agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Deferiprone

Cat. No.: HY-B0568

Deferiprone is the only orally active iron-chelating drug to be used therapeutically in conditions of transfusional iron overload.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Deferiprone-d3

Cat. No.: HY-B0568S

Deferiprone-d3 is the deuterium labeled Deferiprone. Deferiprone is the only orally active iron-chelating drug to be used therapeutically in conditions of transfusional iron overload.



Purity: >98%
Clinical Data:
Size: 5 mg, 50 mg

Deferitrin

(GT-56-252) Cat. No.: HY-108260

Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydro Olmesartan

Cat. No.: HY-131277

Dehydro Olmesartan is a derivative of Olmesartan. Olmesartan is an **angiotensin II receptor (AT1R)** antagonist and has the potential for high blood pressure study.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydro-ZINC39395747

Cat. No.: HY-103061

Dehydro-ZINC39395747 is a derivative of ZINC39395747. ZINC39395747 is a potent cytochrome b5 reductase 3 (CYB5R3) inhibitor with an IC_{50} of 9.14 μM and a K_d of 1.11 μM. ZINC39395747 can increase NO bioavailability in vascular cells.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dehydroevodiamine hydrochloride

Cat. No.: HY-N6029

Dehydroevodiamine hydrochloride is isolated from the leaves of Evodia rutaecarpa.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Delapril hydrochloride

Cat. No.: HY-107337

Delapril hydrochloride is an angiotensin-converting enzyme (**ACE**) inhibitor for the treatment of cardiovascular diseases.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Delcasertib

(KAI-9803; BMS-875944) Cat. No.: HY-106262

Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (**δPKC**) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).

Purity: 98.21%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

Delcasertib hydrochloride

(KAI-9803 hydrochloride; BMS-875944 hydrochloride) Cat. No.: HY-106262B

Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (**δPKC**) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).



Purity: 98.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Delparantag

(PMX-60056) Cat. No.: HY-105240

Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Delphinidin chloride

Cat. No.: HY-N2409

Delphinidin chloride, an anthocyanidin, is isolated from berries and red wine. Delphinidin chloride shows endothelium-dependent vasorelaxation. Delphinidin chloride also can modulate JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Denopamine

((R)-(-)-Denopamine; TA-064) Cat. No.: HY-119515

Denopamine ((R)-(-)-Denopamine) is an orally active, selective **β1-adrenergic** agonist. Denopamine prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart. Cardiovascular effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Denudatine

Cat. No.: HY-N1982

Denudatine, is primarily isolated from plants of the genera Aconitum and Delphinium. Denudatine has effects on action potential of ventricular fibers and inhibits arrhythmogenic action of aconitine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Deoxypodophyllotoxin

Cat. No.: HY-N2500

Deoxypodophyllotoxin (DPT), a derivative of podophyllotoxin, is a lignan with potent antimitotic, anti-inflammatory and antiviral properties isolated from rhizomes of Sinopodophullumhexandrum (Berberidaceae).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Deoxyshikonin

Cat. No.: HY-N2187

Deoxyshikonin is isolated from Lithospermum erythrorhizon Sieb with antitumor activity.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Derenofylline

(SLV 320) Cat. No.: HY-14858

Derenofylline (SLV 320) is a potent, selective and orally active **adenosine A_1 receptor** antagonist, with K_i values of 1 nM, 200 nM and 398 nM for human A_1, A_3 and A_{2A} receptors respectively.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Desethyl KBT-3022

Cat. No.: HY-U00039

Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desethylamiodarone hydrochloride (N-desethylamiodarone hydrochloride; LB 33020 hydrochloride)

Cat. No.: HY-130353

Desethylamiodarone hydrochloride (N-desethylamiodarone hydrochloride) is a major active metabolite of Amiodarone. Desethylamiodarone hydrochloride is formed by CYP3A isoenzymes.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Desfluoro-ezetimibe

Cat. No.: HY-136059

Desfluoro-ezetimibe is a desfluoro impurity of Ezetimibe. Ezetimibe is a potent, metabolically stable **cholesterol absorption** inhibitor. Ezetimibe is a **Niemann-Pick C1-like1 (NPC1L1)** inhibitor, and is a potent **Nrf2** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desidustat

Cat. No.: HY-103227

Desidustat is an inhibitor of **HIF hydroxylase** extracted from patent WO 2014102818 A1, compound example 2.



Purity: 99.87%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Deslanoside

(Deacetyllanatoside C; Desacetyllanatoside C)

Cat. No.: HY-A0154

Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Desmethyl Ketoprofen

Cat. No.: HY-131118

Desmethyl Ketoprofen has anti-inflammatory activities. Desmethyl Ketoprofen can be used for the study of angiogenesis-related disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DETA NONOate

(Diethylamine NONOate; NOC-18)

Cat. No.: HY-136278

DETA NONOate (NOC-18) is an exogenous **nitric oxide (NO)** donor. DETA NONOate exerts neuroprotective effects in vitro.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Dexrazoxane

(ICRF-187; ADR-529; NSC-169780)

Cat. No.: HY-B0581

Dexrazoxane (ICRF-187) is a cardioprotective agent. Target: Others Dexrazoxane is a cardioprotective agent.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg

Dexrazoxane hydrochloride

(ICRF-187 hydrochloride; ADR-529 hydrochloride; NSC-169780 hydrochloride)

Cat. No.: HY-76201

Dexrazoxane hydrochloride (ICRF-187 hydrochloride) is a cardioprotective agent.



Purity: 99.32%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Dextran

(Dextran 40)

Cat. No.: HY-112624

Dextran (Dextran 40) has an inhibitory effect on **thrombocyte aggregation** and coagulation factors and is used as a plasma volume expander.

Purity: ≥95.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg

DG-041

Cat. No.: HY-10835

DG-041 is a potent, high affinity and selective **EP_3 receptor** antagonist with **IC_{50}**s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits **PGE2** facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

DHBP dibromide

(Diheptylviologen dibromide)

Cat. No.: HY-101237

DHBP dibromide is an inhibitor for **calcium** release and a muscle relaxant.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Diacetolol D7

Cat. No.: HY-100635S

Diacetolol D7 is a deuterium labeled Diacetolol. Diacetolol is the major metabolite of Acebutolol. Diacetolol is a **β-adrenoceptor** blocking and anti-arrhythmic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Diaplasinin

(PAI-749)

Cat. No.: HY-122098

Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (**PAI-1**) inhibitor with IC_{50} of 295 nm. Antithrombotic efficacy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diazoxide

(Sch-6783; SRG-95213)

Cat. No.: HY-B1140

Diazoxide (Sch-6783) is an ATP-sensitive **potassium channel** activator, has the potential for hyperinsulinism treatment.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Dibutyryl-cGMP sodium

(Bt2cGMP sodium)

Cat. No.: HY-130354

Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyryl-cGMP sodium preferentially activates **cGMP-dependent protein kinase (PKG)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Didesethyl chloroquine

(Bisdesethylchloroquine)

Cat. No.: HY-100662

Didesethyl chloroquine (Bisdesethylchloroquine) is a major metabolite of the antimalarial drug Chloroquine. Didesethyl chloroquine is a potent myocardial depressant.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg

Difluoro atorvastatin

(Fluoroatorvastatin)

Cat. No.: HY-135151

Difluoro atorvastatin (Fluoroatorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Digitoxin

Cat. No.: HY-B1357

Digitoxin is an effective Na+/K+-ATPase inhibitor, the EC50 value of Digitoxin is 0.78 μM.



Purity: 99.36%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg

Dihomo-γ-linolenic acid

(all-cis-8,11,14-Eicosatrienoic acid)

Cat. No.: HY-A0143

Dihomo-γ-linolenic acid (all-cis-8,11,14-Eicosatrienoic acid) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dihydralazine sulfate

Cat. No.: HY-N7065

Dihydralazine sulfate is an antihypertensive agent.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dihydroberberine

Cat. No.: HY-N1934

Dihydroberberine inhibits **human ether-a-go-go-related gene (hERG)** channels and remarkably reduces **heat shock protein 90 (Hsp90)** expression and its interaction with hERG.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Dihydrotanshinone I

Cat. No.: HY-N0360

Dihydrotanshinone I is a natural compound extracted from Salvia miltiorrhiza Bunge which has been widely used for treating cardiovascular diseases. Dihydrotanshinone I exhibits entry-blocking effect for MERS-CoV.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Dilazep dihydrochloride

Cat. No.: HY-100957

Dilazep dihydrochloride is an inhibitor of **adenosine uptake**. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Diltiazem

Cat. No.: HY-B0632

Diltiazem is an orally active **L-type Ca^{2+} channel** blocker, with antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Diltiazem hydrochloride

(CRD-401)

Cat. No.: HY-14656

Diltiazem hydrochloride is a **Ca^{2+}** influx inhibitor (slow channel blocker or calcium antagonist).



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Dimethyl lithospermate B

(dmLSB)

Cat. No.: HY-N6868

Dimethyl lithospermate B (dmLSB) is a selective **Na^+** channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP).



Purity: 99.28%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diosmin

Cat. No.: HY-N0178

Diosmin is a flavonoid found in a variety of citrus fruits and also an agonist of the **aryl hydrocarbon receptor** (**AhR**).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Diphylline

(Diprophylline)

Cat. No.: HY-B0128

Diphylline (Diprophylline) is a potent **A1/A2 adenosine receptor** antagonist and cyclic nucleotide **phosphodiesterase** inhibitor. Diphylline, a xanthine derivative, is a bronchodilator and vasodilator drug and has the potential for chronic bronchitis and emphysema.



Purity: 99.07%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Dipyridamole

Cat. No.: HY-B0312

Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Dipyridamole-d20

Cat. No.: HY-B0312S

Dipyridamole-d20 is the deuterium labeled Dipyridamole. Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Disopyramide

(Dicorantil; SC-7031)

Cat. No.: HY-12533

Disopyramide (Dicorantil) is a class IA antiarrhythmic drug with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward **sodium** current of cardiac muscle and prolongs the duration of cardiac action potentials.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Disopyramide-d14 tosylate salt

Cat. No.: HY-12533S

Disopyramide-d14 (Dicorantil-d14) tosylate salt is the deuterium labeled Disopyramide. Disopyramide (Dicorantil) is a class IA antiarrhythmic drug with efficacy in ventricular and atrial arrhythmias.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

DL-Arginine

Cat. No.: HY-N0454

DL-Arginine is used in physicochemical analysis of amino acid complexation dynamics and crystal structure formations.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

DL-Cystathionine dihydrochloride

Cat. No.: HY-W009749B

DL-Cystathionine dihydrochloride is a racemic melange of the L-Cystathionine dihydrochloride and D-Cystathionine dihydrochloride. L-Cystathionine dihydrochloride is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DL-m-Tyrosine

Cat. No.: HY-W001940

DL-m-Tyrosine shows effects on Arabidopsis root growth. Carbidopa combination with DL-m-tyrosine shows a potent hypotensive effect.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 500 mg

DMNQ

Cat. No.: HY-121026

DMNQ is a redox cycling agent that generates both superoxide and hydrogen peroxide intracellularly in a concentration dependent manner. DMNQ increases **ROS** generation.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

DMX-5804

Cat. No.: HY-111754

DMX-5804 is a potent, orally active and selective **MAP4K4** inhibitor, with an IC_{50} of 3 nM, a pIC_{50} of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC_{50}, 8.18), and TNIK/MAP4K7 (pIC_{50}, 7.96).



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dobutamine hydrochloride

Cat. No.: HY-15746

Dobutamine hydrochloride is a synthetic catecholamine that acts on **α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors)**. Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR.



Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Docosatrienoic Acid (cis-13,16,19-docosatrienoic acid; (13Z,16Z,19Z)-13,16,19-Docosatrienoic acid)

Cat. No.: HY-101408

Docosatrienoic acid is a rare ω-3 fatty acid; inhibits LTB4 binding to pig neutrophil membranes with an K_i of 5 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mg (149 mM * 200 μL in Ethanol)

Dofetilide

(UK 68789)

Cat. No.: HY-B0232

Dofetilide (UK 68789), as a class III antiarrhythmic agent, is an orally active, potent and specific **IKr** blocker. Dofetilide can be used for the research of cardiovascular disease.



Purity: 98.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Dofetilide D4

(UK 68789 D4)

Cat. No.: HY-B0232S

Dofetilide D4 (UK 68789 D4) is a deuterium labeled Dofetilide. Dofetilide is a class III antiarrhythmic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dofetilide N-oxide

(UK-116856)

Cat. No.: HY-100623

Dofetilide N-oxide (UK-116856) is a metabolite of Dofetilide. Dofetilide is a class III antiarrhythmic agent that blocks **potassium channels**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dooku1

Cat. No.: HY-126010

Dooku1, an analog of Yoda1, is a selective antagonist of the endogenous **Piezo1 channel**. Dooku1 inhibited 2 μM Yoda1-induced Ca^{2+}-entry with IC_{50} values of 1.3 μM (in HEK 293 cells) and 1.5 μM (in HUVECs). Dooku1 inhibits Yoda1-induced relaxation of aorta.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dopexamine hydrochloride

(FPL60278AR)

Cat. No.: HY-U00205

Dopexamine hydrochloride is a **β2 adrenergic receptor** agonist.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dopropidil

Cat. No.: HY-U00151

Dopropidil is a novel anti-anginal calcium ion modulating agent, possessing intracellular calcium antagonist activity and anti-ischemic effects in several predictive animal models.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Doxazosin

(UK 33274)

Cat. No.: HY-B0098

Doxazosin (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic **α1-adrenergic receptors**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Doxazosin D8

(UK 33274 D8)

Cat. No.: HY-B0098S

Doxazosin D8 (UK 33274 D8) is a deuterium labeled Doxazosin (UK 33274). Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1 adrenergic receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Doxazosin mesylate

(UK 33274 mesylate)

Cat. No.: HY-B0098A

Doxazosin mesylate (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic **α1-adrenergic receptors**.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

DPCPX

(PD 116948)

Cat. No.: HY-100937

DPCPX (PD 116948), a xanthine derivative, is a highly potent and selective **Adenosine A1 receptor** antagonist, with a K_i of 0.46 nM in ^{3}H-CHA binding to A1 receptors in rat whole brain membranes.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Dracorhodin

Cat. No.: HY-N4081

Dracorhodin, the main component in sanguis draconis, is a flavylium compound belonging to the anthocyanin family. Dracorhodin can induce vasodilatation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Drobuline hydrochloride

Cat. No.: HY-U00149

Drobuline hydrochloride is an anti-arrhythmic agent with cardiac depressant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dronedarone

(SR 33589)

Cat. No.: HY-A0016

Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III **antiarrhythmic agent** for the study of atrial fibrillation (AF) and atrial flutter.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Dronedarone D6 hydrochloride

Cat. No.: HY-A0016S

Dronedarone D6 hydrochloride is the deuterium labeled Dronedarone. Dronedarone hydrochloride, a derivative of Amiodarone (HY-14187), is a class Ⅲ **antiarrhythmic agent** for the study of atrial fibrillation (AF) and atrial flutter.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dronedarone Hydrochloride

Cat. No.: HY-75839

Dronedarone Hydrochloride is a non-iodinated amiodarone derivative that inhibits **Na^+**, **K^+** and **Ca^{2+}** currents.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Droxicainide

Cat. No.: HY-101617

Droxicainide is an antiarrhythmic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DS-1040 Tosylate

Cat. No.: HY-101918

DS-1040 Tosylate is an orally active, selective inhibitor of activated **thrombin-activatable fibrinolysis inhibitor (TAFIa)** with **IC_{50}**s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases.



Purity: 99.29%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DS88790512

Cat. No.: HY-112298

DS88790512 is a potent, selective, and orally bioavailable **TRPC6** inhibitor with an **IC_{50}** of 11 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DSP-2230

Cat. No.: HY-125079

DSP-2230 is a selective **Nav1.7/Nav1.8** blocker.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DU717

Cat. No.: HY-U00182

DU-717 is an antihypertensive agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DX600 TFA

Cat. No.: HY-P2222

DX600 TFA is an **ACE2** specific inhibitor, and do not cross-react with ACE.

Purity: 99.40%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

D[LEU4,LYS8]-VP

Cat. No.: HY-P1163

D[LEU4,LYS8]-VP is a selective agonist of **vasopressin V_{1b} receptor**, with the **K_is** of 0.16 nM, 0.52 nM, and 0.1.38 nM for rat, human and mouse **V_{1b}** receptor, respectively. D[LEU4,LYS8]-VP has weak antidiuretic, vasopressor, and in vitro oxytocic activities.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D[LEU4,LYS8]-VP TFA

Cat. No.: HY-P1163A

D[LEU4,LYS8]-VP TFA is a selective agonist of **vasopressin V_{1b} receptor**, with the **K_is** of 0.16 nM, 0.52 nM, and 0.1.38 nM for rat, human and mouse **V_{1b}** receptor, respectively. D[LEU4,LYS8]-VP TFA has weak antidiuretic, vasopressor, and in vitro oxytocic activities.

Purity: 98.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

E-4031

Cat. No.: HY-15551

E-4031 is a class III antiarrhythmic agent which selectively blocks **hERG potassium channel**.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

EB-47

Cat. No.: HY-15046

EB-47, a potent and selective **PARP-1/ARTD-1** inhibitor with an IC_{50} value of 45 nM, shows modest potency against ARTD5 with an IC_{50} value of 410 nM. EB-47 mimics the substrate NAD^+ and extends from the nicotinamide to the adenosine subsite.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ecastolol

Cat. No.: HY-101691

Ecastolol is a **beta adrenergic receptor** antagonist, with antianginal activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Echinocystic acid 28-O-β-D-glucoside

Cat. No.: HY-N8102

Echinocystic acid 28-O-β-D-glucoside is a metabolite of Echinocystic acid by microbial oxidation and glucosidation. Echinocystic acid 28-O-β-D-glucoside is a **tissue factor** pathway inhibitor, with an IC_{50} of 10.61 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Edoxaban

(DU-176)

Cat. No.: HY-10264

Edoxaban (DU-176) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with K_is of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Edoxaban impurity 4

Cat. No.: HY-134686

Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with K_is of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Edoxaban tosylate

(DU-176b)

Cat. No.: HY-10264A

Edoxaban tosylate (DU-176b) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with K_is of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively. Edoxaban tosylate is an anticoagulant agent and can be used for stroke prevention.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Edoxaban tosylate monohydrate

(DU-176b monohydrate)

Cat. No.: HY-10264B

Edoxaban tosylate monohydrate (DU-176b monohydrate) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with K_is of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Efaroxan hydrochloride

Cat. No.: HY-B1416A

Efaroxan hydrochloride is a potent, selective and orally active **α2-adrenoceptor** antagonist, with antidiabetic activity. Efaroxan hydrochloride is a selective **I1-Imidazoline receptor** antagonist. Efaroxan hydrochloride can be used for the research of cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Efloxate

(Angorlisin)

Cat. No.: HY-B0930

Efloxate is a vasodilator, used to treat chronic coronary insufficiency and Angina pectoris,.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Efonidipine

(NZ-105; (±)-Efonidipine) Cat. No.: HY-12502

Efonidipine(NZ-105) is a dual T-type and L-type calcium channel blocker (CCB).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Efonidipine hydrochloride

(NZ-105 hydrochloride) Cat. No.: HY-12502B

Efonidipine Hcl (NZ-105) is a dual T-type and L-type calcium channel blocker (CCB).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Efonidipine hydrochloride monoethanolate

(NZ-105 hydrochloride monoethanolate) Cat. No.: HY-12502A

Efonidipine hydrochloride monoethanolate (NZ-105 hydrochloride monoethanolate) is a dual T-type and L-type calcium channel blocker (CCB).



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

EGCG Octaacetate

Cat. No.: HY-N6263

EGCG Octaacetate is a prodrug of Green tea epigallocatechin-3-gallate (EGCG), utilized to enhance the stability and bioavailability of EGCG in vivo. EGCG Octaacetate has high efficacy, bioavailability, anti-oxidation and anti-angiogenesis capacities.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

EHNA hydrochloride

Cat. No.: HY-103160A

EHNA hydrochloride is a potent and selective dual inhibitor of **cyclic nucleotide phosphodiesterase 2 (PDE2)**(IC_{50}=4 μM) and **adenosine deaminase (ADA)**.



Relative stereochemistry

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

ELA-21 (human)

Cat. No.: HY-P2249

ELA-21 (human) is an **apelin receptor** agonist with a **pK_i** of 8.52. ELA-21 (human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment with subnanomolar potencies. ELA-21 (human) is an agonist in G-protein-dependent and -independent pathways.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ELA-32(human)

Cat. No.: HY-P2196

ELA-32 (human) is a potent critical cardiac developmental peptide that acts through the G-protein–coupled apelin receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Elabela(19-32)

Cat. No.: HY-P2106

Elabela(19-32) is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) activates the **$G_{\alpha i1}$** and **β-arrestin-2** signaling pathways with **EC_{50}**s of 8.6 nM and 166 nM.

Purity: 98.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Elabela(19-32) TFA

Cat. No.: HY-P2106A

Elabela(19-32) TFA is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) TFA activates the **$G_{\alpha i1}$** and **β-arrestin-2** signaling pathways with **EC_{50}**s of 8.6 nM and 166 nM.

Purity: 99.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Elinogrel

(PRT060128) Cat. No.: HY-11021

Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet **$P2Y_{12}$** antagonist (**IC_{50}**=20 nM). It is orally and intravenously available and has potent antiplatelet effects.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Elisartan

(HN 65021) Cat. No.: HY-19214

Elisartan is an orally active non-peptide pro-drug of **angiotensin II AT1 receptor** antagonist HN-12206, and shows anti-hypertension activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eltrombopag

(SB-497115) Cat. No.: HY-15306

Eltrombopag (SB-497115) is a **thrombopoietin (TPO) receptor** agonist developed for certain conditions that lead to thrombocytopenia.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Eltrombopag Olamine

(Eltrombopag diethanolamine salt; SB-497115GR) Cat. No.: HY-15306A

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is a **thrombopoietin-receptor** agonist used to treat low blood platelet counts with chronic immune thrombocytopenia.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

EML 425

Cat. No.: HY-110263

EML425 is a potent and selective CREB binding protein (**CBP**)/**p300** inhibitor with IC_{50}s of 2.9 and 1.1 μM, respectively.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Enalapril

(MK-421) Cat. No.: HY-B0331

Enalapril (MK-421) is an angiotensin converting enzyme (ACE) inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Enalapril D5 maleate

(MK-421 D5 maleate) Cat. No.: HY-B0331AS

Enalapril (MK-421) D5 maleate is deuterium labeled Enalapril, which is an angiotensin converting enzyme (ACE) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enalapril maleate

(MK-421 maleate) Cat. No.: HY-B0331A

Enalapril (maleate) (MK-421 (maleate)), the active metabolite of enalapril, is an angiotensin-converting enzyme (ACE) inhibitor.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Enalaprilat D5

(MK-422 D5) Cat. No.: HY-B0231AS

Enalaprilat D5 (MK-422 D5) is the deuterium labeled Enalaprilat(MK-422), which is an angiotensin-converting enzyme (ACE) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Enalaprilat dihydrate

(MK-422) Cat. No.: HY-B0231

Enalaprilat dihydrate (MK-422) is an angiotensin-converting enzyme (ACE) inhibitor with IC_{50} of 1.94 nM.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Enalaprilat-d5 sodium

(MK-422-d5 sodium) Cat. No.: HY-B0231BS

Enalaprilat (MK-422) D5 Sodium Salt is the deuterium labeled Enalaprilat(MK-422), which is an angiotensin-converting enzyme (ACE) inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Encainide

(MJ9067) Cat. No.: HY-130335

Encainide (MJ9067) is an antiarrhythmic drug with class IC activity. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Encainide hydrochloride

(MJ9067 hydrochloride) Cat. No.: HY-12531

Encainide (MJ9067) hydrochloride is an antiarrhythmic drug with class IC activity. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Endothelial lipase inhibitor-1

Cat. No.: HY-112911

Endothelial lipase inhibitor-1 is a potent **endothelial lipase** inhibitor with an IC_{50} of 49 nM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Endothelin 1 (swine, human), Alexa Fluor 488-labeled

Cat. No.: HY-P2496

Endothelin 1 (swine, human), Alexa Fluor 488-labeled is a synthetic Endothelin 1 peptide labled with Alexa Fluor 488. Endothelin 1 (swine, human) is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous **vasoconstrictor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Endothelin-2 (49-69), human

(Endothelin-2 (human, canine); Human endothelin-2) Cat. No.: HY-P0207

Endothelin-2 (49-69), human (Endothelin-2 (human, canine)) is a 21-amino acid vasoactive peptide that binds to G-protein-linked transmembrane receptors, **ET-RA** and **ET-RB**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg

Endothelin-2 (49-69), human TFA

(Endothelin-2 (49-69) (human, canine) TFA; Human endothelin-2 TFA) Cat. No.: HY-P0207A

Endothelin-2 (49-69), human (TFA) (Endothelin-2 (49-69) (human, canine) (TFA)) is a 21-amino acid vasoactive peptide that binds to G-protein-linked transmembrane receptors, **ET-RA** and **ET-RB**.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 500 µg

Endothelin-3, human, mouse, rabbit, rat

(Endothelin 3 (Rat,Human)) Cat. No.: HY-P0204

Endothelin-3, human, mouse, rabbit, rat is a 21-amino acid vasoactive peptide that binds to G-protein-linked transmembrane receptors, **ET-RA** and **ET-RB**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Endothelin-3, human, mouse, rabbit, rat TFA

(Endothelin 3 (Rat,Human) (TFA)) Cat. No.: HY-P0204A

Endothelin-3, human, mouse, rabbit, rat TFA is a 21-amino acid vasoactive peptide that binds to G-protein-linked transmembrane receptors, **ET-RA** and **ET-RB**.

Purity: 99.66%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

Enecadin

Cat. No.: HY-100119

Enecadin is a neuroprotective agent extracted from patent US 8623823 B2.



Purity: 99.71%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

Eniporide hydrochloride

(EMD-96785 hydrochloride) Cat. No.: HY-106150B

Eniporide hydrochloride (EMD-96785 hydrochloride) is a potent **Na^+/H^+** exchange inhibitor.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ENMD-1068 hydrochloride

Cat. No.: HY-124748A

ENMD-1068 hydrochloride is a selective **protease-activated receptor 2 (PAR2)** antagonist with antiangiogenic and anti-inflammatory activities.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Enniatin A

Cat. No.: HY-N6702

Enniatin A is a Fusarium mycotoxin. Enniatin A inhibits acyl-CoA: cholesterol acyltransferase (**ACAT**) activity with an IC_{50} of 22 μM in an enzyme assay using rat liver microsomes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Enniatin B

Cat. No.: HY-N3806

Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (**ACAT**) activity with an IC_{50} of 113 μM in an enzyme assay using rat liver microsomes. Enniatins B decreases the activation of **ERK** (p44/p42).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Enniatin B1

Cat. No.: HY-N3807

Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (**ACAT**) activity with an IC_{50} of 73 μM in an enzyme assay using rat liver microsomes. Enniatin B1 crosss the blood-brain barrier.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Enoximone

Cat. No.: HY-B1639

Enoximone is an inotropic vasodilating agent and a selective and orally active **phosphodiesterase III (PDE3)** inhibitor with an IC_{50} of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

ent-Ezetimibe

(ent-SCH 58235)

Cat. No.: HY-135388

ent-Ezetimibe (ent-SCH 58235) is the RRS-enantiomer of Ezetimibe. Ezetimibe is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (**NPC1L1**) inhibitor, and is a potent **Nrf2** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EPAC 5376753

Cat. No.: HY-111446

EPAC 5376753 is an allosterically inhibitor of **Epac** which inhibits Epac1 with an IC_{50} of 4 μM in Swiss 3T3 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epanolol

(Visacor; ICI141292)

Cat. No.: HY-U00183

Epanolol (Visacor; ICI141292) is a potent **β-adrenoceptor** partial agonist with a greater affinity for **β1**- than β2-adrenoceptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epanolol-d5

Cat. No.: HY-U00183S

Epanolol-d5 (Visacor-d5) is the deuterium labeled Epanolol. Epanolol (Visacor) is a potent **β-adrenoceptor** partial agonist with a greater affinity for **β1**- than β2-adrenoceptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Epimedin K

(Korepimedoside B)

Cat. No.: HY-N8087

Epimedin K (Korepimedoside B), a flavonol glycoside, is isolated from the aerial parts of Epimedium koreanum Nakai.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eplerenone

(Epoxymexrenone) Cat. No.: HY-B0251

Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active **aldosterone** antagonist with an IC_{50} of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Epoprostenol sodium (Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan)

Cat. No.: HY-A0126A

Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Eprosartan

(SKF-108566J free base) Cat. No.: HY-117743

Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active **angiotensin II receptor** antagonist, used as an antihypertensive.



Purity: 95.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Eprosartan mesylate

(SKF-108566J) Cat. No.: HY-15834A

Eprosartan mesylate (SKF-108566J) is a selective, competitive, nonpeptid and orally active **angiotensin II receptor** antagonist, used as an antihypertensive.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Eptifibatide

Cat. No.: HY-B0686

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Eptifibatide acetate

Cat. No.: HY-B0686A

Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

ERK5-IN-2

Cat. No.: HY-128341

ERK5-IN-2 is an orally active, sub-micromolar, selective **ERK5** inhibitor with IC_{50}s of 0.82 μM, 3 μM for **ERK5** and **ERK5 MEF2D**, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ermanin

Cat. No.: HY-N3848

Ermanin is a flavonoid isolated from Tanacetum microphyllum. Ermanin potently inhibits **iNOS**, **COX-2** activities, and inhibits platelet aggregation. Ermanin has anti-inflammatory, anti-tuberculous and anti-viral/bacterial properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Esaxerenone

(CS-3150; XL-550) Cat. No.: HY-100471

Esaxerenone (CS-3150) is a highly potent and selective non-steroidal **mineralocorticoid receptor** antagonist.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ESI-08

Cat. No.: HY-136172

ESI-08 is a potent and selective **EPAC** antagonist, which can completely inhibit both **EPAC1** and **EPAC2** (IC_{50} of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced **EPAC** activation, but does not inhibit cAMP-mediated PKA activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Esmolol hydrochloride

Cat. No.: HY-B1392

Esmolol hydrochloride is a beta adrenergic receptor blocker.



Purity: 99.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Esmolol-d7 hydrochloride

Cat. No.: HY-B1392S

Esmolol-d7 hydrochloride is the deuterium labeled Esmolol hydrochloride. Esmolol hydrochloride is a beta adrenergic receptor blocker.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Estetrol

Cat. No.: HY-15731

Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear **estrogen receptor** modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast.



Purity: 95.46%
Clinical Data: No Development Reported
Size: 1 mg

ETA antagonist 1

Cat. No.: HY-112264

ETA antagonist 1 is a **ETA** selective antagonist with an **IC_{50}** of 0.08 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Etamicastat

(BIA 5-453)

Cat. No.: HY-14838

Etamicastat (BIA 5-453) is a potent and reversible **dopamine-β-hydroxylase** (**DBH**) inhibitor with an **IC_{50}** value of 107 nM. Etamicastat can be used in the research of cardiovascular diseases.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Etamicastat hydrochloride

(BIA 5-453 hydrochloride)

Cat. No.: HY-14838A

Etamicastat hydrochloride (BIA 5-453 hydrochloride) is a potent and reversible **dopamine-β-hydroxylase** (**DBH**) inhibitor with an **IC_{50}** value of 107 nM. Etamicastat can be used in the research of cardiovascular diseases.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Etersalate

(Eterylate; Etherylate)

Cat. No.: HY-101606

Etersalate inhibits platelet function and decreases **thromboxane A2** (**TXA2**) levels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ethacizine hydrochloride

(Ethacizin; NIK-244)

Cat. No.: HY-135121

Ethacizine hydrochloride (Ethacizin; NIK-244) is a longer-lasting **Class Ic antiarrhythmic agent** than Flecainide. Ethacizine hydrochloride (Ethacizin; NIK-244) inhibits the depolarizing current responsible for the intraatrial and His-Purkinje-ventricular conduction.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 5 mg

Ethamsylate

Cat. No.: HY-B1074

Ethamsylate is a haemostatic drug, also inhibits biosynthesis and action of those prostaglandins.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ethyl linoleate

(Linoleic Acid ethyl ester)

Cat. No.: HY-W013812

Ethyl linoleate inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ethyl linolenate

Cat. No.: HY-N2073

Ethyl linolenate is a fatty acid ethyl ester (FAEE). Ethyl linolenate plays an active role in inhibition of the cellular production on melanin with an IC_{50} of 70 μM. Anti-melanogenesis Effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Etofylline

(7-(β-Hydroxyethyl)theophylline)

Cat. No.: HY-B1209

Etofylline (7-(β-Hydroxyethyl)theophylline) is a N-7-substituted derivative of Theophylline. Etofylline is a bronchodilator which can be used for the research of asthma. Etofylline is also an anticholesteremic and reduces total cholesterol level in the blood.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Etofylline clofibrate

Cat. No.: HY-107348

Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction with intimal PGI2.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Etripamil

(MSP-2017; (-)-MSP-2017)

Cat. No.: HY-17611

Etripamil (MSP-2017) is a short-acting **L-type calcium-channel** antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT).



Purity: 98.68%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Eugenin

Cat. No.: HY-33351

Eugenin is a chromone isolated from Peucedanum japonicum, with potent antiplatelet aggregation activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EUK-134

Cat. No.: HY-100594

EUK-134, a synthetic **superoxide dismutase** and catalase mimetic, protects rat kidneys from ischemia-reperfusion-induced damage. EUK-134 is a superoxide dismutase (**SOD**) mimetics (SODm) with catalase activity. EUK-134 is a mitoprotective antioxidant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Euphorbetin

Cat. No.: HY-N7671

Euphorbetin exhibits anticoagulant activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Euphorbia Factor L1

Cat. No.: HY-N2557

Euphorbia Factor L1 is a diterpenoid from Euphorbia lathyris L., reduces the expression of Bcl-2, PI3K, AKT and mTOR protein and mRNA, upregulates cleaved caspase-9 and caspase-3 levels, buts shows no effect on pro-caspase-9 and pro-caspase-3.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Evacetrapib

(LY2484595)

Cat. No.: HY-13327

Evacetrapib is a potent and selective of **CETP** inhibitor, which inhibits human recombinant CETP protein (IC_{50} 5.5 nM) and CETP activity in human plasma (IC_{50} 36 nM) in vitro.



Purity: 99.42%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Evatanepag

(CP-533536 free acid)

Cat. No.: HY-14839

Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM. IC50 value: 0.3 nM (EC50) Target PGE2 in vitro: CP-533536 is a potent and selective EP2agonist.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Ezetimibe

(SCH 58235) Cat. No.: HY-17376

Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (**NPC1L1**) inhibitor, and is a potent **Nrf2** activator.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Ezetimibe ketone

(EZM-K) Cat. No.: HY-133114

Ezetimibe ketone (EZM-K) is a phase-I metabolite of Ezetimibe. Ezetimibe is a Niemann-Pick C1-like1 (**NPC1L1**) inhibitor, and is a potent **Nrf2** activator. Ezetimibe is a potent cholesterol absorption inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Ezetimibe-d4

(SCH 58235-d4) Cat. No.: HY-17376S

Ezetimibe D4 (SCH 58235 D4) is the deuterium labeled Ezetimibe. Ezetimibe is a Niemann-Pick C1-like1 (**NPC1L1**) inhibitor, and is a potent **Nrf2** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

F 16915

Cat. No.: HY-19886

F 16915, a Docosahexaenoic Acid (DHA, HY-B2167) derivative, is a potent pro-drug of DHA. F 16915 can prevent heart failure-induced atrial fibrillation.

Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Fargesin

Cat. No.: HY-N0719

Fargesin is a bioactive neolignan isolated from magnolia plants, with antihypertensive and anti-inflammatory effects.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Fasentin

Cat. No.: HY-101849

Fasentin, a potent glucose uptake inhibitor, inhibits **GLUT-1/GLUT-4** transporters. Fasentin preferentially inhibits GLUT4 (IC_{50}=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fasitibant chloride

(MEN16132 free base) Cat. No.: HY-14886

Fasitibant chloride (MEN16132 free base) is a potent and selective nonpeptide **bradykinin B2 receptor (B2R)** antagonist. Fasitibant chloride reduces joint pain and diminishes joint oedema in Carrageenan-induced arthritis rat model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FC9402

Cat. No.: HY-141552

FC9402 is a potent and selective sulfide quinone oxidoreductase (**SQOR**) inhibitor extracted from patent WO 2020/146636 A1. FC9402 attenuates TAC-induced cardiomyocyte hypertrophy and left ventricle (LV) fibrosis. FC9402 can be used for cardiovascular regulation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FCE 28654

Cat. No.: HY-U00369

FCE 28654 is an inhibitor of acylCoA: cholesterol acyltransferase (**ACAT**), weakly inhibiting **ACAT** in microsomes from rabbit aorta and intestine, and monkey liver, with IC_{50}s of 2.55, 1.08 and 5.69 μM, respcetively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Felodipine

Cat. No.: HY-B0309

Felodipine, a dihydropyridine, is a potent, vasoselective **calcium channel** antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels.



Purity: 98.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Felypressin

(PLV-2) Cat. No.: HY-A0182

Felypressin (PLV-2) is a non-catecholamine vasoconstrictor and a **vasopressin 1** agonist. Felypressin is widely used in dental procedures.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Felypressin acetate

(PLV-2 acetate) Cat. No.: HY-A0182A

Felypressin acetate (PLV-2 acetate) is a non-catecholamine vasoconstrictor and a **vasopressin 1** agonist. Felypressin acetate is widely used in dental procedures.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fendiline hydrochloride

Cat. No.: HY-B0984

Fendiline hydrochloride is a nonselective calcium channel blocker.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Fenobucarb

Cat. No.: HY-B0835

Fenobucarb is a carbamate insecticide. Fenobucarb induces zebrafish developmental neurotoxicity through pathways involved in inflammation, oxidative stress, degeneration and apoptosis.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg

Fenofibrate

Cat. No.: HY-17356

Fenofibrate is a selective **PPARα** agonist with an **EC_{50}** of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with **IC_{50}**s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for **CYP2C19**, **CYP2B6**, **CYP2C9**, **CYP2C8**, and **CYP3A4**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 5 g, 10 g

Fenofibrate-d6

Cat. No.: HY-17356S

Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective **PPARα** agonist with an **EC_{50}** of 30 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fenoldopam

(SKF 82526) Cat. No.: HY-B0735

Fenoldopam(SKF 82526) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Target: D1 Receptor Fenoldopam is a selective dopamine-1 (DA1) agonist with natriuretic/diuretic properties.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fenoldopam mesylate

(Fenoldopam methanesulfonate; SKF-82526 mesylate) Cat. No.: HY-B0735A

Fenoldopam(SKF 82526) mesylate is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Target: D1 Receptor Fenoldopam is a selective dopamine-1 (DA1) agonist with natriuretic/diuretic properties.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Fenoldopam-d4 mesylate

Cat. No.: HY-B0735AS

Fenoldopam-d4 (SKF-82526-d4) mesylate is the deuterium labeled Fenoldopam mesylate. Fenoldopam (SKF 82526) mesylate is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Feretoside

Cat. No.: HY-N6249

Feretoside, a phenolic compound extracted from the barks of E. ulmoides, is a **HSP inducer** which act as cytoprotective agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ferulic acid sodium
(Coniferic acid sodium)

Cat. No.: HY-N0060A

Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (**FGFR1**) inhibitor with IC_{50}s of 3.78 and 12.5 μM for **FGFR1** and **FGFR2**, respectively.



Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

Fibrin

Cat. No.: HY-B0665

Fibrin, isolated from bovine blood, is an insoluble protein produced in response to bleeding. Fibrin is the major component of the blood clot and is used for coagulation.

Fibrin

Purity: >98%
Clinical Data: Phase 4
Size: 50 mg, 100 mg

Fibrinogen Binding Inhibitor Peptide

Cat. No.: HY-P1507

Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.

HHLGGAKQAGDV

Purity: 98.41%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Fibrinogen-Binding Peptide

Cat. No.: HY-P1741

Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fibrinopeptide A, human
(Human fibrinopeptide A)

Cat. No.: HY-P1538

Fibrinopeptide A, human is a 16-residue short polypeptide cleaved from fibrinogen by thrombin. Fibrinopeptide A, human locates at the NH_2-termini of the Aα chain.

ADSGEGDFLAEGGGVR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fibrinopeptide A, human TFA
(Human fibrinopeptide A TFA)

Cat. No.: HY-P1538A

Fibrinopeptide A, human TFA is a 16-residue short polypeptide cleaved from fibrinogen by thrombin. Fibrinopeptide A, human locates at the NH_2-termini of the Aα chain.

ADSGEGDFLAEGGGVR (TFA salt)

Purity: 98.78%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Fibronectin

Cat. No.: HY-P3160

Fibronectin, a glycoprotein (~500 kDa) present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins.

Fibronectins

Purity: 97.40%
Clinical Data: No Development Reported
Size: 1 mg

Fibronectin Adhesion-promoting Peptide
(Heparin Binding Peptide)

Cat. No.: HY-P0306

Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Fibronectin Adhesion-promoting Peptide TFA
(Heparin Binding Peptide TFA)

Cat. No.: HY-P0306A

Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fimasartan
(BR-A-657)

Cat. No.: HY-B0780

Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.



Purity: 98.04%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Finerenone

(BAY 94-8862) Cat. No.: HY-111372

Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal **mineralocorticoid receptor (MR)** antagonist (IC_{50}=18 nM).



Purity: 99.95%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Firibastat

(QGC001; RB150) Cat. No.: HY-109058

Firibastat (QGC001), an orally active brain penetrating prodrug of EC33, is a first-in-class brain **aminopeptidase A (APA)** inhibitor (K_i=200 nM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FKK

Cat. No.: HY-100194

FKK is an indazole derivative and also a novel bronchodilator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flavanomarein

Cat. No.: HY-N7675

Flavanomarein is a predominant flavonoid of Coreopsis tinctoria Nutt with protective effects against diabetic nephropathy. Flavanomarein has good antioxidative, antidiabetic, antihypertensive and anti-hyperlipidemic activities.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg

Flavin adenine dinucleotide

(FAD) Cat. No.: HY-B1654

Flavin adenine dinucleotide (FAD) is a redox cofactor, more specifically a prosthetic group of a protein, involved in several important enzymatic reactions in metabolism.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Flavin adenine dinucleotide disodium salt

(FAD disodium salt; FAD-Na2) Cat. No.: HY-B1654A

Flavin adenine dinucleotide (FAD) disodium salt is a redox cofactor, more specifically a prosthetic group of a protein, involved in several important enzymatic reactions in metabolism.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

Flecainide acetate

(R-818) Cat. No.: HY-17429

Flecainide acetate (R-818) is a class 1C antiarrhythmic drug especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Fluvastatin

(XU 62-320 free acid) Cat. No.: HY-14664

Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fluvastatin D6 sodium

(XU 62-320 (D6)) Cat. No.: HY-14664AS

Fluvastatin D6 sodium (XU 62-320 D6) is deuterium labeled Fluvastatin sodium. Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fluvastatin sodium

(XU 62-320) Cat. No.: HY-14664A

Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.



Purity: 99.48%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Fondaparinux sodium

(Fondaparin sodium; SR-90107A)

Cat. No.: HY-B0597

Fondaparinux sodium is an antithrombin-dependent **factor Xa** inhibitor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Formononetin

(Biochanin B; Flavosil; Formononetol)

Cat. No.: HY-N0183

Formononetin is a potent **FGFR2** inhibitor with an IC_{50} of ~4.31 μM. Formononetin potentially inhibits angiogenesis and tumor growth.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Foropafant

(SR27417)

Cat. No.: HY-128694

Foropafant (SR27417) highly potent, competitive, selective and orally active antagonist of platelet-activating factor (**PAF**) receptor, with a K_i value of 57 pM for [^{3}H]PAF binding, at least 5-fold lower than that of unlabeled PAF itself.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Fosfructose

(Diphosphofructose; Esafosfan; FDP)

Cat. No.: HY-106950

Fosfructose (Diphosphofructose;Esafosfan;FDP) is a cytoprotective natural sugar phosphate for the potential treatment of cardiovascular ischemia, sickle cell anemia and asthma. It acts by stimulating anaerobic glycolysis which generates adenosine triphosphate under ischemic conditions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fosfructose trisodium (Diphosphofructose trisodium; Esafosfan trisodium; FDP trisodium)

Cat. No.: HY-106950A

Fosfructose trisodium (Diphosphofructose trisodium;Esafosfan trisodium;FDP trisodium) is a cytoprotective natural sugar phosphate for the potential treatment of cardiovascular ischemia, sickle cell anemia and asthma.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Fosinopril sodium

(SQ28555)

Cat. No.: HY-B0382

Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.



Purity: 98.48%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Fosinopril-d5 sodium

Cat. No.: HY-B0382S

Fosinopril-d5 sodium (SQ28555-d5 sodium) is the deuterium labeled Fosinopril sodium. Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

FR 58664

Cat. No.: HY-U00025

FR 58664 is a drug to treat heart failure disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FR-171113

Cat. No.: HY-108555

FR171113 is a specific and non-peptide **thrombin receptor** antagonist. FR171113 exhibits the antithrombotic effects of a **PAR1** antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC_{50} of 0.29 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FR-229934

Cat. No.: HY-105686

FR-229934 is a **PDE V** inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FR183998 free base

Cat. No.: HY-100302

FR183998 free base is a potent **Na^+/H^+-exchange** inhibitor, with **IC_{50}**s of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pH_i change in rat lymphocytes, rat and human platelets, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fradafiban

(BIBU-52)

Cat. No.: HY-101720

Fradafiban is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a K_d value of 148 nM.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Fructose

Cat. No.: HY-N0395

Fructose is a simple ketonic monosaccharide found in many plants, where it is often bonded to glucose to form the disaccharide sucrose.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

FSCPX

Cat. No.: HY-116042

FSCPX is a potent and selective irreversible antagonist of **A_1 adenosine receptor (A_1AR)**, with low nanomolar potency for binding to the A_1AR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FTX-6058

Cat. No.: HY-139400

FTX-6058 is a potent and orally active inhibitor of **Embryonic Ectoderm Development (EED)**. FTX-6058 can induce HbF protein expression in cell and murine models. FTX-6058 can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

FTX-6058 hydrochloride

Cat. No.: HY-139400A

FTX-6058 hydrochloride is a potent and orally active inhibitor of **Embryonic Ectoderm Development (EED)**. FTX-6058 hydrochloride can induce HbF protein expression in cell and murine models.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fucoidan

Cat. No.: HY-132179

Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Fulacimstat

(BAY1142524)

Cat. No.: HY-109059

Fulacimstat is an orally available **chymase** inhibitor, with **IC_{50}s** of 4, 3 nM for human and hamster chymase enzyme, respectively.



Purity: 99.00%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fulvine

Cat. No.: HY-133589

Fulvine is a pyrrolizidine alkaloid isolated from the seeds of Crotalaria fulva. Fulvine is **hepatotoxic** and can be used to induce hypertensive pulmonary vascular disease in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Furegrelate sodium

(U-63557A)

Cat. No.: HY-106080A

Furegrelate Sodium (U-63557A) is a potent, orally available, and selective **thromboxane synthase** inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC_{50} of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent.



Purity: ≥99.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

Fuscoside
(OPC-21268)

Cat. No.: HY-15009

Fuscoside (OPC-21268) is an orally effective, nonpeptide, **vasopressin V1** receptor antagonist with an IC_{50} of 0.4 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fuziline
(15α-Hydroxyneoline)

Cat. No.: HY-N1974

Fuziline is a alkaloid isolated from the lateral roots of Aconitum carmichaelii.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

FW1256

Cat. No.: HY-121955

FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H_2S) donor. FW1256 inhibits **NF-κB** activity and induces cell **apoptosis**. FW1256 exerts potent anti-inflammatory effects and has the potential for cancer and cardiovascular disease treatment.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

FXIa-IN-1

Cat. No.: HY-128889

FXIa-IN-1 (compound EP-7041) is a potent β-lactam covalent **heparin-derived factor XIa (fXIa)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gadolinium chloride
(GdCl3)

Cat. No.: HY-103314

Gadolinium chloride is a specific calcium-sensing receptor (**CaSR**) agonist. Gadolinium chloride can be used for the research of cardiovascular disease.

$GdCl_3$

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg, 500 mg

Gallamine Triethiodide

Cat. No.: HY-B0416

Gallamine Triethiodide is a synthetic nondepolarizing blocking drug. Target: mAChR Gallamine triethiodide is a non-depolarising muscle relaxant.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Gallopamil
(Methoxyverapamil)

Cat. No.: HY-14276

Gallopamil (Methoxyverapamil), a methoxy derivative of Verapamil, is a **phenylalkylamine calcium** antagonist. Gallopamil inhibits acid secretion in a concentration-dependent manner with an IC_{50} of 10.9 μM. Gallopamil is a potent antiarrhythmic and vasodilator agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gallopamil hydrochloride
(Methoxyverapamil hydrochloride)

Cat. No.: HY-14276A

Gallopamil hydrochloride (Methoxyverapamil hydrochloride), a methoxy derivative of Verapamil, is a **phenylalkylamine calcium** antagonist. Gallopamil hydrochloride inhibits acid secretion in a concentration-dependent manner with an IC_{50} of 10.9 μM.



H−Cl

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gap 26

Cat. No.: HY-P1082

Gap 26 is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif.

VCYDKSFPISHVR

Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gap 26 TFA

Cat. No.: HY-P1082A

Gap 26 TFA is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif.

VCYDKSFPISHVR (TFA Salt)

Purity: 99.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gap 27

Cat. No.: HY-P0139

Gap 27, a synthetic connexin43 mimetic peptide, is a gap junction inhibitor. Gap 27 possesses conserved sequence homology to a portion of the second extracellular loop leading into the fourth transmembrane connexin segment.

SRPTEKTIFII

Purity: 98.07%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gap19

Cat. No.: HY-P1136

Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective **connexin 43 (Cx43) hemichannel** blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gap19 TFA

Cat. No.: HY-P1136A

Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective **connexin 43 (Cx43) hemichannel** blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL.



Purity: 95.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GATA4-NKX2-5-IN-1

Cat. No.: HY-103484

GATA4-NKX2-5-IN-1 (Compound 3) dose-dependently inhibits the **GATA4–NKX2-5** transcriptional synergy with an IC_{50} of 3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gemfibrozil

(CI-719)

Cat. No.: HY-B0258

Gemfibrozil is an activator of **PPAR-α**, used as a lipid-lowering drug; Gemfibrozil is also a nonselective inhibitor of several **P450** isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Gemfibrozil 1-O-β-glucuronide

Cat. No.: HY-129993

Gemfibrozil 1-O-β-Glucuronide, a metabolite of Gemfibrozil (CI-719; HY-B0258), is a potent and competitive **P450 (CYP)** isoform CYP2C8 inhibitor with an IC_{50} of 4.07 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

GGsTop

(Nahlsgen)

Cat. No.: HY-108467

GGsTop (Nahlsgen) is a potent, non-toxic, highly selective and irreversible **γ−glutamyl transpeptidase (GGT)** inhibitor, with a K_i of 170 μM for Human GGT. GGsTop shows a pK_a of 9.71, also exhibits K_{on}s of 150±10 and 51±3 M^{-1} s^{-1} against E.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Ra1

Cat. No.: HY-N2506

Ginsenoside Ra1 is a component from ginseng, inhibits protein tyrosine kinase (**PTK**) activation induced by hypoxia/reoxygenation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rd

(Gypenoside VIII)

Cat. No.: HY-N0043

Ginsenoside Rd inhibits TNFα-induced **NF-κB** transcriptional activity with an IC_{50} of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of **COX-2** and **iNOS** mRNA. Ginsenoside Rd also inhibits Ca^{2+} influx.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rg2

(Chikusetsusaponin I; Panaxoside Rg2; Prosapogenin C2)

Cat. No.: HY-N0602

Ginsenoside Rg2 is one of the major active components of ginseng. Ginsenoside Rg2 inhibits **VCAM-1** and **ICAM-1** expressions stimulated with lipopolysaccharide (LPS). Ginsenoside Rg2 also reduces $Aβ_{1-42}$ accumulation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rg5

Cat. No.: HY-N0908

Ginsenoside Rg5 is the main component of Red ginseng. Ginsenoside blocks binding of **IGF-1** to its receptor with an IC_{50} of ~90 nM. Ginsenoside Rg5 also inhibits the mRNA expression of **COX-2** via suppression of the DNA binding activities of **NF-κB p65**.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rk3

Cat. No.: HY-N0906

Ginsenoside Rk3 is present in the roots Panax notoginseng herbs. Ginsenoside Rk3 significantly inhibits TNF-α-induced **NF-κB** transcriptional activity, with an IC_{50} of 14.24±1.30 μM in HepG2 cells.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V)

Cat. No.: HY-N0607

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca^{2+}-antagonistic antiplatelet effect with an IC_{50} of 155 μM. Ginsenoside Ro reduces the production of TXA_2 more than it reduces the activities of COX-1 and TXAS.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gitoxin

Cat. No.: HY-136933

Gitoxin, a **Na^+/K^+-ATPase** inhibitor, usually appears as a result of metabolic degradation of Digitoxin, is just the hydroxyl (ZOH) group close to the C-17β position, which changes the pharmacokinetics and pharmacodynamics of these substances considerably.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glabrol

Cat. No.: HY-N4193

Glabrol (Compound 1), One isoprenyl flavonoid was isolated from ethanol extract of licorice roots, is a potent and non-competitive **Acyl-coenzyme A: cholesterol acyltransferase (ACAT)** inhibitor with an IC_{50} value of 24.6 μM for rat liver microsomal ACAT activity.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gliclazide (S1702; SE1702)

Cat. No.: HY-B0753

Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive **potassium currents** blocker with an IC_{50} of 184 nM. Gliclazide is used as an antidiabetic.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Gliclazide-d4

Cat. No.: HY-B0753S

Gliclazide D4 (S1702 D4) is the deuterium labeled Gliclazide. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive **potassium currents** blocker with an IC_{50} of 184 nM. Gliclazide is used as an antidiabetic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Glisoxepid-d4

Cat. No.: HY-A0176S

Glisoxepid-d4 is the deuterium labeled Glisoxepide. Glisoxepide, a sulphonamide derivative, is an orally available nonselective **K(ATP) channel** blocker, with antihyperglycemic activity and cardiovascular regulation effect.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Glisoxepide

Cat. No.: HY-A0176

Glisoxepide, a sulphonamide derivative, is an orally available nonselective **K(ATP) channel** blocker, with antihyperglycemic activity and cardiovascular regulation effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

GLP-1(28-36)amide

Cat. No.: HY-P3101

GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT).



Purity: 96.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GLP-1(28-36)amide TFA

Cat. No.: HY-P3101A

GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glycerol

(Glycerin)

Cat. No.: HY-B1659

Glycerol is used in sample preparation and gel formation for polyacrylamide gel electrophoresis.



Purity: ≥98.0%
Clinical Data: Launched
Size: 100 mL

Glycerol derivative 1

Cat. No.: HY-U00378

Glycerol derivative 1 is a Glycerol derivative extracted from patent EP 672415 A1, compound (1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glycerol phenylbutyrate

(HPN-100)

Cat. No.: HY-B2087

Glycerol phenylbutyrate is a **sigma-2 (σ2)** receptor ligand, with a **pK_i** of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Glycerol phenylbutyrate-D15

(HPN-100-D15)

Cat. No.: HY-B2087S

Glycerol phenylbutyrate-D15 is a deuterium labeled Glycerol phenylbutyrate. Glycerol phenylbutyrate is a **sigma-2 (σ2)** receptor ligand, with a **pK_i** of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glycerol phenylbutyrate-D5

(HPN-100-D5)

Cat. No.: HY-B2087S1

Glycerol phenylbutyrate-D5 is a deuterium labeled Glycerol phenylbutyrate. Glycerol phenylbutyrate is a **sigma-2 (σ2)** receptor ligand, with a **pK_i** of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GlyH-101

Cat. No.: HY-18336

GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with Ki of 1.4 uM. IC50 value: 1.4 uM (Ki, at +60 mV) Target: CFTR in vitro: GlyH-101 reversibly inhibited CFTR Cl- conductance in <1 min.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GOAT-IN-1

Cat. No.: HY-103479

GOAT-IN-1 is an inhibitor of **ghrelin O-acyltransferase (GOAT)**, which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence,...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gomisin J

Cat. No.: HY-N0385

Gomisin J is a small molecular weight lignan found in Schisandra chinensis and has been demonstrated to have vasodilatory activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Gossypin

Cat. No.: HY-125911

Gossypin is a flavone isolated from Hibiscus vitifolius and has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits **NF-κB** and NF-κB-regulated gene expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GP2-114

Cat. No.: HY-U00191

GP2-114 (GP-2-114) produces current-dependent cardiovascular action when administered by transdermal iontophoresis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GP531

Cat. No.: HY-U00116

GP531 is a potent, second-generation **adenosine** regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

GPR30 agonist-1

Cat. No.: HY-138686

GPR30 agonist-1 is a **G protein-coupled receptor 30 (GPR30)** agonist. GPR30 agonist-1 exerts vasorelaxant effects.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GPRP

(Gly-Pro-Arg-Pro; Pefa 6003)

Cat. No.: HY-P0074

GPRP (Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GPRP acetate

(Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate)

Cat. No.: HY-P0074A

GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa).



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GR 125743

Cat. No.: HY-121392

GR 125743 is a selective **5-HT$_{1B/1D}$** receptor antagonist, with **pK$_i$**s of 8.85 and 8.31 for wild-type h5-HT$_{1B}$ and wild-type h5-HT$_{1D}$, respectively. GR 125743 is used for the research of Parkinson's disease and cardiovascular diseases.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GR148672X

Cat. No.: HY-110390

GR148672X is a **triacyglycerol hydrolase (TGH)** inhibitor with an **IC$_{50}$** of 4 nM extracted from patent WO 2001016358 A2.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GRGDSPK

(EMD 56574)

Cat. No.: HY-P0322

GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GRGDSPK TFA

(EMD 56574 TFA)

Cat. No.: HY-P0322A

GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GRK-IN-1

Cat. No.: HY-W036034A

GRK-IN-1 is a potential **G protein-coupled receptor kinase (GRK)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GS967

Cat. No.: HY-12593

GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late I_{Na}) with IC_{50} values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GSK-25

Cat. No.: HY-14362

GSK-25 is a potent, selective and orally bioavailable **ROCK1** inhibitor (IC_{50}=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC_{50}=398 nM, p70S6K: IC_{50}=1 μM).



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GSK-626616

Cat. No.: HY-105309

GSK-626616 is a potent, orally bioavailable inhibitor of **DYRK3** (IC_{50}=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia.



Purity: 99.83%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK1016790A

Cat. No.: HY-19608

GSK1016790A is a potent and selective **transient receptor potential vanilloid 4 (TRPV4)** channel agonist. GSK1016790A can elicit Ca^{2+} influx and elevate intracellular Ca^{2+} in HEK cells.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK1702934A

Cat. No.: HY-111098

GSK1702934A is a selective **TRPC3** agonist. GSK1702934A modulates cardiac contractility and f arrhythmogenesis by activation of TRPC3.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK180736A

Cat. No.: HY-18990

GSK180736A is potent **Rho-associated coiled-coil kinase 1 (ROCK1)** inhibitor with an IC_{50} of 100 nM. GSK180736A is also a selective and ATP-competitive **G protein-coupled receptor kinase 2 (GRK2)** inhibitor with an IC_{50} of 0.77 μM.



Purity: 97.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK2193874

Cat. No.: HY-100720

GSK2193874 is an orally active, potent, and selective **TRPV4** antagonist with IC_{50}s of 2 nM and 40 nM for **rTRPV4** and **hTRPV4**.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK2256294A

(GSK 2256294)

Cat. No.: HY-19644

GSK2256294A is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH.



Purity: 99.53%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2332255B

Cat. No.: HY-121519

GSK2332255B is a potent, selective **TRPC3** and **TRPC6** antagonist with IC_{50}s of 5 nM and 4 nM for rat **TRPC3** and rat **TRPC6**. GSK2332255B shows ≥100-fold selectivity for TRPC3/6 over other calcium-permeable channels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK269962A

(GSK 269962)

Cat. No.: HY-15556

GSK269962A (GSK 269962) is a potent **ROCK** inhibitor with IC_{50}s of 1.6 and 4 nM for recombinant human **ROCK1** and **ROCK2** respectively. GSK269962A has anti-inflammatory and vasodilatory activities.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK269962A hydrochloride

(GSK 269962 hydrochloride)

Cat. No.: HY-15556A

GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent **ROCK** inhibitor with IC_{50}s of 1.6 and 4 nM for recombinant human **ROCK1** and **ROCK2** respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK2798745

Cat. No.: HY-19765

GSK2798745 is a first-in-class, highly potent, selective, orally active transient receptor potential vanilloid 4 (**TRPV4**) **ion channel** blocker with IC_{50}s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively.



Purity: 98.27%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

GSK3395879

Cat. No.: HY-112202

GSK3395879 is a selective and orally bioavailable transient receptor potential vanilloid-4 (**TRPV4**) antagonist with an IC_{50} of 1 nM for hTRPV4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK484 hydrochloride

Cat. No.: HY-100514

GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (**PAD4**) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC_{50}s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK5182

Cat. No.: HY-111226

GSK5182 is a highly selective and orally active inverse agonist of **estrogen-related receptor γ (ERRγ)** with an IC_{50} of 79 nM. GSK5182 does not interact with other nuclear receptors, including ERRα or ERα.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guanabenz Acetate

(BR-750; Wy8678 acetate)

Cat. No.: HY-B0566

Guanabenz (Acetate) (BR-750) is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.



Purity: 98.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Guancydine

(Guancidine)

Cat. No.: HY-101554

Guancydine (Guancidine) is an antihypertensive agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Guanfacine hydrochloride

Cat. No.: HY-17416

Guanfacine hydrochloride, an anti-hypertensive agent, is a selective α2A-adrenoceptor agonist with Kd of 31 nM and displays 60-fold selectivity over α2B-adrenoceptors. IC50 Value: 31 nM(Kd) Target: Adrenergic Receptor Guanfacine is a sympatholytic.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Guanfu base A

Cat. No.: HY-N1483

Guanfu base A is an antiarrhythmic alkaloid isolated from Aconitum coreanum and is a potent noncompetitive **CYP2D6** inhibitor, with a K_i of 1.20 μM in human liver microsomes (HLMs) and a K_i of 0.37 μM for the human recombinant form (rCYP2D6).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guanfu base G

Cat. No.: HY-N5006

Guanfu base G is an antiarrhythmic alkaloid isolated from Aconitum coreanum. Guanfu base G inhibits **HERG** channel current with an IC_{50} of 17.9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guanfu base I

(Acorine)

Cat. No.: HY-N5004

Guanfu base I (Acorine) is an active metabolite of Guanfu base A, isolated from Aconitum coreanum, and has a potent anti-arrhythmic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guanoxabenz

(Hydroxyguanabenz)

Cat. No.: HY-U00123

Guanoxabenz is an **α2 adrenergic receptor** agonist, with a K_i of 4000 nM and the fully activated form 40 nM for an α2A adrenoceptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guanylate cyclase-IN-1

Cat. No.: HY-W021162

Guanylate cyclase-IN-1 (Example 46) is a **guanylate cyclase** inhibitor that can be used for cardiovascular diseases research.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guvacoline hydrochloride

Cat. No.: HY-N5016

Guvacoline hydrochloride, a pyridine alkaloid found in Areca triandra, can act as a weak full agonist of atrial and ileal muscarinic receptors.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW0742

(GW610742)

Cat. No.: HY-13928

GW0742 is a potent **PPARβ** and **PPARδ** agonist, with an IC_{50} of 1 nM for human **PPARδ** in binding assay, and EC_{50}s of 1 nM, 1.1 μM and 2 μM for human **PPARδ**, PPARα, and PPARγ, respectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GW3965

Cat. No.: HY-10627

GW3965 is a potent, selective **liver X receptor (LXR)** agonist with EC_{50}s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW3965 hydrochloride

Cat. No.: HY-10627A

GW3965 hydrochloride is a potent and selective **liver X receptor (LXR)** agonist with EC_{50}s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GW4869

Cat. No.: HY-19363

GW4869 is a noncompetitive **neutral sphingomyelinase (N-SMase)** inhibitor with an IC_{50} of 1 μM. GW4869 is an inhibitor of **exosome** biogenesis/release.



Purity: 95.57%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW7647

Cat. No.: HY-13861

GW7647 is a potent **PPARα** agonist, with EC_{50}s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW9508

Cat. No.: HY-15589

GW9508 is a potent and selective **G protein-coupled receptors FFA1 (GPR40)** and **GPR120** agonist with pEC_{50}s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for **GPR40** over **GPR120**.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Gypenoside XIII

Cat. No.: HY-N6881

Gypenoside XIII is belonging to the gypenosides. Gypenosides, extracted from Gynostemma pentaphyllum, have various pharmacological properties and protect against cardiovascular diseases, especially atherosclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gypenoside XLIX

Cat. No.: HY-N1990

Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Gypenoside XVII

(Gynosaponin S)

Cat. No.: HY-N0553

Gypenoside XVII, a novel phytoestrogen belonging to the gypenosides, can activate **estrogen receptors**.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gypsogenin

Cat. No.: HY-121382

Gypsogenin shows antiangiogenic activity and the significant cytotoxicity against H460.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gypsoside

Cat. No.: HY-N0302

Gypenoside is a triterpene saponin from gypsophila paniculata L.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GYY4137

Cat. No.: HY-107632

GYY4137 is a slow releasing **H2S donor** with vasodilator and antihypertensive activity. GYY4137 also exhibits anti-inflammatory and anticancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg

H-Ile-Pro-Pro-OH

Cat. No.: HY-114424

H-Ile-Pro-Pro-OH, a milk-derived peptide, inhibits angiotensin-converting enzyme (**ACE**) with an IC_{50} of 5 μM. Antihypertensive tripeptides.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

H-Ile-Pro-Pro-OH hydrochloride

Cat. No.: HY-114424A

H-Ile-Pro-Pro-OH hydrochloride, a milk-derived peptide, inhibits angiotensin-converting enzyme (**ACE**) with an IC_{50} of 5 μM. Antihypertensive tripeptides.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

H100

Cat. No.: HY-100322

H100 is a **Cl^- transport** inhibitor, with partial effects against both the NaK2Cl cotransporter and the Band 3 anion exchanger, but no effect against KCl cotransporter, in human erythrocytes.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

H2L 5765834

Cat. No.: HY-15706

H2L 5765834 is an antagonist of **lysophosphatidic acid receptors LPA_1**, **LPA_3**, and **LPA_5**, with IC_{50}s of 94, 752, and 463 nM respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Halofuginone

(RU-19110) Cat. No.: HY-N1584

Halofuginone (RU-19110), a Febrifugine derivative, is a competitive **prolyl-tRNA synthetase** inhibitor with a K_i of 18.3 nM. Halofuginone is a specific inhibitor of **type-I collagen** synthesis and attenuates osteoarthritis (OA) by inhibition of **TGF-β** activity.



Purity: 98.32%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Halofuginone hydrobromide

(RU-19110 hydrobromide) Cat. No.: HY-N1584A

Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive **prolyl-tRNA synthetase** inhibitor with a K_i of 18.3 nM.



Purity: 99.55%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

HAMI 3379

Cat. No.: HY-112248A

HAMI 3379 is a potent and selective **CysLT$_2$** receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCGRP-(8-37)

(Human α-CGRP (8-37)) Cat. No.: HY-P1014

HCGRP-(8-37) is a human calcitonin gene-related peptide (hCGRP) fragment and also an antagonist of **CGRP receptor**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Hederagenin 28-O-beta-D-glucopyranosyl ester

Cat. No.: HY-N2190

Hederagenin 28-O-beta-D-glucopyranosyl ester, a triterpenoid saponin isolated from Ilex cornuta, exhibits protective effects against H_2O_2-induced myocardial cell injury.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hemin

(Hemin chloride) Cat. No.: HY-19424

Hemin is an iron-containing porphyrin. Hemin is an **Heme oxygenase (HO)-1** inducer.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Hemorphin-7

Cat. No.: HY-P0318

Hemorphin-7 is a hemorphin peptide, an endogenous opioid peptide derived from the β-chain of hemoglobin. Hemorphin peptides exhibits antinociceptive and antihypertensive activities, activating opioid receptors and inhibiting angiotensin-converting enzyme (ACE).



Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Heparin

Cat. No.: HY-17567

Heparin is a highly sulfated glycosaminoglycan,that is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. Heparin significantly inhibits exosome-cell interactions.



Purity: >98%
Clinical Data: Launched
Size: 10 mg(10 mg × mL in Water)

Heparin Lithium salt

Cat. No.: HY-17567B

Heparin Lithium salt is an anticoagulant which binds reversibly to **antithrombin III (ATIII)**. Heparin Lithium salt significantly inhibits exosome-cell interactions.



Purity: >98%
Clinical Data: Launched
Size: 10 mg(10 mg × mL in Water), 100 mg, 500 mg

Heparin sodium salt

(Sodium heparin; Sodium heparinate) Cat. No.: HY-17567A

Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to **antithrombin III (ATIII)** and greatly accelerates the rate at which ATIII inactivates coagulation enzymes **thrombin factor IIa** and **factor Xa**.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg, 1 g

Heparin sodium salt (MW 15kDa)

(Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa)) Cat. No.: HY-17567C

Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg

Hepronicate

(Megrin) Cat. No.: HY-101701

Hepronicate is a peripheral vasodilator with blood lipid lowering action.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Heptadecanoic acid

Cat. No.: HY-W004284

Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Heptaminol hydrochloride

(RP-2831 hydrochloride) Cat. No.: HY-B1231

Heptaminol hydrochloride is a vasoconstrictor, used in the treatment of low blood pressure, particularly orthostatic hypotension. in vivo: In the rat, Heptaminol hydrochloride prevents orthostatic hypotension, and increases the noradrenaline plasma concentration.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

HET0016

Cat. No.: HY-124527

HET0016 is a potent and selective **20-hydroxyeicosatetraenoic acid (20-HETE)** synthase inhibitor, with **IC_{50}** values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Hexacosanoic acid

Cat. No.: HY-113301

Hexacosanoic acid is a long-chain fatty acid related to various diseases such as adrenoleukodystrophy (ALD), adrenomyeloneuropathy (AMN) and atherosclerosis.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Hexamethonium Bromide

Cat. No.: HY-B0569

Hexamethonium Bromide is a non-selective ganglionic **nicotinic-receptor antagonist (nAChR)** antagonist, with mixed competitive and noncompetitive activity. Hexamethonium Bromide has anti-hypertensive activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

HIF-1 alpha (556-574)

Cat. No.: HY-P1888

HIF-1 alpha (556-574) is a short hypoxia-inducible factor-1 (HIF-1) 19 residues fragment. HIF-1 functions as master regulator of response to oxygen homeostasis.

DLDLEMLAPYIPMDDDFQL

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIF-1 alpha (556-574) (TFA)

Cat. No.: HY-P1888A

HIF-1 alpha (556-574) TFA is a short hypoxia-inducible factor-1 (HIF-1) 19 residues fragment. HIF-1 functions as master regulator of response to oxygen homeostasis.

DLDLEMLAPYIPMDDDFQL (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIF-PHD-IN-1

Cat. No.: HY-131346

HIF-PHD-IN-1 is an orally active inhibitor of **hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD)**, with an **IC_{50}** of 54 nM for **hHIF-PHD2**. HIF-PHD-IN-1 is promising therapeutic agents for renal anemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Higenamine
(Norcoclaurine) Cat. No.: HY-N2037

Higenamine (Norcoclaurine), a β2-AR agonist, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine (Norcoclaurine) has anti-apoptotic effects.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 20 mg

Higenamine hydrochloride
(Norcoclaurine hydrochloride) Cat. No.: HY-N2037A

Higenamine hydrochloride (Norcoclaurine hydrochloride), a **β2-AR** agonist, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Hispidin
Cat. No.: HY-100618

Hispidin, a **PKC** inhibitor and a phenolic compound from Phellinus linteus, has been shown to possess strong anti-oxidant, anti-cancer, anti-diabetic, and anti-dementia properties.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

HJC0197
Cat. No.: HY-117958

HJC0197 is a potent **Epac1** (exchange protein directly activated by cAMP 1) and **Epac2** (IC_{50}=5.9 μM for Epac2) antagonist. HJC0197 selectively blocks cAMP-induced Epac activation.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HMG499
Cat. No.: HY-114316

HMG499 is a potent and selective **HMG-CoA reductase** inhibitor with an IC_{50} of 0.41 μM. HMG499 can prevent statins-induced accumulation of HMGCR, reduce serum cholesterol levels and decrease atherosclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HMR 1556
Cat. No.: HY-106369

HMR 1556, a chromanol derivative, is a potent I_{Ks} blocker with IC_{50}s of 10.5 nM and 34 nM in canine and guinea pig left ventricular myocytes, respectively.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HNGF6A
Cat. No.: HY-P1184

HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of **ROS** production during oxidative stress.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HNGF6A TFA
Cat. No.: HY-P1184A

HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of **ROS** production during oxidative stress.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HOKU-81
(4-Hydroxytulobuterol) Cat. No.: HY-50291

HOKU-81 (4-Hydroxytulobuterol) is one of the metabolites of Tulobuterol (HY-B1810). HOKU-81 is a potent and selective **β2-adrenoceptor** stimulant. HOKU-81 has bronchodilating effect.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 25 mg

Homoeriodictyol 7-O-β-D-glucoside
Cat. No.: HY-N8218

Homoeriodictyol 7-O-β-D-glucoside is a natural **platelet-activating factor (PAF)** antagonist. Homoeriodictyol 7-O-β-D-glucoside inhibits human and rabbit platelet aggregation induced by PAF, with an IC_{50} of 0.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Homovanillyl alcohol

Cat. No.: HY-N7513

Homovanillyl alcohol is a biological metabolite of Hydroxytyrosol. Hydroxytyrosol is a phenolic compound that is present in virgin olive oil (VOO) and wine. Homovanillyl alcohol protects red blood cells (RBCs) from oxidative injury and has protective effect on cardiovascular disease.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 100 mg

Hordenine

(Ordenina; Peyocactine)

Cat. No.: HY-N0113

Hordenine, an alkaloid found in plants, inhibits melanogenesis by suppression of cyclic adenosine monophosphate (cAMP) production.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

HS-1371

Cat. No.: HY-114349

HS-1371 is a potent and ATP-competitive **receptor-interacting protein kinase 3 (RIP3)** inhibitor with an **IC_{50}** of 20.8nM.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HS38

Cat. No.: HY-15847

HS38 is a potent, selective, and ATP-competitive inhibitor of **death-associated protein kinase 1 (DAPK1)** and **zipper-interacting protein kinase (ZIPK, also called DAPK3)**, with **K_d**s of 300 nM and 280 nM, respectively. HS38 is also a **PIM3** inhibitor with an **IC_{50}** of 200 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

HSF1A

Cat. No.: HY-103000

HSF1A is a cell-permeable activator of heat shock transcription factor 1 (**HSF1**). HSF1A also acts as a specific inhibitor of TRiC/CCT. Chaperonin TCP-1 ring complex (TRiC)/chaperonin containing TCP-1 (CCT) plays a pivotal role in toxin translocation and/or refolding.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Humulone

(α-Lupulic acid)

Cat. No.: HY-N6084

Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent **cyclooxygenase-2 (COX-2)** inhibitor. Humulone acts as a positive modulator of **$GABA_A$ receptor** at low micromolar concentrations. Humulone is an inhibitor of bone resorption.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydralazine hydrochloride

Cat. No.: HY-B0464

Hydralazine hydrochloride is a direct-acting vasodilator that is used as an antihypertensive agent.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Hydrastinine

Cat. No.: HY-B1181A

Hydrastinine is a major alkaloid constituent in goldenseal (Hydrastis canadensis). Hydrastinine can be used as a haemostatic agent.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Hydrastinine hydrochloride

Cat. No.: HY-B1181

Hydrastinine hydrochloride is a major alkaloid constituent in goldenseal (Hydrastis canadensis). Hydrastinine hydrochloride can be used as a haemostatic agent.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydrochlorothiazide

(HCTZ)

Cat. No.: HY-B0252

Hydrochlorothiazide (HCTZ), an orally active diuretic drug of the thiazide class, inhibits transforming **TGF-β/Smad** signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the **calcium-activated potassium (KCA)** channel.



Purity: 99.49%
Clinical Data: Launched
Size: 500 mg, 5 g, 10 g

Hydroquinidine

(Dihydroquinidine; (+)-Hydroquinidine; Hydroconquinine) Cat. No.: HY-B0997

Hydroquinidine (Dihydroquinidine) is a derivative of Quinidine (an antiarrhythmic agent). Hydroquinidine prolongs the QT interval and has antiarrhythmic efficacy.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Hydroxy bosentan

(Ro 48-5033) Cat. No.: HY-121385

Hydroxy bosentan (Ro 48-5033) is a primary metabolite of Bosentan (BOS) metabolized by the cytochrome P450 system in the liver. Ro 48-5033 assists BOS pharmacologically, retaining 10%-20% activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Hydroxy desmethyl Bosentan

(Ro 64-1056) Cat. No.: HY-135390

Hydroxy desmethyl Bosentan (Ro 64-105) is a Bosentan metabolism produced by the cytochrome P450 enzymes CYP2C9 and CYP3A4 in the liver.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxyamine hydrochloride

Cat. No.: HY-Y0882

Hydroxyamine hydrochloride is a selective **monoamine oxidase (MAO)** inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 500 mg

Hydroxyfasudil

(HA-1100) Cat. No.: HY-13911

Hydroxyfasudil is a **ROCK** inhibitor, with IC_{50}s of 0.73 and 0.72 μM for **ROCK1** and **ROCK2**, respectively.



Purity: 98.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Hydroxyfasudil hydrochloride (HA-1100 hydrochloride; HA 1100 hydrochloride; HA1100 hydrochloride)

Cat. No.: HY-13911A

Hydroxyfasudil hydrochloride is a **ROCK** inhibitor, with IC_{50}s of 0.73 and 0.72 μM for **ROCK1** and **ROCK2**, respectively.



Purity: 98.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hydroxyhexamide

((±)-Hydroxyhexamid) Cat. No.: HY-B1103

Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Hypaconine

Cat. No.: HY-N1923

Hypaconine is a C19-diterpenoid alkaloid isolated from Aconitum and Delphinium spp. Hypaconine exhibits strong cardiac activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iberiotoxin

Cat. No.: HY-P0190

Iberiotoxin is a toxin isolated from Buthus tamulus scorpion venom. Iberiotoxin is a selective high conductance high conductance **Ca^{2+}-activated K^+ channel** inhibitor with a K_d of ~1 nM. Iberiotoxin does not block other types of voltage-dependent ion channels.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 μg

Ibrolipim

(NO-1886) Cat. No.: HY-117549

Ibrolipim (NO-1886) is an orally active **lipoprotein lipase (LPL)**-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Ibutilide fumarate

(U70226E) Cat. No.: HY-B0387

Ibutilide fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ICA

(N-[4-(2-Pyridinyl)-2-thiazolyl]-2-pyridinamine) Cat. No.: HY-22044

ICA (N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine) is a **SK channel** inhibitor that has antileishmanial activity with an IC_{50} of 2.1 μM.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

ICA-121431

Cat. No.: HY-16787

ICA-121431 is a nanomolar potent and broad-spectrum **voltage-gated sodium channel (Na_v)** blocker, shows equipotent selectivity for human $Na_v1.1$ and $Na_v1.3$ subtypes with IC_{50} values of 13 nM and 23 nM, respectively.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Icariin

(Ieariline) Cat. No.: HY-N0014

Icariin is a flavonol glycoside. Icariin inhibits **PDE5** and **PDE4** activities with IC_{50}s of 432 nM and 73.50 μM, respectively. Icariin also is a **PPARα** activator.



Purity: 98.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

ICI 153110

Cat. No.: HY-100239

ICI 153110 is an orally active **phosphodiesterase** inhibitor with both vasodilating and inotropic properties which is designed for the treatment of congestive cardiac failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ifenprodil glucuronide

Cat. No.: HY-111587

Ifenprodil glucuronide is a derivative of Ifenprodil. Ifenprodil is a vasodilator and an inhibitor of platelet aggregation, and Ifenprodil glucuronide has no effect on platelet aggregation and arterial contraction.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iganidipine

Cat. No.: HY-101685

Iganidipine is a Ca^{2+} antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IK1 inhibitor PA-6

(PA-6) Cat. No.: HY-112544

IK1 inhibitor PA-6 (PA-6), a pentamidine analogue, is a selective and potent I_{K1} ($K_{IR}2.x$ ion-channel-carried inward rectifier current) inhibitor, with IC_{50} values of 12-15 nM for human and mouse $K_{IR}2.x$ currents.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Ilexoside D

Cat. No.: HY-N5037

Ilexoside D is isolated from the roots of Ilex pubescens Hook. et Arn. Ilexoside D has the anti-tissue factor activity as well as the antithrombotic activity.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ilexsaponin A

Cat. No.: HY-N2638

Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through **anti-apoptotic** pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ilexsaponin B2

Cat. No.: HY-N6256

Ilexsaponin B2 is a saponin isolated from the root of Ilex pubescens Hook. et Arn. Ilexsaponin B2 is a potent **phosphodiesterase 5 (PDE5)** and **PDEI** inhibitor with IC_{50} values of 48.8 μM and 477.5 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ilexsaponin B3

(Ilexoside K)

Cat. No.: HY-N5036

Ilexsaponin B3 has significant hypocholesterolemic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IM-54

Cat. No.: HY-108351

IM-54 is a selective inhibitor of oxidative stress-induced **necrosis**. IM-54 shows potent inhibitory activity against H_2O_2-induced necrosis. IM-54 acts as a potential cardioprotective agent and biological tool for investigating the molecular mechanisms of cell death.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg

Imanixil

(HOE-402(free base))

Cat. No.: HY-101529

Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Imidapril hydrochloride

(TA-6366)

Cat. No.: HY-B1451

Imidapril hydrochloride (TA-6366) is the hydrochloride salt of Imidapril, an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Imidapril-d3 hydrochloride

Cat. No.: HY-B1451S

Imidapril-d3 hydrochloride (TA-6366-d3) is the deuterium labeled Imidapril hydrochloride. Imidapril hydrochloride (TA-6366) is the hydrochloride salt of Imidapril, an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Imidaprilate

(6366A; Imidaprilat)

Cat. No.: HY-109592

Imidaprilate is an active metabolite of TA-6366, acts as a potent angiotensin converting enzyme (**ACE**) inhibitor, with an IC_{50} of 2.6 nM, and is used in the research of hypertensive disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imiglitazar

(TAK-559)

Cat. No.: HY-101649

Imiglitazar (TAK559) is a potent and dual human **PPARα** and **PPARγ1** agonist with EC_{50} values of 67 and 31 nM.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Implitapide

(AEGR 427)

Cat. No.: HY-106130

Implitapide (AEGR 427) is a microsomal triglyceride transfer protein (**MTP**) inhibitor.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Implitapide Racemate

Cat. No.: HY-U00329

Implitapide Racemate is the racemate of Implitapide. Implitapide is a microsomal triglyceride transfer protein (MTP) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Inclisiran

(ALN-PCSsc)

Cat. No.: HY-132591

Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of **PCSK-9**. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.

Inclisiran

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Indanazoline

Cat. No.: HY-U00075

Indanazoline (as monohydrochloride active substance of Farial) is characterized by a pronounced vasoconstrictive action.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indanidine

Cat. No.: HY-101717

Indanidine is an **alpha-adrenergic** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indapamide

Cat. No.: HY-B0259

Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Indobufen

(Ibustrin)

Cat. No.: HY-18763

Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (**Cox**) activity inhibitor. Indobufen suppresses thromboxane A_2 (TxA_2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg

Indoramin D5

(Indoramine D5; Wy-21901 D5)

Cat. No.: HY-12760S

Indoramin D5 is deuterium labeled Indoramin, which is a piperidine antiadrenergic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ingliforib

(CP 368296; GPi 296)

Cat. No.: HY-19396

Ingliforib (CP 368296) is a **glycogen phosphorylase** inhibitor, with IC_{50}s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Inogatran

(H-314-27)

Cat. No.: HY-19660

Inogatran (H-314-27) is a synthetic **thrombin** inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IONIS-DNM2-2.5Rx

(DYM101)

Cat. No.: HY-132583

IONIS-DNM2-2.5Rx (DYM101) is an antisense agent targeting **dynamin 2**. IONIS-DNM2-2.5Rx has the potential for the research of centronuclear myopathy (CNM).

IONIS-DNM2-2.5Rx

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iopromide

Cat. No.: HY-B1362

Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.



Purity: 99.99%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ipramidil

(C80-1324) Cat. No.: HY-U00172

Ipramidil (C80-1324) is a furoxan compound. Ipramidil (C80-1324) reveals marked dilator activity in the coronary circulation of isolated working hearts.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IQB-782

Cat. No.: HY-105940

IQB-782 is a cysteine derivative. IQB-782 has inhibition for **thrombin activatable fibrinolysis inhibitor (TAFI)**, with an K_i(app) of 0.14 μM. IQB-782 shows a potent mucolytic-expectorant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Irbesartan

(SR-47436; BMS-186295) Cat. No.: HY-B0202

Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.



Purity: 98.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Irbesartan-d4

(SR-47436-d4; BMS-186295-d4) Cat. No.: HY-B0202S

Irbesartan D4 is the deuterium labeled Irbesartan, which is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 1 mg

Iristectorigenin B

(Iristectrigenin B) Cat. No.: HY-N2509

Iristectorigenin B (Iristectrigenin B) is a liver X receptor (**LXR**) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IRL 2500

Cat. No.: HY-103460

IRL 2500 is a potent **Endothelin receptor** antagonist. IRL 2500 shows IC_{50} values of 1.3 and 94 nM for ET_B and ET_A receptors, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Isatin

(Indoline-2,3-dione) Cat. No.: HY-Y0265

Isatin (Indoline-2,3-dione) is a potent inhibitor of **monoamine oxidase (MAO)** with an IC_{50} of 3 μM. Also binds to central benzodiazepine receptors (IC_{50} against clonazepam, 123 μM).



Purity: 97.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Isoprenaline hydrochloride

(Isoproterenol hydrochloride) Cat. No.: HY-B0468

Isoprenaline hydrochloride is a non-selective **β-adrenergic receptor** agonist with potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 1 g

Isorhamnetin

(3'-Methylquercetin) Cat. No.: HY-N0776

Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of **MEK1** and **PI3K**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Isorhamnetin 3-O-galactoside

(Cacticin) Cat. No.: HY-N2082

Isorhamnetin 3-O-galactoside (Cacticin), a flavonoid glycoside isolated from Artemisia capillaris Thunberg, which ameliorates CCl4-induced hepatic damage by enhancing the anti-oxidative defense system and reducing the inflammatory signaling pathways.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside

Cat. No.: HY-N8214

Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside is a bioactive constituent that can be found in the seeds of Lepidium apetalum Willd. Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside exhibits significant triglyceride (TG)-lowering effects in HepG2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isorhoifolin

Cat. No.: HY-N3460

Isorhoifolin is a flavonoid glycoside from periploca nigrescens leaves. Isorhoifolin displays an anti-leakage effect.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Isosorbide

(D-Isosorbide; Dianhydro-D-glucitol)

Cat. No.: HY-B1469

Isosorbide (D-Isosorbide), an orally active vasodilating agent that can be used for the research of heart failure and angina (chest pain). Isosorbide is also an oral hyperosmotic diuretic.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

Isosorbide dinitrate

(ISDN)

Cat. No.: HY-B1409

Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI).



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Isosorbide mononitrate

(Isosorbide-5-mononitrate)

Cat. No.: HY-B0642

Isosorbide mononitrate(Isosorbide-5-mononitrate) is a nitrate-class compound used for angina pectoris; acts by dilating the blood vessels so as to reduce the blood pressure.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Isosteviol

((-)-Isosteviol; iso-Steviol)

Cat. No.: HY-N0872

Isosteviol ((-)-Isosteviol) is a derivative of Stevioside through acid catalyzed hydrolysis of Stevioside. Isosteviol inhibits DNA polymerase and DNA topoisomerase and has antibacterial, anticancer and anti-tuberculosis effects.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Isoxsuprine-monoester-1

Cat. No.: HY-101759

Isoxsuprine-monoester-1, a monoester of isoxsuprine, is a long acting peripheral vasodilator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isradipine

(PN 200-110)

Cat. No.: HY-B0233

Isradipine (PN 200-110) is an orally active **L-type calcium channel** blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation.



Purity: 98.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Isradipine-d3

Cat. No.: HY-B0233S

Isradipine-d3 (PN 200-110-d3) is the deuterium labeled Isradipine. Isradipine (PN 200-110) is an orally active **L-type calcium channel** blocker.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Istaroxime

(PST2744)

Cat. No.: HY-15718

Istaroxime (PST2744) is a potent inhibitor of **Na^+,K^+-ATPase** with **IC_{50}** of 0.11 μM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Istaroxime hydrochloride

(PST2744 hydrochloride) Cat. No.: HY-15718A

Istaroxime hydrochloride is a **Na^+/K^+-ATPase** inhibitor (IC_{50}=0.11 μM) and a sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (**SERCA 2**) activator.



Purity: 99.32%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ITD-1

Cat. No.: HY-12704

ITD-1 is the first selective **TGFβ receptor** inhibitor with an IC_{50} of 460 nM.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IU1

Cat. No.: HY-13817

IU1 is a special **Usp14** inhibitor with an IC_{50} of 4-5 μM.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ivabradine hydrochloride

Cat. No.: HY-B0162A

Ivabradine hydrochloride is an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (**HCN**) channel blocker.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Ivabradine metabolite N-Demethyl Ivabradine hydrochloride

(N-Demethyl ivabradine hydrochloride) Cat. No.: HY-12778

N-Demethyl Ivabradine Hcl is a metabolite of Ivabradine, which is a specific inhibitor of the funny channel.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ivachtin

(Caspase-3 Inhibitor VII) Cat. No.: HY-P1095

Ivachtin (Caspase-3 Inhibitor VII; compound 7a) is a nonpeptide, noncompetitive and reversibl **caspase-3** inhibitor with an IC_{50} of 23 nM. Ivachtin has modest selectivity for the remaining caspases.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

JAG-1, scrambled

(scJag-1) Cat. No.: HY-P1849

JAG-1, scrambled (scJag-1) is a scrambled sequence of JAG-1 (Jagged-1 protein). JAG-1, scrambled has a random sequence of the amino acids that are the same as the active fragment. JAG-1, scrambled is usually used as a negative control.

RCGPDCFDNYGRYKYCF

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAG-1, scrambled TFA

(scJag-1 TFA) Cat. No.: HY-P1849A

JAG-1, scrambled (scJag-1) TFA is a scrambled sequence of JAG-1 (Jagged-1 protein). JAG-1, scrambled TFA has a random sequence of the amino acids that are the same as the active fragment. JAG-1, scrambled TFA is usually used as a negative control.

RCGPDCFDNYGRYKYCF (TFA salt)

Purity: 95.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JI-101

Cat. No.: HY-16265

JI-101 is an orally available multi-kinase inhibitor of **VEGFR2**, **PDGFRβ** and **EphB4** with potent anti-cancer activity.



Purity: 99.43%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ 303

Cat. No.: HY-16953

JNJ 303 is a potent I_{Ks} blocker with an IC_{50} value of 64 nM. JNJ 303 does not have any effects on other cardiac channels at concentrations of 3.3 μM for I_{Na}, I_{ca}, I_{to}, and I_{Kr}. JNJ 303 induces QT-prolongations and causes unprovoked torsades de pointes (TdP).



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JTV-519 free base

(K201 free base)

Cat. No.: HY-15293A

JTV-519 free base (K201 free base) is a Ca^{2+}-dependent blocker of sarcoplasmic reticulum Ca^{2+}-stimulated ATPase (**SERCA**) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JTV-519 hemifumarate

(K201 hemifumarate)

Cat. No.: HY-15293B

JTV-519 hemifumarate (K201 hemifumarate) is a Ca^{2+}-dependent blocker of sarcoplasmic reticulum Ca^{2+}-stimulated ATPase (**SERCA**) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Jujuboside B

Cat. No.: HY-N0660

Jujuboside B is one of the major bioactive constituents isolated from Zizyphus jujuba. Jujuboside B can inhibit platelet aggregation.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

K-604 dihydrochloride

Cat. No.: HY-100400A

K-604 dihydrochloride is a potent and selective acyl-CoA:cholesterol acyltransferase 1 (**ACAT-1**) inhibitor with an IC_{50} of 0.45±0.06 μM.



Purity: 98.51%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

K134

(OPC33509)

Cat. No.: HY-U00186

K134 is a **phosphodiesterase 3** (**PDE3**) inhibitor. The IC_{50}s of K134 toward **PDE3A**, **PDE3B**, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 μM, respectively.



Purity: 99.67%
Clinical Data: Phase 2
Size: 5 mg, 10 mg

K41498

Cat. No.: HY-P1106

K41498 is a potent and highly selective **CRF2 receptor** antagonist with K_i values of 0.66 nM, 0.62 nM and 425 nM for human $CRF_{2\alpha}$, $CRF_{2\beta}$ and CRF_1 receptors respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K41498 TFA

Cat. No.: HY-P1106A

K41498 TFA is a potent and highly selective **CRF2 receptor** antagonist with K_i values of 0.66 nM, 0.62 nM and 425 nM for human $CRF_{2\alpha}$, $CRF_{2\beta}$ and CRF_1 receptors respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kaempferol 3-O-β-D-galactopyranoside

(Trifolin)

Cat. No.: HY-N6605

Kaempferol 3-O-β-D-galactopyranoside (Trifolin) is a derivative of flavonoid, which is isolated from the aerial part of Consolida oliveriana.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KF 13218

Cat. No.: HY-U00231

KF 13218 is a potent, selective and long lasting **thromboxane B2** (**TXB2**) synthase inhibitor with an IC_{50} value of 5.3±1.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Khellin

Cat. No.: HY-B1394

Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an **EGFR** inhibitor with an IC_{50} of 0.15 μM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kif15-IN-1

Cat. No.: HY-15948

Kif15-IN-1 is an inhibitor of the mitotic **Kinesin family member 15 (Kif15)**, and is used for the research of cellular proliferative diseases.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kif15-IN-2

Cat. No.: HY-15949

Kif15-IN-2 is an inhibitor of the mitotic **kinesin Kif15**, and is used for the research of cellular proliferative diseases.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kisspeptin-10, human

Cat. No.: HY-P0254

Kisspeptin-10, human is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development.

YNWNSFGLRF-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kisspeptin-10, human TFA

Cat. No.: HY-P0254A

Kisspeptin-10, human TFA is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human TFA acts as a tumor metastasis suppressor via its receptor GPR54.

YNWNSFGLRF-NH_2 (TFA salt)

Purity: 98.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kisspeptin-10, rat

Cat. No.: HY-P1197

Kisspeptin-10, rat is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, rat is a ligand for the rodent kisspeptin receptor (KISS1, GPR54). Kisspeptin-10 reduces Methotrexate-induced reproductive toxicity as a potential antioxidant compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kisspeptin-10, rat TFA

Cat. No.: HY-P1197A

Kisspeptin-10, rat TFA is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, rat TFA is a ligand for the rodent kisspeptin receptor (KISS1, GPR54). Kisspeptin-10 TFA reduces Methotrexate-induced reproductive toxicity as a potential antioxidant compound.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ko-3290

Cat. No.: HY-101721

Ko-3290 is an antagonist of **β-adrenoceptor**, with cardioselectivity and antilipolytic effects in animals.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Korepimedoside C

(Epimedin I)

Cat. No.: HY-N8086

Korepimedoside C (Epimedin I), a flavonol glycoside, is isolated from the aerial parts of Epimedium koreanum Nakai.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRN4884

Cat. No.: HY-U00201

KRN4884 is a **K^+ channel** opener. In the presence of intracellular ATP (1 mM), KRN4884 (0.1-3 μM) activates **K_{ATP}** channels in a concentration-dependent manner (**EC_{50}**=0.55 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KU-32

Cat. No.: HY-108248

KU-32 is a novel, novobiocin-based **Hsp90** inhibitor that can protect against neuronal cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kukoamine A

Cat. No.: HY-N2392

Kukoamine A is a natural occurring spermine derivative, acts as a potent inhibitor of **trypanothione reductase** (K_i 1.8 μM), with antihypertensive activity.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kurarinol

Cat. No.: HY-122933

Kurarinol is a flavanone found in the root of Sophora flavescens. Kurarinol is a competitive **tyrosinase** inhibitor, with IC_{50} of 0.1 μM for mushroom tyrosinase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kushenol N

Cat. No.: HY-N8095

Kushenol N is a prenylated flavonoid that can be isolated from the root of Sophora flavescens. Kushenol N has anti-allergic and vasorelaxation activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KY02111

Cat. No.: HY-13815

KY02111 is a canonical **WNT signaling (β-catenin)** inhibitor which promotes differentiation of hPSCs to cardiomyocytes. KY02111 can be used for the research of human cardiomyocyte regeneration.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

L-159282

(MK 996)

Cat. No.: HY-19191

L-159282 is a highly potent, orally active, nonpeptide **angiotensin II receptor** antagonist, with anti-hypertensive activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-765314

Cat. No.: HY-101385

L-765314 is a potent and selective **α1b adrenergic receptor** antagonist with K_is of 5.4 nM and 2.0 nM for rat and human α1b adrenergic receptor, respectively.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-902688

Cat. No.: HY-119163

L-902688 is a potent, selective and orally active **EP4 receptor** agonist with a K_i of 0.38 nM and an EC_{50} of 0.6 nM. L-902688 shows >4,000-fold selective for **EP4** over other EP and prostanoid receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg

L-Arginine

((S)-(+)-Arginine)

Cat. No.: HY-N0455

L-Arginine ((S)-(+)-Arginine) is the substrate for the endothelial nitric oxide synthase (eNOS) to generate NO.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

L-Aspartic acid

Cat. No.: HY-N0666

L-Aspartic acid is is an amino acid, shown to be a suitable prodrug for colon-specific drug deliverly.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

L-Cystathionine

Cat. No.: HY-W009749

L-Cystathionine is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids. L-Cystathionine protects against Homocysteine-induced mitochondria-dependent apoptosis of vascular endothelial cells (HUVECs).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

L-Glutathione reduced

(GSH; γ-L-Glutamyl-L-cysteinyl-glycine)

Cat. No.: HY-D0187

L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.



Purity: 99.83%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

L-Homocysteine thiolactone hydrochloride

Cat. No.: HY-101404A

L-Homocysteine thiolactone hydrochloride is an intramolecular thioester of homocysteine; prevents translational incorporation of homocysteine into proteins.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

L-Homocystine

Cat. No.: HY-W011690

L-Homocystine is the oxidized member of the L-homocysteine. Homocysteine is a pro-thrombotic factor, vasodilation impairing agent, pro-inflammatory factor and endoplasmatic reticulum-stress inducer used to study cardiovascular disease mechanisms.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

L-Kynurenine

Cat. No.: HY-104026

L-Kynurenine is a metabolite of the amino acid L-tryptophan. L-Kynurenine is an **aryl hydrocarbon receptor** agonist.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 50 mg

L-Lysine hydrochloride

Cat. No.: HY-N0470

L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

L-NIO dihydrochloride

Cat. No.: HY-100986

L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent **nitric oxide synthase (NOS)** inhibitor, with K_is of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively. L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

L-NMMA acetate

(Tilarginine acetate; Methylarginine acetate)

Cat. No.: HY-18732A

L-NMMA acetate is a **nitric oxide synthase** inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The K_i values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 μM, respectively.



Purity: 98.58%
Clinical Data: Phase 4
Size: 5 mg, 10 mg

L-Palmitoylcarnitine

Cat. No.: HY-113147

L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg

L-Palmitoylcarnitine chloride

Cat. No.: HY-113147A

L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-Palmitoylcarnitine TFA

Cat. No.: HY-113147B

L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

L162389

Cat. No.: HY-101618

L162389 is a potent antagonist of **angiotensin AT1 receptor** with K_i of 28 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L748337

Cat. No.: HY-103211

L748337 is a potent **β3-adrenergic receptor** antagonist and displays selectivity over β1 and β2 receptors. The K_i values of L748337 for β3-, β2- and β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg

Labetalol hydrochloride

(AH-5158 hydrochloride; Sch-15719W)

Cat. No.: HY-B1108

Labetalol hydrochloride is a mixed alpha/beta adrenergic antagonist that is used to treat high blood pressure.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Lacidipine

Cat. No.: HY-B0347

Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker. Target: Calcium Channel Lacidipine, a novel third-generation dihydropyridine calcium channel blocker, has been demonstrated effective for hypertension.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Lacidipine-d10

Cat. No.: HY-B0347S

Lacidipine-d10 is the deuterium labeled Lacidipine. Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Lanatoside C

Cat. No.: HY-B1030

Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg

Landiolol hydrochloride

(ONO1101 hydrochloride)

Cat. No.: HY-100607A

Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting **beta**-blocker (β1/β2 selectivity=255:1, a half-life of 4min) acts as an **adrenoceptor** antagonist.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Lappaconitine hydrobromide

(Allapinine)

Cat. No.: HY-N0118

Lappaconitine hydrobromide, a diterpene alkaloid, is a drug for the treatment of cardiac arrhythmias.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

LAS-31180

Cat. No.: HY-101811

LAS-31180 is an inhibitor of **phosphodiesterase 3**, with positive inotropic and vasodilator properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Latinone

Cat. No.: HY-N7326

Latinone, a neoflavonoid isolated from **Dalbergia cochinchinensis**, has antiosteoporotic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

LCB-2853

Cat. No.: HY-101700

LCB-2853 is an antagonist of **thromboxane A2 (TXA2) receptor**, with antiplatelet and antithrombotic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LCKLSL

Cat. No.: HY-P2333

LCKLSL is a N-terminal hexapeptide and a competitive **annexin A2 (AnxA2)** inhibitor. LCKLSL potently inhibits the **binding of tissue plasminogen activator (tPA)** to **AnxA2**. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

LCKLSL hydrochloride

Cat. No.: HY-P2333A

LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive **annexin A2 (AnxA2)** inhibitor. LCKLSL hydrochloride potently inhibits the **binding of tissue plasminogen activator (tPA)** to **AnxA2**. LCKLSL hydrochloride also inhibits the generation of plasmin and has anti-angiogenic roles.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

LDL-IN-3

Cat. No.: HY-U00054

LDL-IN-3 is an anti-atherosclerotic compound extracted from patent WO/2005/039596A1, example C25 and patent US 6133467, example 3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lemildipine

(NB-818; NPK-1886)

Cat. No.: HY-19663

Lemildipine is a new dihydropyridine **calcium** entry blocker.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lercanidipine

Cat. No.: HY-B0612

Lercanidipine is a lipophilic third-generation dihydropyridine-**calcium channel** blocker (DHP-CCB). Lercanidipine has long lasting antihypertensive action and reno-protective effect.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Lercanidipine hydrochloride

Cat. No.: HY-B0612A

Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-**calcium channel** blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Lercanidipine-d3 hydrochloride

Cat. No.: HY-B0612DS1

Lercanidipine-d3 hydrochloride is the deuterium labeled Lercanidipine. Lercanidipine is a lipophilic third-generation dihydropyridine-**calcium channel** blocker (DHP-CCB).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Leucylarginylproline

Cat. No.: HY-P0143

Leucylarginylproline is an angiotensin-converting enzyme (**ACE**) inhibitor with an IC_{50} of 0.27μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leukotriene C4

Cat. No.: HY-113446

Leukotriene C4 is the parent cysteinyl leukotriene produced by the LTC4 synthase catalyzed conjugation of glutathione to LTA4. Leukotriene C4 is produced by neutrophils, macrophages, mast cells, and by transcellular metabolism in platelets.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 25 μg (399.5 μM * 100 μL in Ethanol)

Leukotriene C4 D5

Cat. No.: HY-113446S

Leukotriene C4 D5 is the deuterium labeled Leukotriene C4. Leukotriene C4 is the parent cysteinyl leukotriene produced by the LTC4 synthase catalyzed conjugation of glutathione to LTA4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leukotriene D4

Cat. No.: HY-113456

Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4.



Purity: ≥98.0%
Clinical Data: Phase 4
Size: 10 μg (201.34 μM * 100 μL in Ethanol)

Levamlodipine besylate

((S)-Amlodipine besylate; Levoamlodipine besylate)

Cat. No.: HY-14744A

Levamlodipine besylate ((S)-Amlodipine besylate) is a powerful dihydropyridine **calcium channel** blocker, possessing vasodilation properties and used in the treatment of hypertension and angina.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Levcromakalim

((-)-Cromakalim; BRL 38227)

Cat. No.: HY-14255

Levcromakalim ((-)-Cromakalim) is an ATP-sensitive **K^+ channel** (K_{ATP}) activator.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Levopimaric acid

Cat. No.: HY-N7431

Levopimaric acid is a type of diterpene resin acid produced by plants. Levopimaric acid induces cancer cell **apoptosis** and has anticancer, antioxidant, antibacterial and cardiovascular activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Levosimendan

(Simsndan; OR-1259)

Cat. No.: HY-14286

Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Levosimendan D3

(Simsndan D3; OR-1259 D3)

Cat. No.: HY-14286S

Levosimendan D3 (Simsndan D3) is a deuterium labeled Levosimendan. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lidocaine

(Lignocaine)

Cat. No.: HY-B0185

Lidocaine (Lignocaine) inhibits **sodium channels** involving complex voltage and using dependence.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Lidocaine hydrochloride

(Lignocaine hydrochloride)

Cat. No.: HY-B0185A

Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits **sodium channels** involving complex voltage and using dependence.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Lidocaine-d10 hydrochloride

Cat. No.: HY-B0185AS

Lidocaine-d10 (Lignocaine-d10) hydrochloride is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits **sodium channels** involving complex voltage and using dependence.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 50 mg

Lidoflazine

Cat. No.: HY-112075

Lidoflazine is a high affinity blocker of the **HERG (human ether-a-go-go-related gene) K^+** channel. Lidoflazine is an antianginal **calcium channel** blocker that carries a significant risk of QT interval prolongation and ventricular arrhythmia.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Liensinine

Cat. No.: HY-N0484

Liensinine is an **autophagy/mitophagy** inhibitor.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Liensinine Diperchlorate

Cat. No.: HY-N0485

Liensinine Diperchlorate is a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn. Liensinine Diperchlorate inhibits late-stage **autophagy/mitophagy** through blocking autophagosome-lysosome fusion.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Ligustilide

Cat. No.: HY-N0401

Ligustilide is is a bioactive phthalide derivative isolated from Angelica sinensis and Chuanxiong. Ligustilide exhibits neuroprotective, anti-cancer, anti-inflammatory, and vasodilator effects.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Ligustrazine

(Chuanxiongzine; Tetramethylpyrazine)

Cat. No.: HY-N0264

Ligustrazine (Chuanxiongzine), an alkylpyrazine isolated from Ligusticum wallichii (Chuan Xiong), is present in french fries, bread, cooked meats, tea, cocoa, coffee, beer, spirits, peanuts, filberts, dairy products and soy products as fragrance and flavouring...



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Limaprost

(17α,20-dimethyl-δ2-PGE1; ONO1206; OP1206)

Cat. No.: HY-B0683

Limaprost (OP1206) is a **PGE1** analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Limaprost-d3

Cat. No.: HY-B0683S

Limaprost-d3 (17α,20-dimethyl-δ2-PGE1-d3) is the deuterium labeled Limaprost. Limaprost (OP1206) is a **PGE1** analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation.



Purity: >98%
Clinical Data:
Size: 500 µg, 5 mg

Linalool

Cat. No.: HY-N0368

Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of **Nmethyl d-aspartate (NMDA) receptor**, with anti-tumor, anti-cardiotoxicity activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Linoleic acid

Cat. No.: HY-N0729

Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds.



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

Linolelaidic acid

(Linoelaidic acid)

Cat. No.: HY-W071746

Linolelaidic acid (Linoelaidic acid), an omega-6 trans fatty acid, acts as a source of energy. Linolelaidic acid is an essential nutrient, adding in enteral, parenteral, and infant formulas. Linolelaidic acid can be used for heart diseases research.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 50 mg (1.78 M * 100 µL in Ethanol)

Lisinopril

(MK-521)

Cat. No.: HY-18206

Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Lisinopril dihydrate

(MK-521 dihydrate)

Cat. No.: HY-18206A

Lisinopri dihydrate (MK-521 dihydrate) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Lixivaptan

(VPA-985; WAY-VPA 985)

Cat. No.: HY-14185

Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective **vasopressin receptor** V2 antagonist, with IC_{50} values of 1.2 and 2.3 nM for human and rat V2, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lobetyolinin

Cat. No.: HY-124031

Lobetyolinin shows anti-arrhythmic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lodelaben

(SC-39026; Declaben)

Cat. No.: HY-100240

Lodelaben is a human neutrophil **elastase** inhibitor with an IC_{50} and K_i of 0.5 and 1.5 μM, respectively.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg

Loganic acid

Cat. No.: HY-N0513

Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Lomitapide

(AEGR-733; BMS-201038)

Cat. No.: HY-14667

Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (**MTP**) with an IC_{50} of 8 nM in vitro.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Lomitapide mesylate

(AEGR-733 mesylate; BMS-201038 mesylate)

Cat. No.: HY-14668

Lomitapide mesylate(AEGR-733; BMS-201038) is an inhibitor of microsomal triglyceride-transfer protein (MTP) wtih in vitro IC50 of 8 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Losartan

(DuP-753)

Cat. No.: HY-17512

Losartan is an **angiotensin II receptor** antagonist, competing with the binding of angiotensin II to AT1 receptors with IC_{50} of 20 nM.



Purity: 99.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Losartan (D4 Carboxylic Acid)

(E-3174 D4; EXP-3174 D4)

Cat. No.: HY-12765S

Losartan D4 Carboxylic Acid (E-3174 D4) is the deuterium labeled Losartan(EXP-3174), which is an angiotensin II receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Losartan Carboxylic Acid

(E-3174; EXP-3174) Cat. No.: HY-12765

Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an **angiotensin II receptor type 1 (AT1)** antagonist. The K_i values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Losartan D4

(DuP-753 D4) Cat. No.: HY-17512S

Losartan D4 (DuP-753 D4) is the deuterium labeled Losartan. Losartan is an **angiotensin II receptor** antagonist, competing with the binding of angiotensin II to AT1 receptors with IC_{50} of 20 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Losartan potassium

(DuP-753 potassium) Cat. No.: HY-17512A

Losartan potassium (DuP-753 potassium) is an **angiotensin II receptor type 1 (AT1)** antagonist, competing with the binding of angiotensin II to AT1 with an IC_{50} of 20 nM.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Lotusine

Cat. No.: HY-N4309

Lotusine is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Loureirin A

Cat. No.: HY-N1505

Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit **Akt** phosphorylation, and has antiplatelet activity.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Lovastatin

(Mevinolin) Cat. No.: HY-N0504

Lovastatin is a cell-permeable **HMG-CoA reductase** inhibitor used to lower cholesterol.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

LP-533401

Cat. No.: HY-15849

LP-533401 is a **Tryptophan hydroxylase 1** inhibitor that regulates serotonin production in the gut.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LP-533401 hydrochloride

Cat. No.: HY-15849A

LP-533401 hydrochloride is a **tryptophan hydroxylase 1** inhibitor that regulates serotonin production in the gut.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lp-PLA2-IN-1

Cat. No.: HY-19757

Lp-PLA2-IN-1 is a potent **Lipoprotein-associated phospholipase A2 (Lp-PLA2)** inhibitor. Lp-PLA2-IN-1 has the potential for atherosclerosis, Alzheimer's disease research.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lp-PLA2-IN-3

Cat. No.: HY-133149

Lp-PLA2-IN-3 is a potent and orally bioavailable **lipoprotein-associated phospholipase A2 (Lp-PLA2)** inhibitor, with an IC_{50} of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lucidenic acid D

(Lucidenic acid D2)

Cat. No.: HY-107260

Lucidenic acid D (Lucidenic acid D2) is a highly oxidized lanostane-type triterpenoid.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

LUF6000

Cat. No.: HY-13236

LUF6000 is an orally active allosteric modulator of the **A3 adenosine receptor**. LUF6000 has potent anti-inflammatory effect.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LUF6096

Cat. No.: HY-10915

LUF6096, a potent allosteric enhancer of the **adenosine A3 receptor**, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury.



Purity: 99.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Luteolin-7-O-β-D-glucopyranoside

Cat. No.: HY-N9380

Luteolin-7-O-β-D-glucopyranoside is one of the chemical constituents of the aerial parts of codonopsis nervosa.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LXRβ agonist-2

Cat. No.: HY-100469

LXRβ agonist-2 is a highly potent and β-selective liver X receptor **(LXRβ)** agonist with EC_{50} of 7 nM, displays 28.5-fold selectivity over LXRα (EC_{50}=200 nM) and used in the treatment of atherosclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY285434

Cat. No.: HY-U00202

LY285434 is a suitable **angiotensin II receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lyciumin A

Cat. No.: HY-N9528

Lyciumin A, a cyclic octapeptide, exhibits inhibitory activity on proteases, renin and angiotensin-converting enzyme. Lyciumin A can be used for the research of hypertension.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lyciumin B

Cat. No.: HY-N9526

Lyciumin B is a cyclic peptide isolated from Lysium chinense.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lycopene

Cat. No.: HY-N0287

Lycopene is naturally occurring carotenoids found in tomato, tomato products, and in other red fruits and vegetables; exhibits antioxidant effects.

Purity: ≥95.0%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 25 mg, 50 mg

Lycorenine

Cat. No.: HY-N6050

Lycorenine is an alkaloid that has vasodepressor action. Lycorenine also exhibits anticancer and antibacterial activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-Nifedipine

Cat. No.: HY-135356

m-Nifedipine is an impurity of Nifedipine (BAY-a-1040). Nifedipine is a potent calcium channel blocker and drug of choice for cardiac insufficiencies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

M617

Cat. No.: HY-P1131

M617 is a selective galanin receptor 1 **(GAL1)** agonist, with K_is of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

M617 TFA

Cat. No.: HY-P1131A

M617 TFA is a selective galanin receptor 1 **(GAL1)** agonist, with K_is of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.

Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

M8891

Cat. No.: HY-133016

M8891 is an orally active, reversible and brain penetrant **Methionine Aminopeptidase-2 (MetAP-2)** inhibitor with an IC_{50} of 54 nM and a K_i of 4.33 nM. M8891 does not inhibit MetAP-1 (IC_{50}>10 μM).



Purity: 98.74%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mabuterol-D9

Cat. No.: HY-13338S

Mabuterol-D9 is a deuterium labeled Mabuterol. Mabuterol is an agonist of the **β2-adrenergic receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Macitentan

(ACT-064992)

Cat. No.: HY-14184

Macitentan (ACT-064992) is an orally active, non-peptide dual **ETA** and **ETB** (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Macitentan (n-butyl analogue)

Cat. No.: HY-14184A

Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin **ETA** and **ETB receptor** antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Macitentan-d4

(ACT-064992-d4)

Cat. No.: HY-14184S

Macitentan D4 (ACT-064992 D4) is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual **ETA** and **ETB** (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAFP

(Methyl Arachidonyl Fluorophosphonate)

Cat. No.: HY-103334

MAFP (Methyl Arachidonyl Fluorophosphonate) is an selective, active-site directed and irreversible inhibitor of **cPLA2** and **iPLA2**. MAFP is also a potent irreversible inhibitor of **anandamide amidase**.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg (27 mM * 500 μL in Methyl acetate)

Magnesium Lithospermate B

Cat. No.: HY-126415

Magnesium Lithospermate B, a derivative of caffeic acid tetramer, and is extracted from Salviae miltiorrhizae.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Magnolol

Cat. No.: HY-N0163

Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both **RXRα** and **PPARγ**, with EC_{50} values of 10.4 μM and 17.7 μM, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Manganese(salen) chloride

(EUK-8)

Cat. No.: HY-W001583

Manganese(salen) chloride (EUK-8), a superoxide dismutase and catalase mimetic, is an antioxidant with oxyradical scavenging properties. Manganese(salen) chloride ameliorates acute lung injury in endotoxemic swine.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Manidipine

Cat. No.: HY-B0419

Manidipine is a calcium channel blocker that is used clinically as an antihypertensive.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Manidipine dihydrochloride

(CV-4093)

Cat. No.: HY-17403

Manidipine dihydrochloride (CV-4093) is a dihydropyridine compound and a calcium channel blocker for Ca2+ current with IC50 of 2.6 nM.



Purity: 98.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Manidipine-d4

Cat. No.: HY-B0419S

Manidipine-d4 is the deuterium labeled Manidipine. Manidipine is a calcium channel blocker that is used clinically as an antihypertensive.



Purity: >98%
Clinical Data:
Size: 1 mg

Mant-GTPγS

Cat. No.: HY-115748

Mant-GTPγS, a GTP mimetic, is a potent competitive **adenylyl cyclase (AC)** inhibitor. Mant-GTPγS is a potent **YdeH** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Marein

Cat. No.: HY-N7676

Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the **AMPK signal pathway**.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 5 mg

Marinobufogenin

Cat. No.: HY-N6574

Marinobufogenin is a strong inhibitor of **Na^+/K^+ ATPase** that has been identified in mammalian plasma.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mas7

(Mastoparan 7)

Cat. No.: HY-P0258

Mas7 (Mastoparan 7), a structural analogue of mastoparan, is an activator of heterotrimeric **Gi proteins** and its downstream effectors.

INLKALAALAKALL-NH_2

Purity: 96.77%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Mavacamten

(MYK461; SAR439152)

Cat. No.: HY-109037

Mavacamten (MYK461) is an orally active modulator of **cardiac myosin**, with **IC_{50}s** of 490, 711 nM for bovine cardiac and human cardiac, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

MBCQ

Cat. No.: HY-114672

MBCQ is a potent and selective **cGMP-specific phosphodiesterase (PDE V; PDE5)** inhibitor with an IC_{50} of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC_{50}s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

McN5691

(RWJ26240)

Cat. No.: HY-U00218

McN5691 is a voltage-sensitive **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MDL 29913

Cat. No.: HY-P1017

MDL 29913, a cyclic pseudopeptide, is a competitive **NK_2** tachykinin receptor selective antagonist, with a pA_2 of 8.66.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Meglutol

(Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid)

Cat. No.: HY-B1189

Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Melagatran

Cat. No.: HY-129056

Melagatran is a direct and orally active inhibitor of **thrombin**, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Melanin Concentrating Hormone, salmon

(MCH (salmon))

Cat. No.: HY-P1525

Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Melanin Concentrating Hormone, salmon TFA

(MCH (salmon) (TFA))

Cat. No.: HY-P1525A

Melanin Concentrating Hormone, salmon TFA (MCH (salmon) TFA) is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system.

Purity: 95.03%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Menaquinone-7

(Vitamin K2-7; Vitamin K2(35); Vitamin MK-7)

Cat. No.: HY-112499

Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins .

Purity: ≥98.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

Meranzin

Cat. No.: HY-N3298

Meranzin is an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS). Meranzin, isolated from leaves of Murraya exotica L., regulates the shared alpha 2-adrenoceptor and involves the AMPA-ERK1/2–BDNF signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Meranzin hydrate

Cat. No.: HY-N3297

Meranzin hydrate, an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS), possess anti-depression and anti-atherosclerosis effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mesaconine

Cat. No.: HY-N1922

Mesaconinean, an ingredient from Aconitum carmichaelii Debx., has cardiac effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Metaproterenol

(Orciprenaline)

Cat. No.: HY-B1276A

Metaproterenol (Orciprenaline) is a direct-acting sympathomimetic and a **β2-adrenergic receptor (β2AR)** agonist with an IC_{50} of 68 nM. Metaproterenol also has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Metaproterenol hemisulfate

(Orciprenaline hemisulfate)

Cat. No.: HY-B1276

Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a **β2-adrenergic receptor (β2AR)** agonist with an IC_{50} of 68 nM. Metaproterenol hemisulfate also has anti-inflammatory activity.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Metaproterenol-d7 hemisulfate

Cat. No.: HY-B1276S

Metaproterenol-d7 (Orciprenaline-d7) hemisulfate is the deuterium labeled Metaproterenol hemisulfate. Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a **β2-adrenergic receptor (β2AR)** agonist with an IC_{50} of 68 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Metformin

(1,1-Dimethylbiguanide)

Cat. No.: HY-B0627

Metformin (1,1-Dimethylbiguanide) inhibits the **mitochondrial respiratory chain** in the liver, leading to activation of **AMPK**, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers **autophagy**.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg

Metformin hydrochloride

(1,1-Dimethylbiguanide hydrochloride)

Cat. No.: HY-17471A

Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride) inhibits the **mitochondrial respiratory chain** in the liver, leading to activation of **AMPK**, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers **autophagy**.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg

Metformin-d6 hydrochloride

(1,1-Dimethylbiguanide-d6 hydrochloride)

Cat. No.: HY-110228

Metformin D6 hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the **mitochondrial respiratory chain** in the liver, leading to activation of **AMPK**, enhancing insulin sensitivity for type 2 diabetes research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyclothiazide

Cat. No.: HY-B0562

Methyclothiazide is an orally active **antihypertensive** agent and a **diuretic agent**.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Methyl gallate

(Gallincin; NSC 363001)

Cat. No.: HY-N2010

Methyl gallate is a plant phenolic with antioxidant, anticancer, and anti-inflammatory activities. Methyl gallate also shows **bacterial** inhibition activity. Methyl gallate also has anti-**HIV-1** and **HIV-1** enzyme inhibitory activities.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

Methyl homoveratrate

Cat. No.: HY-W042039

Methyl homoveratrate, a metabolite of RWJ-26240 in vivo, can be identified in plasma, urine and faecal extract. McN5691 (RWJ-26240) is a voltage-sensitive calcium channel blocker.



Purity: 97.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Methyldopa

(L-(-)-α-Methyldopa; MK-351) Cat. No.: HY-B0225

Methyldopa (L-(-)-α-Methyldopa), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for **α2-adrenergic receptors**). Methyldopa is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Methyldopa hydrate

(L-(-)-α-Methyldopa hydrate; MK-351 hydrate) Cat. No.: HY-B0225B

Methyldopa hydrate (L-(-)-α-Methyldopa hydrate), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for **α2-adrenergic receptors**). Methyldopa hydrate is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Methyldopa hydrochloride

(L-(-)-α-Methyldopa hydrochloride; MK-351 hydrochloride) Cat. No.: HY-B0225A

Methyldopa hydrochloride (L-(-)-α-Methyldopa hydrochloride) hydrochloride, a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for **α2-adrenergic receptors**).



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Methyldopate hydrochloride

Cat. No.: HY-B1696A

Methyldopate hydrochloride is an ethyl ester hydrochloride prodrug of α-Methyldopa (α-MD; HY-B0225). Methyldopa (L-(-)-α-Methyldopa) is an α-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopate hydrochloride has the potential for severe hypertension research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Methylnissolin

(Astrapterocarpan) Cat. No.: HY-N2484

Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits **platelet-derived growth factor (PDGF)**-BB-induced cell proliferation with an IC_{50} of 10 μM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Meticrane

Cat. No.: HY-B0908

Meticrane is a diuretic. Meticrane inhibits the reabsorption of **sodium** and **chloride** ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension.



Purity: 98.25%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Metipranolol

Cat. No.: HY-121567

Metipranolol is a nonselective and orally active **β-adrenergic receptor** antagonist. Metipranolol can be used for hypertension and glaucoma research.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Metipranolol hydrochloride

Cat. No.: HY-16316

Metipranolol hydrochloride is a non-selective **β adrenergic receptor** blocking agent.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Metolazone

(SR-720-22) Cat. No.: HY-B0209

Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Metoprolol

Cat. No.: HY-17503

Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension. IC50 value: Target: β1 receptor.



Purity: 99.89%
Clinical Data: Launched
Size: 25 mg, 50 mg, 100 mg

Metoprolol Succinate

Cat. No.: HY-17503A

Metoprolol Succinate (Toprol XL) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension. IC50 value: Target: β1 receptor.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Metoprolol Tartrate

Cat. No.: HY-17503B

Metoprolol is a cardioselective β1-adrenergic blocking agent. Target: β1- adrenergic Receptor Patients took 50 mg metoprolol twice daily with weekly titration to response or 200 mg twice daily.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Metyrosine

Cat. No.: HY-W015007

Metyrosine is a selective **tyrosine hydroxylase enzyme** inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity. Metyrosine is a very effective agent for blood pressure control.



Purity: 98.79%
Clinical Data: Launched
Size: 25 mg, 50 mg, 100 mg

Mevastatin

(Compactin; ML236B)

Cat. No.: HY-17408

Mevastatin (Compactin) is a first **HMG-CoA reductase** inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces **apoptosis**, arrests cancer cells in G_0/G_1 phase.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Mexiletine hydrochloride

(KOE-1173 hydrochloride)

Cat. No.: HY-A0093

Mexiletine hydrochloride (KOE-1173 hydrochloride), a Class IB antianhythmic, is a non-selective **voltage-gated sodium channel** blocker.



Purity: 98.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Mexiletine-d6 hydrochloride

(KOE-1173-d6 hydrochloride)

Cat. No.: HY-A0093S

Mexiletine D6 hydrochloride (KOE-1173 D6 hydrochloride) is a deuterium labeled Mexiletine hydrochloride (KOE-1173 hydrochloride). Mexiletine hydrochloride, a Class IB antianhythmic, is a non-selective voltage-gated sodium channel blocker.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MG 1

Cat. No.: HY-U00110

MG 1 is an α1 **adrenergic receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MGV354

Cat. No.: HY-111516

MGV354 is a **soluble guanylate cyclase** (**sGC**) activator with EC_{50}s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mibefradil

(Ro 40-5967)

Cat. No.: HY-15553

Mibefradil (Ro 40-5967) is a **calcium channel** blocker with moderate selectivity for T-type Ca^{2+} channels displaying IC_{50}s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Mibefradil dihydrochloride

(Ro 40-5967 dihydrochloride)

Cat. No.: HY-15553A

Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a **calcium channel** blocker with moderate selectivity for T-type Ca^{2+} channels (IC_{50}s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively).



Purity: 98.78%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mildronate
(Meldonium; MET-88; Quaterin) Cat. No.: HY-B1836

Mildronate (Meldonium) functions as a cardioprotective drug by cpmpetetively inhibiting **BBOX1** and **OCTN2**. Mildronate (Meldonium) exhibits IC_{50} values of 34-62 μM for human recombinant BBOX and an EC_{50} of 21 μM for human OCTN2.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Mildronate dihydrate (Meldonium dihydrate; MET-88 dihydrate; Quaterin dihydrate)
Cat. No.: HY-B1836A

Mildronate dihydrate (Meldonium dihydrate) functions as a cardioprotective drug by cpmpetetively inhibiting **BBOX1** and **OCTN2**. Mildronate (Meldonium) exhibits IC_{50} values of 34-62 μM for human recombinant BBOX and an EC_{50} of 21 μM for human OCTN2.



Purity: ≥99.0%
Clinical Data: Launched
Size: 5 mg, 10 mg

Milrinone
(Win 47203) Cat. No.: HY-14252

Milrinone is a **PDE3** inhibitor, and also an inotrope and vasodilator.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Milvexian
(BMS-986177; JNJ-70033093) Cat. No.: HY-125856

Milvexian (BMS-986177), an effective antithrombotic agent, is an orally-bioavailable, reversible and direct inhibitor of human and rabbit **factor XIa (FXIa)** with K_i of 0.11, and 0.38 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Minoxidil
(U10858) Cat. No.: HY-B0112

Minoxidil (U10858) is an **ATP-sensitive potassium (K_{ATP}) channel** opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Mioflazine
Cat. No.: HY-U00049

Mioflazine is an orally active **nucleoside transport** inhibitor, has the potential for sleep disorders treatment. Mioflazine inhibits nucleoside uptake.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mitochondrial fusion promoter M1
Cat. No.: HY-111475

Mitochondrial fusion promoter M1 is a mitochondrial dynamic modulator. Mitochondrial fusion promoter M1 preserves the mitochondrial function and promotes cellular respiration.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Mitochonic acid 5
(MA-5) Cat. No.: HY-111536

Mitochonic acid 5 binds **mitochondria** and ameliorates renal tubular and cardiac myocyte damage. Mitochonic acid 5 modulates **mitochondrial ATP** synthesis.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-0354
Cat. No.: HY-13008

MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 μM, showed no activation of GPR109b.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-7145
Cat. No.: HY-18277

MK-7145 is a **ROMK** inhibitor, with an IC_{50} of 0.045 μM.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

MK-8262

Cat. No.: HY-132303

MK-8262 is an orally active and potent **cholesteryl ester transfer protein (CETP)** inhibitor with an IC_{50} of 53 nM and a log D of 5.3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML171

(2-Acetylphenothiazine; 2-APT)

Cat. No.: HY-12805

ML171 (2-Acetylphenothiazine;2-APT) is a potent and selective NADPH oxidase 1 (**Nox1**) inhibitor that blocks Nox1-dependent ROS generation, with an IC_{50} of 0.25 μM in HEK293-Nox1 confirmatory assay.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

ML233

Cat. No.: HY-125976

ML233 is a non-peptide based potent **apelin receptor (APJ)** agonist (EC_{50}=3.7 μM). ML233 displays >21-fold selective over the closely related angiotensin 1 (AT1) receptor (>79 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML277

(CID-53347902)

Cat. No.: HY-12343

ML277(CID53347902) is a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator with EC50 of 270 nM.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ML359

Cat. No.: HY-114086

ML359 is a potent, selctive and reversible inhibitor of **protein disulfide isomerase (PDI)**, with an IC_{50} of 250 nM. ML359 can prevent thrombus formation in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML365

Cat. No.: HY-12345

ML365 is a selective two-pore domain potassium channel **KCNK3/TASK1** inhibitor, with an IC_{50} of 4 nM. ML365 acts as a pharmacological tool that can be used to examine the specific roles of TASK1 channels.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML67-33

Cat. No.: HY-120348

ML67-33 is a selective activator of temperature- and mechano-sensitive K_{2P} **channels**. ML67-33 rapidly and reversibly affects K_{2P}2.1 (TREK-1) with EC_{50}s of 36.3 μM and 9.7 μM in cell-free and HEK293 cells, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

MLN-4760

Cat. No.: HY-19414

MLN-4760 is a potent and selective human **ACE2** inhibitor (IC_{50}, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC_{50}, >100 μM) and bovine carboxypeptidase A (CPDA; IC_{50}, 27 μM).



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

MLS-0437605

Cat. No.: HY-123846

MLS-0437605 is a selective **dual-specificity phosphatase 3 (DUSP3)** inhibitor with an IC_{50} of 3.7 μM. MLS-0437605 is more selective for DUSP3 than DUSP22 and other protein tyrosine phosphatases (PTPs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MM 07

Cat. No.: HY-108003

MM 07 is a biased **apelin receptor** agonist, with a K_D of 300 nM in CHO-K1 cells and a K_D of 172 nM in human heart.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

MMPI-1154

Cat. No.: HY-117970

MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) **MMP-2** inhibitor(**IC_{50}**=6.6 μM) and can be used for the study of acute myocardial infarction.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Modecainide

(BMY 40327; MJ 14030)

Cat. No.: HY-101723

Modecainide is a major metabolite of Encainide, which is an antiarrhythmic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Moexipril hydrochloride

(RS-10085)

Cat. No.: HY-B0378A

Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure.



Purity: 98.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Moexipril-d5

Cat. No.: HY-117281S

Moexipril-d5 is the deuterium labeled Moexipril. Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Molidustat

(BAY 85-3934)

Cat. No.: HY-12654

Molidustat (BAY 85-3934) is a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase (**HIF-PH**) with mean **IC_{50}** values of 480 nM for PHD1, 280 nM for PHD2, and 450 nM for PHD3.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Molsidomine

(SIN-10; Morsydomine)

Cat. No.: HY-B1069

Molsidomine is an orally active, long acting vasodilating drug, metabolized in the liver to the active metabolite linsidomine, which is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Moricizine

(Moracizine)

Cat. No.: HY-B0615

Moricizine (Moracizine), a phenothiazine derivative, inhibits the rapid inward **sodium current (INa)** across myocardial cell membranes. Moricizine is an antiarrhythmia agent and has the potential for ventricular tachycardia.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Morphiceptin

Cat. No.: HY-P1701

Morphiceptin is a potent and specific agonist for **morphine (μ) receptors**. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Morusinol

Cat. No.: HY-N2299

Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an **antiplatelet** activity and significantly inhibits arterial thrombosis in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Moscatin

(Plicatol B)

Cat. No.: HY-N5035

Moscatin inhibits AA-induced platelet aggregation in a concentration-dependent manner with **IC_{50}** values 37.2 μM .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mosliciguat

Cat. No.: HY-137446

Mosliciguat is a guanylate cyclase activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Moxisylyte hydrochloride

(Thymoxamine hydrochloride)

Cat. No.: HY-B1435

Moxisylyte (hydrochloride) is (alpha 1-blocker) antagonist, it can vasodilates cerebral vessels without reducing blood pressure. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g

MPO-IN-28

Cat. No.: HY-115486

MPO-IN-28 (Compound 28) is a **myeloperoxidase** (**MPO**) inhibitor with an **IC_{50}** of 44 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MPO-IN-3

Cat. No.: HY-145197

MPO-IN-3 is a potent **myeloperoxidase (MPO)** inhibitor (WO2013068875A1, example 191). Myeloperoxidase (MPO) is a heme-containing enzyme belonging to the peroxidase superfamily.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRE-269

(ACT-333679)

Cat. No.: HY-79593

MRE-269 is an active metabolite of selexipag, and acts as a selective **IP receptor** agonist.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MRS 1523

Cat. No.: HY-121119

MRS 1523 is a potent and selective **adenosine A_3 receptor** antagonist with **K_i** values of 18.9 nM and 113 nM for **human** and **rat A_3 receptors**, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A_1 and A_{2A} receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRS 2578

Cat. No.: HY-13104

MRS 2578 is a selective and potent **P2Y6 receptor** antagonist with **IC_{50}**s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

MRS1845

Cat. No.: HY-103310

MRS1845 is a selective store-operated calcium (**SOC**) channel inhibitor with an **IC_{50}** of 1.7 μM. MRS1845 is an **ORAI1** inhibitor.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

MRS2179 tetrasodium

Cat. No.: HY-101308

MRS2179 tetrasodium is a competitive **P2Y1** receptor antagonist, with a **K_b** of 102 nM and a **pA_2** of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC_{50}=1.15 μM), P2X3 (12.9 μM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRS2179 tetrasodium hydrate

Cat. No.: HY-101308A

MRS2179 tetrasodium hydrate is a competitive **P2Y1** receptor antagonist, with a **K_b** of 102 nM and a **pA_2** of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC_{50}=1.15 μM), P2X3 (12.9 μM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

MRS2500 tetraammonium

Cat. No.: HY-108658

MRS2500 tetraammonium is a potent, selective and stable antagonist of the **P2Y1** receptor (K_i=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC_{50} value of 0.95 nM. Antithrombotic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

MRS2768 tetrasodium salt

Cat. No.: HY-108649A

MRS2768 tetrasodium salt is a moderately potent and selective **P2Y2 receptor** agonist. MRS2768 tetrasodium salt has a protective effect on cardiomyocytes from ischemic damage in vivo and in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mulberrin

(Kuwanon C)

Cat. No.: HY-N3513

Mulberrin is a strong inhibitor of organic anion-transporting polypeptide 2B1 (OATP2B1)-mediated estrone-3-sulfate (E3S) uptake with an **IC_{50}** value being 1.8±1.5 μM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Muscone

Cat. No.: HY-N0633

Muscone is the main active monomer of traditional Chinese medicine musk. Muscone inhibits **NF-κB** and **NLRP3** inflammasome activation. Muscone remarkably decreases the levels of inflammatory cytokines (**IL-1β**, **TNF-α** and **IL-6**), and ultimately improves cardiac function and survival rate.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

MY-5445

Cat. No.: HY-100933

MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, **phosphodiesterase type 5 (PDE5)**, with a K_i of 1.3 μM. MY-5445 inhibits human platelet aggregation.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MYLS22

Cat. No.: HY-136446

MYLS22 is a first-in-class and selective **optic atrophy 1 (OPA1)** inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Myricitrin

Cat. No.: HY-N0152

Myricitrin is a major antioxidant flavonoid.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

N,N'-Diacetyl-L-cystine

(DiNAC; (Ac-Cys-OH)2)

Cat. No.: HY-114348

N,N'-diacetyl-L-cystine (DiNAC) is the disulphide dimer of N-acetylcysteine with immunomodulating properties. N,N'-diacetyl-L-cystine is a potent, orally active modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

N-(3-Chloro-4-morpholinophenyl)-N'-hydroxyformimidamide

Cat. No.: HY-15603

TS-011 is a selective inhibitor of **20-Hydroxyeicosatetraenoic acid** synthesis.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 5 mg

N-(p-amylcinnamoyl) Anthranilic Acid

(ACA)

Cat. No.: HY-118628

N-(p-amylcinnamoyl) Anthranilic Acid (ACA) is a broad spectrum **Phospholipase A_2 (PLA_2)** inhibitor and **TRP channel** blocker.



Purity: 96.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

N-0861 racemate

Cat. No.: HY-U00143

N-0861 racemate is the racemate of N-0861. N-0861 is a selective adenosine A1 receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Acetyl lysyltyrosylcysteine amide

Cat. No.: HY-125039

N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of **myeloperoxidase (MPO)**. N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

N-Acetyl-Ser-Asp-Lys-Pro

(Ac-SDKP)

Cat. No.: HY-P0266

N-Acetyl-Ser-Asp-Lys-Pro, an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N-terminal site of **ACE**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Acetyl-Ser-Asp-Lys-Pro TFA

(Ac-SDKP TFA)

Cat. No.: HY-P0266A

N-Acetyl-Ser-Asp-Lys-Pro (TFA), an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N-terminal site of **ACE**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

N-Acetylneuraminic acid

(NANA; Lactaminic acid)

Cat. No.: HY-I0400

N-Acetylneuraminic acid is a nine-carbon, sialic acid monosaccharide commonly found in glycoproteins on cell membranes and in glycolipids such as gangliosides in mammalian cells.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg, 1 g

N-Acetylprocainamide

(Acecainide; NAPA)

Cat. No.: HY-B1109

N-Acetylprocainamide is a class III antiarrhythmic, which blocks **K^+ channels**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

N-Demethyl Ivabradine D6 Hydrochloride

Cat. No.: HY-12778S

N-Demethyl Ivabradine D6 Hydrochloride is the deuterium labeled N-Demethyl Ivabradine, which is a metabolite of Ivabradine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Desmethyl Sildenafil

(Desmethylsildenafil; UK-103,320)

Cat. No.: HY-117605

N-Desmethyl Sildenafil (Desmethylsildenafil) is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Feruloylserotonin

((E/Z)-Moschamine)

Cat. No.: HY-118824A

N-Feruloylserotonin, an antioxidative component and bioactive serotonin derivative, from the Seed of Carthamus tinctorius L., ameliorates atherosclerosis and distensibility of the aortic wall in Kurosawa and Kusanagi-hypercholesterolemic (KHC) rabbits.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Nornuciferine

Cat. No.: HY-N2129

N-Nornuciferine is an aporphine alkaloid in lotus leaf that significantly inhibits **CYP2D6** with **IC_{50}** and **K_i** of 3.76 and 2.34 μM, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

N6-(4-Hydroxybenzyl)adenosine

(Para-topolin riboside)

Cat. No.: HY-18775

N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM).



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Nadolol

(SQ-11725)

Cat. No.: HY-B0804

Nadolol (SQ-11725) is a non-selective and orally active **β-adrenergic receptors** blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research.



Purity: 99.97%
Clinical Data: Launched
Size: 100 mg, 250 mg, 500 mg

Nadolol-d9

(SQ-11725-d9)

Cat. No.: HY-B0804S

Nadolol D9 (SQ-11725 D9) is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active **β-adrenergic receptors** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nafamostat

Cat. No.: HY-B0190

Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Nafamostat hydrochloride

Cat. No.: HY-B0190B

Nafamostat hydrochloride, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat hydrochloride supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat hydrochloride blocks activation of SARS-CoV-2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Nafamostat mesylate

(FUT-175)

Cat. No.: HY-B0190A

Nafamostat mesylate, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat mesylate supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat mesylate blocks activation of SARS-CoV-2.



Purity: 98.06%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Naftidrofuryl oxalate

(Nafronyl oxalate salt)

Cat. No.: HY-B1107

Naftidrofuryl oxalate (Nafronyl oxalate salt) is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.



Purity: 95.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Naftopidil

(KT-611; BM-15275)

Cat. No.: HY-B0391

Naftopidil (KT-611) is is a selective **alpha1-adrenoceptor** antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_{1a}-, α_{1b}- and α_{1d}-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects.



Purity: 98.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Nagilactone B

Cat. No.: HY-N3216

Nagilactone B is a liver X receptor (**LXR**) agonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Naminidil

(BMS 234303-01)

Cat. No.: HY-100276

Naminidil is a cyanoguanidine K_{ATP} opener.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nanofin

(2,6-Lupetidine)

Cat. No.: HY-B1191

Nanofin is neuropathic blocker, with antihypertensive effect, used for mild to moderate hypertension.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Naphazoline hydrochloride

Cat. No.: HY-B0446

Naphazoline hydrochloride is an ocular vasoconstrictor and imidazoline derivative sympathomimetic amine. Target: Adrenergic Receptor Naphazoline hydrochloride is the common name for 2-(1-naphthylmethyl)-2-imidazoline hydrochloride.



Purity: 98.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Napsagatran hydrate

(Ro 46-6240 hydrate; Ro 46-6240/010 hydrate)

Cat. No.: HY-15759A

Napsagatran hydrate is a novel and specific **thrombin** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nattokinase

Cat. No.: HY-P2373

Nattokinase is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases.

Nattokinase

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NBTGR

Cat. No.: HY-108322

NBTGR (p-Nitrobenzylthioguanosine) is a potent inhibitor of **nucleoside transport**; inhibits adenosine uptake with a K_i of 70 nM.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

NCX899

Cat. No.: HY-101577

NCX899 is a NO-releasing derivative of enalapril, and shows inhibitory activity against **angiotensin-converting enzyme (ACE)** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neamine

Cat. No.: HY-N7449

Neamine, a degradation product of Neomycin, is a broad-spectrum aminoglycoside antibiotic. Neamine is an anti-angiogenesis agent targeting **angiogenin**. Neamine has potent antibacterial, antitumor and neuroprotective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nebentan

(YM598 free base)

Cat. No.: HY-106994

Nebentan (YM598 free base) is a potent, selective and orally active non-peptide **endothelin ET_A receptor** antagonist through the modification of Bosentan (HY-A0013).



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Nebentan potassium

(YM598)

Cat. No.: HY-106994A

Nebentan potassium (YM598) is a potent, selective and orally active non-peptide **endothelin ET_A receptor** antagonist through the modification of Bosentan (HY-A0013).



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Nebivolol

(R 065824)

Cat. No.: HY-B0203

Nebivolol selectively inhibits β1- adrenergic receptor with IC50 of 0.8 nM. Target: β1-adrenergic receptor Nebivolol reduces cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent maner.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Nebivolol hydrochloride

(R 065824 hydrochloride)

Cat. No.: HY-B0203A

Nebivolol hydrochloride selectively inhibits β1-adrenergic receptor with IC50 of 0.8 nM. Target: β1- adrenergic receptor Nebivolol reduces cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent maner.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Ned-K

Cat. No.: HY-131041

Ned-K is a nicotinic acid adenine dinucleotide phosphate (**NAADP**) antagonist. Ned-K is effective at dampening simulated ischaemia and reperfusion (sIR)-induced Ca^{2+} oscillations in cardiomyocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nelociguat

(BAY60-4552)

Cat. No.: HY-78237

Nelociguat (BAY60-4552) is a nitric oxide sensitive soluble guanylate cyclase stimulator.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Neoglycyrol

Cat. No.: HY-N3961

Neoglycyrol is isolated from the root of Glycyrrhiza uralensis Fisch. Neoglycyrol is a potential myocardial protection active compound screened from traditional patent medicine Tongmai Yangxin pill (TMYXP).



Purity: 99.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neophytadiene

Cat. No.: HY-N8534

Neophytadiene is a diterpene found in Turbinaria ornate, with anti-inflammatory antioxidant and cardioprotective properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NEP-IN-2

Cat. No.: HY-U00336

NEP-IN-2 is an inhibitor of **neutral endopeptidase**, used in the research of proliferation in atherosclerosis, restenosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nepicastat

(SYN117; RS-25560-197)

Cat. No.: HY-13289

Nepicastat (SYN117) is a selective, potent, and orally active inhibitor of **dopamine-beta-hydroxylase**. Nepicastat (SYN117) produces concentration-dependent inhibition of bovine (IC_{50}=8.5 nM) and human (IC_{50}=9 nM) dopamine-beta-hydroxylase.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Nepicastat hydrochloride

(SYN-117 hydrochloride; RS-25560-197 hydrochloride)

Cat. No.: HY-13289A

Nepicastat hydrochloride (SYN-117 hydrochloride) is a selective, potent, and orally active inhibitor of **dopamine-beta-hydroxylase**.



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Neuropeptide FF

(NPFF)

Cat. No.: HY-P1248

Neuropeptide FF (NPFF), an octapeptide belonging to the RF-amide family of peptides, interacts with two distinct G-protein-coupled receptors, NPFF(1) and NPFF(2) and has wide variety of physiological functions in the brain including central cardiovascular and neuroendocrine regulation.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nexopamil racemate

Cat. No.: HY-101727

Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined **Ca^{2+}/5-HT_2** antagonist on thrombus formation in vivo and on platelet aggregation in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NF449 octasodium

Cat. No.: HY-112461A

NF449 octasodium is a highly potent **$P2X_1$ receptor** antagonist, with **IC_{50}**s of 0.28, 0.69, and 120 nM for $rP2X_1$, $rP2X_{1+5}$, $P2X_{2+3}$, respectively. NF449 octasodium is a $G_{s\alpha}$ -selective **G Protein** antagonist.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

NHS-PEG1-SS-PEG1-NHS

Cat. No.: HY-136304

NHS-PEG1-SS-PEG1-NHS is a reversible **linker** for biomacromolecule link with active small molecule. NHS-PEG1-SS-PEG1-NHS can be used in proteins liposomes or nanoparticles.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Nicainoprol

(RU-42924)

Cat. No.: HY-100572

Nicainoprol is a fast-**sodium-channel** blocking drug, which is a potent antiarrhythmic agent.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nicergoline

Cat. No.: HY-B0702

Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of **α_{1A}-adrenoceptor**. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease.



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Nicorandil

(SG-75)

Cat. No.: HY-B0341

Nicorandil (SG-75) is a potent **potassium channel** activator and targets vascular nucleoside diphosphate-dependent K^+ channels and cardiac ATP-sensitive K^+ channels (K_{ATP}).



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Nicorandil-d4

Cat. No.: HY-B0341S

Nicorandil-d4 (SG-75-d4) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent **potassium channel** activator and targets vascular nucleoside diphosphate-dependent K^+ channels and cardiac ATP-sensitive K^+ channels (K_{ATP}).



Purity: >98%
Clinical Data:
Size: 2.5 mg, 5 mg, 10 mg, 25 mg

Nicotinic acid N-oxide

Cat. No.: HY-B1061

Nicotinic acid N-oxide is used to treat hyperlipoidemia.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Nicotinoyl cyclandelate

(RV 12128)

Cat. No.: HY-U00147

Nicotinoyl cyclandelate can be used to lower the perfusion pressure of cerebral blood vessels and the blood pressure of femoral artery.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nifedipine

(BAY-a-1040)

Cat. No.: HY-B0284

Nifedipine (BAY-a-1040) is a potent **calcium channel** blocker and drug of choice for cardiac insufficiencies.



Purity: 99.35%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Nifedipine-d6

(BAY-a-1040-d6)

Cat. No.: HY-B0284S

Nifedipine D6 (BAY-a-1040 D6) is deuterium labeled nifedipine, and nifedipine is a potent calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nifekalant hydrochloride

(MS-551)

Cat. No.: HY-B0772A

Nifekalant hydrochloride (MS-551), a class III antiarrhythmic agent, is a **IKr potassium channel** blocker with an IC_{50} of 10 μM. Nifekalant hydrochloride can be used for refractory ventricular tachyarrhythmias research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Niga-ichigoside F1

Cat. No.: HY-N8144

Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NIH-12848

Cat. No.: HY-101423

NIH-12848 is a putative phosphatidylinositol 5-phosphate 4-kinase γ (**PI5P4Kγ**) inhibitor with an IC_{50} of 1 μM.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nilvadipine

(FK235; FR34235)

Cat. No.: HY-14284

Nilvadipine is a potent **calcium channel** antagonist, and the IC_{50} value is around 0.1 nM.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Nimodipine

(BAY-e 9736)

Cat. No.: HY-B0265

Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive **dihydropyridine calcium** antagonist. Nimodipine can be used for the research of cerebrovascular disorders.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Nisoldipine

(BAY-k 5552)

Cat. No.: HY-17402

Nisoldipine(BAY-k 5552; Sular) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM. IC50 value: 10 nM Target: L-type Cav1.2 Nisoldipine is a potent blocker of L-type calcium channels.



Purity: 99.20%
Clinical Data: Launched
Size: 100 mg, 500 mg, 1 g

Nisoldipine-d4

Cat. No.: HY-17402S1

Nisoldipine-d4 (BAY-k 5552-d4) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC_{50} of 10 nM.



Purity: >98%
Clinical Data:
Size: 1 mg

Nisoldipine-d7

Cat. No.: HY-17402S2

Nisoldipine-d7 (BAY-k 5552-d7) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC_{50} of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nitrendipine

(BAY-E-5009)

Cat. No.: HY-B0424

Nitrendipine (BAY-E-5009), an analogue of Nifedipine (HY-B0284), is a dihydropyridine **calcium channel** blocker with vasodilator action. Nitrendipine has antihypertensive effect.



Purity: 99.25%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Nitroflurbiprofen

(HCT 1206; NO-flurbiprofen; Nitroxybutyl flurbiprofen)

Cat. No.: HY-U00013

Nitroflurbiprofen is a **cyclooxygenase** (**COX**) inhibitor with nitric oxide (NO)-donating properties, modulates the increased intrahepatic vascular tone in portal hypertensive cirrhotic rats.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Nitroprusside disodium dihydrate (Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate)

Cat. No.: HY-A0119

Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts.

$Na_2[Fe(CN)_5NO].2H_2O$

Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 10 g

Nitrosoglutathione (GSNO; RVC-588; S-Nitroso-L-glutathione)

Cat. No.: HY-D0845

Nitrosoglutathione (GSNO), a exogenous NO donor and a substrate for rat alcohol dehydrogenase class Ⅲ isoenzyme, inhibits cerebrovascular angiotensin Ⅱ-dependent and -independent AT1 receptor responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NKH477 (Colforsin dapropate hydrochloride)

Cat. No.: HY-103193

NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of **adenylate cyclase** and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

NLRP3-IN-2

Cat. No.: HY-W011082

NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the **NLRP3** inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

NMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQ

Cat. No.: HY-P3142

NMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQ

is an angiotensin-converting enzyme 2 (ACE2) related peptide that can be used as a tool for understanding ACE2 functions.

Purity: 96.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

NNC 55-0396 (NNC 55-0396 dihydrochloride)

Cat. No.: HY-50722

NNC 55-0396, Mibefradil derivative, is a highly selective T-type calcium channel blocker; displays IC50 values of 6.8 and > 100 μM for inhibition of Cav3.1 T-type channels and HVA currents respectively in INS-1 cells.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Noradrenaline tartrate (Levarterenol tartrate; L-Noradrenaline tartrate)

Cat. No.: HY-13715C

Norepinephrine tartrate (Levarterenol tartrate), a naturally occurring chemical in the body that acts as both a stress hormone and neurotransmitter, is a β_1-selective **adrenergic receptor** agonist with EC_{50} of 5.37 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Norepinephrine (Levarterenol; L-Noradrenaline)

Cat. No.: HY-13715

Norepinephrine (Levarterenol; L-Noradrenaline) is a β_1-selective **adrenergic receptor** agonist with EC_{50} of 5.37 μM.



Purity: 98.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Norepinephrine bitartrate monohydrate (Levarterenol bitartrate monohydrate; ...)

Cat. No.: HY-13715B

Norepinephrine bitartrate monohydrate (Levarterenol bitartrate monohydrate; L-Noradrenaline bitartrate monohydrate) is a β_1-selective **adrenergic receptor** agonist with EC_{50} of 5.37 μM.



Purity: 99.75%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

Norepinephrine hydrochloride (Levarterenol hydrochloride; L-Noradrenaline hydrochloride)

Cat. No.: HY-13715A

Norepinephrine hydrochloride (Levarterenol hydrochloride) is a β_1-selective **adrenergic receptor** agonist with EC_{50} of 5.37 μM.



Purity: 98.75%
Clinical Data: Launched
Size: 500 mg

Norethindrone acetate

(19-Norethindrone acetate) Cat. No.: HY-B1710

Norethindrone acetate is a female hormone used for the research of endometriosis.



Purity: 99.41%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Norethindrone acetate-D8

(19-Norethindrone acetate-D8) Cat. No.: HY-B1710S

Norethindrone acetate-D8 (19-Norethindrone acetate-D8) is the deuterium labeled Norethindrone acetate. Norethindrone acetate is a female hormone used for the research of endometriosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Norswertianolin

Cat. No.: HY-N6617

Norswertianolin acts as a **CSE** activator and is isolated from G. acuta. Norswertianolin may be a potential agent for cardiovascular diseases.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Nortadalafil

(Demethyl Tadalafil) Cat. No.: HY-90009

Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension. IC50 value: Target:.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Norverapamil

((±)-Norverapamil; D591) Cat. No.: HY-135328

Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a **L-type calcium channel** blocker and a **P-glycoprotein (P-gp)** function inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Norverapamil hydrochloride

((±)-Norverapamil hydrochloride; D591 hydrochloride) Cat. No.: HY-100750

Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a **L-type calcium channel** blocker and a **P-glycoprotein (P-gp)** function inhibitor.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Norverapamil-d7

((±)-Norverapamil-d7; D591-d7) Cat. No.: HY-135328S

Norverapamil-d7 ((±)-Norverapamil-d7) is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Norverapamil-d7 hydrochloride

((±)-Norverapamil-d7 hydrochloride; D591-d7 hydrochloride) Cat. No.: HY-135328AS

Norverapamil-d7 ((±)-Norverapamil-d7) hydrochloride is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Notch 1 TFA

Cat. No.: HY-P1985A

Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the **NOTCH** family of proteins.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Notoginsenoside Fc

Cat. No.: HY-N2531

Notoginsenoside Fc, a protopanaxadiol- (PPD-) type saponin isolated from the leaves of Panax notoginseng, effectively counteracts platelet aggregation. Notoginsenoside Fc can accelerate reendothelialization following vascular injury in diabetic rats by promoting **autophagy**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Notoginsenoside FP2

Cat. No.: HY-N4305

Notoginsenoside FP2, a dammarane-Type Bisdesmoside isolated from the Fruit Pedicels of Panax notoginseng, has potential to treat cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Notoginsenoside T5

Cat. No.: HY-N6581

Notoginsenoside T5 is a dammarane 61 glycoside. Notoginsenoside T5 is isolated from the acidic deglycosylation of saponins from the roots of P. 62 notoginseng.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NoxA1ds

Cat. No.: HY-P1435

NoxA1ds is a highly efficacious and selective **Nox1** (NADPH oxidase isoform 1) inhibitor. NoxA1ds establishes a critical interaction site for Nox1-NOXA1 binding required for enzyme activation. NoxA1ds can be used for the research of hypertension, atherosclerosis and neoplasia.

EPVDALGKAKV-NH_2

Purity: 98.82%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

NP118809

(39-1B4)

Cat. No.: HY-14462

NP118809 is a potent **N-type calcium channel** blocker, with an IC_{50} of 0.11 μM; also less potently inhibits **L-type calcium channel** with an IC_{50} of 12.2 μM.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

NQ301

Cat. No.: HY-101054

NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC_{50} of 10 mg/mL.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NS-1619

Cat. No.: HY-12496

NS-1619 is an opener of large conductance Ca^{2+}-activated K^+ (BK) channel. NS-1619 is a highly effective relaxant with an EC_{50} of about 10–30μM in several smooth muscles of blood vessels and other tissues.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

NS309

Cat. No.: HY-15416

NS309 is a potent and selective activator of the **Ca^{2+}-activated SK/IK potassium channels**, but displays no activity at BK channels.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NS5806

Cat. No.: HY-108588

NS5806, a potent **potassium current** activator, increases **K_V4.3/KChIP2** peak current amplitudes with an **EC_{50}** of 5.3 μM. NS5806 slows K_V4.3 and K_V4.2 current dacay in channel complexes containing KChIP2.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

NSC 15364

Cat. No.: HY-108937

NSC 15364 is an inhibitor of **VDAC1 oligomerization** and **apoptosis**.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg

NSP-805

Cat. No.: HY-19102

NSP-805 is a potent and selective inhibitor of guinea pig cardiac **phosphodiesterase 3 (PDE3)**, and a cardiotonic agent with vasodilator properties.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

NTP42

Cat. No.: HY-129851

NTP42 is a **thromboxane A2 (TXA2) receptor** antagonist with an IC_{50} of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca^{2+}] mobilization following stimulation of cells with the alternative TP agonist U46609.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nuvenzepine

Cat. No.: HY-U00119

Nuvenzepine is an **mAChR** antagonist, has the potential for gastrospasm treatment.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

O-304

Cat. No.: HY-112233

O-304 is a first-in-class, orally available pan-**AMPK** activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a drug to treat type 2 diabetes (T2D) and associated cardiovascular complications .



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

O-Desmethyl apixaban

Cat. No.: HY-100655

O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01). Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl apixaban sulfate sodium

Cat. No.: HY-100652A

O-Desmethyl apixaban sulfate sodium is a major circulating metabolite of Apixaban in humans. O-Desmethyl apixaban sulfate sodium inhibits **factor X (FXa)** with a K_i of 58 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Obestatin(rat)

Cat. No.: HY-P1306

Obestatin(rat), encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Obestatin(rat) TFA

Cat. No.: HY-P1306A

Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oblongine

Cat. No.: HY-N3164

Oblongine is isolated from the tuber of Stephania cambodica.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Octreotide

(SMS 201-995)

Cat. No.: HY-P0036

Octreotide is a somatostatin analog that binds to the **somatostatin receptor**, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production.

Purity: 98.84%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Octreotide acetate

(SMS 201-995 acetate)

Cat. No.: HY-17365

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits **growth hormone**, **glucagon**, and **insulin** more potently.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Odatroltide

(DHDMIQK(KAP))

Cat. No.: HY-132828

Odatroltide, as a nanoscale P-selectin inhibitor, is a nano-delivery system of 6,7-dihydroxyl-1,2,3, 4-tetrahydroisoquinoline-3-carboxylic acid and KPAK to target the thrombus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Odiparcil

(SB-424323)

Cat. No.: HY-10277

Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oglufanide

(H-Glu-Trp-OH; L-Glutamyl-L-tryptophan)

Cat. No.: HY-13718

Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits **vascular endothelial growth factor (VEGF)**. Oglufanide can stimulate the immune response to **hepatitic C virus (HCV)** and intracellular bacterial infections.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Okanin

Cat. No.: HY-N6673

Okanin, effective constituent of the flower tea Coreopsis tinctoria, attenuates LPS-induced microglial activation through inhibition of the **TLR4/NF-κB** signaling pathways.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg

Oleoylethanolamide (N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide)

Cat. No.: HY-107542

Oleoylethanolamide is a high affinity endogenous **PPAR-α** agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Oleuropein

Cat. No.: HY-N0292

Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of **PPARγ** transcriptional activity.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Olinciguat

(IW-1701)

Cat. No.: HY-109066

Olinciguat (IW-1701) is an oral **guanylate cyclase** (sGC) stimulator with concentration-dependent stimulation of sGC in purified rat and human enzyme assays and a whole cell assay.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Olmesartan

(RNH-6270)

Cat. No.: HY-17004

Olmesartan (RNH-6270) is an **angiotensin II receptor (AT1R)** antagonist used to treat high blood pressure.



Purity: 99.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Olmesartan lactone impurity

Cat. No.: HY-131276

Olmesartan lactone impurity is a cyclic ester impurity of Olmesartan. Olmesartan is an **angiotensin II receptor (AT1R)** antagonist and has the potential for high blood pressure study.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olmesartan medoxomil

(CS 866)

Cat. No.: HY-17005

Olmesartan medoxomil is a potent and selective **angiotensin AT1 receptor** inhibitor with IC_{50} of 66.2 μM.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Olmesartan medoxomil-d6

Cat. No.: HY-17005S

Olmesartan medoxomil-d6 (CS 866-d6) is the deuterium labeled Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective **angiotensin AT1 receptor** inhibitor with IC_{50} of 66.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olmesartan methyl ester

Cat. No.: HY-131278

Olmesartan methyl ester is an intermediate in the synthesis of Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective **angiotensin AT1 receptor** antagonist with IC_{50} of 66.2 μM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olmesartan-d4 Medoxomil

Cat. No.: HY-17005S1

Olmesartan-d4 Medoxomil (CS 866-d4) is the deuterium labeled Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective **angiotensin AT1 receptor** inhibitor with IC_{50} of 66.2 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Olprinone

(Loprinone)

Cat. No.: HY-14254A

Olprinone (Loprinone) is a potent **phosphodiesterase (PDE) 3** inhibitor, with IC_{50}s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Olprinone Hydrochloride

(Loprinone Hydrochloride)

Cat. No.: HY-14254

Olprinone (Loprinone) Hydrochloride is a potent **phosphodiesterase (PDE) 3** inhibitor, with IC_{50}s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

OM-189

Cat. No.: HY-100245

OM-189 is a selective synthetic **thrombin** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Omapatrilat

(BMS-186716)

Cat. No.: HY-18208

Omapatrilat is a dual inhibitor of the metalloproteases **ACE** and **NEP** with K_i values of 0.64 and 0.45 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ombrabulin

(AVE8062; AC7700)

Cat. No.: HY-14797

Ombrabulin (AVE8062) is a derivative of CA-4 phosphate, which is known to exhibit antivascular effects through selective disruption of the **tubulin** cytoskeleton of endothelial cells.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Ombrabulin hydrochloride

(AVE8062 hydrochloride; AC7700 hydrochloride)

Cat. No.: HY-18256

Ombrabulin hydrochloride is a derivative of CA-4 phosphate, which is known to exhibit antivascular effects through selective disruption of the **tubulin** cytoskeleton of endothelial cells.



Purity: 99.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Omecamtiv mecarbil

(CK-1827452)

Cat. No.: HY-14233

Omecamtiv mecarbil (CK-1827452) is a selective **cardiac myosin** activator.



Purity: 98.89%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ONO 1301

(ONO-AP 500-02)

Cat. No.: HY-106961

ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting **prostacyclin** agonist with thromboxane-synthase inhibitory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ONO-7300243

Cat. No.: HY-100882

ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (**LPA1**) antagonist with IC_{50} of 0.16 μM.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

OPC-28326

Cat. No.: HY-101610

OPC-28326 is a selective peripheral vasodilator and an angatonist of **α2-adrenergic receptor**, with K_i of 2040, 285, and 55nM for α2A-, α2B- and α2C-adrenoceptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ophiogenin

3-O-α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranoside

Cat. No.: HY-N2174

Ophiogenin 3-O-α-L-rhamnopyranosyl-(12)-β-D-glucopyranoside, a terpenoid glycoside from Ophiopogon japonicus roots, has good pharmacological effects on the cardiovascular system.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ophiopogonin D

Cat. No.: HY-N0515

Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C_{29} steroidal glycoside.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

OR-1855

Cat. No.: HY-W050000

OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

OR-1896

Cat. No.: HY-135746

OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective **phosphodiesterase (PDE) III** isoform inhibitor and a powerful vasodilator. OR-1896 can open **ATP-sensitive K^+ channels** and has Ca^{2+}-sensitizing effect.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Oral antiplatelet agent 1

Cat. No.: HY-111755

Oral antiplatelet agent 1 is a potent **antiplatelet** agent with an IC_{50} of 2.94 μM in vitro as well as antithrombotic efficacy in a rat model. P2Y receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ORM-10103

Cat. No.: HY-128678

ORM-10103 is a specific inhibitor of the **Na+/Ca2+ exchanger (NCX)**, which decreases the NCX current with estimated IC_{50}s of 55 and 67 nM at -80 and at 20 mV, respectively.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ornipressin

(POR-8)

Cat. No.: HY-P0083

Ornipressin is a potent vasoconstrictor, hemostatic and renal agent.



Purity: 98.38%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Osajin

(CID 95168; NSC 21565)

Cat. No.: HY-N3125

Osajin is the major bioactive isoflavone present in the fruit of Maclura pomifera with antitumor, antioxidant and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Osthole

(Osthol; NSC 31868)

Cat. No.: HY-N0054

Osthole (Osthol) is a natural antihistamine alternative. Osthole may be a potential inhibitor of **histamine H_1 receptor** activity. Osthole also suppresses the secretion of **HBV** in cells.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 1 g, 5 g

Otamixaban

(FXV673)

Cat. No.: HY-70035

Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.



Purity: 98.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 100 mg

Ouabain Octahydrate

(Acocantherine; G-Strophanthin)

Cat. No.: HY-B0542

Ouabain Octahydrate is an inhibitor of **Na^+/K^+-ATPase**, used for the treatment of congestive heart failure.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Oxprenolol hydrochloride

(Ba 39089)

Cat. No.: HY-B1486

Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable **β-adrenergic** receptor (**β-AR**) antagonist with a K_i of 7.10 nM in a radioligand binding assay using rat heart muscle.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Oxypeucedanin

Cat. No.: HY-N0747

Oxypeucedanin is a furocoumarin derivative isolated from Angelica dahurica. Oxypeucedanin is a selective open-channel blocker, inhibits the **hKv1.5 current** with an IC_{50} value of 76 nM.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ozagrel

(OKY-046)

Cat. No.: HY-B0428

Ozagrel (OKY-046)is an anti-asthmatic agent and a **thromboxane A2** (**TXA2**) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC_{50} of 53.12 μM.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ozagrel hydrochloride

(OKY-046 hydrochloride)

Cat. No.: HY-B0428B

Ozagrel hydrochloride (OKY-046 hydrochloride) is a **thromboxane A2** (**TXA2**) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC_{50} of 53.12 μM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ozagrel sodium

(OKY-046 sodium)

Cat. No.: HY-B0428A

Ozagrel sodium (OKY-046 sodium) is a **thromboxane A2** (**TXA2**) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC_{50} of 53.12 μM.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

P-1075

Cat. No.: HY-108573

P-1075 is a potent activator of **sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-K_{IR}6)**, with an EC_{50} value of 45 nM for SUR2B-K_{IR}6 channel activation.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

p-Tyramine-d4 hydrochloride

Cat. No.: HY-W016823S

Tyramine-d4 hydrochloride is the deuterium labeled Tyramine hydrochloride. Tyramine hydrochloride is an amino acid that helps regulate blood pressure. Tyramine hydrochloride occurs naturally in the body, and it's found in certain foods.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Pactimibe

(CS-505 free base)

Cat. No.: HY-100401

Pactimibe (CS-505 free base) is a dual **ACAT1/2** inhibitor with IC_{50}s of 4.9 μM and 3.0 μM, respectively. Pactimibe (CS-505 free base) inhibits **ACAT** with IC_{50}s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively.



Purity: 98.07%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pactimibe sulfate

(CS-505)

Cat. No.: HY-100401A

Pactimibe sulfate (CS-505) is a dual **ACAT1/2** inhibitor with IC_{50}s of 4.9 μM and 3.0 μM, respectively. Pactimibe sulfate (CS-505) inhibits **ACAT** with IC_{50}s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively.



Purity: 98.22%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PAF-AN-1

Cat. No.: HY-U00040

PAF-AN-1 is a platelet activating factor receptor (**PAF**) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitic acid

Cat. No.: HY-N0830

Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of **glucose-regulated protein 78 (GRP78)** and **CCAAT/enhancer binding protein homologous protein (CHOP)** in in mouse granulosa cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

Palonidipine

Cat. No.: HY-108997

Palonidipine is a **calcium** antagonist which is potential for the therapy of angina-pectoris and hypertension.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palonosetron

Cat. No.: HY-A0018

Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Palonosetron hydrochloride

Cat. No.: HY-A0021

Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Palonosetron-d3 hydrochloride

Cat. No.: HY-A0021S

Palonosetron-d3 hydrochloride is the deuterium labeled Palonosetron hydrochloride. Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Palosuran

(ACT-058362)

Cat. No.: HY-10655

Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of **urotensin II receptor**, with an IC_{50} of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Palosuran hydrochloride

(ACT-058362 hydrochloride) Cat. No.: HY-10655A

Palosuran hydrochloride (ACT-058362 hydrochloride) is a potent, selective, and orally active antagonist of **urotensin II receptor**, with an IC_{50} of 3.6 nM for CHO cell membranes expressing human recombinant receptors.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pamatolol

Cat. No.: HY-U00019

Pamatolol is a cardioselective **beta-adrenoceptor** antagonist without sympathomimetic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pamicogrel

(KBT3022) Cat. No.: HY-U00175

Pamicogrel (KBT3022) is a **cyclooxygenase** (**COX**) inhibitor.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PAMP-12(human, porcine)

Cat. No.: HY-P2198

PAMP-12(human, porcine) is a major component of immunoreactive (ir)-PAMP, is processed from the adrenomedullin precursor, is a potent hypotensive peptide and participates in cardiovascular control.

FRKKWNKWALSR-NH_2

Purity: 99.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PAMP-12(human, porcine) TFA

Cat. No.: HY-P2198A

PAMP-12(human, porcine) TFA is a major component of immunoreactive (ir)-PAMP, is processed from the adrenomedullin precursor, is a potent hypotensive peptide and participates in cardiovascular control.

FRKKWNKWALSR-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pargyline

Cat. No.: HY-A0091A

Pargyline is an irreversible **monoamine oxidase (MAO)** inhibitor with K_is of 13 μM and 0.5 μM for **MAO-A** and **MAO-B**, respectively. Pargyline has antihypertensive and anticancer activities.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pargyline hydrochloride

Cat. No.: HY-A0091

Pargyline hydrochloride is an irreversible **monoamine oxidase (MAO)** inhibitor with K_is of 13 μM and 0.5 μM for **MAO-A** and **MAO-B**, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Parmodulin 2

(ML161) Cat. No.: HY-13965

Parmodulin 2 (ML161) is an allosteric inhibitor of **protease-activated receptor 1 (PAR1)** with an IC_{50} of 0.26 μM.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Parstatin(human)

Cat. No.: HY-P1262

Parstatin(human), a cell-penetrating **PAR-1 thrombin receptor** agonist peptide, is a potent inhibitor of angiogenesis.

MGPRRLLLVAACFSLCGPLLSARTRARRPESKATNATLDPR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Parstatin(human) TFA

Cat. No.: HY-P1262A

Parstatin(human) TFA, a cell-penetrating **PAR-1 thrombin receptor** agonist peptide, is a potent inhibitor of angiogenesis.

MGPRRLLLVAACFSLCGPLLSARTRARRPESKATNATLDPR (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Parstatin(mouse)

Cat. No.: HY-P1261

Parstatin(mouse), a cell-penetrating **PAR-1 thrombin receptor** agonist peptide, is a potent inhibitor of angiogenesis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Parstatin(mouse) TFA

Cat. No.: HY-P1261A

Parstatin(mouse) TFA, a cell-penetrating **PAR-1 thrombin receptor** agonist peptide, is a potent inhibitor of angiogenesis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PCA50941

Cat. No.: HY-U00034

PCA50941 is a 1,4-dihydropyridine derivative, used for treatment for cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PCC0208009

Cat. No.: HY-100771

PCC0208009 is a potent **IDO** inhibitor with an IC_{50} value of 4.52 nM in HeLa cell. PCC0208009 alleviates neuropathic pain and comorbidities by regulating synaptic plasticity of anterior cingulate cortex (ACC) and amygdala .



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

PCSK9-IN-2

Cat. No.: HY-132897

PCSK9-IN-2 is a novel small molecule inhibitor of **PCSK9-LDLR** protein–protein interaction (PPI) with an IC_{50} value of 7.57 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PCSK9-IN-3

Cat. No.: HY-139998

PCSK9-IN-3 is a novel, highly potent, and orally bioavailable next-generation tricyclic peptide **PCSK9** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD 123319

((S)-(+)-PD 123319)

Cat. No.: HY-10259

PD 123319 (ditrifluoroacetate) is a potent, selective **AT2 angiotensin II receptor** antagonist with IC_{50} of 34 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD 123319 ditrifluoroacetate

Cat. No.: HY-10259A

PD 123319 (ditrifluoroacetate) is a potent, selective **AT2 angiotensin II receptor** antagonist with IC_{50} of 34 nM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PD 151746

Cat. No.: HY-19749

PD151746 is a calpain inhibitor, shows a 20-fold selectivity for u-calpain (Ki = 0.26 ± 0.03 μM) over m-calpain (Ki = 5.33 ± 0.77 μM).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD-159020

Cat. No.: HY-101598

PD-159020 is a non-selective **ETA/ETB** antagonist, with IC_{50}s of 30 and 50 nM for hETA and hETB, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg

PD-166793

Cat. No.: HY-107428

PD-166793 is a potent, selective, orally active and widebroad spectrum inhibitor of **MMP**, exhibiting nanomolar potency against **MMP-2**, **MMP-3** and **MMP-13** (IC_{50}=4, 7, and 8 nM, respectively) and micromolar potency vs **MMP-1**, **-7** and **-9** (IC_{50}=6.0, 7.2, and 7.9...



Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg

PD0176078

Cat. No.: HY-U00236

PD0176078 is a newly found N-type **Calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD146176

(NSC168807)

Cat. No.: HY-103157

PD146176 (NSC168807), a **15-Lipoxygenase (15-LO)** inhibitor, inhibits rabbit reticulocyte 15-LO (K_i=197 nM, IC_{50}=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

PDE10A-IN-2 hydrochloride

Cat. No.: HY-131973

PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active **phosphodiesterase 10A (PDE10A)** inhibitor with an IC_{50} of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDE5-IN-2

Cat. No.: HY-112704

PDE5-IN-2 is a potent, highly selective, and orally active **PDE5** inhibitor, with an IC_{50} of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC_{50}s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Penbutolol sulfate

((-)-Terbuclomine)

Cat. No.: HY-B1154

Penbutolol sulfate is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective β blocker. Penbutolol is a sympathomimetic drugused in the treatment of high blood pressure.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Pentoxifylline

(BL-191; PTX; Oxpentifylline)

Cat. No.: HY-B0715

Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective **phosphodiesterase (PDE)** inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects.



Purity: 99.35%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Pentoxifylline-d6

Cat. No.: HY-B0715S

Pentoxifylline-d6 (BL-191-d6) is the deuterium labeled Pentoxifylline.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Perhexiline maleate

Cat. No.: HY-B1334A

Perhexiline maleate is a potent **carnitine palmitoyltransferase 1 (CPT 1)** inhibitor with IC_{50}s of 77 and 148 μM for rat heart and liver CPT 1, respectively.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Perindopril

(S-9490) Cat. No.: HY-B0130

Perindopril (S-9490) is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease. Target: ACE Perindopril is a long-acting ACE inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Perindopril erbumine

(Perindopril tert-butylamine salt; S-9490 erbumine) Cat. No.: HY-B0130A

Perindopril erbumine (Perindopril tert-butylamine salt) is a potent ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease. Target: ACE Perindopril is a long-acting ACE inhibitor.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Perindopril-d4 erbumine

Cat. No.: HY-B0130S

Perindopril-d4 t-butylamine salt is the deuterium labeled Perindopril t-butylamine salt. Perindopril t-butylamine salt is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

PF-06282999

Cat. No.: HY-19321

PF-06282999 is a potent and selective **myeloperoxidase** inhibitor which is potential useful for the treatment of cardiovascular diseases.



Purity: 99.41%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-06446846 hydrochloride

Cat. No.: HY-120088A

PF-06446846 hydrochloride is an orally active and highly selective inhibitor of **translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9)**. PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-1355

(PF-06281355) Cat. No.: HY-100873

PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-3882845

Cat. No.: HY-12738

PF-3882845 is a remarkably high affinity selective and orally efficacious **mineralocorticoid receptor** (**MR** binding IC_{50}=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to **progesterone receptor** (**PR**) with the binding IC_{50} of 310 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-543

(Sphingosine Kinase 1 Inhibitor II) Cat. No.: HY-15425

PF-543 (Sphingosine Kinase 1 Inhibitor II) is a potent, selective, reversible and sphingosine-competitive **SPHK1** inhibitor with an IC_{50} of 2 nM and a K_i of 3.6 nM. PF-543 is >100-fold selectivity for **SPHK1** over SPHK2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-543 Citrate

(Sphingosine Kinase 1 Inhibitor II Citrate) Cat. No.: HY-15425A

PF-543 Citrate (Sphingosine Kinase 1 Inhibitor II Citrate) is a potent, selective, reversible and sphingosine-competitive **SPHK1** inhibitor with an IC_{50} of 2 nM and a K_i of 3.6 nM. PF-543 Citrate is >100-fold selectivity for **SPHK1** over SPHK2.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-543 hydrochloride

(Sphingosine Kinase 1 Inhibitor II hydrochloride) Cat. No.: HY-15425B

PF-543 hydrochloride (Sphingosine Kinase 1 Inhibitor II hydrochloride) is a potent, selective, reversible and sphingosine-competitive **SPHK1** inhibitor with an IC_{50} of 2 nM and a K_i of 3.6 nM. PF-543 hydrochloride is >100-fold selectivity for **SPHK1** over SPHK2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PHD-1-IN-1

Cat. No.: HY-136300

PHD-1-IN-1 is an orally active and potent **HIF prolylhydroxylase domain-1 (PHD-1)** inhibitor with an IC_{50} of 0.034 μM. PHD-1-IN-1 has a unique monodentate binding interaction with the active site Fe^{2+} ion and induces the formation of an "Arg367-out" pocket.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phenidone

Cat. No.: HY-W010144

Phenidone, an orally active dual inhibitor of **cyclooxygenase (COX)** and **lipoxygenase (LOX)**, ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Phenindione

(Rectadione)

Cat. No.: HY-B0325

Phenindione is an anticoagulant which functions as a Vitamin K antagonist. Target: Others Phenindione(Rectadione) is an anticoagulant which functions as a Vitamin K antagonist.



Purity: 98.44%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Phenindione D5

(Rectadione D5)

Cat. No.: HY-B0325S

Phenindione D5 (Rectadione D5) is deuterium labeled Phenindione, which is an anticoagulant which functions as a Vitamin K antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phenoxybenzamine hydrochloride

Cat. No.: HY-B0431A

Phenoxybenzamine hydrochloride is a selective antagonist of both **α-adrenoceptor** and **calmodulin** that is commonly used for the treatment of hypertension, specifically caused by pheochromocytoma.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g

Phentolamine mesylate

(Phentolamine methanesulfonate)

Cat. No.: HY-B0362A

Phentolamine mesylate (Phentolamine methanesulfonate) is a reversible, non-selective, and orally active blocker of **α1** and **α2 adrenergic receptor** that expands blood vessels to reduce peripheral vascular resistance.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Phentolamine-d4 hydrochloride

Cat. No.: HY-12717AS

Phentolamine-d4 (Phentolamine-d4) hydrochloride is the deuterium labeled Phentolamine hydrochloride.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Phenylephrine

((R)-(-)-Phenylephrine; L-Phenylephrine)

Cat. No.: HY-B0769

(R)-(-)-Phenylephrine is a selective **α_1-adrenoceptor** agonist primarily used as a decongestant.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Phenylephrine hydrochloride ((R)-(-)-Phenylephrine hydrochloride; L-Phenylephrine hydrochloride)

Cat. No.: HY-B0471

(R)-(-)-Phenylephrine hydrochloride is a selective **α_1-adrenoceptor** agonist with **pK_is** of 5.86, 4.87 and 4.70 for α_{1D}, α_{1B} and α_{1A} receptors respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

PHM-27 (human)

Cat. No.: HY-P1072

PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the **human calcitonin receptor** agonist with an EC_{50} of 11 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phosphoramidon Disodium

Cat. No.: HY-N2021A

Phosphoramidon Disodium is a **metalloprotease** inhibitor. Phosphoramidon inhibits endothelin-converting enzyme (**ECE**), neutral endopeptidase (**NEP**), and angiotensin-converting enzyme (**ACE**) with IC_{50} values of 3.5, 0.034, and 78 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Phosphorylcholine

(Phosphocholine)

Cat. No.: HY-B2233B

Phosphatidylcholine is the main phospholipid component in eukaryotic biofilms. Phosphatidylcholine exists in commensal or pathogenic bacteria associated with eukaryotes in prokaryotes. Phosphorylcholine exhibits a surprising range of immunomodulatory properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Phosphorylcholine chloride

(Phosphocholine chloride)

Cat. No.: HY-B2233

Phosphorylcholine chloride (Phosphocholine chloride) is an antigenic cell-surface component found on many commensal and pathogenic bacteria that reside in the upper airway.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

PHPS1

Cat. No.: HY-112368

PHPS1 is a potent and selective **Shp2** inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PHPS1 sodium

Cat. No.: HY-125108

PHPS1 sodium is a potent and selective **Shp2** inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Physion 8-O-β-D-glucoside

Cat. No.: HY-N2107

Physion 8-O-β-D-glucoside, a bioactive component of Fallopia multiflora, can be used for the research of dizziness.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Piboserod

(SB-207266)

Cat. No.: HY-15574

Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist. IC50 value: Target: 5-HT4 antagonist in vitro: Piboserod did not modify the basal contractions but concentration-dependently antagonized the ability of 5-HT to enhance bladder strip contractions to EFS.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg

Piboserod hydrochloride

(SB-207266 hydrochloride)

Cat. No.: HY-15574A

Piboserod (SB 207266) Hcl is a selective 5-HT(4) receptor antagonist. IC50 value: Target: 5-HT4 antagonist in vitro: Piboserod did not modify the basal contractions but concentration-dependently antagonized the ability of 5-HT to enhance bladder strip contractions to EFS.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Piceatannol 3'-O-glucoside

(Quzhaqigan)

Cat. No.: HY-N2237

Piceatannol 3'-O-glucoside, an active component of Rhubarb, activates endothelial **nitric oxide** (**NO**) **synthase** through inhibition of arginase activity with IC_{50}s of 11.22 μM and 11.06 μM against **arginase I** and **arginase II**, respectively.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 1 mg

Pimaric acid

Cat. No.: HY-N3063

Pimaric acid is a resin acid that has been found in A. cordata and various pines. Pimaric acid reduces mRNA expression, protein levels, and promoter activity of matrix metalloproteinase-9 (MMP-9) in TNF-α-stimulated human aortic smooth muscle cells (HASMCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pimobendan

(UD-CG115) Cat. No.: HY-B0204

Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC_{50} of 0.32 μM.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pimobendan hydrochloride

(UD-CG115 hydrochloride) Cat. No.: HY-B0204A

Pimobendan hydrochloride (UD-CG115 hydrochloride) is a selective inhibitor of PDE3 with IC_{50} of 0.32 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pinoresinol 4-O-β-D-glucopyranoside

((+)-Pinoresinol 4-O-β-D-glucopyranoside) Cat. No.: HY-N2168

Pinoresinol 4-O-β-D-glucopyranoside ((+)-Pinoresinol 4-O-β-D-glucopyranoside) is the major active furofuran type lignans in Fructus Forsythiae.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Piperlongumine

(Piplartine) Cat. No.: HY-N2329

Piperlongumine is a alkaloid, possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Piperlonguminine

Cat. No.: HY-126562

Piperlonguminine is an alkaloid amide isolated from the Piper species. Piperlonguminine shows various biological properties, including anti-inflammatory, antitumor, neuroprotective, anti-platelet, anti-melanogenic, antifungal and antibacterial activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Piperlotine A

Cat. No.: HY-N3051

Piperlotine A is an alkaloid isolated from Piper lolot, with potent antiplatelet aggregation activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Piperlotine C

Cat. No.: HY-N3049

Piperlotine C is an alkaloid isolated from Piper lolot, with anti-platelet aggregation induced by arachidonic acid, and the **IC_{50}** is 26.6 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pirmenol hydrochloride

(Cl-845; (±)-Pirmenol hydrochlorid) Cat. No.: HY-100795A

Pirmenol hydrochloride inhibits **$I_{K.ACh}$** by blocking **muscarinic receptors**. The **IC_{50}** of Pirmenol for inhibition of Carbachol-induced $I_{K.ACh}$ is 0.1 μM.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pitavastatin lactone

Cat. No.: HY-125643

Pitavastatin lactone is a major metabolite of Pitavastatin in humans. Pitavastatin is a potent competitive inhibitor of HMG-CoA reductase little metabolized in hepatic microsomes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pivalopril

(Pivopril; RHC 3659(S)) Cat. No.: HY-U00041

Pivalopril is a new orally active angiotensin converting enzyme (**ACE**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKG drug G1

Cat. No.: HY-112197

PKG drug G1 targets C42 of **PKG Iα**. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PKR activator 1

Cat. No.: HY-135883

PKR activator 1 is a potent **pyruvate kinase-R (PKR)** activator extracted from patent WO2019035865A1, compound E7-93.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKR activator 2

Cat. No.: HY-135884

PKR activator 2 is a potent **pyruvate kinase-R (PKR)** activator extracted from patent WO2019035863A1, compound 385.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Plantainoside D

Cat. No.: HY-N5063

Plantainoside D shows **ACE** inhibitory activity with **IC_{50}** 2.17 mM. And plantainoside D is a promising **IKK-β** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Platelet Factor 4 (58-70), human

Cat. No.: HY-P1798

Platelet Factor 4 (58-70), human, a peptide based on the amino acid sequence corresponding to residues 58-70 of platelet factor-4 (PF-4), contains the major heparin-binding domain, which is not sufficient for full antiangiogenic activity.

PLYKKIIKKLLES

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PMX-53

(3D53)

Cat. No.: HY-106178

PMX-53 (3D53) is a synthetic peptidic and a potent and orally active **complement C5a receptor (CD88)** antagonist with an **IC_{50}** of 20 nM. PMX-53 is also a low-affinity **MrgX2** agonist that stimulates **MrgX2**-mediated mast cell degranulation.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Polidocanol (Polyoxyethylene lauryl ether; Polyoxyethyleneglycol Dodecyl Ether)

Cat. No.: HY-B2106

Polidocanol is a sclerosing agent used successfully to treat extremity and esophageal varices and telangiectasias.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mg(10 mg × mL in Water), 500 mg, 1 g, 5 g

Poliumoside

Cat. No.: HY-N0033

Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens **aldose reductase** (**RLAR**) inhibitor, with **IC_{50}**s of 19.69 and 8.47 μM, respectively.



Purity: 95.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pparδ agonist 1

Cat. No.: HY-107901

Pparδ agonist 1 is a **PPAR-δ** agonist, with an **EC_{50}** of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PPC-NB

Cat. No.: HY-126530

PPC-NB is a glutathione cleavable **linker** used for the antibody-drug conjugate **(ADC)**.



Purity: 96.32%
Clinical Data: No Development Reported
Size: 100 mg

Practolol

Cat. No.: HY-119802

Practolol is a potent and selective **β1-adrenergic receptor** antagonist. Practolol can be used for the research of cardiac arrhythmias.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Praeruptorin C

Cat. No.: HY-N0079

Praeruptorin C is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a **calcium** antagonist with pD_2' value of 5.7.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Praeruptorin E

Cat. No.: HY-N6066

Praeruptorin E is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a **calcium** antagonist with pD_2' value of 5.2.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Praliciguat

(IW-1973)

Cat. No.: HY-109039

Praliciguat (IW-1973) is a potent and orally active **soluble guanylate cyclase** stimulator, enhances NO signaling, acts as a vasodilator. Praliciguat (IW-1973) stimulates sGC in HEK-293 cells with an EC_{50} of 197 nM.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pranidipine

(OPC-13340)

Cat. No.: HY-19664

Pranidipine (OPC-13340) is a potent, long acting 1,4-dihydropyridine **calcium channel** blocker with antihypertensive activity.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Prasugrel

(PCR 4099)

Cat. No.: HY-15284

Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent **P2Y12** receptor antagonist, and inhibits ADP-induced platelet aggregation.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Prasugrel (Maleic acid)

(PCR 4099 (Maleic acid))

Cat. No.: HY-15284B

Prasugrel (PCR 4099) Maleic acid is a thienopyridine and prodrug, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent **P2Y12** receptor antagonist, and inhibits ADP-induced platelet aggregation.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Prasugrel hydrochloride

(PCR 4099 hydrochloride)

Cat. No.: HY-15284A

Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and prodrug, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent **P2Y12** receptor antagonist, and inhibits ADP-induced platelet aggregation.



Purity: 99.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Pratosartan

(FW 7203; KD 3-671; KT 3671)

Cat. No.: HY-101574

Pratosartan is a selective **angiotensin II receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pravastatin

(CS-514)

Cat. No.: HY-B0165

Pravastatin (CS-514) is a competitive **HMG-CoA reductase** inhibitor against sterol synthesis with IC_{50} of 5.6 μM.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg

Pravastatin sodium
(CS-514 sodium)

Cat. No.: HY-B0165A

Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC_{50} of 5.6 μM.



Purity: 99.49%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Pravastatin-d3 sodium salt

Cat. No.: HY-B0165CS

Pravastatin-d3 (CS-514-d3) sodium salt is the deuterium labeled Pravastatin sodium salt. Pravastatin (CS-514) sodium salt is a competitive **HMG-CoA reductase** inhibitor against sterol synthesis with IC_{50} of 5.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prazosin

Cat. No.: HY-B0193

Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Prazosin hydrochloride

Cat. No.: HY-B0193A

Prazosin hydrochloride is a well-tolerated, CNS-active **α1-adrenergic receptor** antagonist for the research of high blood pressure and alcohol use disorders.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Prepro VIP (81-122), human

Cat. No.: HY-P1767

Prepro VIP (81-122), human is a prepro-vasoactive intestinal polypeptide (VIP) derived peptide, corresponding to residues 81-122.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prifuroline

Cat. No.: HY-100145

Prifuroline is an antiarrhythmic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prinoxodan
(RGW2938)

Cat. No.: HY-U00208

Prinoxodan (RGW2938) is a **phosphodiesterase** inhibitor.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg

Proadrenomedullin (45-92), human

Cat. No.: HY-P1838

Proadrenomedullin (45-92), human, a mid-regional fragment of proadrenomedullin (MR-proADM), comprises amino acids 45–92 of pre-proADM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Proanthocyanidins

Cat. No.: HY-N0794

Proanthocyanidins are a class of polyphenolic that are widely distributed in higher plants, consisted of an electrophilic flavanyl unit. Proanthocyanidins can be used as antioxidant and anti-cancers agent.



Purity: ≥95.0%
Clinical Data: Phase 4
Size: 10 mg, 50 mg, 100 mg

Procion Blue HB
(Reactive Blue 2)

Cat. No.: HY-D0965

Procion Blue HB (Reactive Blue 2) is a **purinergic** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Prodipine hydrochloride

Cat. No.: HY-101605

Prodipine, a diphenyl-phosphonate derivative. The IC_{50}s of Prodipine for purified and plasma **Dipeptidyl peptidase IV** (**DPP IV**) from the rabbit are 4.5 μM and 30 μM, respectively.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 1 mg

Progesterone

(Pregn-4-ene-3,20-dione)

Cat. No.: HY-N0437

Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

Prolyl Hydroxylase inhibitor 1

Cat. No.: HY-112441

Prolyl Hydroxylase inhibitor 1 (Compound 15i) is an orally active hypoxia inducible factor (**HIF**)-prolyl hydroxylase (**PHD**) inhibitor with an IC_{50} of 62.23 nM. Antianemia agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prolylleucine

(((Benzyloxy)carbonyl)-L-prolyl-D-leucine)

Cat. No.: HY-112173

Prolylleucine is a dipeptide containing branched-chain amino acids. Prolylleucine can affect the circadian rhythms and behaviour of animals.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Pronethalol

((±)-Pronethalo)

Cat. No.: HY-B1238

Pronethalol ((±)-Pronethalo) is a non-selective **β-adrenergic** antagonist. Pronethalol is a potent inhibitor of **Sox2** expression. Pronethalol protects against and to reverse Digitalis-induced ventricular arrhythmias and limits the cerebral arteriovenous malformation (AVMs).



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pronethalol hydrochloride

((±)-Pronethalo hydrochloride)

Cat. No.: HY-B1238A

Pronethalol ((±)-Pronethalo) is a non-selective **β-adrenergic** antagonist. Pronethalol is a potent inhibitor of **Sox2** expression. Pronethalol protects against and to reverse Digitalis-induced ventricular arrhythmias, and limits the cerebral arteriovenous malformation (AVMs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Pronethalol-d6

Cat. No.: HY-B1238S

Pronethalol-d6 ((±)-Pronethalo-d6) is the deuterium labeled Pronethalol. Pronethalol ((±)-Pronethalo) is a non-selective **β-adrenergic** antagonist. Pronethalol is a potent inhibitor of **Sox2** expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Propafenone D5 hydrochloride

Cat. No.: HY-B0432AS2

Propafenone D5 (SA-79 D5) hydrochloride is the deuterium labeled Propafenone hydrochloride. Propafenone (SA-79) hydrochloride is a class of anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propafenone hydrochloride

(SA-79 hydrochloride)

Cat. No.: HY-B0432A

Propafenone (hydrochloride) (SA-79 (hydrochloride)) is a class of anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias.



Purity: 99.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Propafenone-d5 (hydrochloride)(Ethyl)

Cat. No.: HY-B0432AS3

Propafenone-d5 hydrochloride(Ethyl) (SA-79-d5 hydrochloride(Ethyl)) is the deuterium labeled Propafenone hydrochloride.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Propranolol

Cat. No.: HY-B0573B

Propranolol is a nonselective **β-adrenergic receptor (βAR)** antagonist, has high affinity for the β1AR and β2AR with K_i values of 1.8 nM and 0.8 nM, respectively. Propranolol inhibits [^{3}H]-DHA binding to rat brain membrane preparation with an IC_{50} of 12 nM.



Purity: 99.87%
Clinical Data: Launched
Size: 100 mg

Propranolol-d7 hydrochloride

Cat. No.: HY-B0573S

Propranolol D7 hydrochloride is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective **β-adrenergic receptor (βAR)** antagonist, has high affinity for the β1AR and β2AR with K_i values of 1.8 nM and 0.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prosaikogenin A

Cat. No.: HY-N9402

Prosaikogenin A is a triterpene saponin isolated from Clinopodium chinense. Prosaikogenin A has significant promoting effects on platelet aggregation with an EC_{50} value of 12.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prostaglandin E1

(Alprostadil; PGE1)

Cat. No.: HY-B0131

Prostaglandin E1 (Alprostadil) is a **prostanoid receptor** ligand, with K_is of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for **mouse EP3**, **EP4**, **EP2**, **IP** and **EP1**, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation.



Purity: 98.03%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg

Prostaglandin E1-d4

Cat. No.: HY-B0131S

Prostaglandin E1-d4 (Alprostadil-d4) is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a **prostanoid receptor** ligand, with K_is of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for **mouse EP3**, **EP4**, **EP2**, **IP** and **EP1**, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Prostaglandin E2

(PGE2; Dinoprostone)

Cat. No.: HY-101952

Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.



Purity: 98.36%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Protogracillin

Cat. No.: HY-N4271

Protogracillin is a steroidal saponin isolated from Dioscorea zingiberensis Wright (DZW). Steroidal saponins from DZW rhizomes have the potential to reduce the risk of cardiovascular diseases by anti-thrombotic action.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Proxyphylline

Cat. No.: HY-B1742

Proxyphylline is a methylxanthine derivative used as a cardiac stimulant, vasodilator and bronchodilator.



Purity: 98.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

PRX-08066

Cat. No.: HY-15472

PRX-08066 is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR, IC50= 3.4 nM) antagonist that causes selective vasodilation of pulmonary arteries.



Purity: 97.04%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

PRX933 hydrochloride

(GW876167 hydrochloride; BVT-933 hydrochloride)

Cat. No.: HY-100171

PRX933 hydrochloride is a **5-HT$_{2c}$ receptor** agonist extracted from patent WO 2014140631 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Przewalskinic acid A

Cat. No.: HY-N5057

Przewalskinic acid A is a phenolic acid found in the Salvia przewalskii Maxim herb. Phenolic acids show potent antioxidant activities and potential effects in protecting against brain and heart damage caused by ischemia reperfusion.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSB-0739

Cat. No.: HY-108660

PSB-0739 is a high-affinity potent, competitive, nonselective platelet **$P2Y_{12}$ receptor** antagonist with a K_i values of 24.9 nM. The $P2Y_{12}$ receptor plays a crucial role in platelet aggregation. Antithrombotic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSB069

Cat. No.: HY-103262

PSB069 bearing a p-chlorophenylamino residue is a potent, well-tolerated and nonselective **NTPDases1, 2, 3** inhibitor(K_i=16~18 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Purpurogallin

Cat. No.: HY-12136

Purpurogallin is a naturally phenol extracted from the plants of Quercus spp, has potent **xanthine oxidase (XO)** inhibitory activity with an **IC_{50}** of 0.2 μM. Purpurogallin has antioxidant and anti-inflammatory effects.



Purity: 95.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pyripyropene A

Cat. No.: HY-117832

Pyripyropene A is a potent and selective **sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2)** inhibitor, with an **IC_{50}** of 0.07 μM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 250 μg

Pyrrophenone

Cat. No.: HY-111376

Pyrrophenone is a potent and specific cytosolic phospholipase $A_2\alpha$ (**$cPLA_2\alpha$**) inhibitor with an IC_{50} value of 4.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pz-1

Cat. No.: HY-U00437

Pz-1 is a potent **RET** and **VEGFR2** inhibitor with **IC_{50}**s of less than 1 nM for both wild type kinases.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PZ-128

(P1pal-7)

Cat. No.: HY-107146

PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible **protease-activated receptor-1 (PAR1)** antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

QF0301B

Cat. No.: HY-101690

QF0301B is an **α1 adrenergic receptor** antagonist and a low α2 adrenoceptor, 5-HT2A, and histamine H1 receptor blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quercetin 3,7-dimethyl ether

Cat. No.: HY-N1798

Quercetin 3,7-dimethyl ether, isolated from Croton schiedeanus Schlecht, has a NO/cGMP pathway-related profile, with increased vasorelaxant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside

Cat. No.: HY-N7607

Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside is main antioxidant from Shuxuening, an herbal medicines injection.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 1 mg

Quinapril hydrochloride

(CI-906)

Cat. No.: HY-B0477

Quinapril (hydrochloride) (CI-906) is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications.



Purity: 99.05%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Quinapril-d5 hydrochloride

Cat. No.: HY-B0477AS1

Quinapril-d5 hydrochloride (CI-906-d5) is the deuterium labeled Quinapril hydrochloride. Quinapril hydrochloride (CI-906) is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Quinaprilat-d5

Cat. No.: HY-127026S

Quinaprilat-d5 is a deuterium-labeled Quinaprilat. Quinaprilat is a nonsulfhydryl ACE inhibitor, the active diacid metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits bradykinin degradation.



Purity: 91.05%
Clinical Data: No Development Reported
Size: 1 mg

Quinidine

Cat. No.: HY-B1751

Quinidine is an antiarrhythmic agent for the treatment of abnormal heart rhythms and also malaria.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Quinidine hydrochloride monohydrate

Cat. No.: HY-B1302

Quinidine hydrochloride monohydrate is an anti-arrythmic agent which is also a potent blocker of **K⁺ channel** with an IC_{50} of 19.9 μM.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Quininic acid

Cat. No.: HY-N7354

Quininic acid, purified from Eucalyptus globulus, cinchona bark, and other plant products, is the most abundant organic acid.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

R 80123

Cat. No.: HY-100615A

R 80123 is the Z-isomer of R 79595, is also a highly selective phosphodiesterase inhibitor. The fuction is similar to R 80122 (HY-100615, Revizinone).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

R-IMPP

(PF-00932239)

Cat. No.: HY-101354

R-IMPP (PF-00932239) is an anti-secretagogue of **PCSK9** (IC_{50}=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

rac Timolol-d5 maleate

Cat. No.: HY-17494S

(Rac)-Timolol-d5 Maleate ((Rac)-L-714,465-d5 Maleate) is a labelled racemic (S)-Timolol maleate. (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic **β-adrenoceptor** blocker.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Rafigrelide

(3,3-Dimethylanagrelide) Cat. No.: HY-U00383

Rafigrelide is a platelet-lowering agent, and also has antithrombotic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ralinepag

(APD811) Cat. No.: HY-16751

Ralinepag is a potent, orally bioavailable and non-prostanoid **prostacyclin (IP) receptor** agonist, with **EC_{50}**s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ramipril

(HOE-498) Cat. No.: HY-B0279

Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC_{50} of 5 nM.



Purity: 98.16%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Ranaconitine

Cat. No.: HY-N2507

Ranaconitine is a diterpene alkaloid isolated from A. leucostomum, with cardiotoxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Ranibizumab

(RG-6321) Cat. No.: HY-P9951

Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research.

Ranibizumab

Purity: 98.60%
Clinical Data: Launched
Size: 1 mg

Ranolazine

(CVT 303; RS 43285-003) Cat. No.: HY-B0280

Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward **sodium** current (I_{Na} and I_{Kr} with **IC_{50}** values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP).



Purity: 99.48%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Ranolazine dihydrochloride

(CVT 303 dihydrochloride; RS 43285) Cat. No.: HY-17401

Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward **sodium** current (I_{Na} and I_{Kr} with **IC_{50}** values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure...



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Ranolazine-d8

Cat. No.: HY-B0280S1

Ranolazine-d8 (CVT 303-d8) is the deuterium labeled Ranolazine.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Raspberry ketone

(Frambione; 4-(4-Hydroxyphenyl)-2-butanone) Cat. No.: HY-N1426

Raspberry ketone is a major aromatic compound of red raspberry, widely used as a fragrance in cosmetics and as a flavoring agent in foodstuff; also shows **PPAR-α** agonistic activity.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Rat CGRP-(8-37)

Cat. No.: HY-P0209

Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective **CGRP receptor** antagonist.

Purity: 98.54%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Razaxaban hydrochloride

(BMS 561389 hydrochloride; DPC 906 hydrochloride) Cat. No.: HY-11091

Razaxaban hydrochloride (BMS 561389 hydrochloride) is a highly potent, selective and orally active **factor Xa** inhibitor with a K_i of 0.19 nM. Razaxaban hydrochloride exhibits excellent selectivity (>5000-fold) for **factor Xa** over other related serine proteases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Regadenoson

(CVT-3146) Cat. No.: HY-A0168

Regadenoson (CVT-3146) is a potent and selective **A2A adenosine receptor** agonist, with K_is of 290 and 1120 nM for rat and pig adenosine A2A receptor, respectively.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Regaloside C

Cat. No.: HY-N7627

Regaloside C is a glycerol glucoside isolated from the bulbs of Lilium genus with anti-inflammatory activities. Regaloside C has cardiomyocyte protective activity by protecting the mitochondria in H_2O_2-induced heart H9C2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Reldesemtiv

(CK-2127107) Cat. No.: HY-109121

Reldesemtiv (CK-2127107) is a selective, orally active and next-generation **fast skeletal muscle troponin** activator (FSTA). Reldesemtiv selectively activates fast skeletal myofibrils with an EC_{50} of 3.4 μM. Reldesemtiv increases exercise performance in a heart failure model.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rentiapril

(SA-446) Cat. No.: HY-106446

Rentiapril is an orally active **angiotensin converting enzyme (ACE)** inhibitor with antihypertensive activity.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rentiapril racemate

(SA-446 racemate) Cat. No.: HY-U00074

Rentiapril racemate (SA-446 racemate) is the racemate of Rentiapril. Rentiapril is an **angiotensin converting enzyme** (**ACE**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Resmetirom

(MGL-3196; VIA-3196) Cat. No.: HY-12216

Resmetirom (MGL-3196) is a highly selective thyroid hormone receptor β (**THR-β**) agonist with an EC_{50} value of 0.21 μM.



Purity: 99.71%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Resorcinolnaphthalein

Cat. No.: HY-122445

Resorcinolnaphthalein is a specific **angiotensin-converting enzyme 2 (ACE2)** enhancer and activates ACE2 activity with an EC_{50} value of 19.5 μM. Resorcinolnaphthalein can be used for the investigation of hypertension and renal fibrosis.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Resveratroloside

(trans-Resveratrol 4'-O-β-D-glucopyranoside) Cat. No.: HY-N4195

Resveratroloside is a competitive inhibitior of **α-glucosidase** with an IC_{50} of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Reticuline

Cat. No.: HY-N1356

Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3. Reticuline exhibits cardiovascular effects.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Retrobradykinin

Cat. No.: HY-P2039

Retrobradykinin has the reverse sequence of Bradykinin (HY-P0206). Retrobradykinin exhibits no kinin activity and can be used as a negative control for Bradykinin.

RFPSFGPPR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Revefenacin

(TD-4208; GSK1160724)

Cat. No.: HY-15851

Revefenacin (TD-4208; GSK1160724) is a potent **mAChR** antagonist; has a high affinity on M3 receptor with a K_i of 0.18 nM.



Purity: 99.78%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Revizinone

(R80122)

Cat. No.: HY-100615

Revizinone is a novel selective phosphodiesterase (PDE) inhibitor with IC50 values on this enzyme to 0.036 microM.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

RF9

Cat. No.: HY-107382

RF9 is a potent and selective **Neuropeptide FF receptor** antagonist, with K_i values of 58 and 75 nM for **hNPFF1R** and **hNPFF2R**, respectively.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

RF9 hydrochloride

Cat. No.: HY-107382A

RF9 hydrochloride is a potent and selective **Neuropeptide FF receptor** antagonist, with K_i values of 58 and 75 nM for **hNPFF1R** and **hNPFF2R**, respectively.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RGH-5526

(GYKI-11679)

Cat. No.: HY-100151

RGH-5526 (GYKI-11679) is a new antihypertensive agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhamnocitrin

Cat. No.: HY-N1353

Rhamnocitrin is a flavonoid isolated from astragalus complanatus R. Br. (Sha-yuan-zi). Rhamnocitrin is a scavenger of DPPH with an IC_{50} of 28.38 mM. Rhamnocitrin has anti-oxidant, anti-inflammatory and an-tiatherosclerosis activity.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhodamine 123

(RH-123; R-22420)

Cat. No.: HY-D0816

Rhodamine 123 (RH-123; R-22420) is a fluorescent dye (λ_{ex}=503 nm, λ_{em}=527 nm).



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rilmenidine

Cat. No.: HY-100490

Rilmenidine, an innovative antihypertensive agent, is an orally active, selective **I1 imidazoline receptor** agonist. Rilmenidine is an **alpha 2-adrenoceptor** agonist. Rilmenidine induces **autophagy**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Rilmenidine hemifumarate

Cat. No.: HY-100490A

Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective **I1 imidazoline receptor** agonist. Rilmenidine hemifumarate is an **alpha 2-adrenoceptor** agonist. Rilmenidine hemifumarate induces autophagy.



Purity: 99.82%
Clinical Data: Launched
Size: 5 mg, 10 mg

Rilmenidine phosphate

Cat. No.: HY-100490B

Rilmenidine phosphate, an innovative antihypertensive agent, is an orally active, selective **I1 imidazoline receptor** agonist. Rilmenidine phosphate is an **alpha 2-adrenoceptor** agonist. Rilmenidine phosphate induces **autophagy**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Riociguat

(BAY 632521)

Cat. No.: HY-14779

Riociguat is an oral stimulator of soluble guanylate cyclase (**sGC**) used in the treatment of pulmonary hypertension.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Riociguat-d6

Cat. No.: HY-14779S1

Riociguat-d6 (BAY 632521-d6) is the deuterium labeled Riociguat. Riociguat is an oral stimulator of soluble guanylate cyclase (**sGC**) used in the treatment of pulmonary hypertension.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Rivaroxaban

(BAY 59-7939)

Cat. No.: HY-50903

Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct **Factor Xa** (**FXa**) inhibitor, achieving a strong gain in anti-FXa potency (IC_{50} 0.7 nM; K_i 0.4 nM).



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Rivaroxaban-d4

(BAY 59-7939-d4)

Cat. No.: HY-50903S

Rivaroxaban D4 (BAY 59-7939 D4) is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potentselective and direct **Factor Xa** (**FXa**) inhibitor, achieving a strong gain in anti-FXa potency (IC_{50} 0.7 nM; K_i 0.4 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

RK-24466

(KIN 001-51)

Cat. No.: HY-108318

RK-24466 (KIN 001-51) is a potent and selective **Lck** inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC_{50}s of less than 1 and 2 nM, respectively.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

RN-1 dihydrochloride

Cat. No.: HY-110130

RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective **lysine-specific demethylase 1 (LSD1)** inhibitor with an IC_{50} of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC_{50} values of 0.51 μM and 2.785 μM respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

RN-1747

Cat. No.: HY-19976

RN-1747 is a selective **transient receptor potential cation channel subfamily V member 4 (TRPV4)** agonist, with EC_{50} values are 0.77 μM, 4.0 μM and 4.1 μM for hTRPV4, mTRPV4 and rTRPV4 respectively. RN-1747 also antagonizes TRPM8, with an IC_{50} of 4 μM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ro 22-3581

(4'-(Imidazol-1-yl) acetophenone)

Cat. No.: HY-109877

Ro 22-3581 (4'-(Imidazol-1-yl) acetophenone) is a selective **thromboxane (Tx) synthetase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ro 31-8220

(Bisindolylmaleimide IX)

Cat. No.: HY-13866A

Ro 31-8220 is a potent **PKC** inhibitor, with IC_{50}s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ro 31-8220 mesylate (Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate)

Cat. No.: HY-13866

Ro 31-8220 mesylate is a potent **PKC** inhibitor, with IC_{50}s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ro 363

Cat. No.: HY-123268

Ro 363, an effective inotropic stimulant, is a potent and highly selective **β1-adrenoceptor** agonist. RO 363 is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ro 363 hydrochloride

Cat. No.: HY-123268A

Ro 363 hydrochloride, an effective inotropic stimulant, is a potent and highly selective **β1-adrenoceptor** agonist. Ro 363 hydrochloride is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.



Purity: 95.88%
Clinical Data: No Development Reported
Size: 10 mg

Ro 46-2005

Cat. No.: HY-19529

Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ro-15-2041

Cat. No.: HY-101807

Ro 15-2041 is a selective platelet **phosphodiesterase** inhibitor with antithrombotic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ro-24-4736

Cat. No.: HY-19097

Ro 24-4736 is a potent, selective, p.o.-active platelet-activating factor (**PAF**) antagonist with a long duration of action.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO2959 hydrochloride

Cat. No.: HY-113618A

RO2959 hydrochloride is a potent and selective **CRAC channel** inhibitor with an IC_{50} of 402 nM. RO2959 hydrochloride is a potent blocker of **store operated calcium entry (SOCE)** mediated by **Orai1/Stim1 channels** with an IC_{50} of 25 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

RO2959 monohydrochloride

Cat. No.: HY-113618B

RO2959 monohydrochloride is a potent and selective **CRAC channel** inhibitor with an IC_{50} of 402 nM. RO2959 monohydrochloride is a potent blocker of **store operated calcium entry (SOCE)** mediated by **Orai1/Stim1 channels** with an IC_{50} of 25 nM.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ROCK inhibitor-2

Cat. No.: HY-119937

ROCK inhibitor-2 is a selective dual **ROCK1** and **ROCK2** inhibitor with IC_{50}s of 17 nM and 2 nM, respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ROCK-IN-1

Cat. No.: HY-U00351

ROCK-IN-1 is a potent inhibitor of **ROCK**, with an IC_{50} of 1.2 nM for ROCK2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ROCK-IN-2

(Azaindole 1; TC-S 7001) Cat. No.: HY-10319

ROCK-IN-2 (Azaindole 1; TC-S 7001) is an orally active and ATP-competitive **ROCK** inhibitor with IC_{50}s of 0.6 and 1.1nM for human **ROCK-1** and **ROCK-2**, respectively.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rodatristat

(KAR5417) Cat. No.: HY-120083

Rodatristat (KAR5417) is a potent **tryptophan hydroxylase 1 (TPH1)** and **TPH2** inhibitor with IC_{50}s value of 33 nM and 7 nM, respectively, and shows robust reduction of **intestinal serotonin (5-HT)** levels in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rodatristat ethyl

(KAR5585) Cat. No.: HY-101124

Rodatristat ethyl (KAR5585) is a first-in-class oral **tryptophan hydroxylase 1 (TPH1)** Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of **5-HT** and significantly reduces pulmonary arterial hypertension (PAH).



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

ROMK-IN-32

Cat. No.: HY-124687

ROMK-IN-32 is a renal outer medullary potassium channel (**ROMK**) inhibitor with an IC_{50} of 35 nM. ROMK-IN-32 also inhibits hERG with an IC_{50} of 22 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ropitoin

(TR 2985) Cat. No.: HY-U00274

Ropitoin (TR 2985) is a novel **antiarrhythmic** drug.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Ropivacaine

Cat. No.: HY-B0563

Ropivacain is a potent **sodium channel** blocker. Ropivacain blocks impulse conduction via reversible inhibition of **sodium ion influx** in nerve fibrese.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ropivacaine hydrochloride

Cat. No.: HY-B0563B

Ropivacaine hydrochloride is a potent **sodium channel** blocker and blocks impulse conduction via reversible inhibition of **sodium ion influx** in nerve fibrese.



Purity: 98.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ropivacaine hydrochloride monohydrate

Cat. No.: HY-B0563A

Ropivacaine hydrochloride monohydrate is a potent **sodium channel** blocker and blocks impulse conduction via reversible inhibition of **sodium ion influx** in nerve fibrese.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ropivacaine mesylate

Cat. No.: HY-B0563C

Ropivacaine mesylate is a long-acting amide local **anaesthetic agent** for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of **sodium ion influx** in nerve fibressup>.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Rostafuroxin

(PST 2238) Cat. No.: HY-12283

Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent **Na^+,K^+-ATPase (ATP1A1)** antagonist.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rosuvastatin

(ZD 4522)

Cat. No.: HY-17504A

Rosuvastatin (ZD 4522) is a competitive **HMG-CoA** reductase inhibitor with an IC_{50} of 11 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Rosuvastatin Calcium

(Rosuvastatin hemicalcium; ZD 4522 Calcium)

Cat. No.: HY-17504

Rosuvastatin Calcium (Rosuvastatin hemicalcium) is a competitive **HMG-CoA** reductase inhibitor with an IC_{50} of 11 nM.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Rosuvastatin D3

(ZD 4522 D3)

Cat. No.: HY-17504AS

Rosuvastatin D3 (ZD 4522 D3) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC_{50} of 11 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Rosuvastatin D3 Sodium

Cat. No.: HY-17504BS

Rosuvastatin D3 Sodium is deuterium labeled Rosuvastatin, which is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rosuvastatin D6 Calcium

Cat. No.: HY-17504S

Rosuvastatin D6 Calcium is deuterium labeled Rosuvastatin, which is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rosuvastatin D6 Sodium

Cat. No.: HY-17504BS1

Rosuvastatin D6 Sodium is deuterium labeled Rosuvastatin, which is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rotigaptide

(ZP123)

Cat. No.: HY-106225

Rotigaptide (ZP123) is a novel and specific modulator of **connexin 43 (Cx43)**. Rotigaptide prevents the uncoupling of Cx43-mediated **gap junction** communication and normalizes cell-to-cell communication during acute metabolic stress.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Rotundatin

Cat. No.: HY-N5061

Rotundatin is useful in inhibition of the aggregation of platelets induced by arachidonic acid and collagen.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rotundic acid

Cat. No.: HY-N2217

Rotundic acid, a triterpenoid obtained from I. rotunda, induces DNA damage and cell apoptosis in hepatocellular carcinoma through **AKT/mTOR** and **MAPK** Pathways. Rotundic acid possesses anti-inflammatory and cardio-protective abilities.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

RP 54275

(2-Octadecyl-1H-indole-5-carboxylic acid)

Cat. No.: HY-100160

RP 54275 (2-Octadecyl-1H-indole-5-carboxylic acid) is a novel hypocholesterolaemic drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RP-64477

Cat. No.: HY-16437

RP-64477 is a potent inhibitor of the cholesterol esterifying enzyme Acyl-coenzyme A:cholesterol O-acyltransferase (**ACAT**).



Purity: 99.68%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

RPR-260243

Cat. No.: HY-16915

RPR-260243, a potent activator of **human ether-a-go-go-related gene (hERG)**, slows deactivation and attenuates inactivation of hERG1 channels. RPR260243-modified HERG currents are inhibited by Dofetilide (IC_{50}=58 nM).



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Rubiayannone A

Cat. No.: HY-N7991

Rubiayannone A is an anthraquinone glycoside with an antiplatelet aggregation activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Runcaciguat

Cat. No.: HY-109136

Runcaciguat is an orally active stimulator of **soluble guanylate cyclase**, and is used in the research of cardiovascular and renal diseases combined with selective partial adenosine A1 receptor agonists.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ruscogenin

Cat. No.: HY-N0496

Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway and exerts significant anti-inflammatory and anti-thrombotic activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Ruthenium red

(Ammoniated ruthenium oxychloride)

Cat. No.: HY-103311

Ruthenium red (Ammoniated ruthenium oxychloride) is a polycationic dye widely used for electron microscopy (EM) of cells, tissues and vegetative bacteria. Ruthenium red strongly reacts with phospholipids and fatty acids and binds to acidic mucopolysaccharides.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

RWJ-445167

(3DP-10017)

Cat. No.: HY-19373

RWJ-445167 (3DP-10017) is a dual inhibitor of **thrombin** and **factor Xa** with K_i of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RWJ-56110

Cat. No.: HY-108556

RWJ-56110 is a potent, selective, peptide-mimetic inhibitor of **PAR-1** activation and internalization (binding IC_{50}=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

RWJ-56110 dihydrochloride

Cat. No.: HY-108556A

RWJ-56110 dihydrochloride is a potent, selective, peptide-mimetic inhibitor of **PAR-1** activation and internalization (binding IC_{50}=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RWJ-67657

(JNJ 3026582)

Cat. No.: HY-15505

RWJ-67657 (JNJ 3026582) is an orally active and selective **p38α** and **p38β MAPK** inhibitor with IC_{50}s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect.
Anti-inflammatory and anti-tumor activity.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

S-1-Propenyl-L-cysteine

Cat. No.: HY-111827

S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S-Nitroso-N-acetyl-DL-penicillamine

(SNAP)

Cat. No.: HY-121526

S-Nitroso-N-acetyl-DL-penicillamine (SNAP) is a nitric oxide donor and acts as a stable inhibitor of platelet aggregation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

S0859

Cat. No.: HY-15529

S0859 is a selective, high-affinity generic **Na^+/HCO_3^- transporter** (**NBC**) inhibitor. S0859 reversibly inhibits NBC-mediated intracellular pH (pHi) recovery (K_i=1.7 μM, full inhibition at approximately 30 μM).



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

S1P1 agonist 3

Cat. No.: HY-115831

S1P1 agonist 3 is a selective G-protein-biased **sphingosine-1 phosphate receptor-1 (S1P1)** agonist for endothelial protection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sacubitril

(AHU-377)

Cat. No.: HY-15407

Sacubitril (AHU-377) is a potent **NEP** inhibitor with an **IC_{50}** of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.



Purity: 99.41%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sacubitril hemicalcium salt

(AHU-377 hemicalcium salt)

Cat. No.: HY-15407A

Sacubitril hemicalcium salt (AHU-377 hemicalcium salt) is a potent **NEP** inhibitor with an **IC_{50}** of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g

Sacubitril-13C4 hemicalcium salt

(AHU-377-13C4 hemicalcium salt)

Cat. No.: HY-15407AS

Sacubitril-13C4 (AHU-377-13C4) hemicalcium salt is a 13C-labeled and deuterium labeled Sacubitril hemicalcium salt. Sacubitril (AHU-377) hemicalcium salt is a potent **NEP** inhibitor with an **IC_{50}** of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Sacubitril-d4

(AHU-377-d4)

Cat. No.: HY-15407S

Sacubitril-d4 (AHU-377-d4) is the deuterium labeled Sacubitril. Sacubitril (AHU-377) is a potent **NEP** inhibitor with an **IC_{50}** of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sacubitril/Valsartan

(LCZ696)

Cat. No.: HY-18204A

Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting **angiotensin receptor-neprilysin (ARN)** inhibitor for hypertension and heart failure.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Safinamide mesylate

(FCE 26743 mesylate; EMD 1195686 mesylate)

Cat. No.: HY-70057A

Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible **monoamine oxidase B (MAO-B)** inhibitor (**IC_{50}**=0.098 μM) over MAO-A (IC_{50}=580 nM).



Purity: 99.18%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Salvianolic acid B

(Lithospermic acid B) **Cat. No.:** HY-N1362

Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Salvianolic acid D

Cat. No.: HY-N0320

Salvianolic acid D, isolated from Salvia miltiorrhiza, is a potential antiplatelet activity compound.



Purity: 96.58%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sampatrilat

(UK-81252) **Cat. No.:** HY-123348

Sampatrilat (UK-81252) is a potent and orally active **vasopeptidase** inhibitor of **ACE** and neutral endopeptidase (**NEP**). Sampatrilat inhibits C-domain ACE (K_i=13.8 nM) 12.4-fold more potent than that for the N-domain (K_i=171.9 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sandaracopimaric acid

Cat. No.: HY-133594

Sandaracopimaric acid is a diterpenoid with anti-inflammatory effect. Sandaracopimaric acid reduces the contraction of phenylephrine-induced pulmonary arteries with an EC_{50} of 43.93 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sanggenon C

Cat. No.: HY-N0617

Sanggenon C is a flavanone Diels-Alder adduct compound, which is isolated from the root bark of Morus cathayana. Sanggenon C exerts protective effects against cardiac hypertrophy and fibrosis via suppression of the **calcineurin/NFAT2** pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sapropterin dihydrochloride ((6R)-BH4 dihydrochloride; (6R)-Tetrahydro-L-biopterin dihydrochloride)

Cat. No.: HY-A0124A

Sapropterin ((6R)-BH4) dihydrochloride is a synthetic form of BH4 that is approved for the treatment of BH4 responsive PKU.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Sarafotoxin S6a

Cat. No.: HY-P1112

Sarafotoxin S6a, a sarafotoxin analogue, is a **endothelin receptor** agonist and has an ET_A/ET_B selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a elicits the pig coronary artery with an EC_{50} value of 7.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sarafotoxin S6a TFA

Cat. No.: HY-P1112A

Sarafotoxin S6a TFA , a sarafotoxin analogue, is a **endothelin receptor** agonist and has an ET_A/ET_B selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a TFA elicits the pig coronary artery with an EC_{50} value of 7.5 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Saralasin TFA

([Sar1,Ala8] Angiotensin II TFA) **Cat. No.:** HY-P0205B

Saralasin ([Sar1,Ala8] Angiotensin II) TFA is a competitive **angiotensin II** antagonist. Saralasin TFA is used to identify renin-dependent (angiotensinogenic) hypertension.



Purity: 99.18%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Sarpogrelate hydrochloride

(MCI-9042) **Cat. No.:** HY-10564

Sarpogrelate hydrochloride (MCI-9042) is a selective **5-HT_2R** antagonist, with **pK_i**s of 8.52, 6.57, and 7.43 for 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} receptors, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Saterinone hydrochloride

(BDF 8634 hydrochloride) Cat. No.: HY-101644A

Saterinone hydrochloride is a **phosphodiesterase III** (**PDE III**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sauvagine

Cat. No.: HY-P1298

Sauvagine, a 40-amino-acid neuropeptide from the skin of the frog, is a **mammalian CRF** agonist. Sauvagine is effective at releasing ACTH from rat pituitary cells. Sauvagine possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sauvagine TFA

Cat. No.: HY-P1298A

Sauvagine TFA, a 40-amino-acid neuropeptide from the skin of the frog, is a **mammalian CRF** agonist. Sauvagine TFA is effective at releasing ACTH from rat pituitary cells.

Purity: 95.17%
Clinical Data: No Development Reported
Size: 5 mg

SB 204741

Cat. No.: HY-103153

SB 204741 is a selective and high affinity **5-HT$_{2B}$** antagonist with a **pK$_i$** value of 7.1.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SB-203186 hydrochloride

Cat. No.: HY-101222

SB-203186 hydrochloride is a potent, selective and competitive **5-HT$_4$** antagonist.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB-206606

Cat. No.: HY-117239

SB-206606, a stereoisomer of BRL 37344, is a potentially specific, beta 3-adrenergic receptor (**β_3-AR**) ligand. The affinity of [3H]SB 206606 is 76 times higher for the β_3-AR than for the beta 1/beta 2-adrenergic receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB-633825

Cat. No.: HY-108333

SB-633825 is a potent and ATP-competitive inhibitor of **TIE2**, **LOK (STK10)** and **BRK** with **IC$_{50}$**s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SB-772077B dihydrochloride

Cat. No.: HY-108518

SB-772077B dihydrochloride is an aminofurazan-based **Rho kinase (ROCK)** inhibitor with **IC$_{50}$**s of 5.6 nM and 6 nM toward ROCK1 and ROCK2, respevtively.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SBC-115076

Cat. No.: HY-12402

SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SBI-425

Cat. No.: HY-124756

SBI-425 is a potent, selective and oral bioavailable **tissue-nonspecific alkaline phosphatase (TNAP)** inhibitor.



Purity: 99.40%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC-236

Cat. No.: HY-W010983

SC-236 is an orally active **COX-2** specific inhibitor (IC_{50} = 10 nM) and a **PPARγ** agonist. SC-236 suppresses activator protein-1 (**AP-1**) through c-Jun NH2-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC-52012

Cat. No.: HY-19163

HY-19163 is an orally active fibrinogen receptor antagonist, with antiplatelet activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

SC99

Cat. No.: HY-124858

SC99 is an orally active, selective **STAT3** inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SCH 42495

Cat. No.: HY-101682

SCH 42495 is an orally active neutral metalloendopeptidase (**NEP**) inhibitor with antihypertensive effect. SCH 42495 is the orally active ethylester prodrug of SCH 42354.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SCH 42495 racemate

Cat. No.: HY-101682A

SCH 42495 racemate is the racemate of SCH 42495. SCH 42495 is an orally active neutral metalloendopeptidase (**NEP**) inhibitor with antihypertensive effect. SCH 42495 is the orally active ethylester prodrug of SCH 42354.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SCH00013

Cat. No.: HY-100718

SCH00013 is a cardiotonic agent that primarily acts via an increase in myofibrillar Ca++ sensitivity, have a significant Ca(2+)sensitizing effect at pH 7.2 to 7.4.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

SCH79797

Cat. No.: HY-14993

SCH79797 is a highly potent, selective nonpeptide **protease activated receptor 1 (PAR1)** antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to **PAR1** with an IC_{50} of 70 nM and a K_i of 35 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SCH79797 dihydrochloride

Cat. No.: HY-14994

SCH79797 dihydrochloride is a highly potent, selective nonpeptide **protease activated receptor 1 (PAR1)** antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to **PAR1** with an IC_{50} of 70 nM and a K_i of 35 nM.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Scoparone

Cat. No.: HY-N0228

Scoparone is isolated from Artemisia capillaris, has anticoagulant, vasorelaxant antioxidant, anti-inflammatory activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Scutellarin methyl ester

Cat. No.: HY-N6925

Scutellarin methyl ester is a constituent of Breviscapine which is a crude extract of several flavonoids of Erigeron breviscapus.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SEA0400

Cat. No.: HY-15515

SEA0400 is a novel and selective inhibitor of the Na^+-Ca^{2+} exchanger (**NCX**), inhibiting Na^+-dependent Ca^{2+} uptake in cultured neurons, astrocytes, and microglia with IC_{50}s of from 5 to 33 nM.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Secoisolariciresinol diglucoside

((S,S)-SDG; (S,S)-LGM2605)

Cat. No.: HY-105008

Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Secoxyloganin

Cat. No.: HY-N3009

Secoxyloganin, isolated from Lonicera japonica Thunb, inhibits the blood flow (BF) decrease. Secoxyloganin has allergy-preventive activity.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Selexipag

(NS-304; ACT-293987)

Cat. No.: HY-14870

Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI_2) receptor (IP receptor).



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Selexipag-d8

Cat. No.: HY-14870S

Selexipag-d8 (NS-304-d8) is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI_2) receptor (IP receptor).



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Sematilide

(CK-1752)

Cat. No.: HY-101436

Sematilide (CK-1752) is a selective I_{Kr} channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier **K^+ current** (IC_{50}=25 μM). Sematilide is a class III antiarrhythmic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sematilide hydrochloride

(CK-1752 hydrochloride)

Cat. No.: HY-101436A

Sematilide hydrochloride (CK-1752 hydrochloride) is a selective I_{Kr} channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier **K^+ current** (IC_{50}=25 μM). Sematilide is a class III antiarrhythmic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Semotiadil recemate fumarate

Cat. No.: HY-U00026

Semotiadil recemate fumarate is the recemate of Semotiadil fumarate. Semotiadil fumarate is a novel vasoselective **Ca^{2+} channel** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Senazodan

(MCI 154)

Cat. No.: HY-101693

Senazodan (MCI 154) is a Ca^{2+} sensitiser, and also shows inhibition effect on **PDE III**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Senazodan hydrochloride

(MCI 154 hydrochloride)

Cat. No.: HY-101693A

Senazodan (MCI 154) (hydrochloride), as a Ca^{2+} sensitiser, shows inhibition effect on **PDE III**.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Seralutinib

(GB002; PK10571) Cat. No.: HY-109190

Seralutinib (GB002) is an inhaled **PDGFRα and PDGFRβ** inhibitor. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.



Purity: 99.77%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SERCA2a activator 1

Cat. No.: HY-124873

SERCA2a activator 1 (Compound A) is a **sarco/endoplasmic reticulum Ca^{2+}-dependent ATPase 2a (SERCA2a)** activator. SERCA2a activator 1 attenuates phospholamban inhibition and enhances the systolic and diastolic functions of the heart. SERCA2a activator 1 can be used for heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Setanaxib

(GKT137831; GKT831) Cat. No.: HY-12298

Setanaxib (GKT137831) is a selective NADPH oxidase (**NOX1/4**) inhibitor with K_is of 140 and 110 nM, respectively.



Purity: 99.43%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Setipafant

(BN-50727; LAU-0901) Cat. No.: HY-101675

Setipafant is a platelet-activating factor (**PAF**) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sfllrnpndkyepf

Cat. No.: HY-P1000

Sfllrnpndkyepf is a synthetic **thrombin** receptor agonist peptide.

SFLLRNPNDKYEPF

Purity: 97.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

sgp91 ds-tat Peptide 2, scrambled

Cat. No.: HY-P1908

sgp91 ds-tat Peptide 2, scrambled is a scrambled sequence of NADPH oxidase inhibitor gp91 ds-tat peptide.

RKKRRQRRRCLRITRQSR-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sibrafiban

(RO 48-3657) Cat. No.: HY-10309

Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-prodrug of Ro 44-3888 and a selective **glycoprotein IIb/IIIa receptor** antagonist. Sibrafiban inhibits platelet aggregation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Siguazodan

(SKF 94836) Cat. No.: HY-19026

Siguazodan (SKF 94836) is a potent, selective and orally active **phosphodiesterase III (PDE-III)** inhibitor with an IC_{50} of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC_{50} of 18.88 μM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Sildenafil

(UK-92480) Cat. No.: HY-15025

Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (**PDE5**) inhibitor with an IC_{50} of 5.22 nM.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Sildenafil citrate

(UK-92480 citrate) Cat. No.: HY-15025A

Sildenafil citrate is a potent phosphodiesterase type 5 (**PDE5**) inhibitor with IC_{50} of 5.22 nM.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Sildenafil-d3

(UK-92480-d3)

Cat. No.: HY-15025S

Sildenafil-d3 is deuterium labeled Sildenafil-d3. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (**PDE5**) inhibitor with an IC_{50} of 5.22 nM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Simvastatin

(MK 733)

Cat. No.: HY-17502

Simvastatin (MK 733) is a competitive inhibitor of **HMG-CoA reductase** with a K_i of 0.2 nM.



Purity: 99.45%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg

Simvastatin acid ammonium

(Tenivastatin ammonium)

Cat. No.: HY-119695A

Simvastatin ammonium is an active metabolite of simvastatin lactone mediated by CYP3A4/5 in the intestinal wall and liver (pKa=5.5).



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Simvastatin-d6

(MK 733-d6)

Cat. No.: HY-110231

Simvastatin-d6 (MK 733-d6) is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of **HMG-CoA reductase** with a K_i of 0.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sitaxsentan

(IPI 1040; TBC-11251)

Cat. No.: HY-76520

Sitaxsentan (IPI 1040; TBC-11251) is a selective endothelin A (ETA) receptor antagonist. Antihypertensive. Sitaxsentan is used in treatment of chronic heart failure. IC50 value: Target: ETA receptor.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Sitaxsentan sodium

(IPI 1040 sodium; TBC11251 sodium)

Cat. No.: HY-11103

Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is an orally active, highly selective antagonist of **endothelin A receptors**.



Purity: 99.03%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SKA-121

Cat. No.: HY-107414

SKA-121 is a selective $K_{Ca}3.1$ activator. SKA-121 exhibits EC_{50}s of 109 nM and 4.4 μM for $K_{Ca}3.1$ and $K_{Ca}2.3$, respectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SKA-31

Cat. No.: HY-111655

SKA-31 is a potent **potassium channel** activator with EC_{50s} of 260 nM, 1.9 μM, 2.9 μM, and 2.9 μM for **KCa3.1**, **KCa2.2**, **KCa2.1** and **KCa2.3**, respectively. SKA-31 potentiates endothelium-derived hyperpolarizing factor response and lowers blood pressure.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SKF-96365 hydrochloride

Cat. No.: HY-100001

SKF-96365 hydrochloride is a potent **TRP channel** blocker and a **store-operated Ca^{2+} entry (SOCE)** inhibitor. SKF-96365 hydrochloride significantly inhibits hERG, hKCNQ1/hKCNE1, hKir2.1 and hKv4.3 current, and significantly prolongs the QTc interval in isolated guinea pig hearts.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SL910102

Cat. No.: HY-100292

SL910102 is a nonpeptide **angiotensin AT_1 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SLC13A5-IN-1

Cat. No.: HY-125990

SLC13A5-IN-1 is a selective sodium-citrate co-transporter (**SLC13A5**) inhibitor. SLC13A5-IN-1 completely blocks the uptake of ^{14}C-citrate with an **IC_{50}** value of 0.022 μM in HepG2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SM 16

Cat. No.: HY-111482

SM 16 is a **ALK5/ALK4** kinase inhibitor with **K_i**s of 10 and 1.5 nM, respectively.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SM-6586

Cat. No.: HY-19062

SM-6586 is a **calcium channel** antagonist and inhibitor of Na^+/H^+ and **Na^+/Ca^{2+} exchange transport**, potentially for the treatment of cerebrovasular diseases and hypertension.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Small Cardioactive Peptide B (SCPB)

Cat. No.: HY-P1495

Small Cardioactive Peptide B (SCP_B), a neurally active peptide, stimulates **adenylate cyclase** activity in particulate fractions of both heart and gill tissues with **EC_{50}**s of 0.1 and 1.0 μM, respectively.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SN 6

Cat. No.: HY-107658

SN 6 is a selective **Na^+/Ca^{2+} exchanger (NCX)** inhibitor, and inhibits $^{45}Ca^{2+}$ uptake by NCX1, NCX2, and NCX3, with **IC_{50}**s of 2.9, 16, and 8.6 μM, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Sodium citrate dihydrate (Trisodium citrate dihydrate; Citric acid trisodium salt dihydrate)

Cat. No.: HY-B1610

Sodium citrate dehydrate is an anticoagulant and also used as a buffer and food preservatives.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Sodium formononetin-3'-sulfonate (Sul-F)

Cat. No.: HY-13063

Sodium formononetin-3'-sulfonate (Sul-F) is a water-sol. derivate of formononetin.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Sodium Houttuyfonate

Cat. No.: HY-N6934

Sodium Houttuyfonate is an orally active compound synthesized by combining sodium bisulfite with houttuynia. Sodium Houttuyfonate exhibits antifungal, antibacterial, anti-inflammatory, and cardiovascular protective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Sodium ionophore III (ETH2120)

Cat. No.: HY-101109

Sodium ionophore III (ETH2120) is a **Na^+** ionophore suitable for the assay of sodium activity in blood, plasma, serum. etc.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 200 mg

Sodium nitroprusside (Ro 21-2498)

Cat. No.: HY-B0564

Sodium nitroprusside (Ro 21-2498) is a potent vasodilator working through releasing NO spontaneously in blood.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sofigatran

(MCC-977)

Cat. No.: HY-14936

Sofigatran (MCC-977) is an orally active **factor IIa (thrombin)** inhibitor, acts as an anticoagulant. Sofigatran is used for the research of cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Solasodine

(Purapuridine; Solancarpidine; Solasodin)

Cat. No.: HY-N0068

Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Solenopsin

Cat. No.: HY-16461

Solenopsin is an ATP-competitive **AKT** inhibitor with IC_{50} value of 10 μM .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Soluble epoxide hydrolase inhibitor

Cat. No.: HY-U00453

Soluble epoxide hydrolase inhibitor is an inhibitor of **soluble epoxide hydrolase**, and inhibits human soluble epoxide hydrolase (h-sEH) with pIC_{50} of 8.4, extracted from patent WO 2010096722 A1, example 57.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sparsentan

(RE-021; DARA-a)

Cat. No.: HY-17621

Sparsentan (RE-021) is a highly potent dual **angiotensin II** and **endothelin A** receptor antagonist with K_is of 0.8 and 9.3 nM, respectively.



Purity: 99.08%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Spirapril hydrochloride

(SCH 33844 hydrochloride)

Cat. No.: HY-A0230A

Spirapril (SCH 33844) hydrochloride is a potent **angiotensin converting enzyme (ACE)** inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

sPLA2-X Inhibitor 31

Cat. No.: HY-112605

sPLA2-X Inhibitor 31 is a selective **secreted phospholipase A_2 type X** (**sPLA$_2$-X**) inhibitor with **IC<Sub>50**s of 26 nM, 310 nM, and 2230 nM for **sPLA$_2$-X**, **sPLA$_2$-IIa**, and **sPLA$_2$-V**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SQ-31765

(SQ31765; SQ 31765)

Cat. No.: HY-101740

SQ-31765 is a benzazepine **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Squalamine lactate

(MSI-1256F)

Cat. No.: HY-16467

Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

Squalene

(Super Squalene; trans-Squalene; AddaVax)

Cat. No.: HY-N1214

Squalene is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, cardioprotective, antioxidant, and antitoxicant activity.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg

SR33805

Cat. No.: HY-136909

SR33805 is a potent **Ca^{2+} channel** antagonist, with **EC_{50}**s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca^{2+} channels. SR33805 can be used for the research of acute or chronic failing hearts.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SR59230A

Cat. No.: HY-100672

SR59230A is a potent, selective, and blood-brain barrier penetrating **β3-adrenergic receptor** antagonist with **IC_{50}**s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SR59230A hydrochloride

Cat. No.: HY-103200

SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating **β3-adrenergic receptor** antagonist with **IC_{50}**s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SRPKIN-1

Cat. No.: HY-116856

SRPKIN-1 is a covalent and irreversible **SRPK1/2** inhibitor with **IC_{50}**s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Stachydrine

Cat. No.: HY-N0298

Stachydrine is a major constituent of Chinese herb leonurus heterophyllus sweet used to promote blood circulation and dispel blood stasis. Stachydrine can inhibit the **NF-κB** signal pathway.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Stachydrine hydrochloride

Cat. No.: HY-N0738

Stachydrine hydrochloride is the major active constituent of Herba Leonuri, which is a potential therapy for cardiovascular diseases. Stachydrine can inhibit the **NF-κB** signal pathway. Anti-hypertrophic activities.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Stepharine

Cat. No.: HY-N9347

Stepharine, an natural alkaloid, directly interactes with **TLR4** and binds to the TLR4/MD2 complex (TLR4 inhibitor). Stepharine possesses anti-aging, anti-viral and anti-hypertensive effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STOCK2S-26016

Cat. No.: HY-112143

STOCK2S-26016 is a **WNK** signalling inhibitors. STOCK2S-26016 inhibits **WNK4** and **WNK1** with **IC_{50}**s of 16 μM and 34.4 μM, respectively. STOCK2S-26016 has potential for antihypertensive research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Streptokinase

Cat. No.: HY-P2824

Streptokinase is a bacteria-derived protein and a plasminogen activator. Streptokinase is widely used for the research of the blood-clotting disorders. Streptokinase improves reperfusion blood flow after coronary artery occlusion.

Streptokinase

Purity: >98%
Clinical Data: No Development Reported
Size: 10 kU

Strophanthidin

Cat. No.: HY-114252

Strophanthidin is a naturally available cardiac glycoside. Strophanthidin 0.1 and 1 nmol/L increases and 1~100 μmol/L inhibits the **Na+/K+-ATPase** activities, but Strophanthidin 10 and 100 nmol/L does not affect **Na+/K+-ATPase** activities in cardiac sarcolemmal.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU5408

(VEGFR2 Kinase Inhibitor I) Cat. No.: HY-103002

SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of **VEGFR2** kinase with an IC_{50} of 70 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Succinobucol

(AGI-1067; Probucol monosuccinate) Cat. No.: HY-14937

Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects.



Purity: 99.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sulamserod

(RS-100302) Cat. No.: HY-101668

Sulamserod is a **5-HT4 receptor** antagonist, with antiarrhythmic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfacarbamide

Cat. No.: HY-B1236

Sulfacarbamide is a blood sugar-lowering drug, also acting on the vegetative nervous system.



Purity: 98.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Sulprostone

(SHB 286; CP-34089; ZK-57671) Cat. No.: HY-19360

Sulprostone (SHB 286) is a potent and selective **EP3 receptor** agonist. Sulprostone (SHB 286) is a prostaglandin E2 (PGE2) analogue and has antiulcer and nonsteroidal abortifacient effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Suramin

Cat. No.: HY-B0879

Suramin is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin is a potent inhibitor of **sirtuins**: SirT1 (IC_{50}=297 nM), SirT2 (IC_{50}=1.15 μM), and SirT5 (IC_{50}=22 μM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Suramin sodium salt

(Suramin hexasodium salt) Cat. No.: HY-B0879A

Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin sodium salt is a potent inhibitor of **sirtuins**: SirT1 (IC_{50}=297 nM), SirT2 (IC_{50}=1.15 μM), and SirT5 (IC_{50}=22 μM).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

Syringin

(Eleutheroside B) Cat. No.: HY-N0824

Syringin is a main bioactive phenolic glycoside in Acanthopanax senticosus, with anti-osteoporosis activity. Syringin prevents cardiac hypertrophy induced by pressure overload through the attenuation of autophagy.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Syrosingopine

(Su 3118) Cat. No.: HY-N4115

Syrosingopine (Su 3118) is an antihypertensive agent. Syrosingopine can decrease brain dopamine levels.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

T0901317

Cat. No.: HY-10626

T0901317 is an orally active and highly selective **LXR** agonist with an EC_{50} of 20 nM for LXRα. T0901317 activates **FXR** with an EC_{50} of 5 μM. T0901317 is **RORα** and **RORγ** dual inverse agonist with K_i values of 132 nM and 51 nM, respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TA-01

Cat. No.: HY-100114

TA-01 is a potent **CK1** and **p38 MAPK** inhibitor, with IC_{50}s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. TA-01 acts as a cardiogenic inhibitor.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TA-02

Cat. No.: HY-100115

TA-02, an analog of SB 203580 (HY-10256), is a **p38 MAPK** inhibitor with an IC_{50} of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TA-316

(Megakaryocytes/platelets inducing agent)

Cat. No.: HY-112486

TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized **c-MPL** agonist (CMA) and **thrombopoietin (TPO) receptor** agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TA-7552

Cat. No.: HY-100253

TA-7552 is a potent cholesterol-lowering agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tadalafil

(IC-351)

Cat. No.: HY-90009A

Tadalafil (IC-351) is a **PDE5** inhibitor with an IC_{50} value of 1.8 nM.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

TAK-024

Cat. No.: HY-100254

TAK-024 is a **platelet** inhibitor with IC_{50}s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Talibegron hydrochloride

(ZD2079 hydrochloride)

Cat. No.: HY-15378

Talibegron hydrochloride (ZD2079 hydrochloride) is a potent **β3-adrenoceptor** agonist with a pD_2 of 3.72 on phenylephrine-preconstricted rat mesenteric artery. Talibegron hydrochloride has potent vasorelaxant effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tanshinone I

(Tanshinone A)

Cat. No.: HY-N0134

Tanshinone I is an inhibitor of type IIA human recombinant **sPLA$_2$** (IC_{50}=11 μM) and rabbit recombinant **cPLA$_2$** (IC_{50}=82 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tanshinone IIA

(Dan Shen ketone)

Cat. No.: HY-N0135

Tanshinone IIA (Tan IIA) is one of the main compositions in the root of red-rooted salvia. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of **VEGF/VEGFR2**.



Purity: 99.74%
Clinical Data: Phase 4
Size: 10 mg, 25 mg, 50 mg

Tanshinone IIA sulfonate sodium (Sodium Tanshinone IIA sulfonate; Tanshinone IIA sodium sulfonate)

Cat. No.: HY-N1370

Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca^{2+} entry (SOCE), and is used to treat cardiovascular disorders.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mg, 25 mg

TAP311

Cat. No.: HY-107997

TAP311 is a cholesteryl ester transfer protein (**CETP**) inhibitor with an IC_{50} of 62 nM.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Taprostene

(CG-4203)

Cat. No.: HY-114671

Taprostene (CG-4203) is a synthetic, chemically stable analogue of **Prostacyclin** (**PGI2**). Taprostene exhibits endothelium and myocardial protecting actions after acute myocardial ischemia and reperfusion in cats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAS-301

Cat. No.: HY-18965

TAS-301 is an inhibitor of smooth muscle cell migration and proliferation, and inhibits **PKC** activation induced by PDGF.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tasosartan

(WAY-ANA 756)

Cat. No.: HY-A0250

Tasosartan is a long-acting **angiotensin II** (**AngII**) **receptor** antagonist.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

TAT-Gap19

Cat. No.: HY-P1136B

TAT-Gap19, a Cx mimetic peptide, is a specific **connexin43 hemichannel (Cx43 HC)** inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice.

YGRKKRRQRRRKQIEIKKFK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAT-Gap19 TFA

Cat. No.: HY-P1136C

TAT-Gap19 TFA, a Cx mimetic peptide, is a specific **connexin43 hemichannel (Cx43 HC)** inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice.

YGRKKRRQRRRKQIEIKKFK (TFA salt)

Purity: 98.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

TBAJ-587

Cat. No.: HY-111747

TBAJ-587, a potent **anti-tuberculosis** agent, inhibits M.tb strain H37Rv growth with MIC_{90}s of 0.006 and <0.02 μg/mL in MABA and LORA assay, respectively.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TC-S 7005

Cat. No.: HY-108597

TC-S 7005 is a **Polo-like kinases (Plks)** inhibitor with IC_{50}s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Tecadenoson

(CVT-510)

Cat. No.: HY-19661

Tecadenoson (CVT-510) is a selective **A1 adenosine receptor** agonist.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tecarfarin

(ATI-5923)

Cat. No.: HY-14854

Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (**VKOR**) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Tecarfarin has the antithrombotic activity .



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Telmisartan

(BIBR 277)

Cat. No.: HY-13955

Telmisartan is a potent, long lasting antagonist of **angiotensin II type 1 receptor (AT1)**, selectively inhibiting the binding of ^{125}I-AngII to AT1 receptors with **IC_{50}** of 9.2 nM.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Temocapril hydrochloride

Cat. No.: HY-B0384

Temocapril hydrochloride is an **angiotensin-converting enzyme (ACE)** inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Temocapril-d5

Cat. No.: HY-100713S

Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an **angiotensin-converting enzyme (ACE)** inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Tenapanor

(AZD1722; RDX5791)

Cat. No.: HY-15991

Tenapanor is an inhibitor of the **Na^+/H^+** exchanger NHE3 with **IC_{50}** values of 5 and 10 nM against human and Rat NHE3, respectively.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tenatoprazole sodium

(TU-199 sodium)

Cat. No.: HY-17421A

Tenatoprazole sodium (TU-199 sodium) is a **proton pump** inhibitor; inhibits hog gastric H^+/K^+-ATPase with an **IC_{50}** of 6.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Teneligliptin D8

(MP-513 D8)

Cat. No.: HY-14806S

Teneligliptin D8 (MP-513 D8) a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Terbogrel

(BIBV 308SE)

Cat. No.: HY-19189

Terbogrel is an orally available **thromboxane A2 receptor** antagonist and a **thromboxane A2 synthase** inhibitor, with both **IC_{50}**s of about 10 nM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Terlipressin

Cat. No.: HY-12554

Terlipressin is a vasopressin analogue with potent vasoactive properties. Terlipressin is a highly selective **vasopressin V1 receptor** agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Terlipressin acetate

Cat. No.: HY-12554A

Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective **vasopressin V1 receptor** agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding.



Purity: 99.76%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Terrestrosin K

Cat. No.: HY-N5078

Terrestrosin K, a steroidal saponin from Tribulus terrestris L., has potential to treat cardiovascular and cerebrovascular diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

tert-Buthyl Pitavastatin

Cat. No.: HY-135384

tert-Buthyl Pitavastatin is the metabolite of Pitavastatin.
Pitavastatin is a potent **HMG-CoA** reductase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

Tertatolol

((±)-Tertatolol; Racemic Tertatolol; dl-Tertatolol)

Cat. No.: HY-U00356

Tertatolol is a potent antagonist of **beta-adrenoceptor** and **5-HT receptor**, with unique renal vasodilatatory effects.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tertiapin-Q

Cat. No.: HY-P1275

Tertiapin-Q is a highly selective blocker of **GIRK1/4** heterodimer and **ROMK1** ($Kir_{1.1}$).



Purity: 99.72%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Terutroban

(S-18886)

Cat. No.: HY-16991

Terutroban is a **thromboxane-prostaglandin receptor** antagonist.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tetrahydrozoline

(Tetryzoline)

Cat. No.: HY-B0556

Tetrahydrozoline (Tetryzoline), a derivative of imidazoline, is an **α-adrenergic** agonist that causes vasoconstriction. Tetrahydrozoline is widely used for the research of nasal congestion and conjunctival congestion.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tetrahydrozoline hydrochloride

(Tetryzoline hydrochloride)

Cat. No.: HY-B0556A

Tetrahydrozoline hydrochloride (Tetryzoline hydrochloride), a derivative of imidazoline, is an **α-adrenergic** agonist that causes vasoconstriction. Tetrahydrozoline hydrochloride is widely used for the research of nasal congestion and conjunctival congestion.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Tezosentan

(RO 610612)

Cat. No.: HY-17351

Tezosentan (RO 610612) is an **endothelin (ET)** receptor antagonist, with pA_2**s** of 9.5, 7.7 for ET_A and ET_B receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tezosentan-d4

Cat. No.: HY-17351S

Tezosentan-d4 (RO 610612-d4) is the deuterium labeled Tezosentan. Tezosentan (RO 610612) is an **endothelin (ET)** receptor antagonist, with pA_2**s** of 9.5, 7.7 for ET_A and ET_B receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

TFLLR-NH2

Cat. No.: HY-P0226

TFLLR-NH2 is a selective **PAR1** agonist with an EC_{50} of 1.9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG100-115

Cat. No.: HY-10111

TG100-115 is a selective **PI3Kγ/PI3Kδ** inhibitor with IC_{50}s of 83 and 235 nM, respectively.



Purity: 99.31%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Theodrenaline

((±)-Theodrenaline) Cat. No.: HY-U00344

Theodrenaline is a cardiac stimulant, also acts as an anti-hypotensive agent together with cafedrine.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Theviridoside

Cat. No.: HY-N1155

Theviridoside is a natural iridoid glucoside found in the leaves of Cerbera odollam, it has cytotoxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thrombin inhibitor 1

Cat. No.: HY-U00370

Thrombin inhibitor 1 is a potent **thrombin** inhibitor (K_i=0.66 nM, 2xaPTT=0.43 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thrombin Inhibitor 2

Cat. No.: HY-10217

Thrombin Inhibitor 2 is a small molecule direct **thrombin** inhibitor, extracted from US8541580B2. Thrombin Inhibitor 2 has antithrombotic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thrombin Receptor Activator for Peptide 5 (TRAP-5)

Cat. No.: HY-P1536

Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or **Proteinase Activated Receptor 1** (1-5), used in the research of coronary heart disease (CHD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tiapamil hydrochloride

(Ro 11-1781) Cat. No.: HY-101674

Tiapamil hydrochloride is a **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ticagrelor

(AZD6140; AR-C 126532XX) Cat. No.: HY-10064

Ticagrelor (AZD6140) is a reversible oral **P2Y12** receptor antagonist for the treatment of platelet aggregation.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ticagrelor-d7

Cat. No.: HY-10064S

Ticagrelor-d7 (AZD6140-d7) is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral **P2Y12** receptor antagonist for the treatment of platelet aggregation.



Purity: >98%
Clinical Data:
Size: 500 μg, 1 mg, 5 mg

Ticlopidine hydrochloride

Cat. No.: HY-B0153A

Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM. Target: Adenosine diphosphate (ADP) Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

TIE-2/VEGFR-2 kinase-IN-1

Cat. No.: HY-112294

TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tilianin

Cat. No.: HY-N2555

Tilianin is an active flavonoid glycoside found in many medical plants, with potential anti-hypertensive, myocardial-protective, anti-diabetic, anti-hyperlipidemic, anti-inflammatory and antioxidant effects.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Timepidium bromide

(Sesden; SA504)

Cat. No.: HY-U00184

Timepidium bromide (Sesden; SA504) is an anticholinergic agent.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Timonacic

(1,3-Thiazolidine-4-carboxylic acid)

Cat. No.: HY-B1169

Timonacic is used as an adjuvant in the treatment of acute and hepatic disorders. It has also been used for the treatment of some cases of cancer, through the induction of the reverse transformation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Tiotidine

(ICI 125211)

Cat. No.: HY-101232

Tiotidine (ICI 125211) is a potent and selective antagonist of **histamine H2-receptor** (pA_2=7.3-7.8 for guinea-pig right atrium). Tiotidine has low affinity for both the H1 and the H3 receptors.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Tirofiban

(L700462; MK383)

Cat. No.: HY-17369B

Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation.



Purity: 98.37%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Tirofiban hydrochloride monohydrate

Cat. No.: HY-17369

Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist IC50 value: Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation.



Purity: 99.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tirofiban-d9 hydrochloride

Cat. No.: HY-17369AS

Tirofiban-d9 (L700462-d9) hydrochloride is the deuterium labeled Tirofiban. Tirofiban(L700462) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

TJ-M2010-5

Cat. No.: HY-139397

TJ-M2010-5 is a **MyD88** inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway. TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI).



Purity: 99.25%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TM5275 sodium

Cat. No.: HY-100447

TM5275 sodium is a plasminogen activator inhibitor (**PAI-1**) with an IC_{50} of 6.95 μM.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TM6089

Cat. No.: HY-118543

TM6089 is a unique **Prolyl Hydroxylase (PHD)** inhibitor which stimulates **HIF** activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TMN355

Cat. No.: HY-107635

TMN355 is a potent chemical **cyclophilin A** inhibitor and reduces foam cell formation and cytokine secretion. TMN355 is used for atherosclerosis.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TN1

Cat. No.: HY-100826

TN1 is a potent fetal hemoglobin (**HbF**) inducer.



Purity: 95.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TNP-470

(AGM-1470)

Cat. No.: HY-101932

TNP-470 is a **methionine aminopeptidase-2** inhibitor and also an **angiogenesis** inhibitor.



Purity: ≥99.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Toddalolactone

Cat. No.: HY-N0518

Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant **human plasminogen activator inhibitor-1 (PAI-1)**, with an IC_{50} value of 37.31 μM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Todralazine

(Ecarazine)

Cat. No.: HY-B1001

Todralazine (Ecarazine) is an anti-hypertensive agent, acts as a β_2**AR** blocker, with antioxidant and free radical scavenging activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Todralazine hydrochloride

(Ecarazine hydrochloride)

Cat. No.: HY-B1001A

Todralazine hydrochloride (Ecarazine hydrochloride) is an anti-hypertensive agent, acts as a β_2**AR** blocker, with antioxidant and free radical scavenging activity.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tolonidine

Cat. No.: HY-B1800

Tolonidine is a derivative of imidazoline. Tolonidine is orally active and has been shown to possess hypotensive and antihypertensive properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tolvaptan

(OPC-41061)

Cat. No.: HY-17000

Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tolvaptan-D7

Cat. No.: HY-17000S

Tolvaptan-D7 (OPC-41061-D7) is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC_{50} of 1.28μM for the inhibition of AVP-induced platelet aggregation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tomatidine

Cat. No.: HY-N2149

Tomatidine acts as an anti-inflammatory agent by blocking **NF-κB** and **JNK** signaling. Tomatidine activates **autophagy** either in mammal cells or C elegans.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Tomatidine hydrochloride

Cat. No.: HY-N2149A

Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking **NF-κB** and **JNK** signaling. Tomatidine hydrochloride activates **autophagy** either in mammal cells or C elegans.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Tonapofylline

(BG 9928)

Cat. No.: HY-14873

Tonapofylline (BG 9928) is an orally active and selective **adenosine A_1 receptor** antagonist with a K_i of 7.4 nM for human adenosine A_1 receptor (hA_1), which displays 915-fold selectivity versus human adenosine A_{2A} receptor and 12-fold selectivity versus human adenosine A_{2B}...



Purity: 96.01%
Clinical Data: Phase 3
Size: 5 mg, 10 mg

Toringin

Cat. No.: HY-N4192

Toringin, a bioflavonoid, is isolated from the bark of Docyniopsis tschonoski. Toringin progressively decreases not only the cis-effect of the expanded CTG repeats but cytotoxicity as well. Exposure to isosakuranetin, Toringin rescues PC12 neuronal cells.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tormentic acid

Cat. No.: HY-N4137

Tormentic acid, a triterpene isolated from Rosa rugosa, exerts anti-inflammatory, antihyperlipidemic, and anti-atherogenic properties.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Torsemide

(Torasemide)

Cat. No.: HY-B0247

Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 100 mg

Tovinontrine

(IMR-687)

Cat. No.: HY-109193

Tovinontrine (IMR-687) is a highly potent and selective **phosphodiesterase-9 (PDE9)** inhibitor specifically for the treatment of sickle cell disease. **IC_{50}**s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TP-10

Cat. No.: HY-14550

TP-10 is a PDE10A inhibitor with IC50 of 0.8 nM.



Purity: 99.33%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TP508

Cat. No.: HY-P0316

TP508 is a 23-amino acid nonproteolytic **thrombin** peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial **NO synthase (eNOS)** and stimulates production of NO in human endothelial cells.

AGYKPDEGKRGDACEGDSGGPFV

Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

TP508 TFA

Cat. No.: HY-P0316A

TP508 TFA is a 23-amino acid nonproteolytic **thrombin** peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial **NO synthase (eNOS)** and stimulates production of NO in human endothelial cells.

AGYKPDEGKRGDACEGDSGGPFV (TFA salt)

Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

TPN171

Cat. No.: HY-128593

TPN171 is a potent, selective and oral bioavailable inhibitor of **phosphodiesterase type 5 (PDE5)** with an **IC_{50}** of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TPO agonist 1

Cat. No.: HY-100380

TPO agonist 1 is a **thrombopoietin (TPO)** agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

TRAF-STOP inhibitor 6877002

Cat. No.: HY-110247

TRAF-STOP inhibitor 6877002, is a selective inhibitor of **CD40-TRAF6** interaction, compound VII, shows inhibition of **NF-κB** activation in RAW cells, extracted from patent WO2014033122A1.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Trandolapril

(RU44570)

Cat. No.: HY-B0592

Trandolapril (RU44570) is a nonsulfhydryl prodrug that is hydrolysed to the active diacid Trandolaprilat.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Trandolapril D5

(RU44570 D5)

Cat. No.: HY-B0592S

Trandolapril D5 (RU44570 D5) is a deuterium labeled Trandolapril (RU44570). Trandolapril is an orally active angiotensin converting enzyme (ACE) inhibitor for hypertension and congestive heart failure (CHF).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trandolaprilate D5

(Trandolaprilat D5; RU 44403 D5)

Cat. No.: HY-A0116S

Trandolaprilate D5 is a deuterium labeled Trandolaprilate (Trandolaprilat). Trandolaprilate is an angiotensin-converting enzyme (ACE) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tranexamic acid

Cat. No.: HY-B0149

Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM. Target: Others Tranexamic acid is a synthetic derivative of the amino acid lysine.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

trans-Ned 19

Cat. No.: HY-103316

trans-Ned 19, a **NAADP** antagonist and **TPC** blocker, suppresses the **calcium signal** in human umbilical vein endothelial cells (HUVEC) and the rat aorta relaxation in response to low histamine concentrations.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

trans-R-138727MP

(Prasugrel metabolite R-138727MP)

Cat. No.: HY-136588

trans-R-138727MP (Prasugrel metabolite R-138727MP) is the active **metabolite derivative** of Prasugrel (HY-15284). Prasugrel, a thienopyridine and prodrug, inhibits platelet function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trapidil

(AR-12008)

Cat. No.: HY-B1016

Trapidil is a vasodilator, is an antiplatelet drug with specific platelet-derived growth factor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Trimetazidine

Cat. No.: HY-B0968A

Trimetazidine is a selective **long chain 3-ketoyl coenzyme A thiolase** inhibitor with an IC_{50} of 75 nM, which can inhibit **β-oxidation** of free fatty acid (FFA).



Purity: 99.12%
Clinical Data: Launched
Size: 10 mg, 50 mg

Trimetazidine dihydrochloride

Cat. No.: HY-B0968

Trimetazidine dihydrochloride is a selective **long chain 3-ketoyl coenzyme A thiolase** inhibitor with an IC_{50} of 75 nM, which can inhibit **β-oxidation** of free fatty acid (FFA).



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Trimetazidine-d8 dihydrochloride

Cat. No.: HY-B0968S

Trimetazidine-d8 dihydrochloride is the deuterium labeled Trimetazidine dihydrochloride.
Trimetazidine dihydrochloride is a selective **long chain 3-ketoyl coenzyme A thiolase** inhibitor with an IC_{50} of 75 nM, which can inhibit **β-oxidation** of free fatty acid (FFA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Trimetazidine-N-oxide

Cat. No.: HY-135408

Trimetazidine-N-oxide is the major active metabolite of Trimetazidine. Trimetazidine is a selective **long chain 3-ketoyl coenzyme A thiolase** inhibitor with an IC_{50} of 75 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trimethylamine N-oxide

Cat. No.: HY-116084

Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the **ROS/NLRP3 inflammasome**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Trombodipine

(PCA-4230)

Cat. No.: HY-19052

Trombodipine is an antithrombotic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tropifexor

(LJN452)

Cat. No.: HY-107418

Tropifexor (LJN452) is a highly potent agonist of **FXR** with an EC_{50} of 0.2 nM.



Purity: 99.35%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tropodifene

(Tropaphen)

Cat. No.: HY-U00313

Tropodifene (Tropaphen) is an **α-Adrenergic receptor** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRPM4-IN-1

(CBA)

Cat. No.: HY-122605

TRPM4-IN-1 (CBA) is a potent and selective inhibitor of the cation channel **TRPM4**, with an IC_{50} of 1.5 μM. TRPM4-IN-1 can be used for the research of cardiac diseases and prostate cancer.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

TRV-120027

Cat. No.: HY-P2141

TRV120027, a β-arrestin-1-biased agonist of **the angiotensin II receptor type 1 (AT1R)**, engages ß-arrestins while blocking G-protein signaling.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

TRV-120027 TFA

Cat. No.: HY-P2141A

TRV120027 TFA, a β-arrestin-1-biased agonist of **the angiotensin II receptor type 1 (AT1R)**, engages ß-arrestins while blocking G-protein signaling.



Purity: 99.21%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

TRV055

Cat. No.: HY-P3136

TRV055 is a Gq-biased ligand of the angiotensin II receptor type 1 (AT1R). TRV055 is efficacious in stimulating cellular Gq-mediated signaling. TRV055 can be used to develop the Gq-biased AT1R agonists.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRV056

Cat. No.: HY-P3137

TRV056 is a Gq-biased ligand of the angiotensin II receptor type 1 (AT1R). TRV056 is efficacious in stimulating cellular Gq-mediated signaling. TRV056 can be used to develop the Gq-biased AT1R agonists.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tulopafant

(RP 59227)

Cat. No.: HY-101594

Tulopafant is a platelet activating factor (**PAF**) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Turkesterone

Cat. No.: HY-N2548

Turkesterone is a potent ecdysteroid. Turkesterone acts as an **ecdysteroid receptor** (**EcR**) agonist in some insect systems.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

TXNIP-IN-1

Cat. No.: HY-115688

TXNIP-IN-1 is **TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex** inhibitor extracted from patent US20200085800A1, Compound 1.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

TY-52156

Cat. No.: HY-19736

TY-52156 is a potent and selective **$S1P_3$** receptor antagonist with a **K_i** value of 110 nM.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Typhaneoside

Cat. No.: HY-N0712

Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive **autophagy** of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Tyramine

Cat. No.: HY-W007606

Tyramine is an amino acid that helps regulate blood pressure. Tyramine occurs naturally in the body, and it's found in certain foods.



Purity: 99.77%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 500 mg, 1 g

Tyramine hydrochloride

Cat. No.: HY-W016823

Tyramine hydrochloride is an amino acid that helps regulate blood pressure. Tyramine hydrochloride occurs naturally in the body, and it's found in certain foods.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 500 mg

Tyrosine kinase-IN-1

Cat. No.: HY-100315

Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with **IC_{50}**s of 4, 20, 4, 2 nM for **KDR**, **Flt-1**, **FGFR1** and **PDGFRα**, respectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG1296

(AG1296) Cat. No.: HY-13894

Tyrphostin AG1296 is a potent and selective inhibitor of **platelet-derived growth factor receptor (PDGFR)**, with an IC_{50} of 0.8 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

U-46619

(9,11-Methanoepoxy PGH2) Cat. No.: HY-108566

U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of thromboxane A2 (TXA2) and acts as a potent **TXA2** agonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg (28.5 mM * 500 μL in Methyl acetate)

U89232

Cat. No.: HY-U00173

U-89232 appears to be a cardioselective K_{ATP} channel opener.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ubrogepant

(MK-1602) Cat. No.: HY-12366

Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (**CGRP**) antagonist in development for acute treatment of migraine.



Purity: 99.69%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

UC-1728

(t-TUCB) Cat. No.: HY-114266

UC-1728 is a potent rabbit soluble epoxide hydrolase **(sEH)** inhibitor, with an IC_{50} of 2 nM on rabbit liver.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ucf-101

Cat. No.: HY-125959

Ucf-101 is a selective and competitive inhibitor of **pro-apoptotic protease Omi/HtrA2**, with an IC_{50} of 9.5 μM for **His-Omi**. Ucf-101 exhibits very little activity against various other serine proteases (IC_{50}>200 μM).



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

UCL 1684 dibromide

Cat. No.: HY-108579

UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (**SK**) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of I_{Na^+}.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UDM-001651

Cat. No.: HY-128345

UDM-001651 is a potent, selective, and orally bioavailable **protease-activated receptor 4 (PAR4)** antagonist (IC_{50}=4 nM; K_d=1.4 nM). UDM-001651 shows antiplatelet potency (IC_{50}=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UFP-803

Cat. No.: HY-P1166

UFP-803 is a potent **urotensin-II receptor (UT)** ligand. UFP-803 has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the **UT** system in physiology and pathology.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UFP-803 TFA

Cat. No.: HY-P1166A

UFP-803 TFA is a potent **urotensin-II receptor (UT)** ligand. UFP-803 TFA has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the **UT** system in physiology and pathology.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UK51656

Cat. No.: HY-101707

UK51656 is a **calcium** antagonist with IC_{50} of 4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC2881

Cat. No.: HY-15798

UNC2881 is a potent and specific Mer kinase inhibitor; inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Urapidil hydrochloride

Cat. No.: HY-B0354A

Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist.



Purity: ≥99.0%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Urapidil-d4 hydrochloride

Cat. No.: HY-B0354AS

Urapidil-d4 hydrochloride is the deuterium labeled Urapidil hydrochloride. Urapidil hydrochloride is an α1-adrenoceptor antagonist and 5-HT_{1A} receptor agonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Urea

(Carbamide; Carbonyldiamide)

Cat. No.: HY-Y0271

Urea is a powerful protein denaturant via both direct and indirect mechanisms. A potent emollient and keratolytic agent. Used as a diuretic agent. Blood urea nitrogen (BUN) has been utilized to evaluate renal function.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Uridine triphosphate

(UTP; Uridine 5'-triphosphate)

Cat. No.: HY-107372

Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Uridine triphosphate trisodium salt (UTP trisodium salt; Uridine 5'-triphosphate trisodium salt)

Cat. No.: HY-W013093

Uridine triphosphate trisodium salt is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.



Purity: ≥96.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg

Urocortin III, mouse

Cat. No.: HY-P1858

Urocortin III, mouse is a corticotropin-releasing factor (**CRF**)-related peptide. Urocortin III preferentially binds and activates **CRF-R2**. Urocortin III (Ucn3) is a known component of the behavioral stress response system.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urocortin III, mouse TFA

Cat. No.: HY-P1858A

Urocortin III, mouse TFA is a corticotropin-releasing factor (**CRF**)-related peptide. Urocortin III preferentially binds and activates **CRF-R2**. Urocortin III (Ucn3) is a known component of the behavioral stress response system.

Purity: 99.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Urotensin I

(Catostomus urotensin I)

Cat. No.: HY-P1542

Urotensin I (Catostomus urotensin I), a CRF-like neuropeptide, acts as an agonist of **CRF receptor** with pEC_{50}s of 11.46, 9.36 and 9.85 for human CRF_1, human CRF_2 and rat $CRF_{2\alpha}$ receptors in CHO cells, and K_is of 0.4, 1.8, and 5.7 nM for $hCRF_1$, $rCRF_{2\alpha}$ and $mCRF_{2\beta}$ receptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Urotensin I TFA

(Catostomus urotensin I TFA)

Cat. No.: HY-P1542B

Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of **CRF receptor** with **pEC$_{50}$**s of 11.46, 9.36 and 9.85 for human CRF$_1$, human CRF$_2$ and rat CRF$_{2\alpha}$ receptors in CHO cells, and **K$_i$**s of 0.4, 1.8, and 5.7 nM for hCRF$_1$, rCRF$_{2\alpha}$ and...

Purity: 98.29%
Clinical Data: No Development Reported
Size: 500 μg

Urotensin II (114-124), human

Cat. No.: HY-P1164

Urotensin II (114-124), human, an 11-amino acid residue peptide, is a potent vasoconstrictor and agonist for the orphan receptor **GPR14**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urotensin II (114-124), human TFA

Cat. No.: HY-P1164A

Urotensin II (114-124), human TFA, an 11-amino acid residue peptide, is a potent vasoconstrictor and agonist for the orphan receptor **GPR14**.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urotensin II, mouse

Cat. No.: HY-P1483

Urotensin II, mouse is an endogenous ligand for the orphan G-protein-coupled receptor **GPR14** or SENR. Urotensin II, mouse is a potent vasoconstrictor. Urotensin II, mouse plays a physiological role in the central nervous system.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Urotensin II, mouse acetate

Cat. No.: HY-P1483B

Urotensin II, mouse acetate is an endogenous ligand for the orphan G-protein-coupled receptor **GPR14** or SENR. Urotensin II, mouse acetate is a potent vasoconstrictor. Urotensin II, mouse acetate plays a physiological role in the central nervous system.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Urotensin II, mouse TFA

Cat. No.: HY-P1483A

Urotensin II, mouse TFA is an endogenous ligand for the orphan G-protein-coupled receptor **GPR14** or SENR. Urotensin II, mouse TFA is a potent vasoconstrictor. Urotensin II, mouse TFA plays a physiological role in the central nervous system.

Purity: 99.58%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Utibapril

(FPL 63547)

Cat. No.: HY-101681

Utibapril is an **angiotensin-converting enzyme (ACE)** inhibitor with antihypertensive activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vadadustat

(PG-1016548; AKB-6548)

Cat. No.: HY-101277

Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (**HIF-PH**) inhibitor. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo.



Purity: 99.25%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Valsartan

(CGP 48933)

Cat. No.: HY-18204

Valsartan (CGP 48933) is an **angiotensin II** receptor antagonist and has the potential for high blood pressure and heart failure research.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Valsartan Ethyl Ester

Cat. No.: HY-135363

Valsartan Ethyl Ester is an impurity of Valsartan. Valsartan is an angiotensin II receptor antagonist for the treatment of high blood pressure and heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Valsartan-d9

(CGP 48933-d9)

Cat. No.: HY-18204S

Valsartan D9 (CGP-48933 D9) is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Vanillyl butyl ether

Cat. No.: HY-W014394

Vanillyl butyl ether is a major contributor to the characteristic flavor and fragrance of vanilla. Vanillyl butyl ether is one of the eco-friendly and nontoxic substances.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vanillylmandelic acid

Cat. No.: HY-113121

Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

Vardenafil hydrochloride

Cat. No.: HY-B0442A

Vardenafil hydrochloride is a selective, orally active, potent inhibitor of **phosphodiesterase-5 (PDE5)**, with an IC_{50} of 0.7 nM. Vardenafil hydrochloride shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM).



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

VAS2870

Cat. No.: HY-12804

VAS2870 is a **NADPH oxidase (NOX)** inhibitor.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vasonatrin Peptide (VNP)

Cat. No.: HY-P1556

Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP).

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

VB124

Cat. No.: HY-139665

VB124 is an orally active, potent, and selective **MCT4** inhibitor. VB124 can specifically inhibit lactate efflux with IC_{50}s of 8.6 nM and 19 nM for lactate import and export in MDA-MB-231 cells, respectively. VB124 is highly selective for MCT4 over MCT1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VEGFR-2-IN-9

(KDR-in-4)

Cat. No.: HY-101628

VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (**KDR/VEGFR2**) inhibitor with an IC_{50} of 7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Veliflapon

(BAY X 1005; DG-031)

Cat. No.: HY-14165

Veliflapon (BAY X 1005; DG-031) is an orally active and selective **5-lipoxygenase activating protein (FLAP)** inhibitor. Veliflapon inhibits the synthesis of the **leukotrienes B4** and **C4**.



Purity: 98.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Verapamil hydrochloride

((±)-Verapamil hydrochloride; CP-16533-1 hydrochloride)

Cat. No.: HY-A0064

Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a **calcium channel** blocker and a potent and orally active first-generation **P-glycoprotein (P-gp)** inhibitor. Verapamil hydrochloride also inhibits **CYP3A4**.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Veratric acid

(3,4-Dimethoxybenzoic acid) Cat. No.: HY-N2007

Veratric acid (3,4-Dimethoxybenzoic acid) is an orally active phenolic compound derived from vegetables and fruits, has antioxidant and anti-inflammatory activities.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Veratrosine

Cat. No.: HY-N6243

Veratramine is a steroidal alkaloid extracted from the roots and rhizomes of Veratrum californicum.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vericiguat

(BAY1021189) Cat. No.: HY-16774

Vericiguat (BAY1021189) is a potent, orally available and soluble **guanylate cyclase** stimulator.



Purity: 99.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Vernakalant

(RSD1235) Cat. No.: HY-14182

Vernakalant(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Vernakalant Hydrochloride

(RSD1235 hydrochloride) Cat. No.: HY-14183

Vernakalant hydrochloride is a mixed voltage- and frequency-dependent **Na^+** and atria-preferred **K^+ channel** blocker.



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Vicagrel

Cat. No.: HY-118284

Vicagrel, an acetate derivative of Clopidogrel, is a **P2Y12** platelet inhibitor potentially for the treatment of thrombosis, the substrate of carboxylesterase 2 (CES2).



Purity: 98.55%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vicenin 2

Cat. No.: HY-N2165

Vicenin 2 is an angiotensin-converting enzyme (**ACE**) inhibitor (**IC_{50}**=43.83 μM) from the aerial parts of Desmodium styracifolium.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Vicenin 3

Cat. No.: HY-N4090

Vicenin 3 is an angiotensin-converting enzyme (**ACE**) inhibitor (**IC_{50}**=46.91 μM) from the aerial parts of Desmodium styracifolium.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Vicenin-1

Cat. No.: HY-125112

Vicenin 1 is a C-glycosylflavone that has an inhibitory effect on angiotensin-converting enzyme (**ACE**)(**IC_{50}**=52.50 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Vinaginsenoside R8

Cat. No.: HY-N4266

Vinaginsenoside R8, a triterpenoid glycoside isolated from the rhizomes of Panacis majoris. Vinaginsenoside R8 displays activities against adenosine diphosphate (ADP)-induced platelet aggregation (**IC_{50}**=25.18 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vinburnine

((-)-Eburnamonine; (-)-Vincamone)

Cat. No.: HY-B1180

Vincamone is a vinca alkaloid and a metabolite of vincamine, is a vasodilator.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Vincamine

Cat. No.: HY-B1021

Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral **vasodilator** and exerts a selective vasoregulator action on the brain microcapilar circulation.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Vinpocetine

(Ethyl apovincaminate)

Cat. No.: HY-13295

Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na^+ channels. The IC_{50} value of Vinpocetine on direct **IKK** inhibition in the cell-free system is 17.17 μM.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Viquidil

(Quinotoxine)

Cat. No.: HY-105559

Viquidil (Quinotoxine), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil shows antithrombotic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Viquidil hydrochloride

(Quinotoxine hydrochloride)

Cat. No.: HY-105559A

Viquidil hydrochloride (Quinotoxine hydrochloride), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil hydrochloride shows antithrombotic activity.



Purity: 95.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Viscumneoside III

Cat. No.: HY-N8223

Viscumneoside III, a dihydroflavone O-glycoside, is a potent **tyrosinase** inhibitor with an IC_{50} of 0.5 mM. Viscumneoside III has anti-angina pectoris.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Visnagin

Cat. No.: HY-N1082

Visnagin, an antioxidant furanocoumarin derivative, possess anti-inflammatory and analgesic properties. Visnagin has substantial potential to prevent Cerulein induced acute pancreatitis (AP). Visnagin possess promising vasodilator effects in vascular smooth muscles.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 5 mg

Vitamin K

Cat. No.: HY-B2172

Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.

Purity: 98.70%
Clinical Data: Launched
Size: 10 mg, 50 mg

Vitamin K1

(Phylloquinone; Phytomenadione)

Cat. No.: HY-N0684

Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Vitamin K1 D7

Cat. No.: HY-N0684S

Vitamin K1 D7 (Phylloquinone D7) is the deuterium labeled Vitamin K1. Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.



Purity: >98%
Clinical Data:
Size: 1 mg

Vitamin K4

(acetomenaphthone)

Cat. No.: HY-B1508

Vitamin K4 is a chemically synthesized Vitamin K which plays an important role in the normal blood coagulation system.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 1 g

Vitexin

Cat. No.: HY-N0013

Vitexin is a c-glycosylated flavone, and is found in various medicinal plants species such as Ficus deltoid and Spirodela polyrhiza. Vitexin has a wide range of pharmacological effects, including anti-oxidant, anti-cancer, anti-inflammatory, anti-hyperalgesic, and neuroprotective effects.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Vitexin arginine

Cat. No.: HY-N7044

Vitexin arginine is a c-glycosylated flavone, and is found in various medicinal plants species such as Ficus deltoid and Spirodela polyrhiza.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vitexin-2"-O-rhamnoside

Cat. No.: HY-N0534

Vitexin-2"-O-rhamnoside, a main flavonoid glycoside of the leaves of Cratagus pinnatifida Bge, contributes to the protection against H_2O_2-mediated oxidative stress damage and has potential to treat cardiovascular system diseases.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Vitexin-4''-O-glucoside

Cat. No.: HY-N5073

Vitexin-4''-O-glucoside is a kind of flavonoid fraction from the leaves of Crataegus pinnatifida.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vorapaxar

(SCH 530348)

Cat. No.: HY-10119

Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor **protease-activated receptor (PAR-1)** antagonist (K_i=8.1 nM).



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Vorapaxar sulfate

(SCH 530348 sulfate)

Cat. No.: HY-10119A

Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor **protease-activated receptor (PAR-1)** antagonist (K_i=8.1 nM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Vorolanib

(CM082; X-82)

Cat. No.: HY-109019

Vorolanib (CM082) is an orally active, potent multikinase **VEGFR/PDGFR** inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895).



Purity: 99.80%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Voxelotor

(GBT 440)

Cat. No.: HY-18681

Voxelotor (GBT 440) is a potent inhibitor of **haemoglobin S (HbS) polymerization**. Voxelotor has the potential for sickle cell disease (SCD) treatment.



Purity: 99.96%
Clinical Data: Phase 3
Size: 25 mg, 50 mg, 100 mg, 200 mg, 500 mg

VTP-27999

Cat. No.: HY-50768

VTP-27999 is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases. Ic50 value: Target: Renin.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

VTP-27999 Hydrochloride

Cat. No.: HY-76652

VTP-27999 HCl is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases. IC50 value: Target: Renin.



Purity: 98.10%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VTP-27999 TFA

Cat. No.: HY-50769

VTP-27999 TFA is an alkyl amine Renin inhibitor; VTP-27999 TFA is useful for Hypertension and End-Organ Diseases.



Purity: 97.20%
Clinical Data: Phase 1
Size: 10 mg, 50 mg, 100 mg

VU0134992

Cat. No.: HY-122560

VU0134992 is the first subtype-preferring, orally active and selective **Kir4.1 potassium channel** pore blocker, with an **IC_{50}** of 0.97 μM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC_{50}=9 μM) at -120 mV.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU0134992 hydrochloride

Cat. No.: HY-122560A

VU0134992 hydrochloride is the first subtype-preferring, orally active and selective **Kir4.1 potassium channel** pore blocker, with an **IC_{50}** of 0.97 μM. VU0134992 hydrochloride is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC_{50}=9 μM) at -120 mV.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VUT-MK142

Cat. No.: HY-122610

VUT-MK142 is a potent new cardiomyogenic synthetic agent promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes, which may be useful to differentiate stem cells into cardiomyocytes for cardiac repair.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Wilforine

Cat. No.: HY-N0899

Wilforine is a sesquiterpene pyridine alkaloid; important bioactive compound in T. wilfordii plants, and is effective in treating idiopathic pulmonary fibrosis.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Win 58237

Cat. No.: HY-101661

Win 58237 is a cyclic nucleotide **phosphodiesterase (PDE)** inhibitor, with **K_i** of 170 nM for PDE V, possessing vasorelaxant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Win-62005

Cat. No.: HY-U00136

Win-62005 is a cyclic AMP phosphodiesterase Ⅲ (**PDE Ⅲ**) inhibitor with **K_i**s of 25 and 26 nM for rat heart and canine aorta, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WNK-IN-11-d3

Cat. No.: HY-112094S

WNK-IN-11 D3 is an orally active, selective and potent With-No-Lysine (**WNK**) kinase inhibitor. WNK-IN-11 D3 is effective at regulating cardiovascular homeostasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Xanthinol Nicotinate

(Xanthinol Niacinate)

Cat. No.: HY-B1815

Xanthinol Nicotinate (Xanthinol Niacinate), a vasodilator, can act directly on the smooth muscle of small arteries and capillaries. Xanthinol Nicotinate expands blood vessels, improves blood rheology and reduces peripheral vascular resistance.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg, 500 mg

XEN445

Cat. No.: HY-12246

XEN445 is a potent and selective EL inhibitor(IC50=0.237 uM), that showed good ADME and PK properties, and demonstrated in vivo efficacy in raising plasma HDLc concentrations in mice.



Purity: 95.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ximelagatran

(H 376/95)

Cat. No.: HY-10787

Ximelagatran (H 376/95) is an orally active **thrombin** inhibitor that selectively and competitively inhibits both free and clot-bound **thrombin**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 μg, 1 mg, 5 mg, 10 mg, 25 mg

Xipamide

Cat. No.: HY-W042301

Xipamide is a sulfonamide-based diuretic. Xipamide is an antihypertensive agent able to selectively inhibit the **anion exchanger (AE)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Xipamide-d6

Cat. No.: HY-W042301S

Xipamide-d6 is the deuterium labeled Xipamide. Xipamide is a sulfonamide-based diuretic. Xipamide is an antihypertensive agent able to selectively inhibit the **anion exchanger (AE)**.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

XL-784

Cat. No.: HY-19485

XL-784 is a selective **matrix metalloproteinases (MMP)** inhibitor, with **IC_{50}s** of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1MMP-2MMP-3MMP-8MMP-9MMP-13respectively.



Purity: 98.20%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XL-784 free base

Cat. No.: HY-112160

XL-784 free base is a selective **matrix metalloproteinases (MMP)** inhibitor, with **IC_{50}s** of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

XL041

(BMS-852927)

Cat. No.: HY-101973

XL041 (BMS-852927) is an **LXRβ**-selective agonist.



Purity: 99.44%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Xylometazoline hydrochloride

Cat. No.: HY-B0475

Xylometazoline hydrochloride is an α-adrenoceptor agonist commonly used as nasal decongestant.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Y-26763

Cat. No.: HY-101069

Y-26763 is a **K^+ channel** opener and active metabolite of Y-27152. Y-26763 is an ATP-sensitive K^+ (K_{ATP}) channel activator.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Y-27152

Cat. No.: HY-108582

Y-27152, a prodrug of the K_{ATP} (Kir6) channel opener Y-26763, is a long-acting **K+ channel** opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Y-9738

Cat. No.: HY-100258

Y-9738 is a hypolipidemic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Yangambin

Cat. No.: HY-N4267

Yangambin, a furofuran lignan, is already isolated from plants such as member of the Annonaceae family, including species of the genus Rollinia: R. pickeli, R. exalbidaand R. mucosa, as well from the Magnolia biondii.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

YM-254890

Cat. No.: HY-111557

YM-254890 is a selective **$G_{\alpha q/11}$ protein** inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the **$P2Y_1$** signal transduction pathway, with an **IC_{50}** value below 0.6 μM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 250 μg

YM-750

Cat. No.: HY-107396

YM-750 is a potent acyl-CoA:cholesterol acyltransferase **(ACAT)** inhibitor (**IC_{50}**=0.18 μM). ACAT catalyzes the formation of cholesteryl esters from cholesterol and long-chain fatty-acyl-coenzyme A.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YM758

Cat. No.: HY-U00309

YM758 is a "funny" I_f current channel (**I_f channel**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Yoda 1

Cat. No.: HY-18723

Yoda 1 is a **Piezo1** agonist. Yoda 1 activates purified Piezo1 channels.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Yohimbic acid

Cat. No.: HY-121936

Yohimbic acid is an amphoteric demethylated derivative of Yohimbine. Yohimbic acid exhibits vasodilatory action. Yohimbic acid also can be used for the research of osteoarthritis (OA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

YRGDS Fibronectin Fragment

Cat. No.: HY-P1921

YRGDS Fibronectin Fragment is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YS-201

Cat. No.: HY-U00137

YS-201 is a dihydropyridine-type **calcium channel** antagonist. YS-201 has the potential for angina pectoris and hypertension treatment.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

YS-49

Cat. No.: HY-15477

YS-49 is a **PI3K/Akt** (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits **angiotensin II (Ang II)**-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

YS-49 monohydrate

Cat. No.: HY-15477A

YS-49 (monohydrate) is a **PI3K/Akt** (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits **angiotensin II (Ang II)**-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Yunaconitine

(Guayewuanine B)

Cat. No.: HY-N0333

Yunaconitine(Guayewuanine B) is a highly toxic aconitum alkaloid.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Z-Gly-Gly-Arg-AMC

Cat. No.: HY-P0019

Z-Gly-Gly-Arg-AMC is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zalunfiban

(RUC-4)

Cat. No.: HY-119350

Zalunfiban (RUC-4) is a potent, selective platelet **αIIbβ3** antagonist (IC_{50}=45 nM). Zalunfiban can be used for the research of myocardial infarction (MI).



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Zalunfiban dihydrochloride

(RUC-4 dihydrochloride)

Cat. No.: HY-119350B

Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet **αIIbβ3** antagonist (IC_{50}=45 nM). Zalunfiban dihydrochloride can be used for the research of myocardial infarction (MI).



Purity: 96.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zamicastat

(BIA 5-1058)

Cat. No.: HY-106004

Zamicastat (BIA 5-1058) is a **dopamine β-hydroxylase (DBH)** inhibitor and can cross the blood-brain barrier (BBB) to cause central as well as peripheral effects.



Purity: 95.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Zaprinast

(M&B 22948)

Cat. No.: HY-B1816

Zaprinast (M&B 22948) is an inhibitor of cGMP-selective **Phosphodiesterases(PDEs)**. Zaprinast is a **G protein-coupled receptor (GPR) 35** agonist which activates rat GPR35 strongly and activates human GPR35 moderately.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Zatebradine

(UL-FS-49 free base; UL-FS-49CL free base)

Cat. No.: HY-13422A

Zatebradine (UL-FS-49 (free base); UL-FS-49CL (free base)) is a potent inhibitor of **hyperpolarization-activated cyclic nucleotide-gated (HCN) channels** with an IC_{50} value of 1.96 μM.



Purity: 99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Zatebradine hydrochloride

(UL-FS-49; UL-FS-49CL)

Cat. No.: HY-13422

Zatebradine (UL-FS-49 (free base)) is a potent inhibitor of **hyperpolarization-activated cyclic nucleotide-gated (HCN) channels** with an IC_{50} values 1.96 μM.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ZD 7155(hydrochloride)

Cat. No.: HY-102093

ZD 7155 hydrochloride is an angiotensin II receptor type 1 (**AT1 receptor**) antagonist.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZD-0892

Cat. No.: HY-19254

ZD-0892 is a selective and potent inhibitor of a **neutrophil elastase** with K_is of 6.7 and 200 nM for human neutrophil elastase and porcine pancreatic elastase, respectively.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg

ZD-1611

Cat. No.: HY-19274

ZD-1611 is a potent, orally active, selective **ETA receptor** antagonist, used for the research of ischemic stroke.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ziconotide acetate

(SNX-111 acetate)

Cat. No.: HY-P0062B

Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research.



Purity: 99.64%
Clinical Data: Launched
Size: 5 mg, 10 mg

Zinc Protoporphyrin

(Zn(II)-protoporphyrin IX; ZnPP; Zinc Protoporphyrin-9)

Cat. No.: HY-101193

Zinc Protoporphyrin (Zn(II)-protoporphyrin IX) is an orally active and competitive **heme oxygenase-1 (HO-1)** inhibitor and markedly attenuates the protective effects of Phloroglucinol (PG) against H_2O_2.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Zinc Pyrithione

Cat. No.: HY-B0572

Zinc Pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump. Target: Proton Pump Zinc pyrithione is considered as a coordination complex of zinc.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

ZINC13466751

Cat. No.: HY-101028

ZINC13466751 is a potent inhibitor of **HIF-1α/von Hippel-Lindau** interaction with an IC_{50} of 2.0 μM.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Zingiberen Newsaponin

Cat. No.: HY-N2282

Zingiberen Newsaponin is extracted from isolated from Dioscorea zingiberensis. Zingiberen Newsaponin exhibits induction effect on platelet aggregation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Zinterol

(MJ 9184)

Cat. No.: HY-14304

Zinterol (MJ 9184) is a potent and selective **β2-adrenoceptor** agonist. Zinterol increases I_{Ca} in a concentration-dependent manner with an EC_{50} of 2.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Zinterol hydrochloride

(MJ 9184 hydrochloride)

Cat. No.: HY-14304A

Zinterol hydrochloride (MJ 9184 hydrochloride) is a potent and selective **β2-adrenoceptor** agonist. Zinterol hydrochloride increases I_{Ca} in a concentration-dependent manner with an EC_{50} of 2.2 nM. Zinterol hydrochloride induces ventricular arrhythmias in conscious heart failure rabbits.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Zofenopril calcium

(SQ26991)

Cat. No.: HY-B0655

Zofenopril Calcium (SQ26991) is an antioxidant that acts as an angiotensin-converting enzyme inhibitor.



Purity: 99.88%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Zoniporide hydrochloride

(CP-597396 hydrochloride) Cat. No.: HY-105064B

Zoniporide (CP-597396) hydrochloride is a potent and selective inhibitor of **sodium-hydrogen exchanger type 1 (NHE-1)**. Zoniporide hydrochloride inhibits human NHE-1 (IC_{50}=14 nM), and has >150-fold selectivity versus other NHE isoforms.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Zoniporide hydrochloride hydrate

(CP-597396 hydrochloride hydrate) Cat. No.: HY-105064D

Zoniporide (CP-597396) hydrochloride hydrate is a potent and selective inhibitor of **sodium-hydrogen exchanger type 1 (NHE-1)**. Zoniporide hydrochloride hydrate inhibits human NHE-1 (IC_{50}=14 nM), and has >150-fold selectivity versus other NHE isoforms.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Zotarolimus

(ABT-578; A 179578) Cat. No.: HY-12424

Zotarolimus (ABT-578) is a derivative of rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis.



Purity: 98.59%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

[Ala1,3,11,15]-Endothelin (53-63) (TFA)

Cat. No.: HY-P1019A

[Ala1,3,11,15]-Endothelin (53-63) (TFA), a linear peptide analog of endothelin (ET)-1, is a highly selective **endothelin B (ETB)** receptor.

ASASSLMDKEAVYFAHLDIIW (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

[Glu1]-Fibrinopeptide B

Cat. No.: HY-P0308

[Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts.

EGVNDNEEGFFSAR

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

[Hyp3]-Bradykinin

Cat. No.: HY-P3061

[Hyp3]-Bradykinin, naturally occurring peptide hormone, is a bradykinin receptor agonist. [Hyp3]-Bradykinin interacts with B2-bradykinin receptors and stimulates inositol phosphate production in cultured human fibroblasts.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

[Leu31,Pro34]-Neuropeptide Y(human,rat)

Cat. No.: HY-P1323

[Leu31,Pro34]-Neuropeptide Y(human,rat) is a specific **neuropeptide Y Y_1 receptor** agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) slao activates Y_4, Y_5. [Leu31,Pro34]-Neuropeptide Y(human,rat) can increase blood pressure in anesthetized rats and increases food intake.

YPSKPDNPGEDAPAEDMARYYSALRHYINLLTRPRY-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Leu31,Pro34]-Neuropeptide Y(human,rat) TFA

Cat. No.: HY-P1323A

[Leu31,Pro34]-Neuropeptide Y(human,rat) TFA is a specific **neuropeptide Y Y_1 receptor** agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA slao activates Y_4, Y_5. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA can increase blood pressure in anesthetized rats and increases food intake.

YPSKPDNPGEDAPAEDMARYYSALRHYINLLTRPRY-NH_2 (TFA salt)

Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

[Orn5]-URP

Cat. No.: HY-P1167

[Orn5]-URP is a potent and selective pure antagonist of **Urotensin-II receptor (UT)**, with an **pEC_{50}** of 7.24. [Orn5]-URP displays no agonist activity.

ACFW-[Orn]-YCV (Disulfide bridge:Cys_6-Cys_{11})

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Orn5]-URP TFA

Cat. No.: HY-P1167A

[Orn5]-URP TFA is a potent and selective pure antagonist of **Urotensin-II receptor (UT)**, with an **pEC_{50}** of 7.24. [Orn5]-URP TFA displays no agonist activity.

ACFW-[Orn]-YCV (Disulfide bridge:Cys_6-Cys_{11}) (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Pyr1]-Apelin-13

([pGlu1]-Apelin-13) **Cat. No.:** HY-P1033

[Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist.

{Glp}-RPRLSHKGPMPF

Purity: 98.76%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

[Sar1, Ile8]-Angiotensin II

Cat. No.: HY-P1564

[Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

α-CGRP(human)

Cat. No.: HY-P1071

α-CGRP(human) is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) is widely distributed in the central and peripheral nervous system. α-CGRP(human) is a potent vasodilator.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-CGRP(human) TFA

Cat. No.: HY-P1071A

α-CGRP(human) TFA is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) is widely distributed in the central and peripheral nervous system. α-CGRP(human) TFA is a potent vasodilator.

Purity: 99.95%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

α-CGRP, rat

Cat. No.: HY-P0203

α-CGRP, rat, a neuropeptide (calcitonin gene-related peptide (CGRP)), is a potent vasodilator, with the potential in cardiovascular, pro-inflammatory and metabolic studies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-CGRP, rat TFA

Cat. No.: HY-P0203A

α-CGRP, rat TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)), is a potent vasodilator, with the potential in cardiovascular, pro-inflammatory and metabolic studies.

Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-D-Glucose-1-phosphate disodium

Cat. No.: HY-128747

α-D-Glucose-1-phosphate disodium is used as a starting material for synthesis of glucuronic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-D-Glucose-1-phosphate disodium hydrate

Cat. No.: HY-128747A

α-D-Glucose-1-phosphate disodium hydrate is used as a starting material for synthesis of glucuronic acid.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

α-Linolenic acid

Cat. No.: HY-N0728

α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of **PI3K/Akt** signaling.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

α-Tocotrienol

Cat. No.: HY-129459

α-Tocotrienol is an **isoform of vitamin E** and found in vegetables, fruits, seeds, nuts, grains, and oils. Vitamin E plays a role as an **antioxidant**, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

αvβ1 integrin-IN-1

Cat. No.: HY-100445

αvβ1 integrin-IN-1 (Compound C8) is a potent and selective **αvβ1 integrin** inhibitor with an IC_{50} of 0.63 nM. Antifibrotic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

αvβ1 integrin-IN-1 TFA

Cat. No.: HY-100445A

αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective **αvβ1 integrin** inhibitor with an IC_{50} of 0.63 nM. Antifibrotic effects.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

β-Amyrin palmitate

Cat. No.: HY-N2924

β-Amyrin palmitate shows HMG-CoA reductase inhibition. And β-Amyrin palmitate has anti-diabetes mellitus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-CGRP, human

(Human β-CGRP; CGRP-II (Human))

Cat. No.: HY-P1548

β-CGRP, human (Human β-CGRP) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC_{50}s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-CGRP, human acetate

(Human β-CGRP acetate; CGRP-II (Human) (acetate))

Cat. No.: HY-P1548B

β-CGRP, human acetate (Human β-CGRP acetate) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC_{50}s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-CGRP, human TFA

(Human β-CGRP TFA; CGRP-II (Human) (TFA))

Cat. No.: HY-P1548A

β-CGRP, human TFA (Human β-CGRP TFA) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC_{50}s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.

Purity: 99.01%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

β-Hydroxypropiovanillone

Cat. No.: HY-N2929

β-Hydroxypropiovanillone, a natural compound, shows significant concentration-dependent inhibitory effects on **α-glucosidase** with an IC_{50} of 257.8 μg/mL.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β3-AR agonist 1

Cat. No.: HY-101514

β3-AR agonist 1 (compound 15) is a highly potent, selective, and orally available **β3-adrenergic receptor (β3-AR)** agonist (EC_{50}=18 nM), being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3>556-fold).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

γ1-MSH

Cat. No.: HY-P1214

γ1-MSH is a **melanocortin MC3 receptor** agonist, with a K_i of 34 nM for the rat MC3 receptor. γ1-MSH displays ~40-fold selectivity over MC4 (K_i=1318 nM).

YVMGHFRWDRF-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

γ1-MSH TFA

Cat. No.: HY-P1214A

γ1-MSH TFA is a **melanocortin MC3 receptor** agonist, with a K_i of 34 nM for the rat MC3 receptor. γ1-MSH TFA displays ~40-fold selectivity over MC4 (K_i=1318 nM).

YVMGHFRWDRF-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

δ-Tocotrienol

Cat. No.: HY-122778

δ-Tocotrienol is a Vitamin E in vegetables, fruits, seeds, nuts, grains and oils. Vitamin E has become well known for its role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.



Purity: 98.89%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg